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Abstract 
 
During development, intrinsic genetic programs give rise to distinct cellular 
lineages through the establishment of cell type specific chromatin states.  These distinct 
chromatin states instruct gene expression primarily through the genome-wide 
demarcation of enhancers.  In addition to maintaining cellular identity, the chromatin 
state of a cell provides a platform for transcriptional responses to environmental signals.  
However, relatively little is known about the influence of extracellular stimuli on 
chromatin state at enhancers, and it is not clear which enhancers among the tens of 
thousands that have been recently identified function to drive stimulus-responsive 
transcription. 
In the nervous system, the chromatin state of terminally differentiated neurons 
not only maintains neuronal identity but also provides a platform for sensory 
experience-dependent gene expression, which plays a critical role in the development 
and refinement of neural circuits and in long-lasting changes in neuronal function that 
  iv 
underlie learning, memory, and behavior.  Using chromatin-immunoprecipitation 
followed by high through put sequencing (ChIP-Seq), we determined the effects of 
neuronal stimuli on the active chromatin landscape of mouse cortical neurons.  We 
discover that stimulation with neuronal activity and brain derived neurotrophic factor 
(BDNF) cause rapid, widespread, and distinct changes in the acetylation of histone H3 
lysine 27 (H3K27Ac) at thousands of enhancers throughout the neuronal genome.  We 
find that functional stimulus-responsive enhancers can be identified by stimulus-
inducible H3K27Ac, and we use this dynamic chromatin signature to discover neuronal 
enhancers that respond to neuronal activity, BDNF, or both stimuli.  Finally, we 
investigate the transcriptional mechanisms underlying the function of stimulus 
responsive enhancers.  We show that a subset of stimulus-responsive enhancers in the 
nervous system require the coordinated action of the stimulus-general transcription 
factor activator protein 1 (AP1) with additional stimulus-specific factors. 
Our studies reveal the genome-wide basis for transcriptional specificity in 
response to distinct neuronal stimuli.  Furthermore, the comprehensive identification of 
neuronal activity and BDNF-dependent enhancers in cortical neurons provides a critical 
resource for elucidating the role of stimulus-responsive transcription in synaptic 
plasticity, learning and memory, behavior, and disease.  Finally, the epigenetic signature 
of stimulus-inducible H3K27Ac may aid in the identification and study of stimulus-
regulated enhancers in other tissues. 
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1 GENERAL INTRODUCTION 
The nervous system enables higher organisms to not only sense and respond to 
the environment, but also to learn from and remember past experiences.  Importantly, 
these fundamental functions of the nervous system are emergent properties that derive 
from the ability of individual neurons to sense, respond, and adapt to sensory stimuli.  A 
characteristic component of the neuronal response and adaptation to extracellular 
stimuli is new gene transcription.  This phenomenon, first discovered over 25 years ago, 
is now know to play a critical role in the development and function of the nervous 
system, and perturbations in this program of gene expression are thought to contribute 
to neurological disease.  Despite great progress over the past decades in understanding 
the mechanisms underlying stimulus-dependent programs of gene expression, major 
question remain.  How is neuronal chromatin affected by extracellular stimuli?  What 
are the enhancers in the genome that drive stimulus-dependent transcription?  What is 
the regulatory logic of these elements?  How are specific transcriptional responses 
generated for different stimuli?  What transcription factors play a role in generating 
these responses?  How do multiple transcription factors work together to achieve this 
purpose?  What are the effector molecules regulated by stimulus-responsive 
transcription factors that mediate adaptive cellular responses to neuronal activity?  
These are some of the questions that have motivated my thesis work. 
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1.1 DISCOVERY OF STIMULUS-RESPONSIVE TRANSCRIPTION IN THE 
NERVOUS SYSTEM 
Stimulus-responsive transcription in the nervous system was discovered nearly 
30 years ago with the discovery of neuronal activity-dependent transcription of the c-
Fos gene.  Stimulation of neuronal cells with either the cholinergic agonist nicotine or 
membrane depolarization with elevated extracellular concentrations of potassium 
chloride (KCl) was shown induce transcription of c-Fos (Greenberg et al., 1986).  In 
addition to discovering this phenomenon, this first study also showed several key 
characteristics of neuronal activity-dependent transcription.  Activity-dependent 
transcription was shown to be rapid, occurring with 5 minutes of stimulation.  
Furthermore, activity-dependent transcription was shown to be transient, lasting 
approximately 30 minutes after stimulus onset.  Finally, activity-dependent 
transcription was shown to be dependent on extracellular calcium, being abolished 
when cells were cultured in the presence of the calcium chelator ethylene glycol 
tetraacetic acid (EGTA).  It is interesting to note that this influential study that set the 
ground for many subsequent discoveries in the nervous system was done in neuronally 
differentiated PC12 cells.  PC12 cells are a cell line derived from a rat 
pheochromocytoma, which is a neuroendocrine tumor of the medulla of the adrenal 
gland.  Previous work had shown that these cells differentiate into neuronal cells when 
exposed to nerve growth factor, establishing PC12 cells as a useful culture system to 
study neuronal cells (Greene and Tischler, 1976).  While the initial discovery of neuronal 
activity-dependent transcription was made in this somewhat artificial cell culture 
system, neuronal activity-dependent transcription was subsequently observed in many 
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additional contexts, demonstrating the power of simplified model systems to observe 
and study biological phenomena. 
Soon after the initial discovery of activity-dependent induction of c-Fos in PC12 
cells in vitro, several groups observed c-Fos induction in response to activity in cultured 
primary neurons in vitro (Hunt et al., 1987; Szekely et al., 1987) and in response to 
diverse stimuli in the nervous system in vivo (Morgan and Curran, 1991).  Many of the 
stimuli that have been shown to induce c-Fos in the nervous system in-vivo are stimuli 
that increase neuronal activity or activate particular neural circuits.  Such stimuli 
include the convulsant pentylenetetrazol (Morgan et al., 1987; Saffen et al., 1988; 
Sonnenberg et al., 1989a; Sonnenberg et al., 1989b; Sonnenberg et al., 1989c), the 
stimulant kainic acid (Le Gal La Salle, 1988; Popovici et al., 1990; Sonnenberg et al., 
1989b), electrical stimulation (Daval et al., 1989; Douglas et al., 1988; Dragunow and 
Robertson, 1987; Hunt et al., 1987; Sagar et al., 1988; Sharp et al., 1989b; Shin et al., 
1990; Sonnenberg et al., 1989b; White and Gall, 1987; Winston et al., 1990; Wisden et 
al., 1990), the glutamate neurotransmitter receptor agonist N-methyl-D-aspartic acid 
(NMDA) (Cole et al., 1989; Kaczmarek et al., 1988; Sonnenberg et al., 1989b), the γ-
aminobutyric acid receptor (GABAR) antagonist picrotoxin (Sonnenberg et al., 1989b), 
D1-dopamine receptor agonists (Robertson et al., 1989a; Robertson et al., 1989b), β-
adrenergic receptor agonists (Gubits et al., 1989), the opiate analgesic morphine (Chang 
et al., 1988), opiate withdrawal (Hayward et al., 1990), nociceptive and peripheral 
stimulation (Bullitt, 1989; Draisci and Iadarola, 1989; Menetrey et al., 1989; Presley et 
al., 1990; Wisden et al., 1990), and light stimulation (Aronin et al., 1990; Rea, 1989; 
Rusak et al., 1990; Sagar et al., 1988).  In addition to the above stimuli that increase 
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neuronal activity and activate neural circuits, additional stimuli not directly related to 
neuronal activity have also been shown to induce c-Fos in the nervous system in vivo, 
including surgical lesions and nerve transections (Dragunow and Robertson, 1988; 
Sharp et al., 1989a; Sharp et al., 1989c), cerebral ischemia (Jorgensen et al., 1989; 
Onodera et al., 1989), heat stress (Dragunow et al., 1989), adrenalectomy (Jacobson et 
al., 1990), intracortical NGF injections (Sharp et al., 1989a), and even intracortical 
saline injections (Kaczmarek et al., 1988).  These data suggest that new gene 
transcription is a general hallmark of a stimulated neuron.  The nature of the stimulus 
does not appear to matter.  Whether a neuron is stimulated with a physiological 
stimulus, a pathological stimulus, a stimulus related to neuronal activity, or a stimulus 
unrelated to neuronal activity, genes such as c-Fos are induced. 
It is important to note that c-Fos is not unique in its transcriptional induction by 
neuronal activity.  Soon after the discovery of the activity-dependent transcription of c-
Fos, other genes were also shown to be induced in response to neuronal activity, 
including c-Jun, JunB, and Egr1 (Saffen et al., 1988; Sukhatme et al., 1988).  More 
recently, investigators have systematically characterized hundred of genes that are 
induced in neurons in response to neuronal activity (Altar et al., 2004; Hong et al., 
2004; Li et al., 2004; Nedivi et al., 1993; Park et al., 2006).  Genes induced in the 
nervous system in response to stimuli can be divided into two waves of induced genes.  
The first wave of genes, termed immediate early genes, consists of genes like c-Fos that 
are expressed rapidly (within minutes) and transiently in response to stimuli.  The 
second wave of genes, termed late response genes, consists of genes like brain-derived 
neurotrophic factor (BDNF) that are expressed more slowly (over hours) in response to 
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stimuli.  In general, the transcription of immediate early genes does not require new 
protein synthesis while the transcription of late response genes does require new protein 
synthesis.  Many immediate early genes encode transcription factors that have been 
proposed to regulate the transcription of late response genes.  Late response genes, in 
turn, are generally thought to encode molecules that effect longer lasting changes within 
the cell (Sheng and Greenberg, 1990). 
Importantly, the stimulus-dependent induction of c-Fos and other genes is not 
limited to the nervous system.  Even before c-Fos was shown to be induced by neuronal 
activity in neuronal cells, it was shown to be induced by serum and growth factors in 
fibroblasts (Greenberg and Ziff, 1984; Muller et al., 1984).  c-Fos has also been shown to 
be induced in numerous other diverse circumstances, including cellular differentiation 
(Mitchell et al., 1985; Muller et al., 1985), wounding of a fibroblast monolayer (Verrier 
et al., 1986), thyroid hormone stimulation of thyroid cells (Colletta et al., 1986), IL-1 
stimulation of lymphocytes (Kovacs et al., 1986), IGF-1 stimulation of skeletal muscle 
(Ong et al., 1987), growth hormone releasing hormone stimulation of pituitary cells 
(Billestrup et al., 1987), heat shock stimulation of HeLa cells (Andrews et al., 1987), 
follicle stimulating hormone stimulation of Sertoli cells (Hall et al., 1988), interferon 
stimulation of various cells (Wan et al., 1988), and steroid and growth factor stimulation 
of breast cancer cells (Wilding et al., 1988).  The diverse circumstances in which c-Fos is 
induced suggests that C-FOS may play a critical role in the cellular response to many 
extracellular signals in many cell types, and that C-FOS may be performing a stimulus-
general function that is required for the cellular response to stimulation. 
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1.2 FUNCTION OF STIMULUS-RESPONSIVE TRANSCRIPTION IN THE 
NERVOUS SYSTEM 
As soon as c-Fos and other genes were shown to be induced in response to 
neuronal activity, there was great interest in understanding the function of stimulus-
responsive transcription in the nervous system.  Neurons were known to exhibit rapid 
responses to synaptic stimulation that could be explained by the opening of ligand gated 
ion channels or second-messenger mediated intracellular signaling.  However, neurons 
were also known to exhibit slower, long-term responses to synaptic stimulation that 
could not be explained by the same mechanisms.  At an organismal level, one of the 
most interesting long-term responses of the nervous system is memory.  An appealing 
hypothesis was that stimulus-responsive genes might underlie memory by facilitating 
adaptive changes in nervous system structures such as synapses (Morgan and Curran, 
1989, 1991; Sheng and Greenberg, 1990).  A large body of work has supported roles for 
stimulus-responsive transcription in memory and synapse development and function 
(Flavell and Greenberg, 2008; Greer and Greenberg, 2008). 
 
1.2.1 Role in long-term memory 
Interestingly, even before the discovery of stimulus-responsive transcription in 
the nervous system and the speculation that this program of gene expression might 
contribute to memory, experiments suggested that new protein synthesis was critical for 
long-term memory.  In a classic paper published over twenty years before the discovery 
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of activity-dependent transcription of c-Fos in the nervous system, investigators 
demonstrated that intracortical injections of the protein synthesis inhibitor puromycin 
in mice caused a loss of memory in a behavioral task (Flexner et al., 1963).  This 
suggested that new protein synthesis was an important component of the mechanisms 
giving rise to memory.  Subsequently, a large number of studies provided evidence that 
extensive inhibition of protein synthesis in the brain through injection of various protein 
synthesis causes loss of long-term memory, without causing changes in short-term 
memory or gross changes in behavior (Davis and Squire, 1984). 
Further evidence for the role of new gene transcription in memory came from 
work done in the sea snail Aplysia californica, reviewed in (Kandel, 2001).  When the 
siphon of the snail is touched, the snail exhibits a protective reflex that leads to 
withdrawal of the gills, similar to how someone might withdraw one’s hand after 
touching a hot object.  The length of time the gills remain retracted serves as an 
indication of learning by the snail.  Normally, the withdrawal reflex leads to retraction of 
the gills for approximately 10 seconds.  However, if the tail of the snail is shocked 
(indicating to the snail a dangerous environment), the subsequent withdrawal reflex 
leads to retraction of the gill and siphon for a longer period of time, in a process called 
sensitization.  Furthermore, the animal remembers the shock and exhibits sensitization 
to subsequent stimuli.  One shock will create a short-term memory that will lead to 
sensitization for a few minutes.  Multiple shocks can create a long-term memory that 
can lead to sensitization for several days.  The discovery of the neural circuitry 
underlying this reflex behavior (Byrne et al., 1978; Hawkins et al., 1981; Kupfermann et 
al., 1974) enabled the discovery that short-term and long-term sensitization lead to the 
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strengthening of synaptic connections between sensory and motor neurons, termed 
heterosynaptic facilitation (Abrams et al., 1984; Brunelli et al., 1976; Castellucci et al., 
1970; Frost et al., 1985; Hawkins et al., 1981; Pinsker et al., 1973).  These discoveries led 
to the hypothesis that heterosynaptic facilitation at the cellular level may underlie 
sensitization seen at the behavioral level.  By studying the neural circuit underlying the 
gill withdrawal reflex, investigators showed that short-term heterosynaptic facilitation 
does not require new protein synthesis whereas long-term heterosynaptic facilitation 
does require new protein synthesis (Montarolo et al., 1986).  These results paralleled the 
results seen in mice with intracortical injections of protein synthesis inhibitors and 
supported a role for new protein synthesis in a cellular correlate of memory.  These 
findings suggested that proteins synthesized during and soon after learning were critical 
for the establishment of long-term memory.  Given that stimulation of neuronal circuits 
during memory formation gives rise to activity-dependent gene expression, it was 
hypothesized that this program of gene expression played a role in memory.  It wasn’t 
until later, however, that this hypothesis could be formally tested with studies of the 
activity-dependent transcription factor CREB (cyclic AMP response element binding 
protein) in this process. 
As investigators began to appreciate the role of new protein synthesis in long-
term memory, details began to emerge regarding the underlying molecular mechanisms.  
Studies of the neural circuit underlying the gill withdrawal reflex showed that the 
neurotransmitter serotonin mediates long-term heterosynaptic facilitation in Aplysia 
(Montarolo et al., 1986) and that a second messenger downstream of serotonin, cyclic 
AMP, was itself capable of producing long-term heterosynaptic facilitation (Schacher et 
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al., 1988; Scholz and Byrne, 1988).  These data suggested that the gene-products 
important for long-term heterosynaptic facilitation might be inducible by cAMP.  It 
turned out that at this time, separate studies had identified the transcription factor 
CREB, or the cyclic AMP response element binding protein, as an important activator 
gene transcription in response to cAMP signaling (Montminy et al., 1986). These 
discoveries provided investigators with a potential molecular handle to study the role of 
stimulus-responsive transcription in memory.  The first evidence that CREB plays a role 
in learning and memory came from a study in which investigators showed that Aplysia 
neurons contained CREB-like proteins and that injection of oligonucleotides of the 
cyclic AMP response element to which these proteins bind into the nucleus of Aplysia 
sensory neurons blocked long-term heterosynaptic facilitation without affecting short-
term heterosynaptic facilitation (Dash et al., 1990).  Separate studies had shown that 
CREB was also as an important activator of c-Fos transcription in mammalian cells in 
response to extracellular stimuli (Sheng et al., 1988) (see section 1.3.1 Initial insights 
from the c-Fos promoter).  Hence, the CREB protein appeared to be an important 
regulator of long-term adaptations in Aplysia as well activity-dependent transcription in 
the mammalian nervous system.  Experiments done in genetically modified mice have 
supported a role for CREB in mammalian long-term plasticity and memory.  Mutation 
of Creb in mice resulted in defective long-term memory and long lasting long-term 
potentiation (L-LTP), a cellular correlate of long-term memory, with no affect on short-
term memory or short term synaptic plasticity (Bourtchuladze et al., 1994).  
Furthermore, transgenic mice overexpressing a constitutively active form of CREB 
exhibit L-LTP in response to weak stimuli that would not normally elicit L-LTP (Barco 
et al., 2002).  These data suggest that CREB plays an important role in long-term 
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cellular adaptations to stimuli and long-term memory.  Since these processes require 
new protein synthesis and since CREB is a transcription factor regulated by extracellular 
stimuli, these results also implicate stimulus-responsive transcription in long-term 
cellular adaptations to stimuli and long-term memory. 
 
1.2.2 Role in dendritic and synaptic development 
In addition to playing a role in long-term cellular adaptations to stimuli and long-
term memory, stimulus-responsive transcription also has been shown to play important 
roles in development of dendrites and synapses that underlie these long-term 
phenomena.  The most convincing evidence supporting a role of stimulus-responsive 
transcription in dendritic and synaptic development has come from detailed studies of 
these processes in the context of genetic alterations to stimulus-responsive genes.  For 
example the activity-dependent transcription factors CREB, CREST, and NEUROD have 
all been shown to play important roles in dendritic development (Aizawa et al., 2004; 
Gaudilliere et al., 2004; Redmond et al., 2002; Wayman et al., 2006).  Furthermore, 
genes whose transcription is regulated by neuronal activity, such as the microRNA 
miRNA132 and candidate plasticity gene 15 (Cpg15), have also been shown to regulate 
dendritic remodeling (Cantallops et al., 2000; Nedivi et al., 1998; Vo et al., 2005; 
Wayman et al., 2008).  Similarly, neuronal activity-dependent genes have also been 
shown to play important roles in synapse development.  The neuronal activity-
dependent transcription factor MEF2 has been shown to negatively regulate excitatory 
synapse number (Barbosa et al., 2008; Flavell et al., 2006).  Furthermore, the protein 
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products of the activity-regulated genes Arc, Homer1a, Npas4, and Plk2 have all been 
shown to regulate various aspects of synapse development (Chowdhury et al., 2006; Lin 
et al., 2008; Pak and Sheng, 2003; Rial Verde et al., 2006; Sala et al., 2003).  These 
studies have demonstrated that neuronal stimulus-responsive transcription plays 
critical roles in the development of both dendrites and synapses in the nervous system. 
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1.3 REGULATION OF STIMULUS-RESPONSIVE TRANSCRIPTION IN THE 
NERVOUS SYSTEM 
Because neuronal stimulus-responsive transcription plays important roles in the 
development and function of the nervous system, there has been great interest in 
understanding the molecular mechanisms underlying this program of gene expression.  
Early work focused on studying the promoters of stimulus-responsive genes.  This 
yielded important insights into the proximal cis-acting elements and proximally bound 
trans-acting factors that regulate stimulus-responsive transcription.  With the 
development of chromatin and transcription factor signatures that identify enhancers, 
and sequencing technologies that enable their unbiased genome-wide identification, 
recent studies have begun to identify distal enhancer elements that may also regulate 
stimulus-responsive transcription.  Since enhancers are though to be the main drivers of 
specificity in gene expression, their identification and study is an important step in 
understanding the regulation of stimulus-responsive transcription in the nervous 
system. 
 
1.3.1 Initial insights from the c-Fos promoter 
Soon after the discovery of the stimulus-dependent transcription of the c-Fos 
gene, investigators sought to understand the mechanisms by which c-Fos was inducibly 
transcribed in response to stimuli.  Initial studies demonstrated that plasmids 
containing several hundred base pairs of sequence upstream of the c-Fos transcriptional 
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start site were sufficient to generate stimulus-responsive transcription similar to that 
exhibited by c-Fos in vivo (Deschamps et al., 1985; Treisman, 1985).  Deletion analysis 
of the c-Fos promoter revealed cis-acting regulatory elements that were critical for 
stimulus-dependent transcription of c-Fos.  Promoter deletion analyses demonstrated 
that c-Fos induction from serum stimulation in fibroblasts required an element termed 
the serum response element (SRE) (Greenberg et al., 1987; Treisman, 1985).  
Subsequent experiments employing DNA affinity chromatography discovered the trans-
acting transcription factor that bound to the SRE, the serum response factor (SRF) 
(Treisman, 1987).  The SRE was subsequently shown to be required for calcium-
dependent transcription of c-Fos (Misra et al., 1994) and SRF was subsequently shown 
to be required for activity-dependent induction of c-Fos in the nervous system 
(Ramanan et al., 2005).  These experiments provided evidence that SRF plays an 
important role in regulating transcriptional responses to neuronal activity by binding to 
SRE sites near the promoters of target genes, such as c-Fos. 
Separate deletion analyses of the c-Fos promoter revealed an additional cis-
acting element required for calcium-dependent induction of the c-Fos gene.  Deletion 
experiments demonstrated that c-Fos induction in response to depolarization in PC12 
cells required an element termed the calcium response element (CaRE) (Sheng et al., 
1988), which bound to the transcription factor CREB (Sheng et al., 1990).  Previous 
experiments had established a role for cAMP responsive transcriptional activation by 
CREB at the cyclic AMP response element (CRE) (Montminy and Bilezikjian, 1987; 
Montminy et al., 1986).  Together, these experiments demonstrated a role for CREB in 
transcriptional activation in response to elevations in both cAMP and calcium, and 
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provided evidence that CREB plays a role in regulating transcriptional responses to 
neuronal activity by binding to CaRE/CRE sites near the promoters of target genes, such 
as c-Fos. 
Careful analyses of the sequences within the c-Fos promoter provided important 
insights into the cis-regulatory elements and trans-acting factors that drive c-Fos 
expression in response to extracellular stimuli.  Importantly, the discovery of SRF and 
CREB proved to not only be important in understanding the stimulus-responsive 
transcription of c-Fos, but also of other stimulus-responsive genes.  For example, the 
SRF knockout animal exhibited no induction of not only c-Fos but also the immediate 
early genes FosB, Egr1, Egr2, c-Jun, JunB, Arc, ActB, and Actg1 in response to 
electroconvulsive shock (Ramanan et al., 2005).  This suggested that SRF is a broadly 
important regulator of activity-dependent transcription in the nervous system.  
Genome-wide analysis of CREB target genes has demonstrated hundreds of genes that 
require CREB for transcription in response to the cAMP agonist forskolin (Zhang et al., 
2005).  While these studies suggest that SRF and CREB are both broadly important in 
generating stimulus-responsive transcriptional programs, the genome-wide sets of 
transcriptional target genes for these factors in the nervous system have not been 
defined. 
 
1.3.2 Discovery of enhancer elements 
As initial understanding of the regulation of stimulus-responsive transcription 
from the promoter regions of c-fos and other genes was developing, the contribution of 
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enhancers to transcriptional regulation was just beginning to be appreciated.  
Enhancers were first discovered through studies of β-globin gene regulation (Banerji et 
al., 1981).  Investigators studying the expression of the β-globin gene from plasmids 
containing a 4.7 kb long segment of chromosomal DNA encompassing the β-globin gene 
found that expression of β-globin was increased a remarkable 200 fold when the 
plasmid also contained a 72 bp sequence of DNA derived from Simian virus 40 (SV40).  
Because of its remarkable ability to enhance β-globin gene transcription, this element 
was referred to as an enhancer.  The investigators also showed that the SV40 enhancer 
functioned to increase β-globin gene transcription independent of its distance from the 
promoter and in either sequence orientation relative to the promoter (Banerji et al., 
1981).  These are now known to be important and defining properties of enhancers. 
After the discovery of viral enhancers (Banerji et al., 1981; Moreau et al., 1981), 
metazoan enhancers were discovered (Banerji et al., 1983; Gillies et al., 1983) thus 
generalizing the relevance of enhancers to transcriptional regulation.  Subsequently, 
several additional endogenous enhancers have been studied in detail, including the β-
globin locus control region (Bender et al., 2000; Grosveld et al., 1987; Hardison et al., 
1997; Moon and Ley, 1990), a limb bud enhancer for the Sonic hedgehog (Shh) gene 
(Lettice et al., 2003; Sagai et al., 2005), the interferon-β enhancer (Munshi et al., 1999; 
Panne, 2008), and the sparkling eye enhancer of the Drosophila dPax2 gene (Evans et 
al., 2012).  These studies have established the importance of enhancers to gene 
regulation and have begun to elucidate the principles underlying enhancer function.  
However, a major hurdle in understanding the function of enhancers and the 
contribution of enhancers to specific programs of gene expression, such as neuronal 
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stimulus regulated transcription, has been the identification of enhancer elements 
within the genome.  Enhancers are short DNA sequences, approximately several 
hundred base pairs in length, that are embedded within the genome.  Because enhancers 
lack defining characteristics, they cannot be identified within the genome on the basis of 
their sequence alone.  Recently, however, great advances have been made in the 
identification of enhancers within the genome (Buecker and Wysocka, 2012).  These 
advances, described in the introduction to the next chapter of my thesis, have facilitated 
my work on the identification and characterization of functional stimulus-responsive 
enhancers in the nervous system. 
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2 GENOME-WIDE IDENTIFICATION OF STIMULUS-RESPONSIVE 
ENHANCERS IN THE NERVOUS SYSTEM 
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2.1 SUMMARY 
Normal brain development and function require stimulus-responsive programs 
of gene expression, but the impact of neuronal stimuli on chromatin, and the specific 
enhancers that regulate stimulus-responsive programs of gene expression are poorly 
understood.  Here, we discover that stimulation with neuronal activity and brain derived 
neurotrophic factor (BDNF) cause rapid, widespread, and distinct changes in the 
acetylation of histone H3 lysine 27 (H3K27Ac) at thousands of promoters and enhancers 
throughout the neuronal genome.  We find that functional stimulus-responsive 
enhancers can be specifically identified by stimulus-inducible H3K27Ac, and we use this 
dynamic chromatin signature to discover enhancers that respond to activity, BDNF, or 
both.  This discovery of these enhancers reveals the genome-wide basis for 
transcriptional specificity in response to distinct stimuli.  Furthermore, this work 
provides a critical resource to begin understanding the cis-regulatory elements that 
transform sensory experience into specific transcriptional programs that facilitate long-
lasting changes in neuronal function.  Finally, stimulus-inducible H3K27Ac may aid in 
the identification and study of stimulus-regulated enhancers in other tissues. 
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2.2 INTRODUCTION 
During development, transcriptional programs give rise to distinct cellular 
lineages through the establishment of cell type specific chromatin states (Davidson, 
2010; Ho and Crabtree, 2010; Kouzarides, 2007; Lee and Young, 2013).  These distinct 
chromatin signatures instruct gene expression primarily through the genome-wide 
demarcation of enhancers, cis regulatory-elements that act at a distance to regulate gene 
transcription (Buecker and Wysocka, 2012; Bulger and Groudine, 2011; Levine, 2010; 
Ong and Corces, 2011; Spitz and Furlong, 2012; Visel et al., 2009b).  Recent efforts to 
identify enhancers using genome-wide sequencing techniques have led to the discovery 
of hundreds of thousands of cis-regulatory elements (Consortium et al., 2012; 
Heintzman et al., 2007; Shen et al., 2012).  Despite this progress, relatively little is 
known about the influence of extracellular stimuli on chromatin state at enhancers, and 
it is not clear which enhancers among the hundreds of thousands that have been 
identified function to promote stimulus-dependent transcription. 
In the nervous system, the chromatin state of terminally differentiated neurons 
must not only maintain neuronal identity but also allow for sensory-experience-
dependent transcription (Borrelli et al., 2008; Day and Sweatt, 2011; Dulac, 2010; Graff 
and Tsai, 2013; Kandel, 2001).  In response to sensory experience, strong bursts of 
synaptic activity induce a program of gene expression in excitatory neurons that is 
required for proper development and refinement of neural circuits and for long-lasting 
changes in neuronal function that underlie learning, memory, and behavior (Greer and 
Greenberg, 2008; Leslie and Nedivi, 2011).  Studies of this neuronal activity-dependent 
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gene program have primarily focused on signaling to promoter bound transcription 
factors (Alberini, 2009; Lyons and West, 2011).  The release of the neurotransmitter 
glutamate at synapses leads to membrane depolarization of the post-synaptic neuron, 
triggering calcium influx through L-type voltage gated calcium channels.  The influx of 
calcium then leads to activation of a complex signaling network that induces the post-
translational modification of promoter bound transcription factors that initiate multiple 
waves of gene expression 
In addition to these critical signaling events at the promoters of activity-regulated 
genes, signaling to enhancers contributes to activity-dependent gene expression, 
although there has been little progress towards characterizing the function of activity-
regulated enhancers because it has been difficult to identify these elements within the 
genome.  However, recent genome-wide studies in a variety of cell types have 
characterized chromatin and transcription factor signatures that now allow for the 
comprehensive identification of enhancers.  For example, enhancers have been 
identified on the basis of their hypersensitivity to DNAseI digestion, enrichment of 
monomethylation of lysine 4 on histone H3 (H3K4Me1), enrichment of acetylation of 
lysine 27 on histone H3, and their ability to bind the transcriptional coactivators 
CBP/P300 (Consortium et al., 2012; Creyghton et al., 2010; Heintzman et al., 2009; 
Rada-Iglesias et al., 2011; Visel et al., 2009a).  However, all enhancers are not 
functionally equivalent.  The cellular repertoire of enhancers consists of both enhancers 
that are thought to be poised for future activation, and enhancers that are currently 
active (Rada-Iglesias et al., 2011).  Poised enhancers are typically identified by their 
enrichment for H3K4me1, whereas active enhancers exhibit additional features (i.e. 
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CBP/P300 binding, eRNA transcription, H3K27Ac).  H3K27Ac has been shown to be 
present specifically at active enhancers and not poised enhancers, and thus has been 
used in several studies of developmentally regulated enhancers to identify active 
enhancers genome-wide (Creyghton et al., 2010; Mikkelsen et al., 2010; Rada-Iglesias et 
al., 2012; Rada-Iglesias et al., 2011). 
Several studies have recently identified enhancers within the nervous system 
(Kim et al., 2010; Shen et al., 2012; Visel et al., 2013).  While most of these studies have 
not attempted to understand the enhancers within the genome that contribute to 
stimulus-dependent transcription in the nervous system, one recent study used 
H3K4Me1 enrichment and inducible CBP binding to identify nearly 12,000 putative 
neuronal activity-dependent enhancers (Kim et al., 2010).  However, this number far 
exceeds the number of activity-regulated genes in excitatory neurons, suggesting that 
many of these enhancers may not directly contribute to activity-dependent transcription.  
Thus, it remains unclear whether all or a subset of these enhancers actually function to 
drive neuronal activity-dependent gene expression.  The activity-regulated regulated 
enhancers identified in excitatory neurons thus far appear to be heterogeneous in terms 
of the transcription factors they bind and their ability to recruit RNA polymerase and 
drive transcription of enhancer associated RNAs (eRNAs). This suggests that these CBP-
bound enhancers may not all function in the same manner.  While some of these 
enhancers might mediate activity-dependent gene transcription, others could respond to 
distinct stimuli such as neurotrophic factors.  It is also possible that some of the CBP-
bound enhancers do not directly regulate stimulus-dependent gene transcription and 
instead might be constitutively active or inactive under the conditions studied.  
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Consistent with these possibilities, studies of developmentally regulated enhancers have 
shown that not all CBP/P300 bound enhancers are active (Rada-Iglesias et al., 2011; 
Visel et al., 2009a).  It is not clear if these observations apply to stimulus-responsive 
enhancers in terminally differentiated cell types since to date no chromatin or 
transcription factor signatures have been defined that identify which of the tens of 
thousands of enhancers within a cell function to drive stimulus-responsive gene 
transcription. 
In this study we determined the effects of neuronal activity on the active 
chromatin landscape of mouse cortical neurons.  We find that neuronal activity can 
induce rapid changes in H3K27Ac at thousands of neuronal enhancers throughout the 
genome.  Notably, increases in H3K27Ac occur specifically at enhancers that function to 
promote activity-dependent gene transcription.  We observed overlapping but distinct 
changes in H3K27Ac at enhancers in response to stimulation with brain derived 
neurotrophic factor (BDNF), revealing the genome-wide basis for transcriptional 
specificity in response to distinct stimuli.  Our studies reveal a previously 
underappreciated heterogeneity among active enhancers in terms of their 
responsiveness to stimuli.  Furthermore, the comprehensive identification of neuronal 
activity and BDNF-dependent enhancers in cortical neurons provides a critical resource 
for elucidating the role of stimulus-responsive transcription in synaptic plasticity, 
behavior and disease.  Finally, the epigenetic signature of acutely inducible H3K27Ac 
may aid in the identification and study of stimulus-regulated enhancers in other tissues. 
  
  23 
2.3 RESULTS 
2.3.1 H3K27Ac changes rapidly in response to neuronal activity 
Despite progress in identifying enhancers in the nervous system, no study has 
systematically determined which of the tens of thousands of enhancers that have been 
identified function to drive stimulus-responsive transcription.  We hypothesized that 
characterizing the active enhancer landscape before and after neuronal activity might 
enable us to identify the set of enhancers that respond to activity.  To test this 
hypothesis, we used ChIP-Seq to measure the genomic distribution of the active 
chromatin associated chromatin mark H3K27Ac in mouse cortical neurons before and 
after two hours of membrane depolarization with elevated extracellular potassium 
chloride (KCl).  Exposure of neuronal cultures to KCl is a well-established in vitro 
experimental paradigm that mimics neuronal activity in vivo by inducing membrane 
depolarization, calcium influx through L-type voltage-sensitive calcium channels, and 
calcium-dependent changes in gene transcription.  We performed two independent 
bioreplicates of ChIP-Seq before and after membrane depolarization with KCl, and 
found that the signal for H3K27Ac was highly correlated in separate bioreplicates in 
each condition (Figure 2.1, Spearman’s rho ρ=0.83 between –KCl experiments, ρ=0.86 
between +KCl experiments).  This suggested that H3K27Ac signal in our experiments 
was replicable across experiments.  As a result, we pooled both bioreplicates for 
subsequent analyses. 
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Figure 2.1: Comparison of H3K27Ac signal in two independent experiments 
before and after membrane depolarization with KCl 
(a) H3K27Ac ChIP-Seq signal in mouse cortical neurons before membrane 
depolarization (-KCl) in two independent experiments (bioreplicate 1, B1; bioreplicate 2, 
B2), quantified at all H3K27Ac peaks in the genome.  H3K27Ac signal was highly 
correlated between experiments, Spearman’s rho ρ=0.83.  (b) H3K27Ac ChIP-Seq signal 
in mouse cortical neurons after 2 hours of membrane depolarization (+KCl) in two 
independent experiments (bioreplicate 1, B1; bioreplicate 2, B2), quantified at all 
H3K27Ac peaks in the genome.  H3K27Ac signal was highly correlated between 
experiments, Spearman’s rho ρ=0.86.  In both plots, each point represents the H3K27Ac 
signal quantified within a 2kb window surrounding an enhancer center. 
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After pooling both H3K27Ac bioreplicates (B1 and B2) in each condition (-KCl 
and +KCl), we identified regions of significant H3K27Ac enrichment in each condition (-
KCl and +KCl) by calling H3K27Ac peaks using MACS with a significance threshold of 
p=1e-5.  We then asked how the genomic distribution of H3K27Ac peaks compared 
before and after membrane depolarization with KCl.  To investigate this, we classified all 
H3K27Ac peaks in each condition based on their location relative to genes in the NCBI 
Reference Sequence Database (RefSeq).  H3K27Ac peaks were classified as being 
proximal if they were within 1kb of an annotated transcriptional start site (TSS).  
H3K27Ac peaks were classified as being distal if they were greater than 1kb from an 
annotated transcriptional start site (TSS).  Distal H3K27Ac peaks were further classified 
as intragenic if they occurred within a RefSeq gene, or as extragenic if they did not 
occurred within a RefSeq gene.  We found that both before and after membrane 
depolarization, the majority of H3K27Ac peaks occurred distal to RefSeq TSSs (Figure 
2.2, 65% distal peaks –KCl, 63% distal peaks +KCl).  Furthermore, the genomic 
distribution of H3K27Ac peaks was similar before and after depolarization.  Before 
depolarization (-KCl), 35% of H3K27Ac peaks were proximal, 32% of H3K27Ac peaks 
were distal intragenic, and 33% of peaks were distal extragenic.  After depolarization 
(+KCl), 37% of H3K27Ac peaks were proximal, 33% of H3K27Ac peaks were distal 
intragenic, and 30% of peaks were distal extragenic.  This suggested that the overall 
distribution of H3K27Ac peaks within the genome did not change with neuronal activity. 
  
  26 
 
 
 
 
 
 
Figure 2.2: Genomic distribution of H3K27Ac peaks before and after 
membrane depolarization with KCl 
(a) Genomic distribution of H3K27Ac peaks before membrane depolarization with KCl 
(-KCl).  The majority of peaks occur distal to RefSeq TSSs, with 32% of distal peaks 
occurring within genes (intragenic) and 33% of distal peaks occurring outside of genes 
(extragenic).  (b) Genomic distribution of H3K27Ac peaks after membrane 
depolarization with KCl (+KCl).  The majority of peaks occur distal to RefSeq TSSs, with 
33% of distal peaks occurring within genes (intragenic) and 30% of distal peaks 
occurring outside of genes (extragenic). 
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While the overall genomic distribution of H3K27Ac peaks did not change with 
neuronal activity, we asked whether the levels of H3K27Ac changed in response to 
neuronal activity at individual enhancer elements.  This raises the question of how 
individual enhancer elements should be identified. H3K27Ac enrichment distal to 
promoter regions has been used to identify enhancers, but H3K27Ac enrichment often 
occurs over broad regions of the genome and can encompass multiple regulatory 
elements.  Furthermore, the accurate localization of individual enhancers within regions 
of H3K27Ac enrichment can prove difficult.  Distal regions of open chromatin identified 
by DNaseI hypersensitivity (DHS) have also been used to identify enhancers.  Compared 
to H3K27Ac, DHS provides the benefit of narrow peaks that allow for accurate 
localization of regulatory elements.  However, distal DNaseI hypersensitivity is not 
specific to enhancers and can indicate the presence of various distal cis-regulatory 
elements, such as silencers and insulators (Gross and Garrard, 1988).  We found that 
98.6% of all H3K27Ac peaks within our system overlapped with previously generated 
DHS data from brain tissues by the ENCODE consortium (Consortium, 2011), and 
reasoned that enhancers within our system could be comprehensively, specifically, and 
accurately identified by integrating our H3K27Ac data with this brain DHS data. 
To identify individual enhancer elements within our system, we isolated the set of 
distal (>1kb from a RefSeq TSS) DHS sites that overlapped with our H3K27Ac peaks.  To 
determine the effect of neuronal activity on H3K27Ac at individual enhancers, we 
quantified the levels of H3K27Ac at individual enhancer elements throughout the 
genome.  While the enhancer-associated chromatin mark H3K4Me1 was largely similar 
at neuronal enhancers before and after neuronal activity (Figure 2.3a, Spearman’s rank 
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correlation coefficient ρ= 0.96, 0.97 in two independent experiments), we found that 
H3K27Ac levels at neuronal enhancers exhibited substantially more variability before 
and after neuronal activity (Figure 2.3b, ρ=0.53, 0.58 in two independent experiments).  
H3K27Ac levels at neuronal enhancers also exhibited substantial variability before and 
after neuronal activity in the merged dataset of both H3K27Ac bioreplicates (Figure 2.3c, 
ρ=0.53). H3K27Ac appeared to increase and decrease at thousands of neuronal 
enhancers and activity-dependent increases in H3K27Ac seemed to occur both at active 
enhancers that displayed H3K27Ac prior to stimulation and at poised enhancers that 
did not display H3K27Ac prior to stimulation (Figure 2.3c).  Inspection of individual loci 
revealed strikingly different H3K27Ac behaviors at neuronal enhancers that appeared 
similar based on other chromatin modifications, transcription factor binding events, 
and DNaseI hypersensitivity (Figure 2.4).  Neuronal enhancers that appeared otherwise 
similar exhibited increasing H3K27Ac, high unchanging H3K27Ac, decreasing H3K27Ac, 
or no H3K27Ac in response to neuronal activity (Figure 2.4).  Hence, H3K27Ac levels 
changed rapidly and dramatically at thousands of neuronal enhancers in response to 
activity, while H3K4Me1 levels were largely constant.  Furthermore, neuronal enhancers 
exhibit significant heterogeneity in both the levels of H3K27Ac and also the dynamics of 
H3K27Ac in response to neuronal activity.  This suggested that neuronal enhancers 
might be heterogeneous in their function and in their responsiveness to neuronal 
activity.  
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Figure 2.3: Chromatin modifications at neuronal enhancers before and 
after membrane depolarization 
Levels and correlation of histone modifications at neuronal enhancers (defined by 
H3K27Ac enrichment and DNaseI hypersensitivity) throughout the genome before 
membrane depolarization (-KCl) and after membrane depolarization (+KCl) in two 
independent experiments (bioreplicate 1, B1; bioreplicate 2, B2).  (a) H3K24Me1 levels.  
(b) H3K27Ac levels.  (c) Levels and correlation of H3K27Ac at neuronal enhancers 
(defined by H3K27Ac enrichment and DNaseI hypersensitivity) throughout the genome 
before membrane depolarization (-KCl) and after membrane depolarization (+KCl) in 
the pooled datasets (merged B1B2). 
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Figure 2.4: Individual enhancers exhibit different H3K27Ac behaviors in 
response to membrane depolarization 
Genome browser views of ChIP-Seq and RNA-Seq tracks at examples of individual 
neuronal enhancers exhibiting increasing H3K27Ac, constant high H3K27Ac, decreasing 
H3K27Ac, or no H3K27Ac in response to membrane depolarization with KCl.  Other 
chromatin marks displayed include the enhancer associated H3K4Me1, the promoter 
associated H3K4Me3, and the repressive chromatin associated H3K27Me3.  
Transcription factor binding events displayed include the transcriptional coactivator 
CREB-binding protein (CBP), and RNA polymerase II (RNAPII).    For all chromatin 
marks and transcription factors, ChIP-Seq tracks display input-normalized reads from 
neurons stimulated with 0 hours (‘-‘) or two hours (‘+’) of KCl.  RNA sequencing tracks 
display sequencing reads aligning to forward (F) and reverse strands (R) of the genome 
from neurons stimulated with 0, 1, or 6 hours of KCl.  Also displayed are DNaseI 
hypersensitivity signal from adult mouse cerebrum and vertebrate conservation by 
PhastCons. 
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To gain initial insight into how neuronal activity-dependent changes in H3K27Ac 
at enhancers might relate to activity-dependent programs of gene expression, we 
inspected the locus of the canonical activity-dependent gene c-Fos.  Previous studies in 
neurons have observed increases in histone acetylation in response to physiological 
stimuli at the promoters of stimulus-responsive genes (Guan et al., 2009; Guan et al., 
2002; Levenson et al., 2004).  Consistent with previous studies, we found that levels of 
H3K27Ac increased at the c-Fos promoter in response to neuronal activity.  We also 
found that levels of H3K27Ac increased at four nearby enhancers in response to 
neuronal activity (Figure 2.5).  This suggested that neuronal activity-dependent gene 
expression might correlate with increasing H3K27Ac in response to neuronal activity 
and that neuronal enhancers that contribute to activity-dependent gene expression may 
exhibit increasing H3K27Ac in response to neuronal activity. 
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Figure 2.5: Enhancers near the c-Fos gene exhibit increases in H3K27Ac in 
response to membrane depolarization 
Genome browser view of ChIP-Seq and RNA-Seq tracks at the c-Fos locus.  Neuronal 
activity-dependent increases in H3K27Ac levels are seen at the c-Fos transcriptional 
start site (TSS) and at four nearby enhancers (e1,2,4,5).  For all chromatin marks and 
transcription factors, ChIP-Seq tracks display input-normalized reads from neurons 
stimulated with 0 hours (‘-‘) or two hours (‘+’) of KCl.  RNA sequencing tracks display 
sequencing reads aligning to forward (F) and reverse strands (R) of the genome from 
neurons stimulated with 0, 1, or 6 hours of KCl. 
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2.3.2 Inducible H3K27Ac identifies functional neuronal activity-
responsive enhancers 
To determine if increases in H3K27Ac occurred at enhancers associated with 
activity-induced genes genome-wide, we first classified enhancers into different groups 
based on their differential H3K27Ac responses to neuronal activity.  We selected three 
subsets of enhancers that exhibited the most distinct H3K27Ac dynamics in response to 
neuronal activity: enhancers with increasing H3K27Ac (n=2868), enhancers with 
decreasing H3K27Ac (n=3746), and enhancers with high constant levels of H3K27Ac 
before and after neuronal activity (n=1395) (Figure 2.6a; see methods).  For comparison, 
we also included a fourth group of enhancers that had H3K4Me1, exhibited inducible 
binding of the transcriptional coactivator CBP in response to neuronal activity, but had 
no appreciable H3K27Ac before or after neuronal activity (n=3223) (Figure 2.6a). This 
fourth group was included because a previous report classified these elements as 
neuronal activity-dependent enhancers (Kim et al., 2010).  Average profiles of H3K27Ac 
ChIP-Seq signal for each group of neuronal enhancers displayed clearly different 
H3K27Ac behaviors in response to neuronal activity (Figure 2.6b).  This suggested that 
these enhancer groups could be meaningfully used to determine whether neuronal 
enhancers with different H3K27Ac behaviors are associated with different 
transcriptional functions within the nervous system. 
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Figure 2.6: Classification of neuronal enhancers with different H3K27Ac 
behaviors 
(a) Classification of neuronal enhancers into subgroups with distinct H3K27Ac 
behaviors.  Enhancers with increasing H3K27Ac, high constant H3K27Ac, decreasing 
H3K27Ac, or no H3K27Ac in response to neuronal activity were classified into separate 
groups.  Each point represents the input normalized H3K27Ac signal quantified within a 
2kb window surrounding an enhancer center, with the x-axis value representing the 
signal before membrane depolarization (-KCl) and the y-axis value representing the 
signal after two hours of membrane depolarization with KCl (+KCl). (b) Average profiles 
of H3K27Ac ChIP-Seq signal at each subgroup of enhancers before membrane 
depolarization (dashed lines) and after membrane depolarization (solid lines).  The y-
axis represents the level of H3K27Ac signal, displayed as the mean number of input-
normalized H3K27Ac ChIP-Seq reads for each subgroup of enhancers.  H3K27Ac signal 
at enhancers was aligned by the centers DNaseI hypersensitive sites. 
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We hypothesized that different H3K27Ac behaviors were likely to reflect different 
transcriptional functions for these enhancers, and that only neuronal enhancers with 
increasing H3K27Ac in response to neuronal activity would promote gene expression in 
response to neuronal activity.  To determine the contribution of each subset of 
enhancers to neuronal gene expression, we performed transcriptome sequencing (RNA-
Seq) in untreated or KCl-depolarized cortical neurons (0, 1, and 6 hours of KCl).  Then, 
for each subset of enhancers, we assessed the expression of nearby genes and the 
expression of enhancer associated RNAs (eRNAs), which are thought to occur at 
enhancers actively engaged in transcriptional regulation (Kim et al., 2010; Wang et al., 
2011).  Strikingly, we found that both nearest gene expression and eRNA transcription 
closely paralleled the H3K27Ac behaviors observed at each subset of enhancers (Figure 
2.7a,b).  As expected enhancers with high unchanging H3K27Ac were near genes that 
exhibited significantly higher levels of expression and had higher levels of eRNA 
transcription than enhancers lacking H3K27Ac, consistent with their classification as 
active enhancers (Figure 2.7a,b).  Notably, only enhancers with increasing H3K27ac in 
response to neuronal activity were associated with activity-dependent increases in the 
expression of nearby genes and eRNAs (Figure 2.7a,b), suggesting that this subset of 
enhancers may function specifically to promote neuronal activity dependent gene 
expression.  Thus, while a large number of active enhancers can be identified by their 
enrichment for H3K27Ac, profiling H3K27Ac in response to neuronal activity revealed 
that these enhancers differ considerably from one another not only in their levels of 
H3K27Ac but also in the expression of nearby genes and in the transcription of eRNAs.  
By measuring H3K27Ac levels before and after a neuronal activity and classifying 
enhancers based on their H3K27Ac dynamics, we find that only enhancers with activity-
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dependent increases in H3K27Ac appear to contribute to neuronal activity-dependent 
transcription.  Our data further suggests that while inducible CBP binding in response to 
neuronal activity has previously been used to identify neuronal activity-dependent 
enhancers, this is clearly not a specific marker.  While enhancers with inducible 
H3K27Ac exhibited greater CBP binding than other acetylated enhancer classes, 
enhancers from all four classes exhibited some level of inducible CBP binding (Figure 
2.7c).  Furthermore, enhancers that lacked H3K27Ac but exhibited inducible robustly 
CBP binding were not associated with genomic correlates of activity-dependent 
enhancer function (Figure 2.7c).  This suggested that inducible H3K27Ac is a much 
more specific and predictive marker of functional neuronal activity-dependent 
enhancers than inducible coactivator binding. 
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Figure 2.7: Enhancers with different H3K27Ac behaviors correlate with 
different patterns of transcription in the genome 
(a) Boxplot of expression of nearest genes for each H3K27Ac enhancer class.  mRNA 
expression is displayed as reads per kilobase per million mapped reads (RPKM).  
Nearest genes with nonzero expression by RNA-SEQ were used for this analysis.  
Expression of the set of genes nearest each enhancer class was assessed at 0, 1, and 6 
hours after membrane depolarization with KCl.  (b) Boxplot of eRNA expression for 
each H3K27Ac enhancer class.  eRNA expression is displayed as reads per kilobase per 
million mapped reads (RPKM).  eRNA expression for each enhancer was calculated as 
the number of reads within a 4kb window surrounding the enhancer center.  For this 
analysis, only extragenic enhancers were used.  Expression of eRNAs for each enhancer 
class was assessed at 0, 1, and 6 hours after membrane depolarization with KCl.  (c) 
Boxplot of CBP binding for each H3K27Ac enhancer class before membrane 
depolarization (0hr KCl) and after membrane depolarization (2hr KCl).  CBP binding at 
each enhancer was calculated as the number of input normalized ChIP-Seq reads within 
an 800bp window surrounding the enhancer center.  * indicates p < 2.2x10-16 in paired 
Wilcoxon test. 
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2.3.3 Functional testing of enhancers in response to neuronal activity 
While genomic correlates of enhancer activity suggested that only enhancers with 
neuronal activity-dependent increases in H3K27Ac function to promote activity-
dependent transcription, we sought to directly test the ability of each class of enhancers 
to drive transcription in an activity-dependent manner.  To accurately measure activity-
regulated transcriptional changes, we developed a neuronal activity-regulated luciferase 
reporter based on the upstream regulatory region of the neuronal activity-regulated 
gene neuronal pentraxin-2 (Nptx2, Figure 2.8a).  Nptx2 encodes a secreted synaptic 
protein that can bind to and induce clustering of AMPA receptors to regulate 
homeostatic scaling of excitatory synapses within the nervous system (Chang et al., 
2010).  We discovered a putative enhancer ~3kb upstream of the Nptx2 transcriptional 
start site (TSS).  The 4.4kb sequence upstream of the Nptx2 TSS was able to drive 
activity-dependent expression of a luciferase reporter gene in a manner that depended 
critically upon the presence of the upstream enhancer (Figure 2.8b).  We used this 
reporter to test the ability of enhancers from each of the four H3K27Ac enhancer classes 
to promote neuronal activity-regulated transcription by replacing the Nptx2 enhancer 
with enhancers from each of the four H3K27Ac enhancer classes and measuring activity-
dependent induction of the reporter.  While our genomic analyses suggested that many 
enhancers inducibly bound by CBP may not contribute to neuronal activity-dependent 
gene expression, we sought to directly test this by selecting enhancers from each 
H3K27Ac enhancers class that were inducibly bound by CBP.  As a result, we replaced 
the Nptx2 enhancer with inducibly CBP-bound enhancers from each H3K27Ac group.  
We then transfected the reporter constructs into mouse cortical neuron cultures, and 
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then measured reporter activity induced by 6 hours of depolarization with KCl.  
Strikingly, all enhancers that exhibited increasing H3K27Ac signal in response to 
neuronal activity drove robust activity-dependent transcription of the reporter (14/14; 
100% with >2 fold induction with KCl; Figure 2.8b), whereas nearly all other enhancers 
failed to do so, despite their recruitment of CBP (1/28; 3.6% with >2 fold induction with 
KCl; Figure 2.8b). 
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Figure 2.8: Functional testing of neuronal enhancers with different 
H3K27Ac behaviors 
(a) Schematic of Nptx2 reporter.  The 4.4kb sequence upstream of the mouse Nptx2 
gene was cloned into a luciferase reporter construct.  Approximately 3kb upstream of 
the Nptx2 TSS is an enhancer element, identified by DNaseI hypersensitivity, CBP 
binding, and H3K27Ac.  (b) Luciferase reporter data for the Nptx2 reporter, reported as 
the fold induction of reporter activity in mouse cortical neurons after 6 hours of 
depolarization with KCl relative to 0 hours.  The wild-type Nptx2 reporter is able to 
induce activity-dependent reporter expression (Nptx2).  However, if the Nptx2 enhancer 
is deleted, the reporter no longer induces activity-dependent reporter expression 
(Nptx2-enh).  Inducibly CBP-bound enhancers from the four H3K27Ac enhancer classes 
were cloned into the Nptx2 reporter, replacing the Nptx2 enhancer, and tested for their 
ability to induce activity-dependent reporter expression.  Only enhancers exhibiting 
increasing H3K27Ac with neuronal activity consistently drove reporter expression in 
response to neuronal activity.  n ≥ 3 for all enhancers tested. 
  
  41 
Across all enhancers tested, neuronal activity-dependent changes in H3K27Ac 
correlated much more strongly with reporter activity (Spearman’s rank correlation 
coefficient ρ=0.88; Figure 2.9a), than did changes in CBP (ρ=0.65; Figure 2.9b), or 
changes in RNAPII (ρ=0.34; Figure 2.9c), which has been previously shown to inducibly 
bind to enhancers (Kim et al., 2010).  This suggested that only enhancers that exhibit 
activity-dependent increases in H3K27ac function to drive activity-regulated gene 
transcription and further supported inducible H3K27Ac as a much more specific and 
predictive marker of functional neuronal activity-dependent enhancers than inducible 
coactivator binding or RNAPII binding.  Thus, we concluded that the dynamic 
chromatin signature of increasing H3K27Ac is a specific and predictive marker of 
functional neuronal activity-dependent enhancers. 
 
 
Figure 2.9: Correlation between reporter induction and genomic variables 
by ChIP-Seq 
The Nptx2 reporter fold induction of each enhancer displayed in Figure 2.8b was plotted 
against the change in H3K27Ac (a), change in CBP (b), or change in RNAPII (c) seen at 
that enhancer.  Green, blue, magenta, and black points represent enhancers with 
increasing, constant, decreasing, or no H3K27Ac ChIP-Seq signal in response to 
neuronal activity.  ρ indicates Spearman’s rank correlation coefficient for the two 
variables plotted in each panel.  
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During development, enhancer elements are thought to be the principal 
determinants of cell-type specific gene expression.  However, numerous studies of 
neuronal activity-regulated transcription have demonstrated that the promoters of 
activity-regulated genes are sufficient to drive activity-dependent expression under 
some conditions (Alberini, 2009; Robertson et al., 1995).  This brings into question 
whether activity-dependent enhancers serve as determinants of stimulus-
responsiveness or if they simply amplify transcription from activity-regulated promoters.  
To gain some insight into this question, we asked whether the ability of activity-
responsive enhancers to promote neuronal activity-regulated transcription depended 
upon their pairing with the activity-regulated Nptx2 promoter.  We cloned four 
enhancers from each H3K27Ac class into two additional luciferase reporter vectors 
containing heterologous promoters not known to drive neuronal activity-dependent 
transcription: an SV40 promoter and a minimal TATA box containing promoter.  We 
hypothesized that if activity-dependent enhancers instructed the transcriptional 
response to neuronal activity, they would be able to drive activity-dependent 
transcription from heterologous promoters.  However, if activity-dependent enhancers 
simply amplified promoter driven transcriptional responses to neuronal activity, we 
hypothesized that they would not be able to drive activity-dependent transcription from 
heterologous promoters.  We found that enhancers with increasing H3K27Ac in 
response to neuronal activity were able to drive robust activity-dependent reporter 
expression when paired with either the SV40 promoter (Figure 2.10c,d) or the minimal 
TATA box promoter (Figure 2.10e,f).  While the minimal TATA box containing promoter 
was weaker than the other promoters (Figure 2.10e,f), enhancer-driven reporter 
expression for the Nptx2 reporter and the SV40 were strongly correlated with one 
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another (ρ=0.95; Figure 2.11), suggesting that the ability to activate transcription in 
response to neuronal activity was intrinsic to the enhancer element itself, with minimal 
contribution from the promoter.  These results suggest that neuronal activity-dependent 
enhancers play a significant role in instructing activity-dependent gene expression, 
rather than functioning to merely amplify transcription from activity-regulated 
promoters.  Furthermore, since enhancers not exhibiting increasing H3K27Ac levels in 
response to neuronal activity did not drive activity-dependent expression of the other 
reporter constructs tested (Figure 2.10c-f), these results provide additional evidence 
from independent reporter contexts that only enhancers with increasing H3K27Ac in 
response to neuronal activity are able to drive activity-dependent transcription. 
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Figure 2.10: Functional testing of neuronal enhancers in different reporter 
constructs 
Luciferase data from neuronal enhancers from each of the four H3K27Ac enhancer 
classes cloned into either the Nptx2 reporter containing the Nptx2 enhancer (a, b), an 
SV40 promoter reporter (c, d), or a minimal TATA box containing promoter reporter (e, 
f). Reporter activity is reported as the fold induction of reporter activity in mouse 
cortical neurons after 6 hours of depolarization with KCl relative to 0 hours of 
depolarization with KCl.  Panels a, c, and e show data for individual enhancers.  Panels b, 
d, and f represent average reporter induction for all enhancers in each enhancer class.  n 
≥ 3 for all enhancers tested. 
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Figure 2.11: Enhancers drive very similar levels of activity-dependent 
reporter expression independent of the promoter 
For each enhancer displayed in Figure 2.10, the fold induction of the SV40 reporter 
(displayed in Figure 2.10c) was plotted against the fold induction of the Nptx2 reporter 
(displayed in Figure 2.10a).  Green, blue, magenta, and black points represent enhancers 
with increasing, constant, decreasing, or no H3K27Ac ChIP-Seq signal in response to 
neuronal activity.  For greater clarity, the data is presented on a log-log scale.  ρ 
indicates Spearman’s rank correlation coefficient between reporter inductions plotted. 
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2.3.4 Neuronal activity-dependent enhancers are increasingly used 
during brain development 
While we were able to use H3K27Ac to identify neuronal activity-dependent 
enhancers in our in vitro culture system with KCl stimulation, we sought to evaluate 
whether these enhancers were also activity-dependent in vivo.  To assess the in vivo 
utilization of our neuronal activity-dependent enhancers, we integrated our datasets 
with H3K27Ac and DNaseI hypersensitivity (DHS) datasets generated by other 
laboratories from mouse brain tissues at different stages in development (Consortium, 
2011; Shen et al., 2012).  We reasoned that since activity levels within the brain increase 
over development, evaluating the H3K27Ac and DNaseI hypersensitivity (DHS) signal at 
our enhancers at different stages in development could shed light on the utilization of 
these enhancers with increasing levels of activity exhibited over development in vivo.  
We found individual examples of enhancers that exhibited increasing H3K27Ac levels in 
response to KCl stimulation that also exhibited increasing H3K27Ac levels and DHS 
signal with brain development (Figure 2.12a).  We quantified H3K27Ac levels and DHS 
signal at all activity-dependent enhancers we previously identified and found that these 
enhancers exhibited significantly more H3K27Ac (Figure 2.12b) and DHS (Figure 2.12c) 
in adult brain tissue compared to embryonic brain tissue.  This suggested that, genome-
wide, neuronal activity-dependent enhancers identified in our system are not only 
utilized in the brain in vivo, but are increasingly utilized as the brain becomes more 
active during development. 
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Figure 2.12: Activity-dependent enhancers are increasing utilized during 
brain development 
(a) Genome browser views of ChIP-Seq tracks at examples of activity-dependent 
enhancers that exhibit increasing H3K27Ac and DNAseI hypersensitivity (DHS) with 
brain development.  (b) Quantification of H3K27Ac signal at all activity-dependent 
enhancers in the genome at two stages of brain development.  (c) Quantification of DHS 
signal at all activity-dependent enhancers in the genome at two stages of brain 
development.  In (b) and (c), * indicates P < 2.2x10-16 by paired Wilcoxon signed rank 
test. 
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2.3.5 Distinct yet overlapping enhancers drive activity-dependent and 
BDNF-dependent transcriptional programs 
While the dynamic chromatin signature of stimulus-inducible H3K27Ac enabled 
us to identify the subset of neuronal enhancers that function to promote neuronal 
activity-dependent transcription, it is not clear whether this group of enhancers contains 
all stimulus-responsive enhancers in neurons or if different stimuli might induce 
distinct changes to the active enhancer landscape.  Neurons must respond to a diverse 
array of stimuli with appropriate transcriptional changes to function properly in vivo.  
However, the mechanisms by which different extracellular stimuli instruct distinct 
programs of gene expression are poorly understood. Furthermore, how cis-regulatory 
elements at stimulus responsive genes activate transcription in response to diverse 
stimuli is not clear.  For example, at genes that are upregulated in response to several 
distinct stimuli in neurons (such as c-Fos), it is not clear whether the response to all 
stimuli is driven by one multifunctional enhancer or if each stimulus activates a distinct 
enhancer element to drive transcription.  At a mechanistic level, the cis-acting DNA 
sequences that determine why some enhancers respond to stimuli and others do not are 
poorly characterized (Evans et al., 2012).  Attempts to understand these issues have 
been limited by challenges in the unbiased, genome-wide identification of the enhancers 
relevant for stimulus-responsive gene transcription.  Our discovery of a dynamic 
chromatin signature that can accurately identify neuronal activity-regulated enhancers 
genome-wide provides a potential solution to this problem. Therefore, we sought to 
utilize this signature to identify neuronal enhancers that respond to an additional 
stimulus.  This would enable a more detailed study of the general principles underlying 
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stimulus-responsive enhancer function and could help begin to decipher the specific 
mechanisms that drive transcriptional changes in response to neuronal activity. 
Brain derived neurotrophic factor (BDNF) is a particularly important 
extracellular signal for nervous system development and functional plasticity (Hong et 
al., 2008; Park and Poo, 2013).  Like neuronal activity, BDNF signaling can induce new 
gene transcription in neurons, although BDNF is thought to regulate a distinct program 
of gene expression (Gaiddon et al., 1996; Watson et al., 2001).  We utilized the dynamic 
chromatin signature of stimulus-inducible H3K27Ac to identify the set of poised and 
active enhancers that respond to BDNF stimulation.  We performed ChIP-Seq to 
measure genome-wide levels of H3K27Ac in mouse cortical neurons before and after 
stimulation with BDNF.  In response to BDNF treatment we observed dynamic changes 
in H3K27Ac across the genome (Spearman rank correlation coefficient ρ=0.39; Figure 
2.13a).  First, we selected a subset of enhancers that exhibited inducible H3K27Ac 
(n=2134) using the same criteria to what was used for the set identified for neuronal 
activity (Figure 2.13b; see methods).  The 4.4kb sequence upstream of the Nptx2 TSS 
was able to drive BDNF-dependent expression of a luciferase reporter gene in a manner 
that depended critically upon the presence of the upstream enhancer (Figure 2.14).  To 
test the ability of enhancers with increasing H3K27Ac with BDNF stimulation to 
promote neuronal BDNF-regulated transcription, we replaced the Nptx2 enhancer with 
enhancers with increasing H3K27Ac and measured BDNF-dependent induction of the 
reporter.  Similar to what was observed for neuronal activity, we found that enhancers 
with increasing H3K27Ac levels in response to BDNF stimulation were able to drive 
BDNF-dependent expression of the Nptx2 reporter (Figure 2.14), providing direct 
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evidence that many of these enhancers function to promote BDNF-dependent 
transcription.  Therefore, the dynamic chromatin signature of stimulus-inducible 
H3K27Ac was able to accurately identify BDNF responsive enhancers. 
 
 
 
Figure 2.13: H3K27Ac at neuronal enhancers before and after BDNF 
stimulation 
(a) Levels and correlation of H3K27Ac at neuronal enhancers (defined by H3K27Ac 
enrichment and DNaseI hypersensitivity) throughout the genome before BDNF 
stimulation (-BDNF) and after BDNF stimulation (+BDNF), Spearman’s rho ρ=0.39.  
(b) Classification of neuronal enhancers into subgroups with distinct H3K27Ac 
behaviors in response to BDNF stimulation.  Enhancers with increasing H3K27Ac, high 
constant H3K27Ac, decreasing H3K27Ac, or no H3K27Ac in response to BDNF 
stimulation were classified into separate groups.  Each point in both panels represents 
the input normalized H3K27Ac signal quantified within a 2kb window surrounding an 
enhancer center, with the x-axis value representing the signal before BDNF stimulation 
(-BDNF) and the y-axis value representing the signal after two hours of BDNF 
stimulation (+BDNF). 
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Figure 2.14: Functional testing of neuronal enhancers with increasing 
H3K27Ac with BDNF stimulation 
Luciferase reporter data for the Nptx2 reporter, reported as the fold induction of 
reporter activity in mouse cortical neurons after 6 hours of BDNF stimulation relative to 
0 hours.  The wild-type Nptx2 reporter is able to induce BDNF-dependent reporter 
expression (Nptx2).  However, if the Nptx2 enhancer is deleted, the reporter no longer 
induces BDNF-dependent reporter expression (Nptx2-enh).  Enhancers exhibiting 
increasing H3K27Ac in response to BDNF stimulation were cloned into the Nptx2 
reporter, replacing the Nptx2 enhancer, and tested for their ability to induce BDNF-
dependent reporter expression.  n ≥ 3 for all enhancers tested. 
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The ability to accurately identify stimulus-responsive enhancers also provides the 
novel opportunity to study the properties of BDNF enhancers and compare their 
properties with those of neuronal activity-dependent enhancers. Having identified two 
sets of stimulus-responsive enhancers in the nervous system, we next asked whether 
stimulus-responsive enhancers responded to a single stimulus or could respond to 
multiple stimuli.  We reasoned that initial insight into the question of stimulus-
responsiveness of enhancers might be obtained by examining the enhancers near genes 
that exhibit different stimulus-responsive patterns of expression. We investigated 
dynamics of H3K27Ac at enhancers near Npas4, a gene that is known to be 
preferentially induced by neuronal activity (Lin et al., 2008), Arc, which is preferentially 
induced in response to BDNF (Kawashima et al., 2009), and c-Fos, which is induced in 
response to both neuronal activity and BDNF (Bonni et al., 1995) (Figure 2.15).  We 
discovered that the enhancers near these genes had H3K27Ac dynamics consistent with 
their stimulus-responsive patterns of expression.  Several putative enhancers near the 
Npas4 gene exhibited inducible H3K27Ac only in response to neuronal activity (Figure 
2.15, left).  Similarly, a well-characterized enhancer (Kawashima et al., 2009) upstream 
of the Arc gene exhibited inducible H3K27Ac only in response to BDNF (Figure 2.15, 
center).  Interestingly, enhancers near the c-Fos gene exhibited distinct patterns of 
H3K27Ac in response to different stimuli.  Two enhancers upstream of the c-Fos TSS 
exhibited inducible H3K27Ac specifically in response to neuronal activity while one 
enhancer downstream of the TSS exhibited inducible H3K27Ac in response to both 
neuronal activity and BDNF (Figure 2.15, right).  These loci demonstrate that while 
some neuronal stimulus-responsive enhancers respond to specific stimuli, others can 
respond to multiple stimuli.  
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Figure 2.15: Differential changes in H3K27Ac with KCl and BDNF 
stimulation 
Genome browser views of H3K27Ac ChIP-Seq tracks at the Npas4 locus (left), the Arc 
locus (center), and the c-Fos locus (right).  ChIP-Seq tracks display input-normalized 
H3K27Ac ChIP-Seq reads from neurons from the indicated stimulation conditions.  Also 
displayed are DNaseI hypersensitivity signal from adult mouse cerebrum and vertebrate 
conservation by PhastCons.  Dashed boxes identify regulatory elements with different 
stimulus-responsive changes in H3K27Ac. 
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From inspection of individual genetic loci, it was clear that while some neuronal 
stimulus-responsive enhancers respond to specific stimuli, others can respond to 
multiple stimuli.  We sought to characterize neuronal enhancers throughout the genome 
that exhibited differential responses to neuronal activity and BDNF.  At a genomic level, 
a distinct yet overlapping set of DNaseI hypersensitive sites exhibited increases in 
H3K27Ac in response to neuronal activity and BDNF.  Thus, we hypothesized that by 
identifying all neuronal enhancers in the genome with different stimulus responsive 
properties, we could begin to understand the mechanisms by which enhancers respond 
to specific stimuli.  In order to accomplish this, we first identified all neuronal activity-
responsive (n=2261; Figure 2.16a), BDNF-responsive (n=1560; Figure 2.16b), or activity 
and BDNF responsive enhancers (n=404; Figure 2.16c) based on the inducibility of 
H3K27Ac at these enhancers in response to KCl, BDNF, or both.  Average profiles of 
H3K27Ac ChIP-Seq signal for each group of neuronal enhancers displayed clearly 
different H3K27Ac behaviors in response to neuronal activity and BDNF (Figure 2.16). 
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Figure 2.16: Identification of neuronal enhancers with differential 
responses to neuronal activity and BDNF stimulation 
Average profiles of H3K27Ac ChIP-Seq signal at KCl specific enhancers (a), BDNF 
specific enhancers (b), or KCl and BDNF responsive enhancers (c).  The y-axis 
represents the level of H3K27Ac signal, displayed as the mean number of input-
normalized H3K27Ac ChIP-Seq reads at each subgroup of enhancers.  H3K27Ac signal 
at enhancers was aligned by the centers DNaseI hypersensitive sites.  H3K27Ac signal at 
enhancers is displayed before KCl depolarization (dashed red line), after KCl 
depolarization (solid red line), before BDNF stimulation (dashed blue line), or after 
BDNF stimulation (solid blue line).  
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For each set of enhancers, the changes in H3K27Ac in response to each stimulus 
predicted the stimulus-specific changes in transcription, as assessed by functional 
testing of these enhancers in Nptx2 luciferase reporter assays (Figure 2.17).  This 
suggested that dynamic stimulus-dependent changes in H3K27Ac can not only 
accurately identify stimulus-responsive enhancers but can also accurately identify 
enhancers throughout the genome that respond differentially to distinct stimuli. 
 
 
Figure 2.17: Functional testing of enhancers with differential responses to 
neuronal activity and BDNF stimulation 
Neuronal enhancers with differential H3K27Ac behaviors in response to neuronal 
activity and BDNF were cloned into the Nptx2 luciferase reporter and tested for their 
ability to induce reporter expression in response to KCl, BDNF, or both (a).  (b) Average 
change in H3K27Ac for all enhancers in each stimulus-responsive enhancer class shown 
in (a).  (c) Average reporter induction for all enhancers in each stimulus-responsive 
enhancer class shown in (a). 
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Having identified neuronal enhancers that respond to either neuronal activity or 
BDNF, we asked whether these different sets of enhancers contribute to stimulus-
dependent transcriptional programs with different biological functions within the 
neuron.  We did this by assessing whether activity-responsive and BDNF responsive 
enhancers were associated with genes of distinct functional annotations by performing 
ontology analysis with the Genomic Regions Enrichment of Annotations Tool (GREAT) 
(McLean et al., 2010).  Each class of enhancers was associated with neuronal cellular 
components, biological processes, mouse phenotypes, and disease ontologies, consistent 
with specific functions of these enhancers in neurons (Table 1).  However, there was 
little overlap in the specific categories enriched from each group (Table 1), consistent 
with the differences in the physiological functions of neuronal activity and BDNF.  
Closer analysis of the enriched terms for each class of enhancers revealed possible 
differences in the biological functions of stimulus-dependent transcriptional programs 
induced by neuronal activity and BDNF (Table 1).  While activity-responsive enhancers 
were linked to genes that localize to dendritic compartments and play a role in behavior, 
BDNF-responsive enhancers were linked to genes that localize to vesicles and play a role 
in signaling.  Enriched terms also revealed distinct mouse phenotypes and human 
diseases associated with each set of enhancers.  While activity-responsive enhancers 
were linked to abnormal brain morphology and psychiatric disease, BDNF-responsive 
enhancers were linked to abnormal synapse function and cancer and neurodegenerative 
disease.  These data suggest that dynamic stimulus-dependent changes in H3K27Ac can 
not only accurately identify enhancers throughout the genome that respond 
differentially to distinct stimuli, but that these different sets of enhancers may 
contribute to different biological functions within the neuron.   
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Table 1: KCl and BDNF specific enhancers are linked to genes with distinct 
functional annotations 
KCl and BDNF specific enhancers were analyzed using the Genomic Regions 
Enrichment of Annotations Tool (GREAT).  Both KCl specific and BDNF specific 
enhancers were linked to genes with nervous system-related annotations but these 
classes of enhancers differed in the specific annotations that were most enriched within 
each ontology category.  Only the top three most significant terms are displayed for each 
ontology category. 
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2.4 DISCUSSION 
In neurons, extracellular stimuli can induce specific and temporally regulated 
changes in gene expression that correlate with the formation and functional plasticity of 
synaptic connections in developing and adult brains (Loebrich and Nedivi, 2009).  In 
order to identify and begin to understand the cis-regulatory elements that function to 
instruct the temporally and spatially circumscribed induction of activity-regulated 
transcription in neurons, we utilized genome-scale tools to map enhancer elements in 
cortical neurons.  While previous studies have begun to identify neuronal enhancers, the 
enhancers that function to promote stimulus-responsive transcription within the 
nervous system have not been specifically identified.  This is in part because no 
chromatin signature has been described for the specific identification of this subset of 
enhancers.  We demonstrate that membrane depolarization with KCl and stimulation 
with BDNF can both induce rapid changes in H3K27Ac at thousands of enhancer 
elements within the genome.  We further show that stimulus-responsive enhancers 
within the nervous system can be specifically identified on the basis of the dynamic 
chromatin signature of stimulus-inducible H3K27Ac.   We utilized this dynamic 
chromatin signature to comprehensively identify and characterize functional KCl and 
BDNF responsive enhancer elements in mouse cortical neurons.  These enhancers are 
sufficient to drive robust and stimulus-specific reporter expression in cortical neurons 
in vitro.  Furthermore, these enhancers are associated with genes with distinct 
functional annotations, suggesting that KCl and BDNF responsive enhancers play 
distinct biological functions within the neuron.  Finally, by integrating our data with 
epigenomic data from other studies, we have gained insight into the cis-regulatory logic 
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of activity-regulated transcriptional control and have identified thousands of previously 
uncharacterized neuronal enhancer elements.  
 
2.4.1 Rapid changes in H3K27Ac at neuronal enhancers 
In the nervous system, it has been proposed that long-term changes in synaptic 
function associated with learning and memory might arise in part from stable changes 
in chromatin modifications that serve as a molecular “mnemonic” devices (Day and 
Sweatt, 2011; Graff and Tsai, 2013).  Interestingly, global levels of histone acetylation 
occur in brain regions that are strongly activated during specific experimental 
behavioral paradigms (Day and Sweatt, 2011; Graff and Tsai, 2013; Peleg et al., 2010).  
Furthermore, reduction or removal of histone deacetylase activity using genetic 
methods or treatment with HDAC inhibitors has been shown to increase memory 
formation and long-term potentiation (Graff and Tsai, 2013; Guan et al., 2009).  It will 
be interesting to explore the possibility that HDAC inhibitors might influence learning 
and memory by acting to increase the magnitude or half-life of inducible acetylation at 
stimulus-responsive enhancers, which could lead to changes in the kinetics of stimulus-
regulated gene transcription, decreases in the levels of stimulation required to induce 
stimulus-regulated gene transcription, or ectopic activation of genes that are not 
activity-regulated under physiological conditions.   
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2.4.2 Heterogeneity among active neuronal enhancers 
Previous studies that have identified active enhancers within the nervous system 
have using distal enrichment of H3K27Ac.  However, these studies have treated 
neuronal enhancers as a homogeneous population.  We find that neuronal enhancers 
are quite heterogeneous, both in terms of their response to extracellular stimuli as well 
as their stimulus specificity.  Our data suggest a previously underappreciated diversity 
of cis-regulatory function among enhancers defined as “active” using H3K27Ac 
enrichment, and suggest that by profiling enhancer activity both during differentiation 
and in specific stimulus paradigms it will be possible to further classify active enhancers 
into discrete functional classes.  A recent report suggests that in macrophages, 
prolonged stimulation with an inflammatory stimulus induces the activation of “latent” 
enhancer elements, which exhibit none of the chromatin marks associated with poised 
enhancer elements (e.g. H3K4me1, nucleosome depletion) prior to exposure to 
inflammatory stimuli (Ostuni et al., 2013).  These latent enhancers were suggested to 
function to prime specific genes for increased expression following a transient stimulus, 
which the authors suggest might provide a chromatin-based mechanism for storing 
information about prior exposure to environmental stimuli.  However, when tested in 
luciferase reporter assays, only ~50% of these regions can drive stimulus responsive 
transcription, suggesting that a substantial portion of these elements are not acutely 
involved in stimulus-regulated transcription and are potentially more important for 
stimulus-induced phenotypic plasticity.  In the brain, sensory experience can induce 
long-lasting changes in neuronal morphology, synapse number and plasticity, and 
survival, but the potential for this limited plasticity is balanced by the need to tightly 
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and stably regulate neuronal fate for the entire lifespan of the organism (Dulac, 2010).  
Further studies will be required to unravel the connection between synaptic activity and 
the active enhancer repertoire during brain development and function in vivo to 
determine whether neurons also utilize stimulus-responsive “latent” enhancers.  It will 
be similarly interesting to investigate whether any observed differences in stimulus-
responsive enhancer “latency” represents a physiologically relevant difference between 
the function of stimulus responsive transcription in macrophages and neurons.  
 
2.4.3 Novel tools to study the role of activity-regulated gene 
transcription in nervous system development and plasticity 
The induction of stimulus-regulated transcription occurs specifically in neurons 
that are highly active during a defined behavior (Alberini, 2009; Lyons and West, 2011).  
The induction of immediate early genes such as c-Fos, FosB, JunB, Nur77, Zif268 and 
Npas4 in vivo has been used as a tool to specifically mark the neurons involved in the 
circuitry governing a defined behavior.  The ability of enhancers to integrate various 
transcription factor inputs and signal responsive cues can also be repurposed to develop 
tools to drive reporter gene expression or Cre recombinase in specific cell populations in 
vivo, providing genetic access to specific neuronal circuits.  Similarly, in order to 
rigorously study the function of stimulus regulated genes it will be necessary to remove 
the enhancer(s) that specifically control a gene’s induction in order to disentangle the 
stimulus-dependent and stimulus-independent effects on synaptic function of these 
often pleiotropic factors (e.g. BDNF, see Hong et al., 2008).  Historically it has been 
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difficult to separate the activity-regulated function of many genes from their functions 
in neural development, so the ability to functionally separate these features will become 
critical for future studies to determine the contribution of specific activity-regulated 
genes to learning and memory in vivo.  Given recent efforts to establish in vitro stem 
cell models of neurological disorders that affect synaptic plasticity and function in vivo, 
activity-responsive enhancers could provide useful tools for the characterization of the 
in vitro maturation of various types of neurons derived from embryonic stem cell 
differentiation protocols (Dolmetsch and Geschwind, 2011; Ming et al., 2011). 
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2.5 MATERIALS AND METHODS 
2.5.1 Mouse cortical cultures 
Embryonic day 16.5 (E16.5) C57BL/6 embryonic mouse cortices were dissected 
and then dissociated for 10 minutes in 1× Hank’s Balanced Salt Solution (HBSS) 
containing 20 mg/mL trypsin (Worthington Biochemicals) and 0.32 mg/mL L-cysteine 
(Sigma).  Trypsin treatment was terminated by washing dissociated cells three times for 
two minutes each in dissociation medium consisting of 1× HBSS containing 10 
mg/mL trypsin inhibitor (Sigma).  Cells were then triturated using a flame-narrowed 
Pasteur pipette to fully dissociate cells.  After dissociation, neurons in were kept on ice 
in dissociation medium until plating.  Cell culture plates were pre-coated overnight with 
a solution containing 20 ug/mL poly-D-lysine (Sigma) and 4 ug/mL mouse laminin 
(Invitrogen) in water.  Prior to plating neurons, cell culture plates were washed three 
times with sterile distilled water and washed once with Neurobasal Medium (Life 
Technologies).  Neurons were grown in neuronal medium consisting of Neurobasal 
Medium containing B27 supplement (2%; Invitrogen), penicillin-streptomycin (50 g/ml 
penicillin, 50 U/mL streptomycin, Sigma) and glutamine (1 mM, Sigma).  At the time of 
plating, cold neuronal medium was added to neurons in dissociation medium to dilute 
neurons to the desired concentration.  Neurons were subsequently plated and placed in 
a cell culture incubator that maintained a temperature of 37 degrees C and a CO2 
concentration of 5%.  Two hours after plating neurons, medium was completely 
aspirated from cells and replaced with fresh warm neuronal medium.  Neurons were 
grown in vitro until the seventh day in vitro (DIV7). 
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2.5.1.1 Mouse cortical cultures for ChIP-Seq experiments 
For ChIP-Seq experiments, mouse cortical neurons were plated at an 
approximate density of 4×107 on 15-cm dishes. Neurons were plated in 30mL neuronal 
medium.  Ten mL of the medium was replaced with 12ml fresh warm medium on DIV3 
and DIV6. 
2.5.1.2 Mouse cortical cultures for luciferase reporter assays 
For luciferase reporter assays, mouse cortical neurons were plated at an 
approximate density of 3×105 per well on 24-well plates. Neurons were plated in 500 uL 
neuronal medium.  On the DIV3, 100 uL fresh warm medium was added to neurons.  On 
DIV5 neurons were transfected (see section on transfection).  At the completion of 
transfection, conditioned medium containing 15% fresh medium was returned to 
neurons. 
 
2.5.2 Stimulation with potassium chloride (KCl) 
Prior to KCl depolarization, neurons were quieted with 1  µM tetrodotoxin (TTX, 
Fisher) and 100  µM DL-2-amino-5-phosphopentanoic acid (DL-AP5, Fisher).  Neurons 
were subsequently stimulated by adding warmed KCl depolarization buffer (170 mM 
KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES) directly to the neuronal culture, to final 
concentration of 31% in the neuronal culture medium within the culture plate or well. 
  
  66 
2.5.2.1 KCl stimulation for ChIP-Seq experiments 
For KCl depolarization of neurons for ChIP-Seq experiments, DIV 6 neurons 
were quieted overnight with 1  µM TTX and 100  µM DL-AP5.  The next morning, neurons 
were left silenced (-KCl condition) or stimulated for 2  hours with KCl (+KCl condition). 
2.5.2.2 KCl stimulation for luciferase reporter assays 
For KCl depolarization of neurons for luciferase reporter assays, DIV 7 neurons 
were quieted for two hours with 1  µM TTX and 100  µM DL-AP5.  Two hours later, 
neurons were left silenced (-KCl condition) or stimulated for 6  hours with KCl (+KCl 
condition). 
 
2.5.3 Stimulation with brain derived neurotrophic factor (BDNF) 
2.5.3.1 BDNF stimulation for ChIP-Seq experiments 
For BDNF stimulation of neurons for ChIP-Seq experiments, the volume of 
conditioned medium on DIV6 neurons was reduced to 25 mL.  On DIV7, neurons were 
left in a basal condition (-BDNF condition) or stimulated for 2  hours with 50ng/mL 
recombinant human BDNF (Fisher) (+BDNF condition). 
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2.5.3.2 BDNF stimulation for luciferase reporter assays 
For BDNF stimulation of neurons for luciferase reporter assays, DIV7 neurons 
were left in a basal condition (-BDNF condition) or stimulated for 6  hours with 
50ng/mL recombinant human BDNF (Fisher) (+BDNF condition). 
 
2.5.4 H3K27Ac Chromatin immunoprecipitation sequencing (ChIP-Seq) 
Forty million mouse cortical neurons cultured to in vitro day 7 were used for each 
ChIP-Seq library construction.  Typically 20-40 million cortical neurons were used for a 
single ChIP experiment.  To cross-link protein-DNA complexes, media was removed 
from neuronal cultures and crosslinking-buffer (0.1 M NaCl, 1 mM EDTA, 0.5 mM 
EGTA, 25 mM HEPES-KOH, pH 8.0) containing 1% formaldehyde was added for 10 
minutes at room temperature.  Cross-linking was quenched by adding 125 mM glycine 
for five minutes at RT. Cells were then rinsed three times in ice-cold PBS containing 
complete protease inhibitor cocktail tablets (Roche) and collected by scraping.  Cells 
were pelleted and either stored at -80 degrees C until use or immediately processed.  
Cell pellets were lysed by 20 cell pellet volumes (CPVs) of buffer 1 (50 mM HEPES-KOH, 
pH 7.5, 140 mM NaCl, 1 mM EDTA, pH 8.0, 10 % Glycerol, 0.5 % NP-40, 0.25 % Triton 
X-100, complete protease inhibitor cocktail) for 10 min at 4 degrees C.  Nuclei were then 
pelleted by centrifugation at 3000 rpm for 10 min at 4 degrees C.  The isolated nuclei 
were rinsed with 20 CPVs of buffer 2 (200 mM NaCl, 1 mM EDTA, pH 8.0, 0.5 mM 
EGTA, pH 8.0, 10 mM Tris-HCl, pH 8.0, complete protease inhibitor cocktail) for 10 
min at RT and re-pelleted.  Next, 4 CPVs of buffer 3 (1 mM EDTA, pH 8.0, 0.5 mM 
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EGTA, pH 8.0, 10 mM Tris-HCl, pH 8.0, complete protease inhibitor cocktail) were 
added to the nuclei and sonication was carried out using a Misonix 3000 Sonicator 
(Misonix) set at a power setting of 7.5 (equivalent to 24 watts).  20 pulses of 15 seconds 
each were delivered at this setting, which resulted in genomic DNA fragments with sizes 
ranging from 200 bp to 2 kb. Insoluble materials were removed by centrifugation at 
20,000 rpm for 10 min at 4 degrees C. The supernatant was transferred to a new tube 
and the final volume of the resulting nuclear lysate was adjusted to 1 mL by adding 
buffer 3 supplemented with 0.3 M NaCl, 1 % Triton X-100, 0.1 % Deoxycholate.  The 
lysate was pre-cleared by adding 100 uL of pre-rinsed Protein A/G Agarose (Sigma) per 
1 ml of the lysate and incubating for 1 hour at 4 degrees C.  After pre-clearing, ten 
percent of the ChIP sample (50 uL from 500 uL lysate) was saved as input material.  The 
remaining lysate was incubated with 0.5 ug H3K27Ac antibody ab4729 (Abcam) for 
immunoprecipitation.  The antibody incubation was carried out overnight at 4 degrees C.  
The next day, 30 uL of pre-rinsed Protein A/G PLUS Agarose beads (Santa Cruz 
Biotechnology) was added to each ChIP reaction and further incubated for 1 hour at 4 
degrees C. The beads bound by immune-complexes were pelleted and washed twice with 
each of the following buffers: low salt buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 
20mM Tris-HCl, pH 8.1, 150mM NaCl), high salt buffer (0.1% SDS, 1% Triton X-100, 
2mM EDTA, 20mM Tris-HCl, pH 8.1, 500mM NaCl) and LiCl buffer (0.25M LiCl, 1% 
IGEPAL CA630, 1% deoxycholic acid (sodium salt), 1mM EDTA, 10mM Tris, pH 8.1).  In 
each wash, the beads were incubated with wash buffer for 10 min at 4 degrees C while 
nutating.  The washed beads were then rinsed once with 1x TE buffer (10 mM Tris-HCl, 
pH 8.0, 1 mM EDTA).  The immunoprecipitated material was eluted from the beads 
twice by adding 100 uL of elution buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, pH 8.0, 
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1 % SDS) to each ChIP reaction and incubating the sample at 65 degree C for 30 min 
with brief vortexing every 2 min.  150 uL of elution buffer was also added to the saved 
input material (50 uL) and this sample was processed together with the ChIP samples.  
The eluates were combined and crosslinking was reversed by incubation at 65 degrees C 
overnight.  The next day, 7 ug RNase A (affinity purified, 1mg/mL; Invitrogen) was 
added to each sample and samples were incubated for 37 degrees C for one hour.  Then, 
7 uL Proteinase K (RNA grade, 20mg/mL; Invitrogen) was added to each sample and 
samples were incubated at 55 degrees C for two hours.  The immunoprecipitated 
genomic DNA fragments were then extracted once with Phenol:Chloroform:Isoamyl 
Alcohol (25:24:1, pH 7.9; Life Technologies) and then back extracted with water.  The 
resulting genomic DNA fragments were then purified using the QIAquick PCR 
purification kit (Qiagen) and DNA fragments were eluted in 100 ul of Buffer EB (elution 
buffer consisting of 10 mM Tris-HCl, pH 8.5, Qiagen).  Samples were assessed for 
enrichment by quantitative PCR using primers to different genomic regions.  Samples 
with significant enrichment over negative regions were submitted to the Beijing 
Genomic Institute (BGI) for 50 base pair single end sequencing on the Illumina Hiseq 
2000 platform.  For each sample, over 20 million clean reads were obtained. 
 
2.5.5 ChIP-Seq analysis 
2.5.5.1 Initial processing 
Sequencing data was obtained from BGI in gzipped fastq file format.  Files were 
transferred and unzipped.  Then, sequencing reads were aligned to the July 2007 
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assembly of the mouse genome (NCBI 37, mm9) using the Burrows-Wheeler Aligner 
(BWA) (Li and Durbin, 2009) with default settings.  The resulting bwa files were then 
converted to sam files and uniquely mapped reads were extracted from the sam files.  
Sam files of the uniquely mapped reads were then converted to bam files.  Bam files 
were then used for peak calling using Model-based Analysis of ChIP-Seq (MACS) (Zhang 
et al., 2008) with the following parameters: -f BAM -g mm --nomodel --shiftsize=150. 
2.5.5.2 Visualizing ChIP-Seq data on the UCSC genome browser 
ChIP-Seq bam files were converted to bigwig track format to display the number 
of input normalized ChIP-Seq reads, normalized to 20 million total reads. 
2.5.5.3 Identifying enhancers by integrating DNaseI hypersensitivity data with 
H3K27Ac ChIP-Seq data 
DNaseI hypersensitivity (DHS) identified by using ENCODE consortium DHS 
peaks data from embryonic day 14.5 whole brain, embryonic day 18.5 whole brain, and 
adult 8 week cerebrum was assessed for overlap with H3K27Ac peaks.  First, the 
genomic ranges of DHS peaks from adult 8week cerebrum in all three bioreplicates were 
concatenated and merged.  Then, merged ranges that overlapped with peaks in three out 
of three DHS bioreplicates were computed (8wk_merged_overlappingwithB1B2B3).  
Similarly, merged ranges that overlapped with two out of two bioreplicates from 
embryonic day 18.5 (e18.5_merged_overlappingwithB1B2) and merged ranges that 
overlapped with two out of two bioreplicates from embryonic day 14.5 
(e14.5_merged_overlappingwithB1B2) were obtained.  Then DHS peaks overlapping 
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with H3K27Ac were obtained through iterations of assessing overlap between the 
datasets.  First, the DHS peaks in 8wk_merged_overlappingwithB1B2B3 that 
overlapped with H3K27Ac peaks (in the –KCl, +KCl, -BDNF, or +BDNF conditions) 
were isolated.  Then, the DHS peaks in e18.5_merged_overlappingwithB1B2 that 
overlapped with the remaining H3K27Ac peaks were isolated.  Then, the DHS peaks in 
e14.5_merged_overlappingwithB1B2 that overlapped with the remaining H3K27Ac 
peaks were isolated.  Then, the DHS peaks in the first bioreplicate from 8-week 
cerebrum that overlapped with the remaining H3K27Ac peaks were isolated.  Then, the 
DHS peaks in the second bioreplicate from 8-week cerebrum that overlapped with the 
remaining H3K27Ac peaks were isolated.  Then, the DHS peaks in the third bioreplicate 
from 8-week cerebrum that overlapped with the remaining H3K27Ac peaks were 
isolated.  Then, the DHS peaks in the first bioreplicate from e18.5 whole brain that 
overlapped with the remaining H3K27Ac peaks were isolated.  Then, the DHS peaks in 
the second bioreplicate from e18.5 whole brain that overlapped with the remaining 
H3K27Ac peaks were isolated.  Then, the DHS peaks in the first bioreplicate from e14.5 
whole brain that overlapped with the remaining H3K27Ac peaks were isolated.  Then, 
the DHS peaks in the second bioreplicate from e14.5 whole brain that overlapped with 
the remaining H3K27Ac peaks were isolated.  Then, CBP peaks previously identified in 
our system (Kim et al., 2010) that overlapped with the remaining H3K27Ac peaks were 
isolated.  This iterative procedure was used rather than simply assessing overlap 
between H3K27Ac signal and either the union or intersection of all DHS data to increase 
accuracy of calling overlaps and to reduce the multiplicity of DHS peaks associated with 
H3K27Ac peaks.  In the end, 98.6% of H3K27Ac peaks were found to overlap with DHS 
peaks, with an average of 1.39 DHS peaks per H3K27Ac peak.  Each DHS peak that 
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overlapped with H3K27Ac and existed greater than 1kb from an annotated RefSeq TSS 
was taken to be an enhancer for subsequent analyses. 
2.5.5.4 Characterization of genomic distribution of enhancers 
H3K27Ac peaks were classified based on their location relative to genes in the 
NCBI Reference Sequence Database (RefSeq).  H3K27Ac peaks were classified as being 
proximal if they were within 1kb of an annotated transcriptional start site (TSS).  
H3K27Ac peaks were classified as being distal if they were greater than 1kb from an 
annotated transcriptional start site (TSS).  Distal H3K27Ac peaks were further classified 
as intragenic if they occurred within a RefSeq gene, or as extragenic if they did not 
occurred within a RefSeq gene. 
2.5.5.5 Quantification of ChIP-Seq signal at enhancers 
For chromatin modifications (H3K4Me1, H3K27Ac), the number of input-
normalized ChIP-Seq reads within a two kb window centered on each enhancer was 
taken to be the ChIP-Seq signal at the enhancer.  For transcription factors (CBP), the 
number of input-normalized ChIP-Seq reads within an 800 bp window centered on each 
enhancer was taken to be the ChIP-Seq signal at the enhancer. 
2.5.5.6 Classification of enhancers with distinct H3K27Ac behaviors 
Enhancers were classified into different categories based on the behavior of the 
quantified H3K27Ac signal at each enhancer.  Enhancers were classified as having 
increasing H3K27Ac if they exhibited a two fold or greater increase in H3K27Ac signal 
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with stimulation and if the stimulated signal for H3K27Ac was not within the bottom 
quartile of H3K27Ac signal at all enhancers identified in the stimulated condition.  
Enhancers were classified as having decreasing H3K27Ac if they exhibited a two fold or 
greater decrease in H3K27Ac signal with stimulation and if the unstimulated signal for 
H3K27Ac was not within the bottom quartile of H3K27Ac signal at all enhancers 
identified in the unstimulated condition.  Enhancers were classified as having constant 
H3K27Ac if they exhibited H3K27Ac signal in the top quartile of all enhancers identified 
in both the unstimulated and stimulated conditions and if the H3K27Ac signal changed 
by 10% or less with stimulation.  Enhancers were classified as having no H3K27Ac if 
they were identified previously on the basis of inducible CBP binding and enrichment 
for H3K4Me1 (Kim et al., 2010) but did not overlap with H3K27Ac peaks within the 
H3K27Ac datasets generated in this study. 
 
2.5.6 RNA-Seq analysis 
RNA-Seq data from a previous study (Kim et al., 2010) was analyzed and 
integrated into this study.  For nearest gene analyses, the nearest gene (with nonzero 
expression) to an enhancer was linked to that enhancer and the expression of the genes 
nearest to each class of enhancers was characterized.  For eRNA analysis, the number of 
RNA-Seq reads within a four kb window centered on each extragenic enhancer was 
taken to be the eRNA signal at the enhancer. 
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2.5.7 Luciferase reporter assays 
2.5.7.1 Nptx2 reporter plasmid design 
All luciferase reporter plasmids used were newly developed for this study.  Most 
luciferase reporter plasmids used were based on the Nptx2 gene, and hence this reporter 
was termed the Nptx2 reporter.  To develop the Nptx2 reporter, we cloned the 4355 bp 
region upstream of the Nptx2 coding sequence from C57BL/6 purified mouse genomic 
DNA between the NheI and EcoRV restriction sites within the multiple cloning site of 
the promoterless pGL4.11 reporter plasmid (Promega) using the primers shown in Table 
2, with 5’ clamp shown in red, NheI and EcoRV sites shown in green. 
 
Table 2: Primers used to clone the Nptx2 upstream regulatory region into 
pGL4.11 
Primer Sequence (5’ à  3’) 
Forward primer 5’ GCGCGCTAGCTTCCTGGCTTGTAGTGACCT 3’ 
Reverse primer 5’ GCGCGATATCCTCGCTGACCTGTGTGCTCACTTCA 3’ 
 
pGL4.11 was chosen as the host plasmid since it contained the luc2P reporter gene, 
which contains an hPEST protein destabilization sequence.  We found that the luc2P 
reporter responded more quickly and with greater magnitude to stimuli than luc2 
reporters.  Using PCR driven overlap extension (Heckman and Pease, 2007), the Nptx2 
reporter was then modified so that the 1216 bp Nptx2 upstream enhancer (located -3607 
to -2391 relative to the start of the Nptx2 coding sequence) was replaced with a multiple 
cloning site containing SbfI, PacI, PmeI, and AscI restrictions sites.  In order to do this, 
the primers shown in Table 3 were used (A, B, C, D nomenclature same as described in 
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(Heckman and Pease, 2007)), with 5’ clamp shown in red; NheI and EcoRV sites shown 
in green; SbfI, PacI, PmeI, and AscI sites shown in blue; and spacers shown in orange. 
 
Table 3: Primers used to replace the Nptx2 upstream enhancer with a 
multiple cloning site 
 
Primer Sequence (5’ à  3’) 
A 5’ GCGCGCTAGCTTCCTGGCTTGTAGTGACCT 3’ 
B 5’ GGCGCGCCACACGTTTAAACGCGCTTAATTAAGTGTCCTGCAGGTTGTGTGAGACACTGTTTCCA 3’ 
C 5’ CCTGCAGGACACTTAATTAAGCGCGTTTAAACGTGTGGCGCGCCAGCTAGTAACAGTTGGCATT 3’ 
D 5’ GCGCGATATCCTCGCTGACCTGTGTGCTCACTTCA 3’ 
 
 
 The multiple cloning site was inserted into the Nptx2 upstream regulatory region 
to create a modified Nptx2 reporter so that various enhancers could be easily cloned into 
this multiple cloning site.  We verified that the modified Nptx2 reporter in which the 
Nptx2 enhancer had been cloned into the multiple cloning site had the same inducibility 
as the wild-type Nptx2 reporter (data not shown).  This suggested that the multiple 
cloning site did not affect the function of the reporter and that other enhancers could be 
similarly cloned into this multiple cloning site without adverse affects on enhancer 
function. 
2.5.7.2 Alternate reporter plasmid design 
We generated 2 additional reporter constructs by modifying pGL4.24 (Promega), 
a luciferase reporter containing a minimal TATA box containing promoter but not 
containing any enhancer elements.  To facilitate cloning of enhancers from the Nptx2 
reporter plasmid into this plasmid, we first modified this plasmid by adding a multiple 
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cloning site containing SbfI, PacI, PmeI, and AscI sites between BamHI and SalI sites 
downstream of the firefly luciferase gene (pGL4.24_minP_MCS).  This multiple cloning 
site was added by annealing together two oligonucleotides containing the multiple 
cloning site as well as overhanging BamHI and SalI restriction sites, and then ligating 
this annealed product into pGL4.24 backbone that had been cut with BamHI and SalI.  
The sequences of the oligonucleotides are shown in Table 4, with BamHI and SalI sites 
shown in green and SbfI, PacI, PmeI, and AscI sites shown in blue. 
Table 4: Primers used to introduce a multiple cloning site into pGL4.24 
Primer Sequence (5’ à  3’) 
F 5’ GATCCGACACCTGCAGGACACTTAATTAAGCGCGTTTAAACGTGTGGCGCGCCATCGG 3’ 
R 5’ TCGACCGATGGCGCGCCACACGTTTAAACGCGCTTAATTAAGTGTCCTGCAGGTGTCG 3’ 
 
We then further modified pGL4.24_minP_MCS by removing the minimal TATA 
box containing promoter from this plasmid and replacing this promoter with an SV40 
promoter from another Promega luciferase reporter, the pGL3-Promoter Vector.  This 
cloning was achieved by using BglII and NcoI restriction sites flanking both promoter 
regions.  This resulted in the generation of a separate reporter construct, 
pGL4.24_SV40_MCS, with which enhancer activity could be assessed. 
2.5.7.3 Enhancer sequences 
Enhancer with different H3K27Ac behaviors were cloned between the SbfI and 
AscI sites within the multiple cloning site of the modified Nptx2 reporter.  Cloned 
enhancer regions varied in size but were approximately 1kb in length.  The following 
enhancers were cloned in this way using the primers listed in Table 5, with 5’ clamp 
shown in red and SbfI and AscI sites shown in blue.  
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Table 5: Primers to clone neuronal enhancers with different H3K27Ac 
behaviors 
Note that enhancers e31, e32, e37, e39, all cloned initially because they displayed 
increasing H3K27Ac in response to KCl, also displayed increasing H3K27Ac in response 
to BDNF.  As a result, these enhancers were subsequently used in BDNF experiments in 
Figure 2.14 and Figure 2.17. 
 
Enhancer 
category 
Name Forward primer (5’ à  3’) Reverse primer (5’ à  3’) 
No 
H3K27Ac 
(with KCl 
stimulation) 
e1 GCGTCCTGCAGGTAAACAGTTCTAGTTCTGGG GTATGGCGCGCCAATGAGCTTCTGTGAAGGAA 
e2 GCGCCCTGCAGGTGTTATTGTCCAATGCGTAG GTATGGCGCGCCCATGGTGCCCACACTCATGT 
e3 GCGTCCTGCAGGCTGCTCAGTAAGAGATATCA GTATGGCGCGCCTAGATCCCAGGTAGATACTCA 
e4 GCGTCCTGCAGGCAGAATGGAGCAAACTGGGT GTATGGCGCGCCGACTTGGTGAAGATGAGGGT 
e5 GCGTCCTGCAGGGTGTGAGTAAGTGTGAGTGC GTATGGCGCGCCGACCTGGAGTGCTTAATCTG 
e6 GCGTCCTGCAGGAGCAGCCAGTAGAAGACTCT GTATGGCGCGCCCCTAGTCTTGAAGAGGGTCA 
e7 GCGTCCTGCAGGAGATACTAGGAACAGGGAGG GTATGGCGCGCCAGTCTCTACTGGCTGTGTCT 
e8 GCGTCCTGCAGGGAGCTTGGAGGGTAGATACA GTATGGCGCGCCGGTGGTGGTACCACAAATAG 
e9 GCGTCCTGCAGGTCCTATGGCAAGTGCCTAGA GCATGGCGCGCCCCAGTCATTGAACATTCTCC 
e10 GCGTCCTGCAGGTGATTTGGTTCCTAGAGCCC GTATGGCGCGCCTTACTGCAGAGCTCAGATGC 
Constant 
H3K27Ac 
(with KCl 
stimulation) 
e11 GCGTCCTGCAGGCATATGTGTGCACGCACATG GTATGGCGCGCCCCAAACTTTTCTGCTTTCAC 
e12 GCGTCCTGCAGGAGGCGACAGAACGATATTAA GTATGGCGCGCCTTATCCTTCAAGCAAGTCTG 
e13 GCGTCCTGCAGGGAGTGGCTTCCATCCCATTT GCATGGCGCGCCGGGATGATCCTGTTAGATAG 
e14 GCGTCCTGCAGGAAGTCAGGCACCAAGTTCTG GTATGGCGCGCCCAGTGACCGTTAGCAGCTAA 
e15 GCGTCCTGCAGGTCAGTGAAAGGTGCTAGCTG GTATGGCGCGCCCACTGAGTAAGACAGAGGTG 
e16 GCGTCCTGCAGGGTGACTATAGAGAGTTGCCC GTATGGCGCGCCTTAGCTTCGTGACACTGCCA 
e17 GCGTCCTGCAGGAGCTTGGAGGAATGTCAGCT GTATGGCGCGCCGAAGGAGTGGCTTAGACACT 
e18 GCGTCCTGCAGGTGGTTAGCCTCAGCGACATA GTATGGCGCGCCCCATCTGCTAGGAAGTCTCA 
Decreasing 
H3K27Ac 
(with KCl 
stimulation) 
e19 GCGTCCTGCAGGTAGTGAGCCTGTAGCTGAAA GTATGGCGCGCCAGAGCAAAGGCATGTTTACT 
e20 GCGTCCTGCAGGGACTGTAGGGAAGGAATTGC GTATGGCGCGCCGCAATTGTGCCGAATACCTG 
e21 GCGTCCTGCAGGTTACGCAACCCATCCGTCAA GTATGGCGCGCCCATTAGGAGCTAGAGACAGC 
e22 GCGTCCTGCAGGTCCTAGCCAACCACTCTCAA GTATGGCGCGCCTTGACATCCAGACTGACCTG 
e23 GCGTCCTGCAGGCATACGATTAATGCTCTCCAG GTATGGCGCGCCCCAGCTTTGCAAAGAGTTGC 
e24 GCGTCCTGCAGGGACGTTTGGATAGCATGCCA GTATGGCGCGCCCCATTTCACAGATCCTCACC 
e25 GCGTCCTGCAGGCTCAATGCAAAGGGCAGTGT GTATGGCGCGCCTGGCACTGGGTAATGAACCA 
e26 GCGTCCTGCAGGGCCACTGAAATAACACAGCC GTATGGCGCGCCATCATGGGAACAGCAACCAG 
e27 GCGTCCTGCAGGCAAATACACGGCATGCTCCA GTATGGCGCGCCGCGTGTGTGTAATGAGAGAG 
e28 GCGTCCTGCAGGGACTCAACATACAGCCAAAGC GTATGGCGCGCCGTCTCAGGACAACCTGATTG 
Increasing 
H3K27Ac 
(with KCl 
stimulation) 
e29 GCGTCCTGCAGGAACTTTGATTTCGGAACCCT GTATGGCGCGCCCACCGAATTCTTTCCTTCTT 
e30 GCGTCCTGCAGGAATTCAGGCCCTAAGTCACC GTATGGCGCGCCTAAAGTAAGAGCTAGGGAGA 
e31 GCGTCCTGCAGGCATCTGTCATCTCTTGAAAG GTATGGCGCGCCAATGTGCCATTGTGGTACTT 
e32 GCGACCTGCAGGATCTTCTGATCATTGGCCTT GTATGGCGCGCCTTGGAGCCAATTAGGAAGAA 
e33 GCGTCCTGCAGGAATAGCAGTTAGGTGCCCAA GTATGGCGCGCCCTCCTGAGATACATCTGCCA 
e34 GCGTCCTGCAGGTCACAGGCAGTAGACAAGGG GTATGGCGCGCCCCTCCATCTGAAGAGGTTCC 
e35 GCGTCCTGCAGGGAAAGCTGAGCACTTTGGCA GTATGGCGCGCCCCATATGTCAGATTGCTGCC 
e36 GCGTCCTGCAGGCCATCCTCATTTCTCTCTCC GTATGGCGCGCCATTCCCAGCAATGTGAGGGA 
e37 GCGTCCTGCAGGTTGTTCTGTGTGACAACGGG GTATGGCGCGCCTGGCACCAGATCTGCACTAA 
e38 GCGTCCTGCAGGAAAGGCATAATAGGGGTGGG GTATGGCGCGCCGGTCCTGTAAGGAACCTTGT 
e39 GCGTCCTGCAGGAGCAAGTAGAGACGGGAAAG GTATGGCGCGCCCCTGACTTGTGGTTGTTACC 
e40 GCGTCCTGCAGGCATGCATGTGGGAAGACTTG GTATGGCGCGCCGATGACATTCAAGTCCGTGG 
e41 GCGTCCTGCAGGTTCTGAAGTTTGCTGCCACC GTATGGCGCGCCCTACCTCATCATCCTCTCAG 
e42 GCGTCCTGCAGGTTGGTAGACCAGGGACTTCT GCATGGCGCGCCGTAACTAGGGAAAGTGCTTC 
Increasing 
H3K27Ac 
(with BDNF 
stimulation) 
e43 GCGTCCTGCAGGACATACAGAAGCCAGGAGAG GTATGGCGCGCCAGCAGGTCAAGGCCTTGTGT 
e44 GCGTCCTGCAGGGCAGAGTTACGAACCAGGAA GTATGGCGCGCCAACCAGAGCTCTAGGGTACA 
e45 GCGTCCTGCAGGTGACATCAGAGCTGATGTGG GTATGGCGCGCCCTGACTTGGGTAGGCATGTT 
e46 GCGTCCTGCAGGGACCAAGCCTCATGAACTCA GTATGGCGCGCCTCTAGTCTCCTCATCACTGG 
e47 GCGTCCTGCAGGCAGTTACCAACTTGATGGGG GTATGGCGCGCCTTGTCCAAAGCAGGATGAGC 
e48 GCGTCCTGCAGGTTACAGCCAGGAGTCTCCAA GTATGGCGCGCCTAAAAGGAGAGGGATGGCTG 
e49 GCGTCCTGCAGGGCACAGCAGGTAGACTCATA GTATGGCGCGCCCAAGGCTCTGCCCTAAAGAA 
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2.5.7.4 Transfection 
Mouse cortical neurons plated on 24 well plates at a density of approximately 
3x105 neurons per well were transfected for luciferase reporter assays using 
Lipofectamine 2000 Reagent (Invitrogen), generally according to the manufacter’s 
protocol.  Briefly, DNA mixes were made immediately preceding the transfection 
consisting of 1ug total plasmid DNA/well diluted in Neurobasal medium (Life 
Technologies).  DNA typically consisted of 450ng firefly luciferase reporter DNA, 50ng 
pGL4.74 renilla luciferase reporter DNA (Promega), and 500ng empty pCS2 plasmid 
(Rupp et al., 1994; Turner and Weintraub, 1994) as filler DNA.  Lipofectamine was used 
at 2uL/well and was diluted in Neurobasal medium just before the transfection.  Within 
each experiment, all conditions were transfected in two to three independent wells, for 
technical duplicates or triplicates.  Thirty minutes prior to the addition of Lipofectamine 
to neurons, the culture medium was removed and replaced with warmed Neurobasal 
medium.  At this time, neurons were returned to the incubator and DNA mixes were 
added to diluted Lipofectamine in a drop-wise manner.  After thirty minutes of 
incubation, DNA-Lipofectamine mixes were added to neurons, again in a drop-wise 
manner.  The cells were left to incubate with the DNA-Lipofectamine mix for two hours, 
after which the transfection medium was replaced with supplemented conditioned 
neuronal medium. 
2.5.7.5 Sample collection and luciferase assay 
After stimulation, neurons were lysed using Passive Lysis Buffer (Dual-Luciferase 
Reporter Assay System, Promega).  Lysates were then collected in microcentrifuge tubes 
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and frozen at -20 degrees C.  At the time of performing the luciferase assay, neuronal  
lysates were thawed, briefly vortexed, briefly spun down, and then 20uL of each sample 
was added to one well of Costar White Polystyrene 96-well Assay Plates (Corning).  The 
reagents to run the luciferase assay, Luciferase Assay Reagent II (LARII) and Stop & Glo 
Reagent (Dual-Luciferase Reporter Assay System, Promega), were aliquoted and thawed 
according to the manufacturer’s protocol.  The luciferase assay was performed using the 
Synergy 4 Hybrid Microplate Reader (BioTek), with 100uL of LARII and Stop & Glo 
Reagent injected per well.  Data was subsequently downloaded and analyzed using 
Microsoft Excel. 
2.5.7.6 Statistical Analyses of Luciferase Assay Data 
Using the Dual-Luciferase Reporter Assay System, we recorded Firefly (FF) and 
Renilla (Ren) luminescence from each well.  To correct for variations in transfection 
efficiency and cell lysate generation, the Firefly values were normalized to Renilla 
luminescence within each well, generating a ratio of FF/Ren.  The stimulus-dependent 
fold induction of each reporter plasmid was obtained by dividing the (+ stimulus) 
FF/Ren value by the (- stimulus) value.  To isolate the induction due to the enhancer, 
the fold induction of an enhancer reporter was divided by the fold induction of the 
appropriate backbone into which the enhancer was cloned, giving fold induction relative 
to backbone.  Fold induction relative to backbone is the value shown in all figures 
containing luciferase reporter data.  All error bars shown are standard error of biological 
replicates. 
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2.5.8 GREAT analysis 
Functional annotations of genes linked to stimulus-responsive enhancers was 
investigated with the Genomic Regions Enrichment of Annotations Tool (GREAT) 
(McLean et al., 2010).  For the analysis, the following settings were used: species 
assembly: Mouse: NCBI build 37 (UCSC mm9, Jul/2007); test regions: BED file 
containing genomic locations of stimulus inducible enhancers; background regions: 
whole genome; association rule setting: basal plus extension including 20 kb upstream, 
20 kb downstream, plus distal up to 250 kb, and including curated regulatory domains.  
Ontology categories investigated include cellular components, biological processes, 
mouse phenotypes, and disease ontologies. 
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3 TRANSCRIPTIONAL MECHANISMS UNDERLYING STIMULUS-
RESPONSIVE ENHANCERS IN THE NERVOUS SYSTEM 
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3.1 SUMMARY 
Normal brain development and function require stimulus-responsive programs 
of gene expression, but how neuronal stimuli interface with stimulus-responsive 
enhancers to regulate gene expression is poorly understood.  We have recently shown 
that functional stimulus-responsive enhancers can be identified by stimulus-inducible 
H3K27Ac, and we used this dynamic chromatin signature to discover enhancers that 
respond to activity, BDNF, or both.  Here, we investigate the transcriptional 
mechanisms that underlie stimulus-responsive enhancer function in the nervous system.  
We show that stimulus-responsive enhancers require the coordinated action of the 
stimulus-general transcription factor activator protein 1 (AP1) with additional stimulus-
specific factors.  This work provides important insights into the cis-acting elements at 
stimulus-responsive enhancers that together with the trans-acting factors that bind to 
these elements transform sensory experience into specific transcriptional programs that 
facilitate long-lasting changes in neuronal function. 
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3.2 INTRODUCTION 
Enhancers consist of binding sites for multiple families of transcription factors, 
the binding of which function synergistically to promote transcription at promoters of 
target genes (Spitz and Furlong, 2012).  The exact complement of transcription factors 
recruited to enhancers determines when and where an enhancer is active.  Much of what 
we know about the transcriptional mechanisms comes from studies of a few enhancers 
in detail.  Recently, genome-wide methods have been developed to comprehensively 
identify the enhancer elements within the genome.  These methods have been used to 
catalog enhancer elements in various cells and tissues in different organisms.  
Furthermore, genomic characterization has led to new understanding of how enhancer 
elements function and contribute to the establishment and maintenance of cellular 
identity.  However, enhancers also play an important role in transcriptional responses to 
extracellular stimuli.  Only recently have studies attempted to identify and characterize 
enhancers that contribute to stimulus-responsive programs of gene expression. 
Stimulus responsive enhancers play an important role in the nervous system.  In 
response to sensory experience, strong bursts of synaptic activity induce a program of 
gene expression in excitatory neurons that is required for proper development and 
refinement of neural circuits and for long-lasting changes in neuronal function that 
underlie learning, memory, and behavior.  Studies of this neuronal activity-dependent 
gene program have primarily focused on signaling to promoter bound transcription 
factors.  The release of the neurotransmitter glutamate at synapses leads to membrane 
depolarization of the post-synaptic neuron, triggering calcium influx through L-type 
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voltage gated calcium channels.  The influx of calcium then leads to activation of a 
complex signaling network that induces the post-translational modification of promoter 
bound transcription factors that initiate multiple waves of gene expression.  In addition 
to these critical signaling events at the promoters of activity-regulated genes, signaling 
to enhancers contributes to activity-dependent gene expression, although there has been 
little progress towards characterizing the function of activity-regulated enhancers 
because it has been difficult to identify these elements within the genome. 
Recently, we have discovered that the dynamic chromatin signature of stimulus-
inducible H3K27Ac specifically identifies functional stimulus-responsive enhancers.  We 
employed this dynamic chromatin signature to identify neuronal enhancers that 
respond to neuronal activity, BDNF stimulation, or both.  Here, we characterize the 
transcriptional mechanism underlying these stimulus-responsive enhancers within the 
nervous system.  We identify the transcription factor motifs enriched at neuronal 
stimulus-responsive enhancers.  We further study the binding of activity-dependent 
transcription factors predicted to bind to stimulus-responsive enhancers.  The motif for 
the stimulus-responsive transcription factor activator protein 1 (AP1) is enriched at 
neuronal enhancers that respond to activity and those that respond to BDNF 
stimulation.  AP1 transcription factors within the Fos family of transcription factors 
bind to stimulus responsive enhancers in response to neuronal activity and BDNF 
stimulation.  We show that AP1 is necessary but not sufficient at a subset of enhancers 
for their response to both neuronal activity and BDNF stimulation.  These data 
demonstrate that AP1 functions as a stimulus-general transcription factor that 
coordinates stimulus-responsive transcription at enhancers with other stimulus-specific 
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factors.  These findings begin to elucidate the transcriptional mechanisms underlying 
stimulus responsive enhancers within the nervous system.  These mechanisms will be 
important to not only understand how these elements function, but also to begin to 
understand how sequence variation at stimulus-responsive enhancers affects their 
function and may contribute to human variation and disease. 
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3.3 RESULTS 
3.3.1 Sequence determinants of stimulus-responsive enhancers 
To begin to understand the sequence determinants and transcription factors that 
regulate the function of stimulus-responsive enhancers, we performed de novo motif 
analysis on enhancers with different stimulus-responsive properties.  Given that we had 
previously shown that reporter activity driven by enhancer elements appeared to be 
intrinsic to the sequence of these elements rather than genomic context or chromatin 
structure, we reasoned that de novo motif discovery might enable us to find important 
sequence determinants that drive distinct patterns of enhancer activity.  De-novo motif 
analysis was performed using Multiple Em for Motif Elicitation (MEME) (Bailey and 
Elkan, 1994), beginning with neuronal enhancers that respond to membrane 
depolarization with elevated extracellular potassium chloride (KCl).  Enhancers with 
increasing H3K27Ac in response to neuronal depolarization showed enrichment for 
motifs for the neuronal-activity regulated transcription factors AP-1, MEF2, and CREB 
(Figure 3.1a), suggesting that these transcription factors may drive neuronal activity-
regulated transcriptional programs via enhancer mediated mechanisms.  The AP1 
transcription factor complex generally consists of dimers of FOS and JUN family 
transcription factors, many of which are canonical immediate early genes that are 
rapidly expressed in a protein synthesis-independent manner in response to 
extracellular stimuli in diverse cell types (Eferl and Wagner, 2003; Greenberg and Ziff, 
1984; Sheng and Greenberg, 1990).  MEF2 family transcription factors (MEF2A-D) are 
known to be activated via dephosphorylation in response to neuronal activity and to 
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play an important role in activity-dependent transcription in the nervous system 
(Barbosa et al., 2008; Flavell et al., 2006; Potthoff and Olson, 2007).  The transcription 
factor CREB is known to be activated by phosphorylation in response to neuronal 
activity and to play an important role in activity-dependent transcription in the nervous 
system (Gonzalez and Montminy, 1989; Sheng et al., 1991).  Notably, none of these 
activity-dependent transcription factor motifs were significantly enriched among 
enhancers with constant or decreasing levels of H3K27Ac, suggesting that the 
transcription factors that bind these motifs may function specifically at activity-
responsive enhancers within the genome. 
In addition to these activity-dependent transcription factor motifs, we also noted 
enrichment at activity-responsive enhancers for additional motifs for developmental 
transcription factors (Figure 3.1b).  For example, we found that the X-box motif and the 
E-box motif were both significantly enriched among stimulus-responsive enhancers.  
These motifs are known to be bound by RFX and proneural bHLH transcription factors, 
respectively, both of which have been implicated in neuronal differentiation and 
development.  RFX1 binding (as well as the X-box motif) has been shown to be enriched 
at active enhancers in cultured neural progenitor cells (Creyghton et al., 2010).  
Numerous bHLH transcription factors have also been shown to be expressed in neural 
progenitor cells (e.g. ASCL1, NGN1, NGN2) and differentiated neurons (e.g. NGN2, 
NEUROD, NHLH) and in many cases have been shown to play critical roles during 
nervous system development (Bertrand et al., 2002).  Thus, neuronal stimulus-
responsive enhancers may achieve tissue specificity through the action of RFX1 and 
proneural bHLH transcription factors at these enhancers, although further studies will 
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be required to understand how these and other transcription factors establish the active 
enhancer landscape in neurons. 
 
 
 
 
Figure 3.1: Motifs enriched among neuronal activity-responsive enhancers 
To understand the sequence determinants that contribute to the function of neuronal 
activity-responsive enhancers, we performed de novo motif analysis of the DNA 
sequences from all neuronal enhancers exhibiting increasing H3K27Ac levels in 
response to neuronal activity.  De-novo motif analysis was performed using Multiple Em 
for Motif Elicitation (MEME) (Bailey and Elkan, 1994).  The position weight matrices 
(PWM) for top neuronal activity-dependent transcription factor motifs (a) and the top 
developmental transcription factor motifs (b) identified by MEME are displayed, along 
with the E value reported by MEME for each de novo PWM.  In addition, for each de 
novo PWM, the most similar PWM in the JASPAR or UniPROBE transcription factor 
motif databases, identified using TOMTOM (Gupta et al., 2007), is displayed. 
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Having characterized the transcription factor motifs and binding events enriched 
at neuronal activity-responsive enhancers, we next investigated the transcription factor 
motifs present at neuronal BDNF-responsive enhancers by performing de novo motif 
analysis on this set of enhancers.  Surprisingly, the most enriched motif at BDNF-
responsive enhancers was the same motif that was enriched at neuronal activity-
responsive enhancers, the AP-1 motif (Figure 3.2b, top).  Furthermore, the AP1 motif 
was also the most significantly enriched motif at neuronal enhancers exhibiting 
increasing H3K27Ac in response to neuronal activity but not BDNF (activity-specific 
enhancers; Figure 3.2a, bottom), increasing H3K27Ac in response to BDNF but not 
neuronal activity (BDNF-specific enhancers; Figure 3.2b, bottom), and increasing 
H3K27Ac in response to neuronal activity and BDNF (KCl and BDNF inducible 
enhancers; Figure 3.2c).  This suggested that AP1 transcription factors may play a 
critical role in mediating transcriptional responses at enhancers to multiple stimuli. 
 
Figure 3.2: AP1 is the most significantly enriched motif at all classes of 
neuronal stimulus-responsive enhancers 
De novo motif analysis of the DNA sequences from neuronal enhancers exhibiting 
increasing H3K27Ac levels in response to neuronal activity (a), BDNF (b), or both (c).  
De-novo motif analysis was performed using Multiple Em for Motif Elicitation (MEME) 
(Bailey and Elkan, 1994).  The position weight matrices (PWM) for top neuronal 
transcription factor motifs are displayed, along with the E value reported by MEME for 
each de novo PWM.  In addition, for each de novo PWM, the most similar PWM in the 
JASPAR or UniPROBE transcription factor motif databases, identified using TOMTOM 
(Gupta et al., 2007), is displayed.  
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3.3.2 Transcription factor binding to activity-responsive enhancers 
Given the enrichment of activity-regulated transcription factor motifs at 
enhancers with increasing H3K27Ac in response to activity, we asked whether the 
transcription factors corresponding to these motifs would show greater binding at these 
enhancers.  First, we performed ChIP-Seq for MEF2A and MEF2D before and after 
neuronal depolarization and found that these activity-dependent transcription factors 
were enriched at enhancers with increasing H3K27Ac in response to neuronal 
depolarization (Figure 3.3).  We further integrated our H3K27Ac data with previously 
generated ChIP-Seq data for CREB, NPAS4, CBP, and RNAPII (Kim, 2010) in order to 
more thoroughly investigate the contribution of activity-regulated transcription factor 
binding to inducible H3K27ac at enhancers.  Interestingly, all of these transcription 
factors also showed significantly more binding to enhancers with increasing H3K27Ac 
compared to other enhancers (Figure 3.3).  Binding of the stimulus regulated 
transcription factor SRF was not enriched at enhancers with increasing H3K27ac, in line 
with the SRF motif not being significantly enriched these enhancers.  Hence, many but 
not all activity-dependent transcription factors in the nervous system show not only 
enrichment of their motifs but also increased binding to activity-dependent enhancers 
in the genome.  This suggests that several activity-dependent transcription factors 
collaborate at enhancers to regulate neuronal activity-dependent transcription, and that 
many such transcription factors may drive activity-dependent transcription via 
enhancer-mediated mechanisms.  
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Figure 3.3: Neuronal activity-responsive enhancers are enriched for 
binding by neuronal activity-dependent transcription factors 
ChIP-Seq was performed (MEF2A) or analyzed (CREB, NPAS4, CBP, RNAPII) for the 
displayed transcription factors.  Input normalized ChIP-Seq reads within an 800bp 
window surrounding each enhancer center were quantified at enhancers with increasing 
H3K27Ac or other enhancers, before and after membrane depolarization with KCl.  Data 
is displayed in boxplots and * indicates p < 2.2x10-16 in paired Wilcoxon test. 
  
  92 
Given that our genomic analyses suggested that neuronal activity-responsive 
enhancers are enriched for binding by neuronal activity-dependent transcription factors, 
we asked whether this enrichment could be seen at any individual loci of neuronal 
activity regulated genes.  Two intragenic enhancers within the genomic locus for the 
activity-regulated neuronal gene Prkg2 reflect the preferential and activity-dependent 
binding of several activity-dependent transcription factors at enhancers with increasing 
but not constant H3K27Ac in response to membrane depolarization (Figure 3.4). 
 
 
Figure 3.4: Activity-dependent transcription factor binding at the Prkg2 
locus 
Genome browser view of ChIP-Seq tracks for the indicated factors at the activity-
regulated Prkg2 locus.  ChIP-Seq tracks display input-normalized H3K27Ac ChIP-Seq 
reads from neurons before membrane depolarization (-KCl) or after membrane 
depolarization (+KCl).  Also displayed are DNaseI hypersensitivity signal from adult 
mouse cerebrum and vertebrate conservation by PhastCons.  Dashed boxes identify 
regulatory elements with different stimulus-responsive changes in H3K27Ac.  Activity-
dependent transcription factors (MEF2A, CREB, Cs, NPAS4) and general transcription 
factors (CBP, RNAPII) exhibit activity-dependent binding at the enhancer with 
increasing H3K27Ac in response to neuronal activity (‘Inc.’) but not at the enhancer 
with constant H3K27Ac in response to neuronal activity (‘Con.’). 
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3.3.3 AP1 is required for both neuronal activity-dependent and BDNF-
dependent enhancer function 
Given the enrichment of the AP1 motif at enhancers that respond to neuronal 
activity or BDNF and the lack of enrichment for the AP1 motif in active enhancers at 
which H3K27Ac did not change in response to either stimuli, we reasoned that the AP1 
transcription factor complex may be critical for stimulus-responsive enhancers to 
promote transcription in response to extracellular stimuli.  This would represent a novel 
mechanism for AP1 transcription factors in the nervous system, as AP1 has long been 
assumed to function at the promoters of neuronal activity-regulated genes to regulate 
transcription.  First, we sought to characterize AP1 transcription factor binding to 
stimulus-responsive enhancers.  Since FOS transcription factors have been shown to be 
an important component of the AP1 complex with important roles in the nervous system 
(Brown et al., 1996; Fleischmann et al., 2003; Jin et al., 2002; Zhang et al., 2002), we 
focused on members of this family of transcription factors.  We first asked which Fos 
genes exhibited significant inducibility in response to extracellular stimuli, reasoning 
that inducible FOS transcription factors are likely to contribute to stimulus-dependent 
transcriptional control mediated by the AP-1 complex.  Using RNA-Seq data we 
generated from mouse cortical neurons after 0, 1, or 6 hours of stimulation with KCl or 
BDNF, we characterized the expression of the genes of the four FOS family transcription 
factors: c-Fos, FosB, Fosl1, and Fosl2.  We found that c-Fos and FosB were the most 
robustly induced Fos family members in response to stimuli, being similarly induced by 
KCl and BDNF (Figure 3.5).  As a result, we chose to focus on these transcription factors.   
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Figure 3.5: c-Fos and FosB are induced in response to both KCl and BDNF 
stimulation 
RNA-Seq data from mouse cortical neurons stimulated with 0, 1, 6 hours KCl or 0, 1, 6 
hours BDNF was analyzed to assess the levels of expression of genes in the Fos family of 
transcription factors.  c-Fos and FosB (displayed) were the most inducible transcription 
factors and were found to be similarly induced in response to both KCl and BDNF.  
mRNA is expressed as reads per kilobase per million mapped reads (RPKM). 
 
Since c-Fos and FosB were the most inducible AP1 transcription factors within 
the Fos family of transcription factors (by both KCl and BDNF stimulation), we next 
sought to characterize the binding of these transcription factors by ChIP-Seq in 
response to both KCl and BDNF stimulation.  We first characterized binding in response 
to KCl.  Using two independent C-FOS antibodies, we identified only 654 C-FOS peaks 
prior to KCl stimulation but identified 16,131 C-FOS peaks after KCl stimulation, 
consistent with the low baseline levels of C-FOS expression and the strong inducibility 
of C-FOS in response to neuronal activity.  Furthermore, levels of C-FOS binding at C-
FOS peaks exhibited strong inducibility with KCl stimulation (Figure 3.6a).  In order to 
further confirm the specificity of these peaks, we performed an additional ChIP-Seq 
experiment for C-FOS and found that the majority of these peaks replicated in an 
independent experiment (79%).  We also performed ChIP-Seq for C-FOS from neuronal 
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cultures expressing a lentiviral shRNA knockdown construct targeting c-Fos.  C-FOS 
ChIP-Seq signal was substantially reduced by c-Fos RNAi throughout the genome 
(Figure 3.6b) and the majority of C-FOS peaks identified exhibited significantly reduced 
C-FOS signal after c-Fos knockdown (71%).  Finally, we performed de novo motif 
analysis on the set of 16,131 peaks and found that the AP1 motif was the most strongly 
enriched motif within this set of loci.  These data suggest that we were able to identify a 
high confidence set of C-FOS binding sites within the genome that were reproducible 
and specific. 
 
Figure 3.6: ChIP-Seq signal for C-FOS is inducible and specific in response 
to KCl stimulation 
(a) C-FOS ChIP-Seq was performed in mouse cortical neurons before membrane 
depolarization with KCl (-KCl) and after membrane depolarization with KCl (+KCl).  
Average profiles of input-normalized C-FOS ChIP-Seq signal before membrane 
depolarization (dashed lines) and after membrane depolarization (solid lines) are shown.  
(b) C-FOS ChIP-Seq was also performed after membrane depolarization with KCl in 
mouse cortical neurons that had been infected with lentivirus expressing either a control 
shRNA or an shRNA targeting c-Fos, in two independent experiments.  Average profiles 
of C-FOS ChIP-Seq signal from control RNAi lentivirus infected neurons (dashed lines) 
and C-FOS RNAi lentivirus infected neurons (solid lines) are shown.  
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Having identified a high confidence set of C-FOS binding sites, we asked where 
C-FOS binding occurred within the genome.  While we found the AP1 motif to be 
enriched at enhancers, AP1 factors have been long thought to act at promoters of target 
genes.  An analysis of the genomic location of our rigorously defined set of C-FOS 
binding sites indicated that C-FOS binding was observed predominantly at gene distal 
sites across the genome, with the vast majority of peaks occurring greater than 1kb from 
an annotated TSS (82% of all replicating peaks, 94% of replicated peaks reduced by 
RNAi; Figure 3.7a).  Analysis of a similarly verified set of high confidence FOSB peaks 
(n=8687; see methods) indicated that FOSB binding also occurred almost exclusively at 
sites greater than 1kb from an annotated TSS (96% of replicating peaks; Figure 3.7b).  
This strongly suggested that in our system, the AP1 transcription factors C-FOS and 
FOSB generally do not bind to promoters but rather bind to regions of the genome 
distant to promoters. 
 
Figure 3.7: Genomic distribution of C-FOS and FOSB peaks after 
stimulation with KCl 
ChIP-Seq for C-FOS and FOSB were performed before and after stimulation with KCl 
and peaks were called with MACS (Zhang et al., 2008).  Peaks called after stimulation 
with KCl were then classified as proximal if they occurred within 1kb of an annotated 
RefSeq TSS, and as distal if they occurred outside of this window.  The majority of C-
FOS (a) and FOSB (b) peaks occur distal to TSSs.  
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Since the AP1 motif was enriched at stimulus-responsive enhancers, we 
hypothesized that C-FOS and FOSB binding to gene distal regions may be occurring at 
enhancers.  Characterization of the chromatin modifications and transcription factor 
binding at distal C-FOS peaks demonstrated enrichment for enhancer associated 
H3K4Me1 (Figure 3.8a), H3K27Ac (Figure 3.8b), and CBP (Figure 3.8c), suggesting that 
C-FOS and binds to enhancers.  Thus, in our system, FOS transcription factors appear to 
bind to enhancers rather than promoters in response to neuronal activity. 
 
 
 
Figure 3.8: Distal C-FOS peaks induced by KCl exhibit features of enhancers 
Chromatin modifications and transcription factor binding was assessed at distal C-FOS 
peaks within the genome before membrane depolarization (-KCl, dashed lines) and after 
membrane depolarization (+KCl, solid lines).  (a) C-FOS peaks exhibit enrichment for 
the enhancer associated chromatin mark H3K4Me1 but not the promoter associated 
chromatin mark H3K4Me3.  (b) C-FOS peaks exhibit enrichment for the active enhancer 
associated chromatin mark H3K27Ac, and H3K27Ac increases at C-FOS peaks with KCl 
stimulation.  (c) C-FOS peaks exhibit enrichment for the transcriptional coactivator CBP 
with KCl stimulation.  The y-axis for all plots represents the level of ChIP-Seq signal for 
the indicated factor, displayed as the mean number of input-normalized H3K27Ac 
ChIP-Seq reads at C-FOS peaks within the genome. 
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Given the enrichment of the AP1 motif among not only activity-responsive 
enhancers but also BDNF-responsive enhancers, and given our ability to detect bona 
fide C-FOS and FOSB binding by ChIP-Seq, we sought to characterize the binding of 
each of these factors in response to BDNF.  We hypothesized that C-FOS and FOSB 
binding in response to BDNF would also occur at enhancers within the neuronal 
genome.  We performed ChIP-Seq for each factor in response to BDNF.  In BDNF 
stimulated neurons, we identified 15057 C-FOS peaks (93% gene distal; Figure 3.9a) and 
13362 FOSB peaks (96% gene distal; Figure 3.9b), indicating that FOS transcription 
factors function primarily at gene distal regulatory elements in response to both 
neuronal activity and BDNF.  These data strongly suggest that the current model of FOS 
function through promoters needs to be revisited. 
 
Figure 3.9: Genomic distribution of C-FOS and FOSB peaks after 
stimulation with BDNF 
ChIP-Seq for C-FOS and FOSB were performed before and after stimulation with BDNF 
and peaks were called with MACS (Zhang et al., 2008).  Peaks called after stimulation 
with BDNF were then classified as proximal if they occurred within 1kb of an annotated 
RefSeq TSS, and as distal if they occurred outside of this window.  The majority of C-
FOS (a) and FOSB (b) peaks occur distal to TSSs.  
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Having shown that FOS transcription factors bind predominantly to gene distal 
regions within the genome likely to be enhancers, we next determined the extent to 
which FOS transcription factors bound to neuronal stimulus-responsive enhancers.  We 
assessed C-FOS binding at neuronal stimulus-responsive enhancers.  We found 
significant enrichment for C-FOS binding at KCl and BDNF responsive enhancers 
(Figure 3.10).  Furthermore, we found that a significant percentage of stimulus-
responsive enhancers overlapped with C-FOS or FOSB peaks (39% of activity-
responsive enhancers, 61% of BDNF-responsive enhancers).  These large percentages 
further suggest that FOS transcription factors likely contribute significantly to the 
function of both activity-responsive and BDNF-responsive enhancers. 
 
Figure 3.10: C-FOS binding at stimulus-responsive enhancers 
(a) Heatmap of H3K27Ac and C-FOS binding before and after KCl stimulation at KCl 
responsive enhancers, sorted by magnitude of H3K27Ac after KCl stimulation.  (b) 
Average profile of input-normalized C-FOS ChIP-Seq signal before membrane 
depolarization (dashed lines) and after membrane depolarization (solid lines).  (c) 
Heatmap of H3K27Ac and C-FOS binding before and after BDNF stimulation at BDNF 
responsive enhancers, sorted by magnitude of H3K27Ac after BDNF stimulation.  (d) 
Average profile of input-normalized C-FOS ChIP-Seq signal before BDNF stimulation 
(dashed lines) and after BDNF stimulation (solid lines).    
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Importantly, a large percentage of stimulus-responsive enhancers were not 
bound by FOS transcription actors, suggesting that FOS-independent mechanisms may 
exist to activate enhancers in response to stimuli.  This is to be expected since enhancers 
that are needed to express Fos transcription factors in response to stimuli are unlikely to 
require FOS for this response.  There are likely distinct enhancers that function to 
activate the distinct waves of transcription that have been shown to occur in response to 
extracellular stimulation. 
Interestingly, we found that a significant percentage of C-FOS and FOSB peaks in 
the genome did not occur at stimulus-responsive enhancers or at regions with any 
appreciable H3K27Ac.  We asked whether these FOS binding sites functioned to 
regulate stimulus responsive transcription.  We cloned several such loci into reporter 
constructs and found that none of these loci were able to drive transcription in an 
activity-dependent manner.  This suggested that only a subset of all C-FOS and FOSB 
binding sites within the genome might contribute to stimulus-responsive transcription. 
Since the AP1 transcription factors C-FOS and FOSB bind to stimulus-responsive 
enhancers within the genome, we hypothesized that AP1 may play a critical role in the 
function of these enhancers.  To directly assess whether AP1 contributes to neuronal 
stimulus-inducible enhancer activity, we asked whether binding of the AP1 complex is 
necessary for the function of these enhancers.  To accomplish this, we tested the 
function of Nptx2 reporter plasmids containing eight separate stimulus-inducible 
enhancers with canonical AP1 motifs that also exhibited high levels of binding by AP1 
components (measured by ChIP-Seq).  We disrupted the function of AP1 at these 
functional enhancers by either subtly mutating the AP1 motifs to block AP-1 binding or 
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by co-transfecting the dominant negative AP1 protein A-FOS (Ahn et al., 1998; Olive et 
al., 1997) with the Nptx2 reporter.  We found that both manipulations significantly 
reduced activity-dependent and BDNF-dependent expression of each reporter tested, 
often down to levels exhibited by the reporter in the absence of any enhancer, suggesting 
that in some cases the AP1 motif is strictly required to achieve any enhancer activity. 
 
Figure 3.11: AP1 is critical for the function of KCl and BDNF responsive 
enhancers 
The impact of AP1 motif mutations (a, c) and expression of the AP1 dominant negative 
A-Fos (b, d) on the function of eight enhancers containing AP1 sites and exhibiting 
binding by FOS transcription factors were assessed.  Luciferase reporter data of each 
enhancer within the Nptx2 reporter is shown, reported as the fold induction of reporter 
activity in mouse cortical neurons after 6 hours of stimulation with KCl (a, b) or BDNF 
(c, d) relative to 0 hours. n=3 in panels a and c.  n=1 in panels b and d.  
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 Importantly, not all enhancers exhibiting inducible H3K27Ac in response to 
extracellular stimuli were sensitive to AP1 manipulations.  Several enhancers with 
increasing H3K27Ac and robust reporter expression in response to neuronal activity 
were not affected by the AP1 dominant negative A-Fos in reporter assays (Figure 3.12).  
This not only provided evidence of the specificity of the function of the A-FOS dominant 
negative protein, but also suggested that AP1 independent mechanisms likely exist to 
enable enhancers to respond to neuronal activity.  This is consistent with our earlier 
observations that not all enhancers with increasing H3K27Ac were bound by FOS 
transcription factors. 
 
Figure 3.12: AP1 is not required at all KCl responsive enhancers 
The expression of the AP1 dominant negative A-Fos has no impact on the function of 
seven enhancers that exhibit increasing H3K27Ac in response to neuronal activity and 
display responsiveness to KCl when cloned into the Nptx2 luciferase reporter.  
Luciferase reporter data of each enhancer within the Nptx2 reporter is shown, reported 
as the fold induction of reporter activity in mouse cortical neurons after 6 hours of 
stimulation with KCl relative to 0 hours. n=3 for all plasmids tested.  
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These data reveal a critical requirement for AP1 transcription factors at a subset 
of stimulus-responsive enhancers.  Furthermore, these data suggest that AP1 plays a 
critical role in the function of enhancers with diverse stimulus-responsive properties, 
such as responsiveness to activity or BDNF.  Given that AP1 transcription factors are 
expressed in a wide variety of cells in response to numerous extracellular stimuli, AP1 
may play a critical role in the acquisition of stimulus-responsiveness of enhancers in 
multiple cellular contexts. 
 
3.3.4 C-FOS regulates stimulus-responsive gene expression in the 
nervous system 
C-FOS and other activity-regulated components of the AP1 complex bind to 
neuronal activity-dependent enhancers and abrogation of the binding of these 
components to enhancers through AP1 motif mutations leads to significant reductions 
in activity-dependent reporter induction.  These data suggest that C-FOS may be 
important for neuronal activity-dependent enhancers.  Since neuronal activity-
dependent enhancers are associated with neuronal activity-dependent gene expression 
(Figure 2.7), we hypothesized that C-FOS may play a critical role in driving neuronal 
activity-dependent gene expression.  To test this hypothesis directly, we performed 
genome-wide microarray analysis on neuronal RNA obtained from mouse cortical 
neurons that had been stimulated with 0, 1, 3, or 6 hours of KCl and infected with 
lentivirus expressing either a control RNAi or c-Fos RNAi.  Western blot analysis of 
protein lysates obtained from simultaneously infected and stimulated cortical neurons 
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demonstrated that c-Fos RNAi was effective and specific.  At each stimulus timepoint 
tested, c-Fos RNAi significantly reduced levels of C-FOS protein without affecting levels 
of the related FOSB protein, levels of activity-dependent posttranslational modifications, 
or cell viability as assessed by levels of β-actin (Figure 3.13). 
 
 
Figure 3.13: c-Fos RNAi effectively and specifically reduces levels of C-FOS 
protein 
Western blot analysis of protein lysates obtained from mouse cortical neurons that had 
been stimulated with 0, 1, 3, or 6 hours of KCl and infected with lentivirus expressing 
either a control RNAi or c-Fos RNAi.  At each stimulus timepoint tested, c-Fos RNAi 
significantly reduced levels of C-FOS protein without affecting levels of the related FOSB 
protein, levels of activity-dependent posttranslational modifications, or cell viability as 
assessed by levels of β-actin. 
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Since C-FOS protein levels appear greatest after 3 hours of stimulation among the 
timepoints tested in this experiment (Figure 3.13), we hypothesized that the greatest 
effects on activity-dependent gene expression would be seen after 3 or 6 hours of KCl 
stimulation.  Analysis of the 1, 3, and 6 hour fold inductions of all expressed genes 
revealed, with the greatest misregulation seen after 6 hours of KCl stimulation (Figure 
6B, an increasing number of genes that were less inducible with c-Fos RNAi compared 
to control RNAi red). 
 
Figure 3.14: Genome-wide microarray analysis with c-Fos RNAi 
Genome-wide microarray analysis was performed on neuronal RNA obtained from 
mouse cortical neurons that had been stimulated with 0, 1, 3, or 6 hours of KCl and 
infected with lentivirus expressing either a control RNAi or c-Fos RNAi.  Scatterplots 
show fold induction of gene expression at 1, 3, or 6 hrs after KCl stimulation relative to 0 
hrs (unstimulated neurons) for all expressed genes (n=17767).  In order to be considered 
expressed, a gene must have been detected by a probe in both microarray bioreplicates 
at at least one of the timepoints assessed and must have achieved a minimal expression 
value of 250.  The x-axis displays the fold induction exhibited in neurons infected with 
control RNAi.  The y-axis displays the fold induction exhibited in neurons infected with 
c-Fos RNAi.  The diagonal black line represents unity (y=x).  The vertical red line 
represents a three-fold cutoff for fold induction with control RNAi.  Red points 
represent genes induced at least three fold with control RNAi and exhibited a reduced 
fold induction by at least 1.75 fold with c-Fos RNAi.  An increasing number of genes 
were less inducible with c-Fos RNAi compared to control RNAi with increasing time 
after KCl stimulation (red numbers). 
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Investigation of genes misregulated with c-Fos RNAi revealed several genes with 
known functions in the nervous system including the postsynaptic scaffolding protein 
Grasp that has been shown to regulate metabotropic glutamate receptors (Kitano et al., 
2002), the secreted protein Nptx2 that has been shown to regulate AMPA receptor 
clustering (O'Brien et al., 2002; O'Brien et al., 1999) and homeostatic scaling (Chang et 
al., 2010), the hormone Igf1 that has been shown to be important for brain development 
(Beck et al., 1995; Fernandez and Torres-Aleman, 2012), and the chromatin regulator 
Hdac9 that has been shown to be highly expressed within the nervous system (Zhou et 
al., 2001) and regulate dendrite development (Sugo et al., 2010) (Figure 3.15a).  While 
these and other important neuronal genes were misregulated with c-Fos RNAi, we 
sought to determine which genes may be direct targets of C-FOS within neurons.  We 
hypothesized that direct targets may be identifiable not only on the basis of 
misexpression with c-Fos RNAi but also on the basis of a nearby activity-dependent 
enhancer bound by C-FOS.  To investigate this possibility, we integrated our microarray 
data with our ChIP-Seq data and assessed the genomic regions surrounding these 
putative C-FOS target genes.  We found that each of these genes was near an activity-
regulated enhancer bound by C-FOS and other activity-dependent AP1 transcription 
factors (Figure 3.15b).  This suggested that these genes may indeed be direct 
transcriptional targets of C-FOS.  The identification of high confidence C-FOS target 
genes using integrated analysis of gene expression and ChIP-Seq data enables us to 
begin to understand the effector genes regulated by immediate early genes in the 
nervous system and how immediate early genes may mediate adaptive changes in the 
nervous system in response to neuronal activity.  
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Figure 3.15: High confidence C-FOS target genes with important functions 
in the nervous system 
(a) Lineplots of fold induction of Grasp, Nptx2, Igf1, and Hdac9 after 1, 3, or 6 hours of 
KCl stimulation (relative to 0 hrs) in neurons that had been infected with lentivirus 
expressing control RNAi (black line) or c-Fos RNAi (red line).  Data is plotted as the 
average of two microarray bioreplicates +/- SEM.  (b) Genome browser views of ChIP-
Seq data at Grasp, Nptx2, Igf1, and Hdac9 loci.  All four of these genes are near 
enhancers that display increasing H3K27Ac in response to KCl stimulation and are 
bound by C-FOS and other inducible AP1 transcription factors.  For all chromatin marks 
and transcription factors, ChIP-Seq tracks display input-normalized reads from 
neuronas stimulated with 0 hours (‘-‘) or two hours (‘+’) of KCl. 
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3.3.5 Functional dissection of stimulus responses of the Nptx2 enhancer 
While our data reveal that AP1 is required for enhancer responses to neuronal 
activity and BDNF, it is not clear if AP1 is sufficient to generate these responses or if 
other transcription factors are also required.  We sought to understand this issue by 
dissecting the function of a neuronal stimulus-responsive enhancer.  We hypothesized 
that an enhancer that responded to both neuronal activity and BDNF might require AP1 
to respond to each stimulus and might require additional stimulus-specific transcription 
factors to induce H3K27Ac at enhancers that respond to only one stimulus.  We further 
hypothesized that mechanisms that enable an enhancer to respond to neuronal activity 
might be distinct from the mechanisms that enable an enhancer to respond to BDNF.  
To test these hypotheses, we chose to study the Nptx2 enhancer, which served as the 
basis for our luciferase reporter construct.  The Nptx2 gene is robustly expressed in 
cortical neurons in response to both neuronal activity and BDNF, with highest 
expression at 6hrs, and greater expression in response to BDNF stimulation than KCl 
stimulation (Figure 3.16a).  The enhancer ~3kb upstream of the Nptx2 gene exhibits 
inducible H3K27Ac in response to neuronal activity and BDNF (Figure 3.16b) and is 
required for the response of the Nptx2 reporter to both stimuli in a reporter assay 
(Figure 3.11a,c).  The Nptx2 enhancer also exhibits robust binding of the AP1 
transcription factors C-FOS and FOSB in response to each stimulus (Figure 3.16b and 
data not shown).  All of these data suggest that the Nptx2 enhancer may be useful for 
determining how neuronal stimulus-responsive enhancers function to contribute to 
stimulus-responsive transcription in the nervous system. 
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Figure 3.16: Characterization of Nptx2 expression and Nptx2 locus 
(a) RNA-Seq data from mouse cortical neurons stimulated with 0, 1, 6 hours KCl or 0, 1, 
6 hours BDNF was analyzed to assess the levels of expression of Nptx2.  Nptx2 is 
induced in response to both KCl and BDNF stimulation but is more induced in response 
to BDNF.  mRNA is expressed as reads per kilobase per million mapped reads (RPKM).  
(b) Genome browser view of ChIP-Seq tracks for the indicated factors at the stimulus-
regulated Nptx2 locus.  ChIP-Seq tracks display input-normalized ChIP-Seq reads from 
neurons before membrane depolarization (-KCl), after two hours of membrane 
depolarization (+KCl), before BDNF stimulation (-BDNF), or after two hours of BDNF 
stimulation (+BDNF).  Also displayed are DNaseI hypersensitivity signal from adult 
mouse cerebrum and vertebrate conservation by PhastCons.  Dashed boxes identify 
nearby enhancer elements.   
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We utilized the Nptx2 reporter to dissect the function of the Nptx2 enhancer.  We 
first sought to identify the core element within the enhancer that was sufficient to 
generate transcriptional responses to neuronal activity and BDNF.  To do this, we first 
generated truncation mutants of the Nptx2 enhancer and measured the ability of each 
mutant to respond to neuronal activity and BDNF in reporter assays.  We found that a 
core 180bp region retained the full activity of the full-length enhancer, suggesting that 
the sequence determinants that give rise to neuronal activity-dependent and BDNF-
dependent responses from this enhancer reside within this region of the enhancer 
(Figure 3.17). 
 
 
Figure 3.17: Identification of the minimal sequence within the Nptx2 
upstream enhancer that drives responses to both KCl and BDNF 
Luciferase reporter data for truncation mutants of the Nptx2 upstream enhancer (NUe) 
cloned into the Nptx2 reporter, reported as the fold induction of reporter activity in 
mouse cortical neurons after 6 hours of KCl or BDNF stimulation relative to 0 hours.  
Error bars represent standard error of the mean (S.E.M.).  n ≥ 3 for all enhancers tested.  
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To discover motifs in an unbiased fashion that contribute to the function of the 
Nptx2 enhancer, we comprehensively scrambled the sequence of a minimized version of 
the enhancer and measured the ability of mutant enhancer sequences to respond to 
neuronal activity and BDNF in reporter assays.  We scrambled approximately 7-10 base 
pairs at a time by converting all adenine nucleotides to cytosine nucleotides (AàC), all 
cytosine nucleotides to adenine nucleotides (CàA), all thymine nucleotides to guanine 
nucleotides (TàG), and all guanine nucleotides to thymine nucleotides (GàT).  We 
found several regions within the enhancer whose mutation reduced reporter expression 
by more than 50% compared to the wild type sequence (Figure 3.18).  Some stretches of 
sequence appeared to be important for the response of the Nptx2 enhancer to both KCl 
and BDNF, while other sequences appeared to be important for the response to either 
KCl or BDNF.  Closer inspection of the critical sequences revealed three AP1 motifs 
within the enhancer that appeared to be critical for the responses to both KCl and BDNF 
(Figure 3.18).  This suggested that AP1 might be important for generating responses to 
both KCl and BDNF at the Nptx2 enhancer, consistent with our earlier findings about 
AP1.  
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Figure 3.18: Comprehensive scrambling of the Nptx2 enhancer reveals 
sequences important for responsiveness to KCl and BDNF 
A minimized version of the Nptx2 enhancer (schematic, top) was scrambled 7-10 base 
pairs at a time and the ability of each mutant to drive luciferase reporter expression in 
response to KCl (top bar graph) and BDNF (bottom bar graph) was assessed.  Sequences 
whose mutation reduced reporter expression by more than 50% are highlighted in red 
for KCl and blue for BDNF.  Luciferase activity is reported as the fold induction of 
reporter activity in mouse cortical neurons after 6 hours of KCl or BDNF stimulation 
relative to 0 hours.  Error bars represent standard error of the mean (S.E.M.).  n ≥ 3 for 
all enhancers tested with KCl, n ≥ 3 for all enhancers tested with BDNF. 
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To determine the functional contribution of each AP1 site while minimally 
impacting the sequence of the Nptx2 enhancer, we subtly mutated each AP1 motif 
within the full length Nptx2 enhancer, which included four AP1 motifs in total.  A single 
base pair mutation of the second nucleotide of the AP1 motif from G to A has previously 
been shown to abrogate AP1 activity, and we independently confirmed that this subtle 
manipulation of AP1 sites phenocopied the effect of deletion of the entire AP1 site.  
Using AP1 single base pair point mutations, we found that both AP1 motifs that 
appeared to be critical for generating responses of the Nptx2 enhancer to KCl and BDNF 
in our scrambling experiments were critical to generate responses to neuronal activity 
and BDNF (AP1 #2,3; Figure 3.19a, b).  The AP1 site not contained within the minimal 
enhancer region (AP1 #1) and the AP1 site that appeared to impact BDNF but not KCl 
responsiveness of the Nptx2 enhancer in our scrambling experiments (AP1 #4) did not 
appear to contribute significantly to the responsiveness of the Nptx2 enhancer to either 
KCl or BDNF.  Mutation of individual AP1 motifs reduced reporter expression to 
different extents, and mutation of all four AP1 motifs within the Nptx2 enhancer 
eliminated nearly all reporter expression induced by both activity and BDNF.  These 
data indicate that AP1 is required for responses of the Nptx2 enhancer to both neuronal 
activity and BDNF.  Interestingly, while the AP1 motifs within the Nptx2 enhancer 
appear to contribute variably to the magnitude of the stimulus response, they do not 
appear to be used differentially in the context of different stimuli.  This suggests that 
AP1 may function similarly in the context of different stimuli, and that other factors may 
collaborate with AP1 to generate responses to specific stimuli. 
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Figure 3.19: Functional contribution of individual AP1 sites to the 
responsiveness of the Nptx2 enhancer to KCl and BDNF 
AP1 sites within the Nptx2 enhancer were subtly mutated (TGAGTCAàTAAGTCA) 
individually (AP#1, AP1#2, AP1#3, AP1#4) or all together (AP1#1-4) and the ability of 
each mutant to drive luciferase reporter expression in response to KCl (a) and BDNF (b) 
was assessed.  Luciferase activity is reported as the fold induction of reporter activity in 
mouse cortical neurons after 6 hours of KCl or BDNF stimulation relative to 0 hours.  
Error bars represent standard error of the mean (S.E.M.).  n ≥ 3 for all enhancers tested. 
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Having demonstrated that AP1 plays a critical role in the responsiveness of the 
Nptx2 enhancer to both activity and BDNF, we asked whether AP1 was sufficient to 
drive responses to these stimuli.  To test this possibility, we mutated the entire sequence 
of a minimized version of the Nptx2 enhancer outside of the critical AP1 sites and tested 
whether the AP1 sites (retained with their native spacing and GC content) were 
sufficient to retain responsiveness to neuronal activity or BDNF.  We found that 
scrambling the non-AP1 sequence of the enhancer eliminated responses to both activity 
and BDNF, suggesting that AP1 motifs are not sufficient to drive stimulus-responses of 
this enhancer and that additional sequences within the enhancer are required to 
generate stimulus responses. 
To discover additional motifs that may contribute to the stimulus-responsive 
function of this enhancer, we searched the sequences identified in our scrambling 
experiment (Figure 3.18) for known transcription factor motifs other than AP1.  
Interestingly, we found that a sequence within the Nptx2 enhancer that appeared to be 
important for responses of this enhancer to KCl but not BDNF contained a “TCGTG” 
motif that has been shown to be the preferred motif for NPAS4 (Ooe et al, 2004 PMID: 
14701734).  ChIP-Seq data also revealed that the Nptx2 enhancer is bound by NPAS4 in 
response to neuronal activity (Figure 3.16b).  NPAS4 is a basic helix loop helix PAS 
domain containing (bHLH-PAS) transcription factor that is expressed specifically in the 
nervous system in response to neuronal activity (Lin et al., 2008).  Thus, we 
hypothesized that NPAS4 might also contribute to the ability of stimulus-responsive 
enhancers to respond to neuronal activity.  To test this hypothesis, we abrogated the 
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function of NPAS4 at the Nptx2 enhancer by mutating the NPAS4 motif from the 
enhancer and by depleting NPAS4 levels by RNAi (Figure 3.20). 
 
 
 
 
Figure 3.20: NPAS4 contributes to the KCl but not BDNF responsiveness of 
the Nptx2 enhancer 
(a) The putative NPAS4 motif within the Nptx2 enhancer was deleted (NPAS4 del) and 
the ability of this mutant to drive luciferase reporter expression in response to KCl and 
BDNF was assessed.  (b) The activity of the Nptx2 reporter in response to KCl and 
BDNF was assessed in neurons that had been transfected with scrambled shRNA or 
Npas4 shRNA.  Luciferase activity is reported as the fold induction of reporter activity in 
mouse cortical neurons after 6 hours of KCl or BDNF stimulation relative to 0 hours.  
Error bars represent standard error of the mean (S.E.M.).  n ≥ 3 for all enhancers tested. 
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We found that both manipulations significantly reduced the activity-dependent 
expression of the reporter, but neither manipulation significantly reduced the BDNF-
dependent expression of the reporter.  This suggested that the Nptx2 enhancer requires 
NPAS4 to respond to neuronal activity but not to respond to BDNF.  Consistent with 
this possibility, data from a previous study shows that Nptx2 is less induced by neuronal 
activity after Npas4 RNAi (Lin et al., 2008).  On the genome scale, analysis of the 
NPAS4 ChIP-Seq data indicated that Npas4 was bound preferentially to neuronal 
activity-dependent enhancers compared to other neuronal enhancers, providing further 
evidence that NPAS4 may be important for neuronal activity-dependent enhancer 
function. 
These data together reveal that AP1 family transcription factors and NPAS4 
collaborate to promote stimulus responsive transcription through enhancers.  AP1 is 
required for both activity-dependent and BDNF dependent responses while NPAS4 is 
required for only the activity-dependent response.  These experiments begin to elucidate 
how stimulus-dependent and stimulus specific transcriptional responses are generated 
within the nervous system.  Further experiments will be required to reveal the 
additional determinants of stimulus-responsiveness of neuronal enhancers. 
 
3.3.6 NPAS4 and CBP collaborate with C-FOS to drive activity-dependent 
enhancers 
Our data from the functional dissection of the Nptx2 enhancer revealed a critical 
role for NPAS4 is driving enhancer responses to neuronal activity.  To evaluate whether 
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NPAS4 and other factors collaborated with C-FOS to drive neuronal activity-dependent 
enhancers throughout the genome, we assessed the binding of NPAS4 and other 
transcription factors to C-FOS bound loci throughout the genome, reasoning that 
significant binding of transcription factors with C-FOS may indicate a function with C-
FOS.  Using previously generated data from our system (Kim et al., 2010), we found 
significant binding for both NPAS4 and CBP at C-FOS peaks within the genome.  This 
suggested that NPAS4 and CBP may collaborate with C-FOS to drive neuronal activity-
dependent enhancers. 
 
Figure 3.21: ChIP-Seq signal for NPAS4 and CBP and C-FOS peaks 
Previously generated ChIP-Seq data for CBP and NPAS4 (Kim et al., 2010) was analyzed 
to evaluate the binding of these factors at sites of C-FOS binding throughout the genome.  
Average profiles of input-normalized CBP (black) and NPAS4 (red) ChIP-Seq signal 
before KCl stimulation (dashed lines) and after KCl stimulation (solid lines) are shown.  
Here, sites of C-FOS binding are defined as regions of the genome that exhibited a called 
C-FOS peak in three or more out of four separate C-FOS ChIP-Seq bioreplicates that 
were reduced by 50% or more in two out of two c-Fos RNAi ChIP-Seq bioreplicates.  
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We hypothesized that if CBP and NPAS4 collaborated with C-FOS to drive 
neuronal activity-dependent enhancers, we may expect a higher percentage of loci 
bound by C-FOS/NPAS4/CBP to exhibit increasing H3K27Ac in response to neuronal 
activity than loci bound by C-FOS but not NPAS4 or CBP.  To investigate this possibility, 
we evaluated the H3K27Ac behaviors of C-FOS peaks that were bound without NPAS4 
and CBP or were bound with NPAS4 and CBP.  We found that while only 5% of C-FOS 
peaks that were not bound by NPAS4 and CBP exhibited increasing H3K27Ac in 
response to neuronal activity, a striking 47% of C-FOS peaks that were bound by NPAS4 
and CBP exhibited increasing H3K27Ac in response to neuronal activity.  This suggested 
that sites within the genome that are bound by C-FOS/NPAS4/CBP are nearly 10 times 
more likely to function as neuronal activity-dependent enhancers than sites within the 
genome bound by C-FOS but not NPAS4 or CBP.  This suggested that NPAS4 and CBP 
may collaborate with C-FOS to drive neuronal activity-dependent enhancers throughout 
the genome.  Additional experiments will have to be done to understand the specific 
function of each of these factors in neuronal activity-dependent enhancer function. 
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Figure 3.22: H3K27Ac behaviors at loci bound by different complements of 
transcription factors 
The H3K27Ac behaviors of C-FOS peaks that were bound without NPAS4 and CBP (left 
panel) or were bound with NPAS4 and CBP (right panel) were investigated.  While only 
5% of C-FOS peaks that were not bound by NPAS4 and CBP exhibited increasing 
H3K27Ac in response to neuronal activity, a striking 47% of C-FOS peaks that were 
bound by NPAS4 and CBP exhibited increasing H3K27Ac in response to neuronal 
activity 
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3.4 DISCUSSION 
We have recently discovered that stimulus-responsive enhancers can be 
identified on the basis of rapidly increasing H3K27Ac levels in response to stimulation.  
We employed this dynamic chromatin signature to identify stimulus-responsive 
enhancers within the nervous system that respond to neuronal activity and BDNF 
stimulation.  Here, we characterized the transcriptional mechanisms underlying 
activity-responsive and BDNF-responsive neuronal enhancers.  We find that the AP1 
transcription factor complex plays an important role at neuronal enhancers that 
respond to neuronal activity, BDNF, or both.  We show that the AP1 motif is the most 
significantly enriched motif at all subsets of neuronal stimulus-responsive enhancers, 
that the AP1 transcription factors C-FOS and FOSB bind to stimulus-responsive 
enhancers, and that AP1 is required for responses to both neuronal activity and BDNF 
stimulation at a subset of neuronal enhancers.  By dissecting the function of the activity 
and BDNF responsive Nptx2 enhancer, we confirm the necessity of the AP1 
transcription factor in coordinating responses to activity and BDNF and also show that 
AP1 is not sufficient to generate responses to these stimuli.  AP1 must coordinate with 
other stimulus-specific transcription factors to generate stimulus-responses at 
enhancers.  In the case of the Nptx2 enhancer, AP1 coordinates with the activity-specific 
transcription factor NPAS4 to generate responses to neuronal activity.  These results 
begin to elucidate the transcriptional mechanisms underlying stimulus-responsive 
enhancers within the nervous system. 
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3.4.1 Multiple transcriptional mechanisms underlying stimulus 
responsive enhancers 
While AP1 transcription factors play a critical role at a subset of neuronal 
enhancers, transcriptional mechanisms independent of AP1 also exist to drive stimulus 
responses at enhancers.  We show that not all stimulus responsive enhancers are bound 
by FOS transcription factors and not all stimulus responsive enhancers are affected by 
the expression of a potent AP1 dominant negative transcription factor.  Hence, other 
mechanism likely exists at these enhancers.  This is consistent with the observation that 
multiple waves of transcription occur in response to extracellular stimuli.  Extracellular 
stimuli rapidly activate pre-existing transcription factors (such as CREB, MEF2, and 
SRF) within the cell that drive a first wave of transcription.  Many genes expressed in 
this first wave of transcription encode transcription factors (such as FOS, JUN, and 
NPAS4) that, once expressed, activate a second wave of transcription in response to 
extracellular stimuli.  It is possible that the assessment of H3K27Ac 2 hours after 
stimulation with KCl or BDNF best reveals active enhancers mediating the second wave 
of transcription.  This may be why AP1 appears to play a dominant role within the 
enhancers characterized in this study.  Assessment of inducible H3K27Ac at earlier time 
points after stimulation may better enable the understanding of AP1-independent 
mechanisms at stimulus-responsive enhancers.  
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3.4.2 Role of AP1 at neuronal stimulus-responsive enhancers 
While we find AP1 to play a critical role at neuronal stimulus-responsive 
enhancers, this is in stark contrast to historical studies of AP1.  Since enhancers have 
been difficult to identify until recently, historically much of the work on AP1 has focused 
on promoter elements that contain AP1 motifs.  The presence of AP1 motifs within 
promoter regions, the importance of these motifs in reporter assays, and the ability of 
AP1 transcription factors to bind these motifs in gel-shift assays was all taken as 
evidence that AP1 functioned predominantly at promoters of target genes to regulate 
transcription.  However, the studies that proposed this mechanism of function, being 
done long ago, were not able to demonstrate binding of AP1 transcription factors to 
promoters in neurons in vivo.  Here, we present for the first time ChIP-Seq data from 
mouse cortical neurons that clearly demonstrates that the vast majority of C-FOS and 
FOSB binding does not occur at promoter regions.  Furthermore, we find no evidence of 
C-FOS or FOSB binding at the promoters of reported FOS target genes in the nervous 
system.  For example, the first reported target gene for FOS in the nervous system was 
proenkephalin (Sonnenberg et al., 1989c).  The study that reported this target gene 
suggested that FOS bound to AP1 motifs near the promoter to regulate expression of this 
gene.  However, we find no evidence of C-FOS or FOSB binding at the promoter of this 
gene in any of our ChIP-Seq bioreplicates in response to neuronal activity or BDNF.  
While proenkephalin or other proposed target genes may be regulated by FOS 
transcription factors, our data suggests that the mechanisms of such regulation do not 
occur at promoters but likely occur at enhancers. 
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3.4.3 Genetic control of activity-regulated enhancers and human disease 
We have found that the human versions of many of our identified mouse activity-
regulated enhancers can drive reporter expression in response to depolarization when 
introduced into cultured mouse neurons (data not shown), which suggests that many of 
these regions might be functionally conserved between mouse and human.  Thus, the 
ability to identify a refined set of functional stimulus responsive enhancers should 
permit an accurate identification of activity-regulated enhancers in human neurons. 
Instances in which function is not conserved could provide insights into how the 
transcriptional responses of human neurons to synaptic activity have evolved.  Changes 
in the activity-regulated gene program during human evolution might allow for 
adaptations in synaptic plasticity and function that are thought to be critical for human 
specific cognitive abilities (Dolmetsch and Geschwind, 2011; Konopka and Geschwind, 
2010).  We have begun to elucidate how these elements are regulated by activity-
dependent transcription factors in mouse and how various transcription factor motifs 
correlate with inducible acetylation.  These data could be potentially utilized to better 
interpret the potential functional consequences of human single nucleotide 
polymorphisms (SNPs) in these regulatory regions (Maurano et al., 2012).  Indeed, the 
majority of variants within the genome appear to be in noncoding regions.  As a result, 
human variation at enhancer elements may contribute to different traits, common 
diseases, and rare diseases.  Exome sequencing studies of autistic individuals and their 
unaffected relatives have largely failed to identify recurrent de novo coding mutations 
that can explain the disease burden, indicating that non-coding variation could 
potentially play an important role in the genetics of autism (Buxbaum et al., 2012).  
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Given the proposed importance of synaptic signaling in autism spectrum disorders 
(Ebert and Greenberg, 2013), the identification of the cis-regulatory control of human 
activity-regulated transcription could provide a critical resource for the further 
elucidation of the genetics of these disorders. 
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3.5 MATERIALS AND METHODS 
3.5.1 Mouse cortical cultures 
Embryonic day 16.5 (E16.5) C57BL/6 embryonic mouse cortices were dissected 
and then dissociated for 10 minutes in 1× Hank’s Balanced Salt Solution (HBSS) 
containing 20 mg/mL trypsin (Worthington Biochemicals) and 0.32 mg/mL L-cysteine 
(Sigma).  Trypsin treatment was terminated by washing dissociated cells three times for 
two minutes each in dissociation medium consisting of 1× HBSS containing 10 
mg/mL trypsin inhibitor (Sigma).  Cells were then triturated using a flame-narrowed 
Pasteur pipette to fully dissociate cells.  After dissociation, neurons in were kept on ice 
in dissociation medium until plating.  Cell culture plates were pre-coated overnight with 
a solution containing 20 ug/mL poly-D-lysine (Sigma) and 4 ug/mL mouse laminin 
(Invitrogen) in water.  Prior to plating neurons, cell culture plates were washed three 
times with sterile distilled water and washed once with Neurobasal Medium (Life 
Technologies).  Neurons were grown in neuronal medium consisting of Neurobasal 
Medium containing B27 supplement (2%; Invitrogen), penicillin-streptomycin (50 g/ml 
penicillin, 50 U/mL streptomycin, Sigma) and glutamine (1 mM, Sigma).  At the time of 
plating, cold neuronal medium was added to neurons in dissociation medium to dilute 
neurons to the desired concentration.  Neurons were subsequently plated and placed in 
a cell culture incubator that maintained a temperature of 37 degrees C and a CO2 
concentration of 5%.  Two hours after plating neurons, medium was completely 
aspirated from cells and replaced with fresh warm neuronal medium.  Neurons were 
grown in vitro until the seventh day in vitro (DIV7). 
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3.5.1.1 Mouse cortical cultures for ChIP-Seq experiments 
For ChIP-Seq experiments, mouse cortical neurons were plated at an 
approximate density of 4×107 on 15-cm dishes. Neurons were plated in 30mL neuronal 
medium.  Ten mL of the medium was replaced with 12ml fresh warm neuronal medium 
on DIV3 and DIV6. 
3.5.1.2 Mouse cortical cultures for luciferase reporter assays 
For luciferase reporter assays, mouse cortical neurons were plated at an 
approximate density of 3×105 per well on 24-well plates. Neurons were plated in 500 ul 
neuronal medium.  On the DIV3, 100 uL fresh warm medium was added to neurons.  On 
DIV5 neurons were transfected (see section on transfection).  At the completion of 
transfection, conditioned medium containing 15% fresh neuronal medium was returned 
to neurons. 
3.5.1.3 Mouse cortical cultures for microarray experiments 
For microarray experiments, mouse cortical neurons were plated at an 
approximate density of 3×105 per well on 24-well plates.  Neurons were plated in 500 ul 
neuronal medium.  On the DIV5, neurons were infected for 6 hours with viral 
supernatant containing lentivirus expressing either a control RNAi or c-Fos RNAi.  At 
the completion of infection, wells were washed three times with warmed neuronal 
medium, and then conditioned medium containing 15% fresh medium was returned to 
neurons.  Four wells were used for each condition: one well was used to obtain protein 
lysates for western blot, three wells were used to obtain RNA for microarrays.  
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3.5.2 Stimulation with potassium chloride (KCl) 
Prior to KCl depolarization, neurons were quieted with 1  µM tetrodotoxin (TTX, 
Fisher) and 100  µM DL-2-amino-5-phosphopentanoic acid (DL-AP5, Fisher).  Neurons 
were subsequently stimulated by adding warmed KCl depolarization buffer (170 mM 
KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES) directly to the neuronal culture, to final 
concentration of 31% in the neuronal culture medium within the culture plate or well. 
3.5.2.1 KCl stimulation for ChIP-Seq experiments 
For KCl depolarization of neurons for ChIP-Seq experiments, DIV 6 neurons 
were quieted overnight with 1  µM TTX and 100  µM DL-AP5.  The next morning, neurons 
were left silenced (-KCl condition) or stimulated for 2  hours with KCl (+KCl condition). 
3.5.2.2 KCl stimulation for luciferase reporter assays 
For KCl depolarization of neurons for luciferase reporter assays, DIV 7 neurons 
were quieted for two hours with 1  µM TTX and 100  µM DL-AP5.  Two hours later, 
neurons were left silenced (-KCl condition) or stimulated for 6  hours with KCl (+KCl 
condition). 
3.5.2.3 KCl stimulation for microarray experiments 
For KCl depolarization of neurons for microarray experiments, DIV 7 neurons 
were quieted for two hours with 1  µM TTX and 100  µM DL-AP5.  Two hours later, 
neurons were left silenced (0 hour condition) or stimulated for 1, 3, or 6  hours with KCl.  
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3.5.3 Stimulation with brain derived neurotrophic factor (BDNF) 
3.5.3.1 BDNF stimulation for ChIP-Seq experiments 
For BDNF stimulation of neurons for ChIP-Seq experiments, the volume of 
conditioned medium on DIV6 neurons was reduced to 25 mL.  On DIV7, neurons were 
left in a basal condition (-BDNF condition) or stimulated for 2   hours with 50ng/mL 
recombinant human BDNF (Fisher) (+BDNF condition). 
3.5.3.2 BDNF stimulation for luciferase reporter assays 
For BDNF stimulation of neurons for luciferase reporter assays, DIV7 neurons 
were left in a basal condition (-BDNF condition) or stimulated for 6   hours with 
50ng/mL recombinant human BDNF (Fisher) (+BDNF condition). 
 
3.5.4 Lentivirus infection 
The pLLx3.7 backbone was used for generation of lentivirus as previously 
described (Lois et al., 2002; Rubinson et al., 2003). 
 
3.5.5 H3K27Ac Chromatin immunoprecipitation sequencing (ChIP-Seq) 
Forty million mouse cortical neurons cultured to in vitro day 7 were used for each 
ChIP-Seq library construction.  Typically 20-40 million cortical neurons were used for a 
single ChIP experiment.  To cross-link protein-DNA complexes, media was removed 
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from neuronal cultures and crosslinking-buffer (0.1 M NaCl, 1 mM EDTA, 0.5 mM 
EGTA, 25 mM HEPES-KOH, pH 8.0) containing 1% formaldehyde was added for 10 
minutes at room temperature.  Cross-linking was quenched by adding 125 mM glycine 
for five minutes at RT. Cells were then rinsed three times in ice-cold PBS containing 
complete protease inhibitor cocktail tablets (Roche) and collected by scraping.  Cells 
were pelleted and either stored at -80 degrees C until use or immediately processed.  
Cell pellets were lysed by 20 cell pellet volumes (CPVs) of buffer 1 (50 mM HEPES-KOH, 
pH 7.5, 140 mM NaCl, 1 mM EDTA, pH 8.0, 10 % Glycerol, 0.5 % NP-40, 0.25 % Triton 
X-100, complete protease inhibitor cocktail) for 10 min at 4 degrees C.  Nuclei were then 
pelleted by centrifugation at 3000 rpm for 10 min at 4 degrees C.  The isolated nuclei 
were rinsed with 20 CPVs of buffer 2 (200 mM NaCl, 1 mM EDTA, pH 8.0, 0.5 mM 
EGTA, pH 8.0, 10 mM Tris-HCl, pH 8.0, complete protease inhibitor cocktail) for 10 
min at RT and re-pelleted.  Next, 4 CPVs of buffer 3 (1 mM EDTA, pH 8.0, 0.5 mM 
EGTA, pH 8.0, 10 mM Tris-HCl, pH 8.0, complete protease inhibitor cocktail) were 
added to the nuclei and sonication was carried out using a Misonix 3000 Sonicator 
(Misonix) set at a power setting of 7.5 (equivalent to 24 watts).  20 pulses of 15 seconds 
each were delivered at this setting, which resulted in genomic DNA fragments with sizes 
ranging from 200 bp to 2 kb. Insoluble materials were removed by centrifugation at 
20,000 rpm for 10 min at 4 degrees C. The supernatant was transferred to a new tube 
and the final volume of the resulting nuclear lysate was adjusted to 1 mL by adding 
buffer 3 supplemented with 0.3 M NaCl, 1 % Triton X-100, 0.1 % Deoxycholate.  The 
lysate was pre-cleared by adding 100 ul of pre-rinsed Protein A/G Agarose (Sigma) per 1 
ml of the lysate and incubating for 1 hour at 4 degrees C.  After pre-clearing, ten percent 
of the ChIP sample (50 ul from 500 ul lysate) was saved as input material.  The 
  131 
remaining lysate was incubated with 4 ug antibodies for immunoprecipitation.  The 
antibodies used in this study are shown in Table 6: 
Table 6: Antibodies used for ChIP-Seq experiments 
Transcription factor Antibody or antibodies used 
MEF2A Custom 
MEF2D Custom 
C-FOS sc52, sc7202 (Santa Cruz) 
FOSB sc7203 (Santa Cruz) 
 
 
The antibody incubation was carried out overnight at 4 degrees C.  The next day, 30 ul of 
pre-rinsed Protein A/G PLUS Agarose beads (Santa Cruz Biotechnology) was added to 
each ChIP reaction and further incubated for 1 hour at 4 degrees C. The beads bound by 
immune-complexes were pelleted and washed twice with each of the following buffers: 
low salt buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris-HCl, pH 8.1, 
150mM NaCl), high salt buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris-
HCl, pH 8.1, 500mM NaCl) and LiCl buffer (0.25M LiCl, 1% IGEPAL CA630, 1% 
deoxycholic acid (sodium salt), 1mM EDTA, 10mM Tris, pH 8.1).  In each wash, the 
beads were incubated with wash buffer for 10 min at 4 degrees C while nutating.  The 
washed beads were then rinsed once with 1x TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM 
EDTA).  The immunoprecipitated material was eluted from the beads twice by adding 
100 ul of elution buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, pH 8.0, 1 % SDS) to each 
ChIP reaction and incubating the sample at 65 degree C for 30 min with brief vortexing 
every 2 min.  150 ul of elution buffer was also added to the saved input material (50 ul) 
and this sample was processed together with the ChIP samples.  The eluates were 
combined and crosslinking was reversed by incubation at 65 degrees C overnight.  The 
next day, 7 ug RNase A (affinity purified, 1mg/mL; Invitrogen) was added to each 
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sample and samples were incubated for 37 degrees C for one hour.  Then, 7 uL 
Proteinase K (RNA grade, 20mg/mL; Invitrogen) was added to each sample and 
samples were incubated at 55 degrees C for two hours.  The immunoprecipitated 
genomic DNA fragments were then extracted once with Phenol:Chloroform:Isoamyl 
Alcohol (25:24:1, pH 7.9; Life Technologies) and then back extracted with water.  The 
resulting genomic DNA fragments were then purified using the QIAquick PCR 
purification kit (Qiagen) and DNA fragments were eluted in 100 ul of Buffer EB (elution 
buffer consisting of 10 mM Tris-HCl, pH 8.5, Qiagen).  Samples were assessed for 
enrichment by quantitative PCR using primers to different genomic regions.  Samples 
with significant enrichment over negative regions were submitted to the Beijing 
Genomic Institute (BGI) for 50 base pair single end sequencing on the Illumina Hiseq 
2000 platform.  For each sample, over 20 million clean reads were obtained. 
 
3.5.6 ChIP-Seq analysis 
3.5.6.1 Initial processing 
Sequencing data was obtained from BGI in gzipped fastq file format.  Files were 
transferred and unzipped.  Then, sequencing reads were aligned to the July 2007 
assembly of the mouse genome (NCBI 37, mm9) using the Burrows-Wheeler Aligner 
(BWA) (Li and Durbin, 2009) with default settings.  The resulting bwa files were then 
converted to sam files and uniquely mapped reads were extracted from the sam files.  
Sam files of the uniquely mapped reads were then converted to bam files.  Bam files 
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were then used for peak calling using Model-based Analysis of ChIP-Seq (MACS) (Zhang 
et al., 2008) with the following parameters: -f BAM -g mm. 
3.5.6.2 Visualizing ChIP-Seq data on the UCSC genome browser 
ChIP-Seq bam files were converted to bigwig track format to display the number 
of input normalized ChIP-Seq reads, normalized to 20 million total reads. 
3.5.6.3 Characterization of genomic distribution of FOS binding sites 
C-FOS and FOSB peaks were classified based on their location relative to genes in 
the NCBI Reference Sequence Database (RefSeq).  Peaks were classified as being 
proximal if they were within 1kb of an annotated transcriptional start site (TSS).  
H3K27Ac peaks were classified as being distal if they were greater than 1kb from an 
annotated transcriptional start site (TSS). 
3.5.6.4 Quantification of ChIP-Seq signal at enhancers 
For transcription factors (MEF2A, MEF2D, C-FOS, FOSB), the number of input-
normalized ChIP-Seq reads within an 800 bp window centered on each enhancer was 
taken to be the ChIP-Seq signal at the enhancer. 
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3.5.7 Luciferase reporter assays 
3.5.7.1 Nptx2 reporter plasmid design 
All luciferase reporter plasmids used were newly developed for this study.  Most 
luciferase reporter plasmids used were based on the Nptx2 gene, and hence this reporter 
was termed the Nptx2 reporter.  To develop the Nptx2 reporter, we cloned the 4355 bp 
region upstream of the Nptx2 coding sequence from C57BL/6 purified mouse genomic 
DNA between the NheI and EcoRV restriction sites within the multiple cloning site of 
the promoterless pGL4.11 reporter plasmid (Promega) using the primers shown in Table 
7, with 5’ clamp shown in red, NheI and EcoRV sites shown in green: 
Table 7: Primers used to clone the Nptx2 upstream regulatory region into 
pGL4.11 
Primer Sequence (5’ à  3’) 
Forward primer 5’ GCGCGCTAGCTTCCTGGCTTGTAGTGACCT 3’ 
Reverse primer 5’ GCGCGATATCCTCGCTGACCTGTGTGCTCACTTCA 3’ 
 
pGL4.11 was chosen as the host plasmid since it contained the luc2P reporter gene, 
which contains an hPEST protein destabilization sequence.  We found that the luc2P 
reporter responded more quickly and with greater magnitude to stimuli than luc2 
reporters.  Using PCR driven overlap extension (Heckman and Pease, 2007), the Nptx2 
reporter was then modified so that the 1216 bp Nptx2 upstream enhancer (located -3607 
to -2391 relative to the start of the Nptx2 coding sequence) was replaced with a multiple 
cloning site containing SbfI, PacI, PmeI, and AscI restrictions sites.  In order to do this, 
the primers shown in Table 8 were used (A, B, C, D nomenclature same as described in 
(Heckman and Pease, 2007)), with 5’ clamp shown in red; NheI and EcoRV sites shown 
in green; SbfI, PacI, PmeI, and AscI sites shown in blue; and spacers shown in orange.  
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Table 8: Primers used to replace the Nptx2 upstream enhancer with a 
multiple cloning site 
Primer Sequence (5’ à  3’) 
A 5’ GCGCGCTAGCTTCCTGGCTTGTAGTGACCT 3’ 
B 5’ GGCGCGCCACACGTTTAAACGCGCTTAATTAAGTGTCCTGCAGGTTGTGTGAGACACTGTTTCCA 3’ 
C 5’ CCTGCAGGACACTTAATTAAGCGCGTTTAAACGTGTGGCGCGCCAGCTAGTAACAGTTGGCATT 3’ 
D 5’ GCGCGATATCCTCGCTGACCTGTGTGCTCACTTCA 3’ 
 
 
 The multiple cloning site was inserted into the Nptx2 upstream regulatory region 
to create a modified Nptx2 reporter so that various enhancers could be easily cloned into 
this multiple cloning site.  We verified that the modified Nptx2 reporter in which the 
Nptx2 enhancer had been cloned into the multiple cloning site had the same inducibility 
as the wild-type Nptx2 reporter (data not shown).  This suggested that the multiple 
cloning site did not affect the function of the reporter and that other enhancers could be 
similarly cloned into this multiple cloning site without adverse affects on enhancer 
function. 
3.5.7.2 Enhancer sequences for wild-type of mutated C-FOS bound enhancers 
Activity-dependent enhancers containing AP1 sites, exhibiting reproducible and 
specific binding by the AP1 transcription factor C-FOS, were cloned between the SbfI 
and AscI sites within the multiple cloning site of the modified Nptx2 reporter.  For most 
enhancers, we observed that the trough between H3K27Ac peak shoulders as well as 
DNAseI hypersensitivity typically could be localized to a region less than 500bp.  As a 
result, we synthesized approximately 500 bp genomic blocks for each enhancer of 
interest using gBlocks Gene Fragments (IDT).  For each enhancer, we designed a wild-
type version and a version of the enhancer in which the AP1 sites were mutated by one 
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base pair (TGAGTCAàTAAGTCA), which has been shown previously to abrogate AP1 
binding (Risse et al., 1989).  These gBlocks are shown in Table 9, with the clamp shown 
in bold, the SbfI site in green, and the AscI site in red..  In the case where no gBlock is 
shown, the sequence was obtained via PCR. 
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Table 9: gBlocks designed to create wild-type and AP1 mutant versions of 8 
neuronal enhancers 
Enh 500bp gBlock AP1 mutant gBlock 
e4 GCGTCCTGCAGGcagagagctgcctatgcgtctatttatgtctcactggccaaaacttactcac
atgtctacccctcaaagaaagtaagaatgtcttctattatttgggtgactcatctagccaATGAGCAG
GAAGAGAGTGAAATGTGGGGTGCGCCAGACTCTCCCAGCCATAGAGC
ATCACGCCAAAATGTGGAAACAGCAAAGCAAACCCCTGGGAAGCCAGC
CGCCCAGCCTGTGTGAGTCACACAACTCGGTGACTCACTCCCGCCCCC
AGAGCTTGTCAGTGCAGCTGAGTTTCTCAGCATCGTGAAACTTAAGAG
ATTGCTAAAATAGTCACCGCTCTGGATGGTGTGCTCCTGGATGCAAAG
CATCTACTTAGCATTTAGCATGTTTCCTAAGTGTCCAAATTACATGTTT
CACACAAAAATTACCGTCTCTGTCAAGCACTAAAGGTAAATGCTCTTTA
ACATCAACAGTTACTTCAGGGCGCGCCATAC 
GCGTCCTGCAGGcagagagctgcctatgcgtctatttatgtctcactggccaaaactaactcacatg
tctacccctcaaagaaagtaagaatgtcttctattatttgggtaactcatctagccaATGAGCAGGAAG
AGAGTGAAATGTGGGGTGCGCCAGACTCTCCCAGCCATAGAGCATCACGC
CAAAATGTGGAAACAGCAAAGCAAACCCCTGGGAAGCCAGCCGCCCAGCC
TGTGTaAGTCACACAACTCGGTaACTCACTCCCGCCCCCAGAGCTTGTCAG
TGCAGCTGAGTTTCTCAGCATCGTGAAACTTAAGAGATTGCTAAAATAGTC
ACCGCTCTGGATGGTGTGCTCCTGGATGCAAAGCATCTACTTAGCATTTA
GCATGTTTCCTAAGTGTCCAAATTACATGTTTCACACAAAAATTACCGTCT
CTGTCAAGCACTAAAGGTAAATGCTCTTTAACATCAACAGTTACTTCAGG
GCGCGCCATAC 
e16 No wild-type gBlock ordered; wild-type sequence was obtained by PCR GCGTCCTGCAGGTTAGATGTGCCCAGAGAACGCTTGTTTGCTTTCAGTG
CCCCTAAATTACAATTCTTTGTGCACTTCCTGTTTCACAGTTAATGGCTGA
GATCTGTGACTCTAGCAACACTGTTGTTTTTCACTCCAGTCCGTTTCTGCT
AGAAACTACGCAGCCTGTGTACTGTCTGGAACATGTTGCACGCATGTGCT
TTGAGAAGAACAGCATGCATAGCTaACTAATTTCAAAAACAGCCTATTTAT
AGTCCTTCAGAGTAATTGTCAGACACTTGGTCTGTGCGCTTTTGCTCACGT
CATGTGGATCAACATGGCTTTTTAAATGGAGATAAATTGTTTTTTATGTGT
GGGTaATTCATTTGATACTTCTCTATAAATTCATACCCCAACTGTGTCTCTG
AAGTaTGTCACTGCAGTAATAGCCCAGGGAGGAGTTTTCAACAATTAGCAT
TGGATTCAATATGAGATGGTGCTTTAGAGAAGGCGCGCCATAC 
e17 GCGTCCTGCAGGCATAATCATTTTGGAAAATTCAGTTTCAGCACAGA
GATTTACAAAAGCCCAGCGGATCCTTTTGTCATCCAGCCTAAGTATTTA
CCGGGTGCCCTTAGGGTGCCTAATACTGGATGAGACTGCTTTTGTGAG
CAAGCCAGCGGGTCCTCAGCCATGAAAATAGAAATTTAATCACTTGCT
CATCCAAGCATTTCCCTTCTGCTTCTGCAATATGCTTTTTTTGTGTGTG
TGAATGACTAACCAAACGCTACAAAGAGCTTTCAGGTCCGGGCTGAAG
ATGCGGGGAGGAGAGATGACTCATCCCTCTGACGTCAGAGCCTCCTTC
CTTTCAGAGGCGGAGGAAGAGAGTGGCAAAGGCCTGACAGAAAGGAG
AATGACCCAAATGCCCTCCTGAGAACTGTGTGGGTCAGAACTGCTTCC
TCCTCCCCCGCCAGGCAAAGATGATTATCACTCAAAGTTTAAACTGTG
AAATTTCGGGCGCGCCATAC 
GCGTCCTGCAGGCATAATCATTTTGGAAAATTCAGTTTCAGCACAGAGA
TTTACAAAAGCCCAGCGGATCCTTTTGTCATCCAGCCTAAGTATTTACCGG
GTGCCCTTAGGGTGCCTAATACTGGATGAGACTGCTTTTGTGAGCAAGCC
AGCGGGTCCTCAGCCATGAAAATAGAAATTTAATCACTTGCTCATCCAAGC
ATTTCCCTTCTGCTTCTGCAATATGCTTTTTTTGTGTGTGTaAATaACTAAC
CAAACGCTACAAAGAGCTTTCAGGTCCGGGCTGAAGATGCGGGGAGGAG
AGATaACTCATCCCTCTGACGTCAGAGCCTCCTTCCTTTCAGAGGCGGAGG
AAGAGAGTGGCAAAGGCCTGACAGAAAGGAGAATGACCCAAATGCCCTCC
TGAGAACTGTGTGGGTCAGAACTGCTTCCTCCTCCCCCGCCAGGCAAAGA
TGATTATaACTCAAAGTTTAAACTGTGAAATTTCGGGCGCGCCATAC 
e18 GCGTCCTGCAGGCTTTATTTGGAATATTTCCGTTTCTTCTGACATTTA
GTGAGCCGCTAGAGAAAGCTGATGCGCGTAGCCTGCTGTCTTTTACAT
CAGTTATTTAGTGAGTCGAGCAAGAATACATTAGGCCTATTTTTAGCA
TGTTCTTTCTTATAAGCGCATCATGAACGTCAGAGAGTCTTAgcagcctcac
taatgtgggaagtgaacttgtcagatatcagttcctctgcagggtcaggcttaattgaaacgccgagatg
gagatagggaaccacactaaagaaaactccaagtgattcaaggagtggtatttataaacctgagtcagc
agtgaatcagctctcaagtgggggctcaggggacTGCTTGGTTAAAGCGACAACAAAG
CCAAATTGAAGCTGAGCCCGCCCGCCTGGGCTTCTTGTTCGATATCCT
GGGTTTTCTCTGGAATTACTGCTGTACCTCTGCAGAAGTCTGAGGAGG
GCGCGCCATAC 
GCGTCCTGCAGGCTTTATTTGGAATATTTCCGTTTCTTCTGACATTTAGT
GAGCCGCTAGAGAAAGCTGATGCGCGTAGCCTGCTGTCTTTTACATCAGT
TATTTAGTaAGTCGAGCAAGAATACATTAGGCCTATTTTTAGCATGTTCTT
TCTTATAAGCGCATCATGAACGTCAGAGAGTCTTAgcagcctcactaatgtgggaagt
gaacttgtcagatatcagttcctctgcagggtcaggcttaattgaaacgccgagatggagatagggaaccaca
ctaaagaaaactccaagtaattcaaggagtggtatttataaacctaagtcagcagtaaatcagctctcaagtg
ggggctcaggggacTGCTTGGTTAAAGCGACAACAAAGCCAAATTGAAGCTGAG
CCCGCCCGCCTGGGCTTCTTGTTCGATATCCTGGGTTTTCTCTGGAATTAC
TGCTGTACCTCTGCAGAAGTCTGAGGAGGGCGCGCCATAC 
e28   
e29 GCGTCCTGCAGGCAGTGCTAAAAAGCTTACAGAGATTGTCTGGCAA
GCACTGAAATATAAAAATTTACTGAAAGCTGAAGACTAATTTAGAAGT
GTGTTTTAAAAAGAACTCGTTGCCTAGGCTTTTTGGTGCTACCCATTAA
ACAAACAAATGTTGCTAATGTTAAAATGTGATTAGACCTAGTCAAATA
GACAAACATCTCTAATGTAACGCATAAGCATTACAGCAAGCACGATGA
CACAGAAAGTGAGTCATCTGTGTCTGAGAGATGCCTGGAATTCTGTGA
CTCAATGCTCACAATACTATGAAGCTATTTTATGACTCATACAAACATA
GCATTCTTCTATGCAAATCAAAATAAAAGGGAATTAATTAATAATGAA
AGAAAAAATACAGATCTTATTTCACTCTACTAGAGTTCAACACTGAAAA
TTAGGCATTAAAATAGCTAAAAGTCCCTTTAGTAAAATATGGCTTTAAA
ACTTATGGCGCGCCATAC 
GCGTCCTGCAGGCAGTGCTAAAAAGCTTACAGAGATTGTCTGGCAAGCA
CTGAAATATAAAAATTTACTGAAAGCTGAAGACTAATTTAGAAGTGTGTTT
TAAAAAGAACTCGTTGCCTAGGCTTTTTGGTGCTACCCATTAAACAAACAA
ATGTTGCTAATGTTAAAATGTGATTAGACCTAGTCAAATAGACAAACATCT
CTAATGTAACGCATAAGCATTACAGCAAGCACGATaACACAGAAAGTaAGT
CATCTGTGTCTGAGAGATGCCTGGAATTCTGTaACTCAATGCTCACAATAC
TATGAAGCTATTTTATaACTCATACAAACATAGCATTCTTCTATGCAAATCA
AAATAAAAGGGAATTAATTAATAATGAAAGAAAAAATACAGATCTTATTTC
ACTCTACTAGAGTTCAACACTGAAAATTAGGCATTAAAATAGCTAAAAGTC
CCTTTAGTAAAATATGGCTTTAAAACTTATGGCGCGCCATAC 
e30 GCGTCCTGCAGGGCATTGCTACTAGGTGATATAAATGAAATGTCATT
TCACTTCACAGAAGGAGCTGCCAGTTATTTTGCATAACAGACCAAGAA
TGAAAAGGATCATTTTGTACTGTTAAAGCCTTTGAGAGGAAGTGATCT
ATAACATGGAACTGAACAGGAAACTTCTTAAAGCAAGCCTGAGTCACT
GCAAGCActcagaaagacagctgtgactcatcacaggtcacccagaggctggggctagagctgga
aatagaacacagacctcggccttttctccccacctacttcctctgACGACTTACATCGATCTG
TTGAGTCATGAGACCATAACGTAGTGCAGCTGTTTCCTGAACAGCTTT
TCATTAAGGATTTTTGGCTTGTTCTAGTTTACTCAGCAGAAGCAGTACT
TACTAAAGAGGCATTGAATTTTTATGCAGTGAACAAAGAAGCTAAGAA
ATGCAACAACAGAATTTGCTTACAGGCGCGCCATAC 
GCGTCCTGCAGGGCATTGCTACTAGGTGATATAAATGAAATGTCATTTC
ACTTCACAGAAGGAGCTGCCAGTTATTTTGCATAACAGACCAAGAATGAA
AAGGATCATTTTGTACTGTTAAAGCCTTTGAGAGGAAGTGATCTATAACAT
GGAACTGAACAGGAAACTTCTTAAAGCAAGCCTaAGTCACTGCAAGCActca
gaaagacagctgtaactcatcacaggtcacccagaggctggggctagagctggaaatagaacacagacctc
ggccttttctccccacctacttcctctgACGACTTACATCGATCTGTTaAGTCATGAGACC
ATAACGTAGTGCAGCTGTTTCCTGAACAGCTTTTCATTAAGGATTTTTGGC
TTGTTCTAGTTaACTCAGCAGAAGCAGTACTTACTAAAGAGGCATTGAATT
TTTATGCAGTGAACAAAGAAGCTAAGAAATGCAACAACAGAATTTGCTTA
CAGGCGCGCCATAC 
e31 GCGTCCTGCAGGaaaccctgaGACAGCAAGGATTACAAAAATGTCTAAA
ATTTTTGGGATCTAGTATTATGATTTTCATCATTCTATAATGTGAACAT
ATGTTAAAGTGCTACACTGGACCCATAATTTTAGTAATTACAGCAATAC
TTTCTAATTTTAAGTTCAACACATTTTATTTGAATCATCAGAGACTTGT
GCCAGAAAGCAAACATCTTAGTTCTTAAATGTGTTCTATCTTTAAAATG
TCTTTGCTAATTTAAATAGGAAAAATGTTTAGTTGATTCAATGATTCAG
TCGGTGGTAATGATGTAATTCAGTGAATCATAGCTCTCCCTTCTTTCTT
CTCACAGTAACTCTAGATTTGATAGTGTTTGAAAATCTTTTGGTTATTT
TAAAAAACTCTGAATGAGACATAGAGTTCTGAATTCTAAGGAAAGTAC
ACAGCAAGGCGGCACCAAAGGTCTATTCTTCTGTTAAGTAGTAGCAAG
GGCGCGCCATAC 
GCGTCCTGCAGGaaaccctgaGACAGCAAGGATTACAAAAATGTCTAAAAT
TTTTGGGATCTAGTATTATGATTTTCATCATTCTATAATGTGAACATATGT
TAAAGTGCTACACTGGACCCATAATTTTAGTAATTACAGCAATACTTTCTA
ATTTTAAGTTCAACACATTTTATTTaAATCATCAGAGACTTGTGCCAGAAA
GCAAACATCTTAGTTCTTAAATGTGTTCTATCTTTAAAATGTCTTTGCTAAT
TTAAATAGGAAAAATGTTTAGTTaATTCAATaATTCAGTCGGTGGTAATGA
TGTAATTCAGTaAATCATAGCTCTCCCTTCTTTCTTCTCACAGTAACTCTAG
ATTTGATAGTGTTTGAAAATCTTTTGGTTATTTTAAAAAACTCTGAATGAG
ACATAGAGTTCTGAATTCTAAGGAAAGTACACAGCAAGGCGGCACCAAAG
GTCTATTCTTCTGTTAAGTAGTAGCAAGGGCGCGCCATAC 
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Due to a low quantity of gBlock DNA provided, we also designed primers to PCR 
amplify the desired sequence from gBlock fragments.  These primers are shown in Table 
10, with the clamp shown in red, and the SbfI and AscI sites shown in blue. 
Table 10: PCR primers to amplify gBlock fragments 
Enh Forward primer (5’ à  3’) Reverse primer (5’ à  3’) 
e4 GCGTCCTGCAGGCAGAGAGCTGCCTATGCGTC GTATGGCGCGCCCTGAAGTAACTGTTGATGTT 
e16 GCGTCCTGCAGGTTAGATGTGCCCAGAGAACG GTATGGCGCGCCTTCTCTAAAGCACCATCTCA 
e17 GCGTCCTGCAGGCATAATCATTTTGGAAAATT GTATGGCGCGCCCGAAATTTCACAGTTTAAAC 
e18 GCGTCCTGCAGGCTTTATTTGGAATATTTCCG GTATGGCGCGCCCTCCTCAGACTTCTGCAGAG 
e28 GCGTCCTGCAGGCCATTTCTCTTTCCTCCCCA GTATGGCGCGCCGGACCCCTACCTCTCACTTT 
e29 GCGTCCTGCAGGCAGTGCTAAAAAGCTTACAG GTATGGCGCGCCATAAGTTTTAAAGCCATATT 
e30 GCGTCCTGCAGGGCATTGCTACTAGGTGATAT GTATGGCGCGCCTGTAAGCAAATTCTGTTGTT 
e31 GCGTCCTGCAGGAAACCCTGAGACAGCAAGGA GTATGGCGCGCCCTTGCTACTACTTAACAGAA 
3.5.7.3 Generation and use of the AP1 dominant negative A-Fos 
A plasmid containing N-terminal Flag-tagged A-Fos (Ahn et al., 1998; Olive et al., 
1997) was obtained from Addgene (Plasmid #33353, Addgene). The A-Fos gene was 
PCR amplified and cloned into a custom designed pLenti-GB-hUb-IRES-EGFP lentiviral 
vector between the human Ubiquitin C promoter and the IRES sequence using AscI and 
EcoR1 sites.  For use in a luciferase assay, the 500ng filler pCS2 DNA was replaced 
250ng pCS2, 125 ng empty pLenti-GB-hUb-IRES-EGFP vector, and 125ng A-Fos.  This 
was compared to a condition transfected with 250ng pCS2, 250 ng empty pLenti-GB-
hUb-IRES-EGFP vector. 
3.5.7.4 Nptx2 upstream enhancer truncations  
To identify the minimal enhancer element within the Nptx2 upstream enhancer 
capable of driving stimulus-responsive transcription, we first minimized the Nptx2 
reporter to 560bp, removing the regions further outside the H3K27Ac trough and 
DNAseI hypersensitive site. In an attempt to truncate the Nptx2 enhancer further, we 
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sequentially removed about 50bp at a time.  We designed eight constructs to clone from 
the Nptx2 reporter, the primers for which are listed in Table 11. 
Table 11: Primers to truncate the Nptx2 enhancer to identify the minimal 
sequence capable of driving stimulus-responsive transcription 
 Forward primer (5’ -> 3’) Reverse primer (5’ -> 3’) 
NUe560bp GCGTCCTGCAGGTGAAATTCAGCACCGAGGAT GTATGGCGCGCCTTCTTCCTCACAGCACAGAA 
   
mNUedel1 gcatgtCCTGCAGGCCTTGAATTCCGTGCTATTGAGCAC gcatgtGGCGCGCCTTCTTCCTCACAGCACAGAAACCGTCC 
mNUedel2 gcatgtCCTGCAGGTGGCTAAGAGGGGAGGAAATGC gcatgtGGCGCGCCTTCTTCCTCACAGCACAGAAACCGTCC 
mNUedel3 gcatgtCCTGCAGGGATAGGTTCTTCTGACATCGTGGTGG gcatgtGGCGCGCCTTCTTCCTCACAGCACAGAAACCGTCC 
mNUedel4 gcatgtCCTGCAGGTGCATGTGAGAAAGAACCAGGGAGCC gcatgtGGCGCGCCTTCTTCCTCACAGCACAGAAACCGTCC 
mNUedel5 gcatgtCCTGCAGGTGGAGGTAGAACAGCTCATTAGG gcatgtGGCGCGCCTTCTTCCTCACAGCACAGAAACCGTCC 
mNUedel6 gcatgtCCTGCAGGGGTTAAGTCTGTACCCGGCTCT gcatgtGGCGCGCCTTCTTCCTCACAGCACAGAAACCGTCC 
mNUedel7 gcatgtCCTGCAGGGCCGACATAGTGAATGAGTGGG gcatgtGGCGCGCCTTCTTCCTCACAGCACAGAAACCGTCC 
mNUedel8 gcatgtCCTGCAGGTGAAATTCAGCACCGAGGATAGTTCC gcatgtGGCGCGCCGCGTGCATGACTCACCCTACCCA 
   
NUe180bp gcatgtCCTGCAGGGCCGACATAGTGAATGAGTGGG gcatgtGGCGCGCCGCGTGCATGACTCACCCTACCCA 
 
3.5.7.5 Nptx2 reporter scrambling 
To identify the crucial sequences within the minimized Nptx2 enhancer that 
contributed to the responsiveness of this enhancer to KCl and BDNF stimulation, we 
sequentially scrambled ~7-10 bases at a time from an already minimized reporter.  As 
before, we designed genomic blocks (gBlocks Gene Fragments, IDT) containing the 
scrambled mutations that we used as PCR templates.  gBlocks were PCR amplified using 
a common forward primer (5’ ttcctggcttgtagtgacct 3’) and a common reverse primer (5’ 
agcaagccttgttgtttctg 3’).  The gBlocks are shown in Table 12. 
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Table 12: gBlock sequences synthesized to comprehensively scramble the 
minimal Nptx2 enhancer 
 
Name primer/gBlock 
  
5_mNUeSC
RATtoCG-9-
-1 
ttcctggcttgtagtgacctGCGTCCTGCAGGTAATCACGCGTGAATGAGTGGGTGGTTACTATGCTGTTGCACCGGTTACACTAAGAGATTAGGTGGCAGTG
ATTCACTGCTGCAGATCTGCACGACTTTCTCAAGTAGCAGAAAAATCTGTGGGCCCTGGGCTCTGTCACTCGCACAGCCCTTCTCATGGGTAGGGT
GAGTCATGCACGCAGGATCTTTCAGGTGGACGGTTTCTGTGCTGTGAGGAAGAAGGCGCGCCATACcagaaacaacaaggcttgct 
6_mNUeSC
RATtoCG1-9 
ttcctggcttgtagtgacctGCGTCCTGCAGGGCCGACATATGTCCGTCTTGGGTGGTTACTATGCTGTTGCACCGGTTACACTAAGAGATTAGGTGGCAGTG
ATTCACTGCTGCAGATCTGCACGACTTTCTCAAGTAGCAGAAAAATCTGTGGGCCCTGGGCTCTGTCACTCGCACAGCCCTTCTCATGGGTAGGGT
GAGTCATGCACGCAGGATCTTTCAGGTGGACGGTTTCTGTGCTGTGAGGAAGAAGGCGCGCCATACcagaaacaacaaggcttgct 
7_mNUeSC
RATtoCG10-
19 
ttcctggcttgtagtgacctGCGTCCTGCAGGGCCGACATAGTGAATGAGGTTTGTTGGCCTATGCTGTTGCACCGGTTACACTAAGAGATTAGGTGGCAGTG
ATTCACTGCTGCAGATCTGCACGACTTTCTCAAGTAGCAGAAAAATCTGTGGGCCCTGGGCTCTGTCACTCGCACAGCCCTTCTCATGGGTAGGGT
GAGTCATGCACGCAGGATCTTTCAGGTGGACGGTTTCTGTGCTGTGAGGAAGAAGGCGCGCCATACcagaaacaacaaggcttgct 
8_mNUeSC
RATtoCG20-
29 
ttcctggcttgtagtgacctGCGTCCTGCAGGGCCGACATAGTGAATGAGTGGGTGGTTAAGCGTAGTGGGCACCGGTTACACTAAGAGATTAGGTGGCAGT
GATTCACTGCTGCAGATCTGCACGACTTTCTCAAGTAGCAGAAAAATCTGTGGGCCCTGGGCTCTGTCACTCGCACAGCCCTTCTCATGGGTAGG
GTGAGTCATGCACGCAGGATCTTTCAGGTGGACGGTTTCTGTGCTGTGAGGAAGAAGGCGCGCCATACcagaaacaacaaggcttgct 
9_mNUeSC
RATtoCG30-
39 
ttcctggcttgtagtgacctGCGTCCTGCAGGGCCGACATAGTGAATGAGTGGGTGGTTACTATGCTGTTTACAATTGGCCACTAAGAGATTAGGTGGCAGTG
ATTCACTGCTGCAGATCTGCACGACTTTCTCAAGTAGCAGAAAAATCTGTGGGCCCTGGGCTCTGTCACTCGCACAGCCCTTCTCATGGGTAGGGT
GAGTCATGCACGCAGGATCTTTCAGGTGGACGGTTTCTGTGCTGTGAGGAAGAAGGCGCGCCATACcagaaacaacaaggcttgct 
10_mNUeSC
RATtoCG40-
49 
ttcctggcttgtagtgacctGCGTCCTGCAGGGCCGACATAGTGAATGAGTGGGTGGTTACTATGCTGTTGCACCGGTTAACAGCCTCTCTTAGGTGGCAGTG
ATTCACTGCTGCAGATCTGCACGACTTTCTCAAGTAGCAGAAAAATCTGTGGGCCCTGGGCTCTGTCACTCGCACAGCCCTTCTCATGGGTAGGGT
GAGTCATGCACGCAGGATCTTTCAGGTGGACGGTTTCTGTGCTGTGAGGAAGAAGGCGCGCCATACcagaaacaacaaggcttgct 
11_mNUeSC
RATtoCG50-
59 
ttcctggcttgtagtgacctGCGTCCTGCAGGGCCGACATAGTGAATGAGTGGGTGGTTACTATGCTGTTGCACCGGTTACACTAAGAGAGGCTTGTTACGTG
ATTCACTGCTGCAGATCTGCACGACTTTCTCAAGTAGCAGAAAAATCTGTGGGCCCTGGGCTCTGTCACTCGCACAGCCCTTCTCATGGGTAGGGT
GAGTCATGCACGCAGGATCTTTCAGGTGGACGGTTTCTGTGCTGTGAGGAAGAAGGCGCGCCATACcagaaacaacaaggcttgct 
12_mNUeSC
RATtoCG60-
68 
ttcctggcttgtagtgacctGCGTCCTGCAGGGCCGACATAGTGAATGAGTGGGTGGTTACTATGCTGTTGCACCGGTTACACTAAGAGATTAGGTGGCATGT
CGGACATGCTGCAGATCTGCACGACTTTCTCAAGTAGCAGAAAAATCTGTGGGCCCTGGGCTCTGTCACTCGCACAGCCCTTCTCATGGGTAGGG
TGAGTCATGCACGCAGGATCTTTCAGGTGGACGGTTTCTGTGCTGTGAGGAAGAAGGCGCGCCATACcagaaacaacaaggcttgct 
13_mNUeSC
RATtoCG69-
80 
ttcctggcttgtagtgacctGCGTCCTGCAGGGCCGACATAGTGAATGAGTGGGTGGTTACTATGCTGTTGCACCGGTTACACTAAGAGATTAGGTGGCAGTG
ATTCACGTAGTACTCGAGGCACGACTTTCTCAAGTAGCAGAAAAATCTGTGGGCCCTGGGCTCTGTCACTCGCACAGCCCTTCTCATGGGTAGGG
TGAGTCATGCACGCAGGATCTTTCAGGTGGACGGTTTCTGTGCTGTGAGGAAGAAGGCGCGCCATACcagaaacaacaaggcttgct 
14_mNUeSC
RATtoCG81-
87 
ttcctggcttgtagtgacctGCGTCCTGCAGGGCCGACATAGTGAATGAGTGGGTGGTTACTATGCTGTTGCACCGGTTACACTAAGAGATTAGGTGGCAGTG
ATTCACTGCTGCAGATCTTACATCATTTCTCAAGTAGCAGAAAAATCTGTGGGCCCTGGGCTCTGTCACTCGCACAGCCCTTCTCATGGGTAGGGT
GAGTCATGCACGCAGGATCTTTCAGGTGGACGGTTTCTGTGCTGTGAGGAAGAAGGCGCGCCATACcagaaacaacaaggcttgct 
15_mNUeSC
RATtoCG88-
97 
ttcctggcttgtagtgacctGCGTCCTGCAGGGCCGACATAGTGAATGAGTGGGTGGTTACTATGCTGTTGCACCGGTTACACTAAGAGATTAGGTGGCAGTG
ATTCACTGCTGCAGATCTGCACGACGGGAGACCTGAGCAGAAAAATCTGTGGGCCCTGGGCTCTGTCACTCGCACAGCCCTTCTCATGGGTAGGG
TGAGTCATGCACGCAGGATCTTTCAGGTGGACGGTTTCTGTGCTGTGAGGAAGAAGGCGCGCCATACcagaaacaacaaggcttgct 
16_mNUeSC
RATtoCG98-
107 
ttcctggcttgtagtgacctGCGTCCTGCAGGGCCGACATAGTGAATGAGTGGGTGGTTACTATGCTGTTGCACCGGTTACACTAAGAGATTAGGTGGCAGTG
ATTCACTGCTGCAGATCTGCACGACTTTCTCAAGTCTACTCCCCCTCTGTGGGCCCTGGGCTCTGTCACTCGCACAGCCCTTCTCATGGGTAGGGT
GAGTCATGCACGCAGGATCTTTCAGGTGGACGGTTTCTGTGCTGTGAGGAAGAAGGCGCGCCATACcagaaacaacaaggcttgct 
17_mNUeSC
RATtoCG10
8-117 
ttcctggcttgtagtgacctGCGTCCTGCAGGGCCGACATAGTGAATGAGTGGGTGGTTACTATGCTGTTGCACCGGTTACACTAAGAGATTAGGTGGCAGTG
ATTCACTGCTGCAGATCTGCACGACTTTCTCAAGTAGCAGAAAAAGAGTGTTTAACTGGGCTCTGTCACTCGCACAGCCCTTCTCATGGGTAGGG
TGAGTCATGCACGCAGGATCTTTCAGGTGGACGGTTTCTGTGCTGTGAGGAAGAAGGCGCGCCATACcagaaacaacaaggcttgct 
18_mNUeSC
RATtoCG118
-127 
ttcctggcttgtagtgacctGCGTCCTGCAGGGCCGACATAGTGAATGAGTGGGTGGTTACTATGCTGTTGCACCGGTTACACTAAGAGATTAGGTGGCAGTG
ATTCACTGCTGCAGATCTGCACGACTTTCTCAAGTAGCAGAAAAATCTGTGGGCCAGTTTAGAGTTCACTCGCACAGCCCTTCTCATGGGTAGGG
TGAGTCATGCACGCAGGATCTTTCAGGTGGACGGTTTCTGTGCTGTGAGGAAGAAGGCGCGCCATACcagaaacaacaaggcttgct 
19_mNUeSC
RATtoCG128
-137 
ttcctggcttgtagtgacctGCGTCCTGCAGGGCCGACATAGTGAATGAGTGGGTGGTTACTATGCTGTTGCACCGGTTACACTAAGAGATTAGGTGGCAGTG
ATTCACTGCTGCAGATCTGCACGACTTTCTCAAGTAGCAGAAAAATCTGTGGGCCCTGGGCTCTGGACAGATACAAGCCCTTCTCATGGGTAGGG
TGAGTCATGCACGCAGGATCTTTCAGGTGGACGGTTTCTGTGCTGTGAGGAAGAAGGCGCGCCATACcagaaacaacaaggcttgct 
20_mNUeS
CRATtoCG1
38-147 
ttcctggcttgtagtgacctGCGTCCTGCAGGGCCGACATAGTGAATGAGTGGGTGGTTACTATGCTGTTGCACCGGTTACACTAAGAGATTAGGTGGCAGTG
ATTCACTGCTGCAGATCTGCACGACTTTCTCAAGTAGCAGAAAAATCTGTGGGCCCTGGGCTCTGTCACTCGCACCTAAAGGAGAATGGGTAGGG
TGAGTCATGCACGCAGGATCTTTCAGGTGGACGGTTTCTGTGCTGTGAGGAAGAAGGCGCGCCATACcagaaacaacaaggcttgct 
21_mNUeSC
RATtoCG148
-156 
ttcctggcttgtagtgacctGCGTCCTGCAGGGCCGACATAGTGAATGAGTGGGTGGTTACTATGCTGTTGCACCGGTTACACTAAGAGATTAGGTGGCAGTG
ATTCACTGCTGCAGATCTGCACGACTTTCTCAAGTAGCAGAAAAATCTGTGGGCCCTGGGCTCTGTCACTCGCACAGCCCTTCTCCGTTTGCTTGT
GAGTCATGCACGCAGGATCTTTCAGGTGGACGGTTTCTGTGCTGTGAGGAAGAAGGCGCGCCATACcagaaacaacaaggcttgct 
22_mNUeS
CRATtoCG15
7-165 
ttcctggcttgtagtgacctGCGTCCTGCAGGGCCGACATAGTGAATGAGTGGGTGGTTACTATGCTGTTGCACCGGTTACACTAAGAGATTAGGTGGCAGTG
ATTCACTGCTGCAGATCTGCACGACTTTCTCAAGTAGCAGAAAAATCTGTGGGCCCTGGGCTCTGTCACTCGCACAGCCCTTCTCATGGGTAGGTG
TCTGACGGCACGCAGGATCTTTCAGGTGGACGGTTTCTGTGCTGTGAGGAAGAAGGCGCGCCATACcagaaacaacaaggcttgct 
23_mNUeSC
RATtoCG166
-175 
ttcctggcttgtagtgacctGCGTCCTGCAGGGCCGACATAGTGAATGAGTGGGTGGTTACTATGCTGTTGCACCGGTTACACTAAGAGATTAGGTGGCAGTG
ATTCACTGCTGCAGATCTGCACGACTTTCTCAAGTAGCAGAAAAATCTGTGGGCCCTGGGCTCTGTCACTCGCACAGCCCTTCTCATGGGTAGGGT
GAGTCATTACATACTTCTCTTTCAGGTGGACGGTTTCTGTGCTGTGAGGAAGAAGGCGCGCCATACcagaaacaacaaggcttgct 
24_mNUeS
CRATtoCG17
6-185 
ttcctggcttgtagtgacctGCGTCCTGCAGGGCCGACATAGTGAATGAGTGGGTGGTTACTATGCTGTTGCACCGGTTACACTAAGAGATTAGGTGGCAGTG
ATTCACTGCTGCAGATCTGCACGACTTTCTCAAGTAGCAGAAAAATCTGTGGGCCCTGGGCTCTGTCACTCGCACAGCCCTTCTCATGGGTAGGGT
GAGTCATGCACGCAGGAGAGGGACTTGGGACGGTTTCTGTGCTGTGAGGAAGAAGGCGCGCCATACcagaaacaacaaggcttgct 
25_mNUeSC
RATtoCG186
-195 
ttcctggcttgtagtgacctGCGTCCTGCAGGGCCGACATAGTGAATGAGTGGGTGGTTACTATGCTGTTGCACCGGTTACACTAAGAGATTAGGTGGCAGTG
ATTCACTGCTGCAGATCTGCACGACTTTCTCAAGTAGCAGAAAAATCTGTGGGCCCTGGGCTCTGTCACTCGCACAGCCCTTCTCATGGGTAGGGT
GAGTCATGCACGCAGGATCTTTCAGGTTTCATTGGGATGTGCTGTGAGGAAGAAGGCGCGCCATACcagaaacaacaaggcttgct 
26_mNUeS
CRATtoCG1
96-212 
ttcctggcttgtagtgacctGCGTCCTGCAGGGCCGACATAGTGAATGAGTGGGTGGTTACTATGCTGTTGCACCGGTTACACTAAGAGATTAGGTGGCAGTG
ATTCACTGCTGCAGATCTGCACGACTTTCTCAAGTAGCAGAAAAATCTGTGGGCCCTGGGCTCTGTCACTCGCACAGCCCTTCTCATGGGTAGGGT
GAGTCATGCACGCAGGATCTTTCAGGTGGACGGTTTCGTGTAGTGTCTTCCTCCGGCGCGCCATACcagaaacaacaaggcttgct 
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3.5.7.6 Mutating AP1 motifs within the Nptx2 enhancer 
We observed four AP1 motifs within the full-length 1216bp Nptx2 enhancer.  
Using PCR driven overlap extension (Heckman and Pease, 2007), we sequentially 
mutated the second base pair of each AP1 motif with a mutation 
(TGAGTCAàTAAGTCA) that has been previously shown to abrogate the binding of AP1 
(Risse et al., 1989).  In order to do this, the primers shown in Table 13 were used (A, B, C, 
D nomenclature same as described in (Heckman and Pease, 2007)), with 5’ clamp 
shown in red. 
Table 13: Primers to subtly mutate each AP1 motif present within the 
sequence of the Nptx2 enhancer 
Primer Sequence (5’ à  3’) 
A 5’ GCGTCCTGCAGGCAGAAACAACAAGGCTTGCT 3’ 
D 5’ GTATGGCGCGCCTACTAGCTAAGTGGTTTGGG 3’ 
  
AP1 #1 B CTTCCTGCAAACATGACTTAGGAACTATCCTCGGTGCTGA 
AP1 #1 C CGAGGATAGTTCCTAAGTCATGTTTGCAGGAAGCTGTCCT 
AP1 #2 B GATCCTGCGTGCATGACTTACCCTACCCATGAGAAGGGCT 
AP1 #2 C CTCATGGGTAGGGTAAGTCATGCACGCAGGATCTTTCAGG 
AP1 #3 B AGATCTGCAGCAGTGAATTACTGCCACCTAATCTCTTAGT 
AP1 #3 C GATTAGGTGGCAGTAATTCACTGCTGCAGATCTGCACGAC 
AP1 #4 B CCAGCCGACATAGTAAATGAGTGGGTGGTTACTATGCTGT 
AP1 #4 C AGTAACCACCCACTCATTTACTATGTCGGCTGGTCCCGGG 
 
3.5.7.7 Mutating the NPAS4 motif within the Nptx2 reporter 
Using PCR driven overlap extension (Heckman and Pease, 2007), we deleted a 
putative NPAS4 binding site located directly under the ChIP-Seq peak. In order to do 
this, the primers shown in Table 14 were used (A, B, C, D nomenclature same as 
described in (Heckman and Pease, 2007)), with 5’ clamp shown in red.  
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Table 14: Primers used to delete NPAS4 motif from Nptx2 enhancer 
Primer Sequence (5’ à  3’) 
A 5’ GCGTCCTGCAGGCAGAAACAACAAGGCTTGCT 3’ 
B 5’ TTTTCTGCTACTTGAGAAAGCAGATCTGCAGCAGTGAATC 3’ 
C 5’ GATTCACTGCTGCAGATCTGCTTTCTCAAGTAGCAGAAAA 3’ 
D 5’ GTATGGCGCGCCTACTAGCTAAGTGGTTTGGG 3’ 
 
3.5.7.8 Transfection 
Mouse cortical neurons plated on 24 well plates at a density of approximately 
3x105 neurons per well were transfected for luciferase reporter assays using 
Lipofectamine 2000 Reagent (Invitrogen), generally according to the manufacter’s 
protocol.  Briefly, DNA mixes were made immediately preceding the transfection 
consisting of 1ug total plasmid DNA/well diluted in Neurobasal medium (Life 
Technologies).  DNA typically consisted of 450ng firefly luciferase reporter DNA, 50ng 
pGL4.74 renilla luciferase reporter DNA (Promega), and 500ng empty pCS2 plasmid 
(Rupp et al., 1994; Turner and Weintraub, 1994) as filler DNA.  Lipofectamine was used 
at 2uL/well and was diluted in Neurobasal medium just before the transfection.  Within 
each experiment, all conditions were transfected in two to three independent wells, for 
technical duplicates or triplicates.  Thirty minutes prior to the addition of Lipofectamine 
to neurons, the culture medium was removed and replaced with warmed Neurobasal 
medium.  At this time, neurons were returned to the incubator and DNA mixes were 
added to diluted Lipofectamine in a drop-wise manner.  After thirty minutes of 
incubation, DNA-Lipofectamine mixes were added to neurons, again in a drop-wise 
manner.  The cells were left to incubate with the DNA-Lipofectamine mix for two hours, 
after which the transfection medium was replaced with supplemented conditioned 
neuronal medium. 
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3.5.7.9  Sample collection and luciferase assay 
After stimulation, neurons were lysed using Passive Lysis Buffer (Dual-Luciferase 
Reporter Assay System, Promega).  Lysates were then collected in microcentrifuge tubes 
and frozen at -20 degrees C.  At the time of performing the luciferase assay, neuronal  
lysates were thawed, briefly vortexed, briefly spun down, and then 20uL of each sample 
was added to one well of Costar White Polystyrene 96-well Assay Plates (Corning).  The 
reagents to run the luciferase assay, Luciferase Assay Reagent II (LARII) and Stop & Glo 
Reagent (Dual-Luciferase Reporter Assay System, Promega), were aliquoted and thawed 
according to the manufacturer’s protocol.  The luciferase assay was performed using the 
Synergy 4 Hybrid Microplate Reader (BioTek), with 100uL of LARII and Stop & Glo 
Reagent injected per well.  Data was subsequently downloaded and analyzed using 
Microsoft Excel. 
3.5.7.10 Statistical Analyses of Luciferase Assay Data 
Using the Dual-Luciferase Reporter Assay System, we recorded Firefly (FF) and 
Renilla (Ren) luminescence from each well.  To correct for variations in transfection 
efficiency and cell lysate generation, the Firefly values were normalized to Renilla 
luminescence within each well, generating a ratio of FF/Ren.  The stimulus-dependent 
fold induction of each reporter plasmid was obtained by dividing the (+ stimulus) 
FF/Ren value by the (- stimulus) value.  To isolate the induction due to the enhancer, 
the fold induction of an enhancer reporter was divided by the fold induction of the 
appropriate backbone into which the enhancer was cloned, giving fold induction relative 
to backbone.  Fold induction relative to backbone is the value shown in all figures 
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containing luciferase reporter data.  All error bars shown are standard error of biological 
replicates. 
 
3.5.8 DNA Microarrays and data analysis 
For all microarray experiments, total RNA was purified using RNeasy mini kits 
(Qiagen).  Ten micrograms of RNA was hybridized to Affymetrix Mouse Genome 430 
2.0 Array with Affymetrix processing.  To identify activity-regulated genes regulated by 
C-FOS, mouse cortical neurons were cultured for 5 days, infected with lentivirus 
expressing control or c-Fos RNAi, and then depolarized with mM KCl for 0, 1, 3, or 6 
hours.  Two microarray bioreplicates were performed for all conditions.  The DNA-Chip 
(dChip) software package (Li and Wong, 2001) was used to analyze the microarray data. 
Genes were considered C-FOS targets if they met the following criteria: (1) the gene was 
present and expressed at a level of at least 250 at at least one of the timepoints in both 
bioreplicates of the experiment, (2) there was at least a 3-fold induction of the gene 
relative to the o hour timepoint, (3) there was at least a 1.75 fold reduction in the 
induction of the gene with c-Fos RNAi compared to control RNAi. 
 
3.5.9 de novo motif analysis 
For de novo motif analysis, MEME (Bailey and Elkan, 1994) was used to analyze 
the 200 bps surrounding enhancer centers.  The following parameters were used: -dna -
mod anr -nmotifs 15 -minw 5 -maxw 10 -revcomp. 
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4 GENERAL DISCUSSION 
The work presented in this thesis advances our understanding of stimulus 
responsive enhancers in the nervous system.  By discovering that H3K27Ac changes 
rapidly at neuronal enhancers, and that stimulus-dependent increases in H3K27Ac at 
neuronal enhancers can be used to identify enhancers that function to promoter 
stimulus-responsive transcription, we now have a much more accurate picture of the 
enhancers that respond to stimuli.  We used the dynamic chromatin signature of 
stimulus-inducible H3K27Ac to identify and characterize neuronal enhancers that 
respond to neuronal activity (modeled in vitro by the application of KCl) as well as 
neuronal enhancers that respond to BDNF.  We now know that neuronal enhancers can 
respond to specific stimuli or to multiple stimuli and that activity and BDNF responsive 
enhancers are linked to genes with distinct functions.  We also know that the function of 
neuronal stimulus responsive enhancers appears to be intrinsic to the DNA sequence of 
these enhancers.  Because of this, understanding the sequences that give rise to stimulus 
responsiveness of enhancers should be computationally and experimentally tractable.  
We have begun to understand the sequence determinants of stimulus responsive 
enhancers by performing de novo motif finding and studying the function of neuronal 
stimulus responsive enhancers in luciferase reporter assays in vitro, a system in which 
stimulus-responsive enhancer function can be effectively recapitulated.  These 
approaches have shown that AP1 transcription factors play a critical role in the function 
of a subset of stimulus-responsive enhancers.  One enhancer context in which AP1 is 
required is the enhancer upstream of the neuronal stimulus-regulated gene Nptx2.  We 
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have begun to understand the sequence determinants underlying the Nptx2 enhancer.  
This work has revealed the critical importance of AP1 for the KCl and BDNF-dependent 
responses of this enhancer, but has also revealed that AP1 is insufficient to drive the 
responses of this enhancer to either KCl or BDNF.  At the Nptx2 enhancer, both AP1 and 
NPAS4 are required for responses to neuronal activity, but these two factors are still 
insufficient to drive activity-dependent responses from the Nptx2 enhancer.  Further 
work will be required to understand the additional factors that collaborate with AP1 and 
NPAS4 to drive responses to activity, and the factors that collaborate with AP1 to drive 
responses to BDNF.  These advances in our understanding of stimulus-responsive 
enhancers in the nervous system were possible because of the approaches that we 
employed to study this biology.  However, there are limitations to the experiments we 
have performed and conclusions we are able to draw from these experiments.  We would 
like to discuss some of the advantages and limitations of the methods we have used to 
study stimulus-responsive transcription in the nervous system. 
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4.1 ADVANTAGES AND LIMITATIONS OF THE EXPERIMENTS PERFORMED IN 
THIS THESIS 
4.1.1 In vitro studies 
4.1.1.1 Advantages of in vitro studies 
While all of the work described in this thesis has been performed in primary 
mouse cortical neurons, all experiments have been done using these neurons in vitro.  
Studying neuronal stimulus-responsive transcriptional regulation in vitro has several 
advantages.  First, neurons from a single source can be plated onto multiple cell culture 
dishes that can be treated differently and then compared with one another.  In studying 
stimulus-responsive transcription, this is of critical importance.  All stimulus-responsive 
phenomena require the comparison of a stimulated state with an unstimulated state.  To 
isolate the effects of the stimulus, stimulated and unstimulated cells need to be as 
similar to one another as possible.  In practice, the only way for this to be achieved is 
through in vitro experiments.  In experiments that I did not describe in this thesis, I 
have characterized stimulus-responsive transcription in vivo using kainic acid-induced 
seizures in mice.  All experiments were performed on mice from a pure C57BL/6 genetic 
background that were litter-mates born and raised to the time of the experiment in the 
same cage.  Despite their identical genetic background and identical environment from 
birth, these mice exhibited significant variability in the levels of immediate-early gene 
protein products (such as CFOS, FOSB, JUNB, and NPAS4) induced in response to 
seizure, assessed by western blot.  This could be due to differences between the mice, 
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such as differences is nourishment and development.  It is often observed that some 
mice within a litter are larger and better nourished than others.  Alternatively, 
differences in the inducibility of immediate early genes could be due to differences in the 
stimulation of different mice.  This brings me to the second major advantage of studying 
neuronal stimulus-responsive transcription in vitro: the ability to uniformly and 
reproducibly stimulate cells. 
Stimulating neurons in vitro by adding the stimulus directly to the neuronal cell 
culture medium allows for uniform and reproducible stimulation.  In contrast, 
stimulating mice to study neuronal stimulus-responsive transcription in vivo is 
extremely challenging.  To study robust transcriptional responses, we and others have 
employed kainic acid induced seizures in juvenile or adult mice.  However, the delivery 
of kainate by subcutaneous injections, is inherently variable.  The site of injection, the 
depth of injection, the volume of injected liquid that remains within the animal, can all 
vary considerably and lead to significant differences in the level of seizure induced in the 
animal.  After subcutaneous kainate injections, some mice begin to visibly seize after 10 
minutes, other mice begin to seize after 30 minutes, and some mice never display visible 
seizure-related behaviors.  This variability contributes to variability in seizure induced 
transcriptional programs activated in the nervous system, thus making it extremely 
difficult to achieve reproducible results.  This challenge in achieving reproducible 
stimulation brings me to the third major advantage of studying neuronal stimulus-
responsive transcription in vitro: the ability to perform and compare experimental 
manipulations with one another. 
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In vitro neuronal cultures can be easily experimentally manipulated to study 
mechanisms underlying stimulus-responsive transcription.  By employing lentivirus 
containing shRNA to knockdown particular protein products, or cDNAs to overexpress 
particular protein products, the role of candidate proteins in stimulus-responsive 
transcription can be studied.  In this thesis, we have begun using these tools to 
understand the role of AP1 transcription factors in neuronal stimulus-responsive 
transcription.  While methods exist to study gene function in vivo (such as the 
generation of transgenic mouse lines, in utero electroporation of knockdown or 
overexpressing plasmids, or stereotactic viral injections), these methods are more 
challenging and time consuming than in vitro approaches.  Furthermore, the inability to 
consistently and reproducibly stimulate animals in vivo becomes a major issue.  For 
example, if a gene is knocked down via virally delivered shRNA in one animal in vivo, 
the relevant control is another animal that has been infected with a control shRNA.  
However, if these two animals cannot be similarly stimulated in vivo, the control animal 
differs from the experimental animal, and the effects of the knockdown cannot be 
rigorously assessed. 
4.1.1.2 Limitations of in vitro studies 
While there are many advantages of employing an in vitro approach to study 
stimulus responsive transcription within the nervous system, as detailed above, there 
are also important limitations to this approach.  While in vitro neuronal cultures 
recapitulate many aspects of neuronal biology, including stimulus-responsive 
transcription, this is clearly an artificial system.  Normally neurons form and maintain 
precise synaptic contacts with other neurons, and precise cellular contacts with glial 
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cells, through a carefully orchestrated process of development within the three 
dimensional environment of a brain that is nourished by blood and cerebrospinal fluid.  
In contrast, when neurons are cultured in vitro, they are stripped of their synaptic and 
cellular contacts through harsh trituration, plated on a two dimensional plastic surface, 
and grown in culture medium in an incubator.  This artificiality in vitro will cause 
differences in neuronal function compared to in vivo.  As a result, any phenomenon 
observed in vitro should be demonstrated in vivo in to ensure that it is not a artifact of 
the in vitro system. 
Another disadvantage of in vitro studies of stimulus responsive transcription is 
that there is no way to physiologically stimulate cells in vitro.  Normally, the brain is 
activated by sensory experience which in turn activates specific neural circuits within 
the brain.  When studying cortical neurons in vitro, not only are there no sensory inputs 
to speak of, neural circuits and synaptic connectivity are completely disorganized.  As a 
result, any stimulation of neurons in vitro is artificial.  We have utilized the extracellular 
potassium chloride (KCl) to depolarize neurons and mimic neuronal activity.  While KCl 
does depolarize neurons, it does so by depolarizing the neuronal membrane as a whole 
rather than by activating neurotransmitter gated ion channels at synapses as occurs in 
vivo.  Hence, KCl is an artificial stimulus of neurons grown in an artificial system.  
Nonetheless, KCl has proved to be a useful discovery tool for many activity-dependent 
phenomena that have been recapitulated in vivo with physiological stimuli. 
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4.1.2 Chromatin immunoprecipitation (ChIP) 
4.1.2.1 Advantages of ChIP 
ChIP has emerged as one of the most powerful tools available to survey 
transcription factor binding and chromatin modifications in the genome.  ChIP enables 
transcription factor binding and chromatin modifications to be assessed in vivo.  When 
combined with high throughput sequencing, ChIP enables genome-wide assessments of 
transcription factor binding events and chromatin modifications.  Furthermore, ChIP is 
a relatively simple assay that can be easily scaled to investigate multiple proteins of 
histone modifications simultaneously. 
4.1.2.2 Limitations of ChIP 
While ChIP has significant advantages, it also has limitations that need to be kept 
in mind.  First of all, ChIP is normally performed under crosslinking conditions to 
maintain protein-DNA interactions through the experiment.  Crosslinking can introduce 
artifacts causing a locus within the genome to appear artificially enriched for certain 
transcription factor binding events or chromatin modifications, when it is only in 
proximity to a locus truly exhibiting these features.  ChIP also relies on antibodies that 
recognize the desired epitope within the cell.  All antibodies bind nonspecifically to 
proteins within the cell, as any silver stain of an immunoprecipitation will demonstrate.  
Hence, it is not always clear if a signal in a ChIP experiment is due to the 
immunoprecipitation of the desired epitope or of another protein.  For these reasons, it 
is preferable to utilize multiple pieces of evidence to confirm a result by ChIP.  In the 
  152 
case of ChIP for transcription factors, it can be useful to assess whether known motifs 
for the transcription factor are enriched underneath ChIP signal and if the signal is 
specific to the protein of interest by performing ChIP using the same antibody in cells in 
which that protein has been knocked down or knocked out.  We have utilized both motif 
enrichment and ChIP from shRNA infected cells to increase our confidence in our ChIP 
results for C-FOS and FOSB in this work. 
Another limitation of ChIP is the fact that it is a biochemical assay that provides 
the average signal over millions of cells (ChIP experiments done for the work described 
in this thesis were done with 20 million neurons).  As a result ChIP does not provide 
information about the variability that may exist between cells processed together or at 
the two alleles of each locus within a cell.  If the two alleles of a locus vary in sequence, 
allele specificity can be studied using high throughput sequencing. 
Finally, ChIP, in particular ChIP-SEQ, is a variable assay.  It is essential that 
bioreplicates be performed to ensure that a given peak or region of enrichment is 
reproducible.  We have performed multiple bioreplicates of our H3K27Ac and 
transcription factor ChIP experiments in this work. 
4.1.3 Luciferase reporter assays 
4.1.3.1 Advantages of luciferase reporter assays 
Luciferase reporter assays provide several advantages for studying gene 
expression and the function of DNA sequences.  Luciferase reporter assays provide high 
sensitivity, a wide dynamic range, and easy methodology.  Furthermore, luciferase 
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reporter assays enable direct investigations into the function of sequences of regulatory 
DNA, unlike studies of endogenous gene expression.  Finally, since luciferase reporter 
plasmids can be delivered to cells via transfection or infection, luciferase reporter assays 
enable signaling to DNA sequences to be studied in the context of the cell and its 
environment.  In comparison, studies of transcription using reconstituted systems in 
vitro do not enable one to study transcriptional regulation in the context of normal 
cellular signaling. 
4.1.3.2 Limitations of luciferase reporter assays 
While luciferase reporter assays offer several advantages, these assays are 
artificial.  DNA cloned into a plasmid is very different than DNA that exists within the 
cell as part of chromatin.  In the cell, modifications of chromatin during development 
instruct programs of gene expression.   Luciferase plasmids lack the normal chromatin 
structure of cellular DNA and as a result lack this important regulatory component.  As a 
result, DNA sequences that are normally not available for transcription actor binding 
can be exposed in luciferase reporters causing ectopic activity to be observed from a 
DNA sequence.  As a result, luciferase data alone should not be taken to indicate activity 
in the context of the cell.  In the case of our work, we couple luciferase reporter assays 
with ChIP-Seq data obtained in vivo to increase our confidence in our findings.  It is 
only because the stimulus-responsive enhancers we have identified exhibit both 
increasing H3K27Ac within the neuron as well as the ability to drive stimulus responsive 
reporter expression within a plasmid that we take these enhancers to promote stimulus-
responsive gene expression with the neuron.  Still, luciferase reporter assays do not 
inform us of endogenous gene expression directly.  For example, while many of the 
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enhancers cloned in this work are active in luciferase reporter assays, we still do not 
know which genes within the cell these enhancers may regulate.  Further studies will be 
required to understand the specific contributions of the stimulus responsive enhancers 
we have identified to stimulus-responsive transcription within the neuron. 
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4.2 FUTURE DIRECTIONS 
The work I have performed for my thesis has advanced our understanding of 
stimulus-responsive enhancers in the nervous system.  It is bittersweet that my work 
has opened more questions than it has answered.  It is sweet because I take this as an 
indication that these findings will have importance for developing further 
understanding of this biology.  However, it is also bitter because I will not be able to 
myself continue performing these experiments to find out the answers.  Hopefully 
others will be motivated to do so!  Here, I outline the most interesting future directions 
that I see from this point that I would pursue if I could have more time in the laboratory. 
4.2.1 Demonstrating stimulus-inducible H3K27Ac in the nervous system 
in vivo 
As mentioned above, there are limitations to the findings we have obtained from 
our experiments in vitro.  It will be important to determine whether we detect changes 
in H3K27Ac in the nervous system in vivo.  This can be done using strong, artificial 
stimuli such as kainic acid induced seizures, or using more physiological stimuli, such as 
enriched environment or light exposure after dark rearing.  Investigating stimulus-
inducible H3K27Ac in vivo also opens the door to the exciting possibility of identifying 
and studying enhancers that are activated in vivo in response to specific stimuli or 
within particular brain regions. 
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4.2.2 Performing H3K27Ac at different time points after stimulation 
As mentioned earlier in the thesis, multiple waves of transcription occur in 
response to extracellular stimulation.  A first wave of transcription mediated by pre-
existing transcription factors within the cell (such as CREB, MEF2, and SRF) occurs 
rapidly.  Among the genes expressed in this first wave of transcription are transcription 
factors (such as C-FOS, FOSB, JUNB, and NPAS4) that activate a subsequent wave of 
transcription.  In this work, we have only investigated H3K27Ac at 0 hours or 2 hours 
after sustained stimulation.  It could be interesting to perform H3K27Ac ChIP-Seq at 
several additional time points after sustained stimulation or a brief pulse of stimulation.  
Such experiments may demonstrate that some enhancers exhibit inducible H3K27Ac 
early after a stimulus, while other enhancers may exhibit inducible H3K27Ac later after 
a stimulus.  Such a finding may enable us to distinguish the enhancers that function to 
promote the first wave of transcription from those that promote the second wave of 
transcription, and study these two classes of enhancers separately.  We have observed 
that only a subset of neuronal stimulus-responsive enhancers are bound by AP1 
transcription factors and appear sensitive to the AP1 dominant negative A-Fos.  It is 
possible that enhancers mediating the first wave of transcription do not require AP1 
while enhancers mediating the second wave of transcription do require AP1.  These 
interesting possibilities can only be explored if better temporal resolution of changes in 
H3K27Ac after stimulation is achieved.  It may be the case that stimulus-responsive 
enhancers exhibit even greater diversity of responses than just early and late inducibility.  
Some enhancers may be activated transiently while others may exhibit longer lasting 
activity after a stimulus.  Performing H3K27Ac ChIP-Seq at additional time points will 
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not only reveal if this is the case but will also enable us to begin understanding the 
sequences and transcription factors that give rise to diverse temporal responses from 
enhancers. 
4.2.3 Better understanding the mechanisms underlying stimulus-
responsive enhancers 
While we have shown that AP1 plays critical roles at a subset of activity and 
BDNF responsive neuronal enhancers, the exact contribution of AP1 to enhancer 
function is not clear.  Whether AP1 binding is necessary for recruitment of other 
transcription factors, recruitment of CBP/P300, activation of CBP/P300, deposition of 
H3K27Ac, or looping to target promoters is not clear.  Insight into these questions can 
be achieved by delivering the AP1 dominant negative A-Fos to neurons via lentiviral 
infection, thereby disrupting the activity of AP1, and assessing any number of variables 
from transcription factor binding, to looping interactions, to gene expression.  
Furthermore, more work will be needed to understand the additional transcription 
factors that drive stimulus-responsive enhancers, and the contribution of each of these 
factors to enhancer function.  Additional factors could be identified computationally 
based on presence of motifs, biochemically based on mass spectrometry of factors 
bound to AP1 factors or to stimulus responsive enhancers, or based on a candidate 
approach.  Hopefully, detailed investigations at individual enhancers, such as the Nptx2 
enhancer, will shed light onto not only the additional transcription factors that drive 
stimulus-responsive enhancers, but also the cis regulatory logic of enhancer function 
and stimulus-specific transcriptional responses. 
  158 
4.2.4 Performing H3K27Ac ChIP-Seq in response to stimuli in human 
neurons 
Recently, it has become feasible to obtain and culture human neurons in vitro.  
This provides the exciting possibility of performing H3K27Ac ChIP-Seq in human 
neurons in response to stimuli.  This would not only enable the identification of 
stimulus-responsive enhancers in human neurons, it would also enable comparisons to 
be made between mouse and human.  Such comparisons would not only be interesting 
from an evolutionary standpoint, they could also shed light onto the cis-regulatory logic 
of stimulus-responsive enhancers.  Any variations in the H3K27Ac behaviors at 
orthologous enhancers in human and mouse could then be attempted to be understood 
on the basis of the variation in the underlying orthologous sequences.  Similarly, if 
H3K27Ac ChIP-Seq is done from human neurons obtained from different individuals for 
whom whole genome sequencing is also obtained, the contribution of human variation 
to enhancer function can be studied using H3K27Ac as a readout.  This need not be 
limited to stimulus responsive enhancers, and could be done for constitutively active 
enhancers as well.  Studies performed in human neurons may enable us to begin to 
understand the functional contribution of sequence variation to gene regulation and 
human cognition.  
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6 APPENDIX A: STIMULUS-RESPONSIVE GENES IN THE 
NERVOUS SYSTEM 
 
  
  181 
6.1 TOP KCL RESPONSIVE GENES 
 
Table 15: Top 25 KCl-induced early response genes 
RNA-Seq was performed from mouse cortical neurons that were stimulated with 0, 1, or 
6 hours (h) of KCl or BDNF.  Displayed are the top 25 KCl-induced early response genes, 
defined as genes with greater induction at 1 h than at 6 h after KCl stimulation.  Only 
genes expressed in the top 50th percentile of all expressed genes within at least one of 
the time points (0 h, 1 h, 6 h KCl) were considered for this analysis.  Genes are displayed 
in decreasing order of fold induction at the 1 h time point after KCl stimulation relative 
to the 0 h time point after KCl stimulation.  mRNA expression values are reported as 
reads per kilobase per million mapped reads (RPKM).  For each gene, gene name (Gene), 
NCBI GeneID, chromosome number (Ch), DNA strand (St), start and stop position are 
also displayed. 
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Table 16: Top 25 KCl-induced late response genes 
RNA-Seq was performed from mouse cortical neurons that were stimulated with 0, 1, or 
6 hours (h) of KCl or BDNF.  Displayed are the top 25 KCl-induced late response genes, 
defined as genes with greater induction at 6 h than at 1 h after KCl stimulation.  Only 
genes expressed in the top 50th percentile of all expressed genes within at least one of 
the time points (0 h, 1 h, 6 h KCl) were considered for this analysis.  Genes are displayed 
in decreasing order of fold induction at the 6 h time point after KCl stimulation relative 
to the 0 h time point after KCl stimulation.  mRNA expression values are reported as 
reads per kilobase per million mapped reads (RPKM).  For each gene, gene name (Gene), 
NCBI GeneID, chromosome number (Ch), DNA strand (St), start and stop position are 
also displayed. 
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6.2 TOP BDNF RESPONSIVE GENES 
 
Table 17: Top 25 BDNF-induced early response genes 
RNA-Seq was performed from mouse cortical neurons that were stimulated with 0, 1, or 
6 hours (h) of KCl or BDNF.  Displayed are the top 25 BDNF-induced early response 
genes, defined as genes with greater induction at 1 h than at 6 h after BDNF stimulation.  
Only genes expressed in the top 50th percentile of all expressed genes within at least one 
of the time points (0 h, 1 h, 6 h BDNF) were considered for this analysis.  Genes are 
displayed in decreasing order of fold induction at the 1 h time point after BDNF 
stimulation relative to the 0 h time point after BDNF stimulation.  mRNA expression 
values are reported as reads per kilobase per million mapped reads (RPKM).  For each 
gene, gene name (Gene), NCBI GeneID, chromosome number (Ch), DNA strand (St), 
start and stop position are also displayed. 
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Table 18: Top 25 BDNF-induced late response genes 
RNA-Seq was performed from mouse cortical neurons that were stimulated with 0, 1, or 
6 hours (h) of KCl or BDNF.  Displayed are the top 25 BDNF-induced late response 
genes, defined as genes with greater induction at 6 h than at 1 h after BDNF stimulation.  
Only genes expressed in the top 50th percentile of all expressed genes within at least one 
of the time points (0 h, 1 h, 6 h BDNF) were considered for this analysis.  Genes are 
displayed in decreasing order of fold induction at the 6 h time point after BDNF 
stimulation relative to the 0 h time point after BDNF stimulation.  mRNA expression 
values are reported as reads per kilobase per million mapped reads (RPKM).  For each 
gene, gene name (Gene), NCBI GeneID, chromosome number (Ch), DNA strand (St), 
start and stop position are also displayed. 
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6.3 UCSC GENOME BROWSER VIEWS OF CHIP-SEQ AND RNA-SEQ DATA 
NEAR STIMULUS RESPONSIVE GENES IN THE NERVOUS SYSTEM 
All genes listed in Appendix A are displayed on the subsequent pages, in alphabetical order. 
The window displayed ranges from 50kb upstream of the gene to 50kb downstream of the gene. 
 
For each gene, the following tracks are displayed: 
1) RNA-Seq after 0 hr of KCl stimulation, silenced conditions 
2) RNA-Seq after 1 hr of KCl stimulation 
3) RNA-Seq after 6 hr of KCl stimulation 
4) RefSeq gene 
5) PhastCons vertebrate conservation 
6) DNaseI hypersensitivity from embryonic 14.5 whole brain* 
7) DNaseI hypersensitivity from embryonic 18.5 whole brain* 
8) DNaseI hypersensitivity from 8 week adult cerebrum* 
9) H3K27Ac ChIP-Seq from embryonic 14.5 whole brain* 
10) H3K27Ac ChIP-Seq from 8 week adult cortex* 
11) H3K27Ac ChIP-Seq in silenced conditions 
12) H3K27Ac ChIP-Seq after 2hrs of KCl stimulation 
13) H3K4Me1 ChIP-Seq in silenced conditions** 
14) H3K4Me1 ChIP-Seq after 2hrs of KCl stimulation** 
15) H3K4Me3 ChIP-Seq in silenced conditions** 
16) H3K4Me3 ChIP-Seq after 2hrs of KCl stimulation** 
17) H3K27Me3 ChIP-Seq in silenced conditions** 
18) H3K27Me3 ChIP-Seq after 2hrs of KCl stimulation** 
19) CBP ChIP-Seq in silenced conditions** 
20) CBP ChIP-Seq after 2hrs of KCl stimulation** 
21) CBP ChIP-Seq in silenced conditions 
22) CBP ChIP-Seq after 2hrs of KCl stimulation 
23) P300 ChIP-Seq in silenced conditions 
24) P300 ChIP-Seq after 2hrs of KCl stimulation 
25) RNAPII ChIP-Seq in silenced conditions** 
26) RNAPII ChIP-Seq after 2hrs of KCl stimulation** 
27) C-FOS ChIP-Seq in silenced conditions 
28) C-FOS ChIP-Seq after 2hrs of KCl stimulation 
29) C-FOS ChIP-Seq after 2hrs of KCl stimulation from control shRNA lentivirus infected neurons 
30) C-FOS ChIP-Seq after 2hrs of KCl stimulation from c-Fos shRNA lentivirus infected neurons 
31) FOSB ChIP-Seq in silenced conditions 
32) FOSB ChIP-Seq after 2hrs of KCl stimulation 
33) FOSB ChIP-Seq after 2hrs of KCl stimulation from control shRNA lentivirus infected neurons 
34) FOSB ChIP-Seq after 2hrs of KCl stimulation from FosB shRNA lentivirus infected neurons 
35) NPAS4 ChIP-Seq in silenced conditions** 
36) NPAS4 ChIP-Seq after 2hrs of KCl stimulation** 
37) CREB ChIP-Seq in silenced conditions** 
38) CREB ChIP-Seq after 2hrs of KCl stimulation** 
39) SRF ChIP-Seq in silenced conditions** 
40) SRF ChIP-Seq after 2hrs of KCl stimulation** 
41) MEF2A ChIP-Seq in silenced conditions 
42) MEF2A ChIP-Seq after 2hrs of KCl stimulation 
43) SNPs 
44) RepeatMasker 
45) RNA-Seq after 0 hr of BDNF stimulation, basal conditions 
46) RNA-Seq after 1 hr of BDNF stimulation 
47) RNA-Seq after 6 hr of BDNF stimulation 
48) UCSC gene 
49) PhastCons mammalian conservation 
50) H3K27Ac ChIP-Seq in basal conditions 
51) H3K27Ac ChIP-Seq after 2hrs of BDNF stimulation 
52) C-FOS ChIP-Seq in basal conditions 
53) C-FOS ChIP-Seq after 2hrs of BDNF stimulation 
54) FOSB ChIP-Seq in basal conditions 
55) FOSB ChIP-Seq after 2hrs of BDNF stimulation 
 
* denotes data from ENCODE, ** denotes data from Kim et al., 2010  
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Figure 6.1: 4930431J08Rik locus  
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Figure 6.2: 4931440P22Rik locus  
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Figure 6.3: 5430433G21Rik locus  
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Figure 6.4: Acan locus  
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Figure 6.5: Arc locus  
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Figure 6.6: Areg locus  
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Figure 6.7: Arl4d locus  
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Figure 6.8: Atf3 locus  
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Figure 6.9: Axud1 locus  
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Figure 6.10: Bdnf locus  
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Figure 6.11: Btg2 locus  
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Figure 6.12: C030019I05Rik locus  
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Figure 6.13: C1ql2 locus  
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Figure 6.14: Cartpt locus  
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Figure 6.15: Cckbr locus  
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Figure 6.16: Ccl2 locus  
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Figure 6.17: Ccnu locus  
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Figure 6.18: Cited1 locus  
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Figure 6.19: Col10a1 locus  
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Figure 6.20: Cort locus  
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Figure 6.23: Dusp1 locus  
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Figure 6.27: E530001K10Rik locus  
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Figure 6.37: Gadd45b locus  
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Figure 6.38: Galr1 locus  
  224 
 
Figure 6.39: Gpr3 locus  
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Figure 6.40: Hsd11b1 locus  
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Figure 6.47: LOC100038842 locus  
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Figure 6.53: Npas4 locus  
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7 APPENDIX B: NEURONAL ENHANCERS WITH DIFFERENT 
H3K27AC BEHAVIORS 
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7.1 UCSC GENOME BROWSER VIEWS OF CHIP-SEQ AND RNA-SEQ DATA 
AT NEURONAL ENHANCERS WITH DIFFERENT H3K27AC BEHAVIORS 
All enhancers tested in luciferase assays within this thesis are displayed on the subsequent pages, in order 
of enhancer number.  A 20kb window surrounding each enhancer center is displayed. 
 
For each enhancer, the following tracks are displayed: 
1) RNA-Seq after 0 hr of KCl stimulation, silenced conditions 
2) RNA-Seq after 1 hr of KCl stimulation 
3) RNA-Seq after 6 hr of KCl stimulation 
4) RefSeq gene 
5) PhastCons vertebrate conservation 
6) DNaseI hypersensitivity from embryonic 14.5 whole brain* 
7) DNaseI hypersensitivity from embryonic 18.5 whole brain* 
8) DNaseI hypersensitivity from 8 week adult cerebrum* 
9) H3K27Ac ChIP-Seq from embryonic 14.5 whole brain* 
10) H3K27Ac ChIP-Seq from 8 week adult cortex* 
11) H3K27Ac ChIP-Seq in silenced conditions 
12) H3K27Ac ChIP-Seq after 2hrs of KCl stimulation 
13) H3K4Me1 ChIP-Seq in silenced conditions** 
14) H3K4Me1 ChIP-Seq after 2hrs of KCl stimulation** 
15) H3K4Me3 ChIP-Seq in silenced conditions** 
16) H3K4Me3 ChIP-Seq after 2hrs of KCl stimulation** 
17) H3K27Me3 ChIP-Seq in silenced conditions** 
18) H3K27Me3 ChIP-Seq after 2hrs of KCl stimulation** 
19) CBP ChIP-Seq in silenced conditions** 
20) CBP ChIP-Seq after 2hrs of KCl stimulation** 
21) CBP ChIP-Seq in silenced conditions 
22) CBP ChIP-Seq after 2hrs of KCl stimulation 
23) P300 ChIP-Seq in silenced conditions 
24) P300 ChIP-Seq after 2hrs of KCl stimulation 
25) RNAPII ChIP-Seq in silenced conditions** 
26) RNAPII ChIP-Seq after 2hrs of KCl stimulation** 
27) C-FOS ChIP-Seq in silenced conditions 
28) C-FOS ChIP-Seq after 2hrs of KCl stimulation 
29) C-FOS ChIP-Seq after 2hrs of KCl stimulation from control shRNA lentivirus infected neurons 
30) C-FOS ChIP-Seq after 2hrs of KCl stimulation from c-Fos shRNA lentivirus infected neurons 
31) FOSB ChIP-Seq in silenced conditions 
32) FOSB ChIP-Seq after 2hrs of KCl stimulation 
33) FOSB ChIP-Seq after 2hrs of KCl stimulation from control shRNA lentivirus infected neurons 
34) FOSB ChIP-Seq after 2hrs of KCl stimulation from FosB shRNA lentivirus infected neurons 
35) NPAS4 ChIP-Seq in silenced conditions** 
36) NPAS4 ChIP-Seq after 2hrs of KCl stimulation** 
37) CREB ChIP-Seq in silenced conditions** 
38) CREB ChIP-Seq after 2hrs of KCl stimulation** 
39) SRF ChIP-Seq in silenced conditions** 
40) SRF ChIP-Seq after 2hrs of KCl stimulation** 
41) MEF2A ChIP-Seq in silenced conditions 
42) MEF2A ChIP-Seq after 2hrs of KCl stimulation 
43) SNPs 
44) RepeatMasker 
45) RNA-Seq after 0 hr of BDNF stimulation, basal conditions 
46) RNA-Seq after 1 hr of BDNF stimulation 
47) RNA-Seq after 6 hr of BDNF stimulation 
48) UCSC gene 
49) PhastCons mammalian conservation 
50) H3K27Ac ChIP-Seq in basal conditions 
51) H3K27Ac ChIP-Seq after 2hrs of BDNF stimulation 
52) C-FOS ChIP-Seq in basal conditions 
53) C-FOS ChIP-Seq after 2hrs of BDNF stimulation 
54) FOSB ChIP-Seq in basal conditions 
55) FOSB ChIP-Seq after 2hrs of BDNF stimulation 
 
* denotes data from ENCODE, ** denotes data from Kim et al., 2010  
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Figure 7.1: Enhancer 1 locus  
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8 APPENDIX C: ACTIVITY-DEPENDENT LATE RESPONSE GENES 
LESS INDUCED WITH C-FOS RNAI 
On the subsequent pages are displayed all microarray probesets (n=128) that detected 
activity-dependent genes that were three fold or more induced (6hr/0hr expression>=3) 
in neurons infected with control RNAi but whose fold induction was reduced by at least 
1.75 fold with c-Fos RNAi (fold induction c-Fos RNAi/fold induction control RNAi <= 
1/1.75).  Probesets are sorted alphabetically by the gene to which they correspond.  Fold 
inductions from control RNAi and c-Fos RNAi infected cells are reported as the average 
fold induction of two microarray bioreplicates. 
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ARTICLES
Activity-dependent regulation of
inhibitory synapse development by Npas4
Yingxi Lin1, Brenda L. Bloodgood1, Jessica L. Hauser1{, Ariya D. Lapan2, Alex C. Koon1{, Tae-Kyung Kim1,
Linda S. Hu1, Athar N. Malik1,3 & Michael E. Greenberg1
Neuronal activity regulates the development and maturation of excitatory and inhibitory synapses in the mammalian brain.
Several recent studies have identified signalling networks within neurons that control excitatory synapse development.
However, less is known about the molecular mechanisms that regulate the activity-dependent development of GABA
(c-aminobutyric acid)-releasing inhibitory synapses. Here we report the identification of a transcription factor, Npas4, that
plays a role in the development of inhibitory synapses by regulating the expression of activity-dependent genes, which in turn
control the number of GABA-releasing synapses that form on excitatory neurons. These findings demonstrate that the
activity-dependent gene program regulates inhibitory synapse development, and suggest a new role for this program in
controlling the homeostatic balance between synaptic excitation and inhibition.
Sensory experience controls multiple steps in the development and
maturation of synapses in the mammalian brain1–4. Many of the
effects of neuronal activity are mediated by the release of glutamate
at excitatory synapses and the subsequent influx of calcium (Ca21)
into the postsynaptic neuron. This results in changes in the number
and strength of synapses, a process that underlies learning andmem-
ory as well as animal behaviour.
Neurons in the central nervous system receive excitatory synaptic
input from glutamatergic neurons and inhibitory input fromGABA-
releasing (GABAergic) interneurons, except during early develop-
ment when the first GABAergic synapses are depolarizing and
provide the excitatory drive critical for the subsequent development
of glutamatergic synapses5. The proper balance between excitatory
and inhibitory synapses is crucial for representation of sensory
information6,7, execution of motor commands8,9 and higher-order
cognitive functions10. Neurological disorders such as autism, schizo-
phrenia and epilepsy are associated with an imbalance between excit-
atory and inhibitory synapses11–13. The number or strength of
excitatory synapses can be modified in response to changes in acti-
vity, and the molecular mechanisms of these processes have been
extensively investigated14–16. Less is known about the activity-
dependent regulation of inhibitory synapses.
The density of inhibitory synapses in brain regions such as primary
sensory cortex, hippocampus and cerebellum is regulated by the level
of excitatory synaptic activity and sensory input17–22. In addition,
initiation of the critical period for synaptic plasticity in the visual
cortex is dependent on visual activity and strongly influenced by the
maturation of inhibitory synapses23, suggesting that the activity-
dependent regulation of GABAergic synapses is important for the
plasticity of the nervous system. Finally, recent studies indicate that
regulation of GABAergic synapses in response to neuronal activity
may be a critical component of the homeostatic mechanism that
maintains a balance between excitation and inhibition in the face
of fluctuations in the level of sensory input into neural circuits24.
Despite the accumulating evidence that neuronal activity regulates
the development and maintenance of inhibitory synapses, the
molecular mechanisms that control these processes remain to be
characterized.
Here we identify a transcription factor, Npas4, that is critical for
activity-dependent regulation of GABAergic synapse development.
Npas4 expression is rapidly activated by excitatory synaptic activity
and turns on a program of gene expression that triggers the forma-
tion and/or maintenance of inhibitory synapses on excitatory neu-
rons. These findings provide a molecular link between neuronal
excitation and GABAergic synapse development, and suggest a new
role for the activity-dependent gene program in controlling inhib-
itory synapse formation/maintenance on excitatory neurons.
Npas4 is regulated by neuronal activity
The formation of inhibitory synapses onto excitatory neurons is
regulated by neuronal activity, takes place over several days, and is
a cell-wide process that results in the formation of synapses onto both
the cell body and dendrites18,25. These features led us to hypothesize
that activity-dependent development of inhibitory synapses might be
controlled postsynaptically by one or more activity-regulated genes.
To test this hypothesis, we used DNA microarrays to identify genes
that are induced by membrane depolarization in mouse cortical
neurons at the time when inhibitory synapses are developing.
We identified more than 300 genes whose expression levels were
altered upon membrane depolarization (Gene Expression Omnibus
accession number GSE11256), a third of which were novel activity-
regulated genes not seen in previous screens26,27. We looked for genes
predicted to encode transcription factors, reasoning that, through
genome-wide characterization of the targets of an activity-regulated
transcription factor that controls inhibitory synapse number, we
could gain insight into the biological program that is important for
inhibitory synapse development. Among the approximately 20
known or putative transcription factors identified, we focused on
genes that are selectively induced by Ca21 influx in neurons but
not other cell types, that are transcribed in response to excitatory
1F. M. Kirby Neurobiology Center, Children’s Hospital and Departments of Neurology and Neurobiology, Harvard Medical School, 300 Longwood Avenue, Boston, Massachusetts
02115, USA. 2Program in Biological and Biomedical Sciences, HarvardMedical School, 240 LongwoodAvenue, Boston,Massachusetts 02115, USA. 3Program inNeuroscience, Harvard
Medical School, 300 Longwood Avenue, Boston, Massachusetts 02115, USA. {Present addresses: Baylor College of Medicine, Medical Scientist Training Program, One Baylor Plaza
Suite N201, MS:BCM215, Houston, Texas 77030-7498, USA (J.L.H.); University of Massachusetts Medical School, Lazare Medical Research Building, Room 760C, 364 Plantation
Street, Worcester, Massachusetts 06105, USA (A.C.K.).
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synaptic activity, and that are expressed coincidently with the
development of inhibitory synapses. One transcription factor, the
bHLH-PAS family member Npas4 (refs 28–31), fulfilled all these
criteria (Fig. 1) and was investigated further.
Unlike other activity-dependent transcription factors such asCREB
and c-fos, Npas4 expression in neurons is selectively induced by Ca21
influx but not by several neurotrophic factors, growth factors or for-
skolin, an activator of protein kinase A (Fig. 1b). Furthermore, Npas4
induction is transient (Fig. 1c), occurs selectively in neurons, and
predominately in excitatory neurons (data not shown). Npas4
expression is barely detectable in immature primary hippocampal
neurons, when there are few synapses32, and increases with the forma-
tion and maturation of synapses25 (Fig. 1d).
Npas4 is induced in cultured neurons by the GABAA-receptor ant-
agonist bicuculline, which increases action-potential firing and excit-
atory synaptic transmission (Fig. 1e). This induction requires an
influx of extracellular Ca21 through L-type voltage-sensitive calcium
channels (L-VSCCs) and is partly dependent on the activation of
N-methyl-D-aspartate (NMDA) and a-amino-3-hydroxy-5-methyl-
4-isoxazole propionic acid (AMPA) receptors (Fig. 1e). Npas4
expression is also induced in pertinent brain regions in vivo in res-
ponse to specific stimuli: visual stimulation of mice after a period of
dark-rearing results in an increase in Npas4messenger RNA (mRNA)
and protein levels specifically in the visual cortex (Fig. 1f, g).
Npas4 regulates the development of inhibitory synapses
The effect of Npas4 on inhibitory synapse development was investi-
gated by RNA interference (RNAi)-mediated knockdown in excit-
atory neurons of rat dissociated hippocampal cultures, before
synapse formation was underway. A small hairpin RNA targeting
Npas4 (Npas4-RNAi) effectively reduced Npas4 expression (Fig. 2a)
without affecting the overall health of the neurons (Supplementary
Fig. 1). Tomeasure inhibitory synapse number, neurons were immu-
nostained for presynaptic GABA-producing enzyme GAD65 and
postsynaptic GABAA-receptor c2 subunit (GABAA-c2). Co-local-
ization of GAD65 and GABAA-c2 puncta on a green fluorescent
protein (GFP)-transfected glutamatergic neuron was considered
indicative of a synapse (Fig. 2b). Expression of Npas4-RNAi, but
not a scrambled RNAi (control-RNAi), significantly reduced the
number of inhibitory synapses (Fig. 2c). Analysis of synapse number
using antibodies that recognize a second pair of inhibitory synaptic
proteins (GAD67 and GABAA-b2/3) gave a similar result (data not
shown). These data suggest that Npas4 positively regulates the num-
ber of inhibitory synapses that form on excitatory neurons.
Different classes of inhibitory neurons synapse onto distinct peri-
somatic or dendritic regions of pyramidal neurons33. We found that
Npas4-RNAi leads to a reduction in the number of inhibitory
synapses formed on both the perisomatic and dendritic regions, sug-
gesting that Npas4 regulates the number of inhibitory synapses
formed by multiple classes of inhibitory neurons (Fig. 2c). In both
regions, Npas4-RNAi significantly reduced the density of post-
synaptic GABAA-c2 puncta but had less effect on presynaptic
GAD65 puncta, compared with the control-RNAi (Fig. 2d). These
findings suggest that Npas4 regulates inhibitory synapse number by
controlling the number of postsynaptic specializations, resulting in
subsequent remodelling or retraction of the presynaptic terminals.
To test whether Npas4 is important for the development of func-
tional inhibitory synapses in a more intact neural circuit, rat organo-
typic hippocampal cultures were biolistically co-transfected with GFP
and either a control vector or Npas4-RNAi, and whole-cell recordings
were performed on GFP-positive CA1 pyramidal neurons to measure
spontaneous miniature inhibitory postsynaptic currents (mIPSCs,
Fig. 3a). Knocking down Npas4 expression in organotypic cultures
significantly increased the inter-event interval anddecreased the ampli-
tude of mIPSCs (Fig. 3b, c). This effect of Npas4-RNAi in organotypic
slices may be indicative of a decrease in inhibitory synapse number,
consistent with our observation that Npas4-RNAi reduces inhibitory
synapse number in dissociated cultures. Together, these findings indi-
cate that Npas4 plays an important role in regulating the number of
functional inhibitory synapses received by an excitatory neuron.
Consistent with a role forNpas4 in inhibitory synapse development,
Npas4 knockout mice (Npas42/2, Supplementary Fig. 2) appear
anxious and hyperactive, are prone to seizures and have a shortened
lifespan compared with their wild-type littermates, phenotypically
resembling other knockout mice lacking genes that control the forma-
tion or function of inhibitory circuits34–36. However, we found that the
frequencies of mIPSCs in acute hippocampal slices prepared from
wild-type and Npas42/2 mice were similar (Supplementary Fig. 3),
in contrast to the clear change in mIPSC frequency caused by disrupt-
ingNpas4 expression acutely in organotypic slices. This differencemay
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be due to the activation of compensatory pathways during develop-
ment in the absence of Npas4. Alternatively, it may reflect the fact that
Npas4 is absent in both pre- and postsynaptic cells in acute slices from
Npas42/2mice,whereas in the experimentswithorganotypic slices the
disruption of Npas4 expression occurs in postsynaptic neurons only.
To determine conclusively the involvement of Npas4 in inhibitory
synapse development, we generated an Npas4 conditional knockout
mouse (Npas4flx/flx) inwhich the coding region ofNpas4 is flanked by
loxP sites and can be acutely removed by Cre-mediated recombina-
tion (Supplementary Fig. 4). Organotypic hippocampal slices were
prepared fromNpas4flx/flx mice andwhole-cell recordingsmade from
CA1 pyramidal neurons transfected with GFP and either a control
vector or a vector encoding Cre recombinase. Cre expression had no
effect on mIPSCs in wild-type neurons (Supplementary Fig. 5).
However, compared with transfection with the control construct,
transfection of Npas4flx/flx neurons with Cre led to a significant
increase in the mIPSC inter-event interval (Fig. 3d, e). This finding
provides further evidence that CA1 pyramidal neurons lackingNpas4
receive fewer inhibitory synaptic inputs.
We next investigated whether the number of inhibitory synapses
forming onto a cell is controlled by the amount of Npas4 expressed in
response to excitatory stimuli. If this is the case, increasing the level of
Npas4 should lead to an increase in the number of inhibitory
synapses formed on the Npas4-expressing neuron. Additional
copies of the Npas4 gene were introduced into neurons using an
Npas4-minigene cassette consisting of all Npas4 introns and exons
as well as 5 kilobases (kb) of genomic sequence 59- and 39- to the
coding region. We verified that the Npas4-minigene drives ectopic
expression of Npas4 that is activity regulated and functions similarly
to the endogenous gene (Supplementary Fig. 6). We found that sig-
nificantly more inhibitory synapses were formed onto cultured hip-
pocampal neurons expressing the Npas4-minigene than onto
neurons transfected with a control vector (Fig. 2e), largely because
of an increase in the number of postsynaptic GABAA-c2 puncta
(Fig. 2f). Furthermore, expression of the Npas4-minigene in CA1
pyramidal neurons of hippocampal slices significantly decreases the
mIPSC inter-event interval and significantly increases the amplitude
(Fig. 3b, c), consistent with the presence of additional and stronger
inhibitory synapses on neurons expressing higher levels of Npas4.
Effect of Npas4 on excitatory synapses
The appropriate balance between excitation and inhibition is critical
for the function of neural circuits. To maintain this balance, changes
in the number or strength of inhibitory synapses are often coupled to
changes in excitatory synapses24. We next asked whether excitatory
synapse number or function is also affected whenNpas4 expression is
perturbed.
We first determined whether Npas4 regulates the number of excit-
atory synapses in dissociated hippocampal cultures. As before, neu-
rons were transfected with either Npas4-RNAi or control constructs,
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before synaptogenesis was underway and thus before the balance
between excitation and inhibition was established. Cultures were
immunostained for the presynaptic marker synapsin1 and the excit-
atory postsynaptic marker PSD95, and the numbers of co-localized
synapsin1 and PSD95 puncta on transfected glutamatergic neurons
were quantified. Neither the total numbers of excitatory synapses nor
the individual numbers of pre- or postsynaptic markers changed
significantly upon expression of Npas4-RNAi (Fig. 4a, b), under
conditions that significantly decreased the number of inhibitory
synapses. Likewise, expression of the Npas4-minigene had no effect
on excitatory synapse number (Fig. 4c, d). Because perturbation of
the level of Npas4 expression occurred before synaptic connections
were established, these experiments suggest that Npas4 is not a major
contributor to excitatory synaptogenesis.
We next examined whether Npas4 affects excitatory synapse func-
tion in organotypic hippocampal slices, where homeostatic mechan-
isms are known to control excitatory/inhibitory balance within
neural circuits. Deletion of the Npas4 gene from neurons in
Npas4flx/flx organotypic hippocampal slices by Cre recombination
significantly decreased the inter-event interval of spontaneous mini-
ature excitatory postsynaptic currents (mEPSCs, Fig. 4e, f), whereas
elevating the level of Npas4 with the Npas4-minigene significantly
increased the inter-event interval and decreased the amplitude of
mEPSCs (Fig. 4g, h), compared with control-transfected neurons.
Thus, abolishing Npas4 expression in a pyramidal neuron increases,
whereas enhancing the level of Npas4 decreases, the number and/or
presynaptic release probability of excitatory synapses that form on
the neuron. Therefore, the net result of Npas4 activation in an intact
neural circuit is an increase in synaptic inhibition and a decrease in
excitation of a neuron. We conclude that Npas4 induction in res-
ponse to increased excitatory input acts to reduce the level of activity,
and therefore may function as a negative feedback mechanism to
maintain the homeostatic balance between excitation and inhibition.
Npas4 regulates genes that control inhibitory synapse
development
To uncover the program of gene expression controlled by Npas4, we
acutely knocked downNpas4 expression in a high percentage of wild-
type neurons using a lentivirus expressing Npas4-RNAi
(Supplementary Fig. 7) and performed a second DNA microarray
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experiment to identify activity-regulated genes that are misregulated
in the absence of Npas4. The expression levels of 327 microarray
probe sets representing 270 unique genes were significantly different
in cultures expressing Npas4-RNAi compared with those expressing
the control virus (Gene Expression Omnibus accession number
GSE11258, Supplementary List). The expression of 182 of these genes
was also acutely regulated by membrane depolarization in the
absence of Npas4-RNAi, indicating that many putative Npas4-
regulated genes are activity regulated (Fig. 5a). Although Npas4 has
been shown to function as a transcriptional activator
(Supplementary Fig. 6b)28, we found that many genes are negatively
regulated by Npas4 (Fig. 5a). This may reflect the fact that Npas4
functions as a transcriptional repressor as well as an activator, and/or
that Npas4 indirectly affects gene expression by altering neuronal
excitation.
Npas4 appears to regulate a wide variety of genes, such as activity-
regulated immediate early genes, various classes of transcription fac-
tors, channel proteins, G-protein signalling molecules, kinases and
phosphatases, and genes involved in pathways that modulate syn-
aptic functions, such as ubiquitination, trafficking and receptor
endocytosis (Fig. 5b and Supplementary List). Interestingly, the func-
tions of 94 of the 270 putative Npas4-regulated genes are uncharac-
terized (Fig. 5b), suggesting that Npas4 regulates many genes that
could affect inhibitory synapses in novel ways.
As a first step towards understanding the genetic program regu-
lated by Npas4, we focused on targets that might be directly involved
in the development of GABAergic synapses. Brain-derived neuro-
trophic factor (BDNF) stood out because it had previously been
shown to regulate GABAergic synapse maturation and func-
tion18,20,37–39. BDNF expression is consistently reduced by almost two-
fold in cultures expressing Npas4-RNAi compared with control
cultures (Fig. 5c). Primary cultures from Npas42/2 mice showed a
similar decrease in depolarization-induced BDNF expression com-
pared with their wild-type littermates (Fig. 5d).
The BDNF gene has many promoters and the activity-dependent
BDNF mRNA transcripts are controlled by promoters I and IV40–42.
Using a chromatin immunoprecipitation assay, we asked whether
Npas4 binds to these promoters in primary cortical cultures that were
left untreated ormembrane-depolarized to trigger Npas4 expression.
Although no Npas4 binding was detected in untreated neurons, in
membrane-depolarized neurons Npas4 was found to be associated
with BDNF promoters I and IV, but not with the coding region or 39
untranslated region (Fig. 5e), suggesting that Npas4 may directly
regulate activity-dependent expression of BDNF.
To determine whether BDNF contributes to the effects of Npas4
on GABAergic synapse development, we tested whether the ability of
the Npas4-minigene to increase the number of inhibitory synapses is
attenuated by knockdown of BDNF expression, using a previously
validated small hairpin RNA that targets the BDNF coding region
(BDNF-RNAi)43. Confirming that BDNF increases inhibitory syn-
apse number44, BDNF-RNAi increased mIPSC inter-event inter-
vals compared with control values (2986.36 109.7 and 4086.16
140.7ms, control and BDNF-RNAi, respectively, P, 0.01).
Expression of the Npas4-minigene alone led to an approximately
40% decrease in the inter-event interval of mIPSCs recorded from
CA1 neurons (Fig. 3b, c), as previously observed, but this was partly
attenuated to approximately 20% by the presence of BDNF-RNAi
(Fig. 6a). In addition, in the presence of BDNF-RNAi, the effect of the
Npas4-minigene on the amplitude of mIPSCs was completely
reversed (Fig. 6b). These findings suggest that BDNF mediates a
portion of the effect of Npas4 on inhibitory synapse number, but
that additional Npas4 targets may also be involved.
Discussion
We have identified the activity-regulated transcription factor Npas4
as a key regulator of GABAergic synapse development. Excitatory
synaptic activity induces Npas4 in a Ca21-dependent manner, and
the level of Npas4 determines the number of functional GABAergic
synapses by controlling a program of activity-dependent gene
expression. Future characterization of Npas4 target genes will help
to determine whether Npas4 acts by initiating inhibitory synapse
formation, stabilizing nascent inhibitory synapses or promoting
the maturation of weak inhibitory synapses. It is possible that differ-
ent subsets of Npas4 targets control the development of GABAergic
synapses formed by distinct classes of interneurons, providing a
mechanism for the independent regulation of inhibition received
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putative Npas4 target genes) based on their expression profiles using
dChip49. The expression level of each probe set is normalized to a mean of 0
and a standard deviation of 1. Expression values are displayed within the
range [23, 3] with levels above, equal to or below themean displayed in red,
white and blue, respectively. Dark red represents 3 or higher, and dark blue
23 or lower. b, Biological functions of 270 putativeNpas4 target genes based
on Gene Ontology information provided by Affymetrix (http://
www.affymetrix.com). c, BDNF expression is reduced by Npas4-RNAi
(1.96 0.11-fold reduction,P, 0.01, one-tailed paired t-test).Mean6 s.e.m.
from three independent experiments is shown, and each data point was
generated by averaging the hybridization intensity of two BDNF probe sets
(1422168_a_at and 1422169_a_at). d, BDNF levels are consistently reduced
in neurons from Npas42/2 mice compared with their wild-type littermates
(58.466 6.49% decrease, 95% confidence interval 30.5–86.4%). Cortical
cultures prepared from Npas41/1 and Npas42/2 littermates (7DIV) were
stimulated with KCl (55mM), and BDNF mRNA levels were measured by
quantitative reverse transcriptase PCR using primers in BDNF coding
region. Three littermate pairs from three different litters were analysed; data
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by subregions of a neuron. Another intriguing possibility is that
Npas4 controls experience-dependent developmental processes,
such as critical period plasticity in the visual cortex, which depend
on the function and maturation of GABAergic synapses.
Although Npas4 is not required for the initial formation of excit-
atory synapses, activation of Npas4 in excitatory neurons within a
neural circuit appears to diminish the excitatory synaptic input they
receive. It is not known whether this effect is mediated directly by
Npas4 or is an indirect consequence of changes in inhibitory input. In
either case, our findings suggest that Npas4 functions as part of the
homeostatic mechanism that stabilizes the activity of a neuron in the
face of changing glutamatergic input. Further investigation of the
function of Npas4 and other activity-dependent regulators of inhib-
itory synapses45 will provide insight into the mechanism by which
neuronal activity controls the balance between excitation and inhibi-
tion in the brain, and how the disruption of this balance leads to
neurological disorders such as autism, epilepsy and schizophrenia.
METHODS SUMMARY
Dissociated neuron culture and transfection. Dissociated cortical and hippo-
campal neuronswere prepared fromE18 rat or E16mouse embryos as previously
described46. Cultures were maintained in Neurobasal Medium supplemented
with B27 (Invitrogen), penicillin–streptomycin and glutamine. Neurons were
plated at 100,000–150,000 per well in a 24-well plate or 15,000,000 per 10-cm
plate. For synapse assays, hippocampal neurons (60,000 per well, 24-well plate)
were plated on amonolayer of astrocytes47. Neurons were transfected at 5–6 days
in vitro (DIV) using the calcium phosphate method46.
Organotypic slice culture and transfection. Organotypic hippocampal slice
cultures were prepared from P6 rats or mice as previously described48. Slices
were biolistically transfected with a Helios Gene Gun (Biorad) after 2 days.
Bullets for the gene gun were 1.6-mm gold particles coated with 15 mg eGFP
and either 5 or 10 mg RNAi construct, 45 mg Npas4-minigene or 30mg Cre.
Empty plasmid was added to bring the total DNA to 60 mg in each case.
Synapse density assay. Hippocampal neurons (14–18DIV) were immuno-
stained for synaptic markers and imaged on a Zeiss LSM5 Pascal microscope
using a 363 objective lens. Image acquisition and synapse quantification were
performed in a blindedmanner. Glutamatergic neuronswere identified based on
morphology and the absence of cytosolic GAD65 staining. Synapse density was
measured using Metamorph software as previously described47. Within each
experiment, density of puncta was normalized against the control, and the error
of the control propagated into each experimental condition. Statistical analysis
was performed on the raw data (without normalization) using multifactorial
analysis of variance in StatView 4.5 (Abacus Concepts).
Electrophysiology.Whole-cell patch clamp recordings were made at room tem-
perature from CA1 pyramidal neurons 7–10 days after transfection. Data were
analysed in IgorPro (Wavemetrics) using custom-written macros. Statistical
significance was determined by Kolmogorov–Smirnov test and Monte Carlo
simulation.
Full Methods and any associated references are available in the online version of
the paper at www.nature.com/nature.
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METHODS
DNA constructs. Npas4-RNAi, 59-GGTTGACCCTGATAATTTA-39, and con-
trol-RNAi with a scrambled sequence (underlined), 59-GGTTCAGCGTCATAA
TTTA-39, were cloned into the pSuper expression vector (OligoEngine). The
same Npas4-RNAi was used to generate the lentivirus construct (Cellogenetics,
Inc). The control lentivirus construct, pLenti-shGL3 (Cellogenetics, Inc), targets
the luciferase gene, which is not expressed by mouse hippocampal neurons.
The Npas4-minigene was generated by subcloning the mouse genomic region
from CTCGGTTTCTATCTTCATGCC to GCCATGTGGCCTGCCGGTAC into
a pBluescriptIIk1 vector between the SacII and KpnI digestion sites. The
sequence targeted byNpas4-RNAiwasmutated toAgtCgaTccCgataattta, preserv-
ing the amino-acid sequence, to generate an RNAi-resistant Npas4-minigene.
The Npas4 luciferase reporter was constructed by replacing the tandemMEF2
responsive elements with three copies of the Npas4 responsive element28 in the
33MRE-luc plasmid50.
Immunocytochemistry and immunohistochemistry. Cultured neurons were
fixed and immunostained as previously described47. For immunohistochemistry,
mice were perfused intracardially with cold PBS followed by 4% paraformalde-
hyde in PBS. Brains were post-fixed in 4% paraformaldehyde in PBS at 4 uC
overnight followed by incubation in 30% sucrose in PBS at 4 uC for 24 h. These
cryo-protected brains were immediately sectioned on a cryostat (Leica) or stored
in Tissue-Tec O.C.T. at 280 uC for later sectioning. Matching brain sections
(35mm) were incubated in blocking solution (3% BSA, 3% goat serum, 0.3%
Triton X-100, 0.2% Tween-20 in PBS) at room temperature for 2 h.
Subsequently, sections were incubated with primary antibodies overnight at
4 uC and with secondary antibodies at room temperature for 2 h, both in block-
ing solution. Finally, sections were mounted on slides with Aquamount (Lerner
Laboratories).
The following antibodies were used: GAD65 (mouse, 1:1,000, Chemicon),
GABAA-receptor c2 subunit (rabbit, 1:400, Chemicon), PSD95 (mouse, 1:300,
Affinity BioReagents), synapsin I (rabbit, 1:500, Chemicon), c-fos (rabbit,
1:1,000, Santa Cruz sc-52), phosphor-serine 133 CREB (mouse, 1:2,000,
Upstate). The Npas4 antibody (rabbit, 1:2,000) was raised against a carboxy-
terminal region of Npas4 (amino acids 597–802) and its specificity was tested in
Npas42/2 mice (Supplementary Fig. 2).
Synapse density assay. Confocal image acquisition and synapse density mea-
surement were performed as previously described47. The perisomatic region of a
neuron was defined as the cell body plus a 20-pixel circumference. Each pixel is
approximately 0.143mm. The perisomatic region was excluded from the excit-
atory synapse density analysis.
Because synapse density and immunostaining vary significantly between
experiments, it is necessary to normalize each experiment before combining
them. Normalization and error propagation were performed as previously
described47.
Electrophysiology. Slices were perfused with artificial cerebrospinal fluid con-
taining (inmM) 127 NaCl, 25 NaHCO3, 1.25 Na2HPO4, 2.5 KCl, 2 CaCl2, 1
MgCl2, 25 glucose, and saturated with 95% O2, 5% CO2. The internal solution
for mIPSCs contained (inmM) 147 CsCl, 5 Na2-phosphocreatine, 10 HEPES, 2
MgATP, 0.3 Na2GTP and 1 EGTA. The internal solution for mEPSCs contained
(inmM) 120 cesium methane sulfonate, 10 HEPES, 4 MgCl2, 4 Na2ATP, 0.4
Na2GTP, 10 sodium phosphocreatine and 1 EGTA. Osmolarity and pH were
adjusted to 300mOsm and 7.3 with Millipore water and CsOH, respectively.
mIPSCs were pharmacologically isolated by bath application of (in mM) 0.5
tetrodotoxin, 10 (R)-CPP and 10 NBQX disodium salt (all from Tocris
Bioscience); mEPSCs were isolated with 0.5 tetrodotoxin and 50 picrotoxin
(Tocris Bioscience), and augmented with 10 cyclothiazide. Cells with series
resistance larger than 25MV during the recordings were discarded.
Data were analysed in IgorPro (Wavemetrics) using custom-written macros.
For each trace, the event threshold was set at 1.5 times the root-mean-square
current. Currents were counted as events if they crossed the event threshold, had
a rapid rise time (1.5 pAms21) and had an exponential decay (2, t, 200ms,
1, t, 50ms for mIPSC and mEPSC, respectively).
Statistical significance was determined by two methods. First, 50 random
points selected from each cell were concatenated to describe the cumulative
distributions of events in each condition and then compared by a
Kolmogorov–Smirnov test. Second, a Monte Carlo simulation was performed
in which points were randomly sampled from each condition and the mean of
these samples compared at least 1,000 times. P, 0.05 from both tests was con-
sidered significant.
DNAmicroarrays and data analysis. For all microarray experiments, total RNA
was purified using RNeasy mini kits (Qiagen) and biotin-labelled cRNA was
generated following Affymetrix standard protocols. Ten micrograms of the
labelled cRNA was hybridized to Affymetrix mouse MOE430 arrays.
To identify activity-regulated genes, P0 mouse cortical neurons were cultured
for 7 days and then depolarized with 50mM KCl for 1 and 6 h. To identify
Npas4-regulated genes, E16 mouse hippocampal neurons were infected
(3DIV) with Npas4-RNAi or control lentivirus, depolarized (8DIV) with
50mM KCl, and total RNA was collected 0, 1, 3 and 6 h later. Drebrin, an
Npas4 target previously identified in a neuroblastoma cell line28 was not affected
by Npas4-RNAi in post-mitotic neurons.
The DNA-Chip (dChip) software package49 was used to analyse the micro-
array data. Genes were considered candidates if they met the following criteria:
(1) there was at least a 1.5-fold difference between the experimental and control
conditions (depolarized versus non-depolarized, or Npas4-RNAi virus versus
control virus) at any of the time points; and (2) there was an absolute difference
ofmore than 100 normalized hybridization intensity units in the expression level
between the experimental and control samples.
Chromatin immunoprecipitation. Rat cortical neurons were treated with 1mM
tetrodotoxin and 100mM AP5 overnight and then stimulated with 55mM KCl
for 2 h at 8DIV. Chromatin immunoprecipitation was performed as previously
described49. The following primers were used for quantitative PCR: Chr3, for-
ward: 59-GACCCCATCCTGTGGTTATG-39, reverse: 59-GCAACAAAGGCA
AATGGAAT-39; Npas4, forward: 59-CAGGATGACTCACACTGACAGTATT
TTTAG-39, reverse: 59-GTGGGAGAAGAGCTATTTATATCACCAG-39; BDNF
promoter I, forward: 59-GTGCCTCTCGCCTAGTCATC-39, reverse: 59-AGGG
AACAACTGCGTGAATC-39; BDNF promoter IV, forward: 59-CAGGGAGC
TACTCACCCAAC-39, reverse: 59-GCACACAGAAGCCAAACCTT-39; BDNF
coding region, forward: 59-GACAAGGCAACTTGGCCTAC-39, reverse: 59-TC
GTCAGACCTCTCGAACCT-39; BDNF 39 untranslated region, forward: 59-GA
AACGCCACACCTACGAAT-39, reverse: 59-GGCACCGAATCCAATTCTAA-39.
Quantitative reverse transcriptase PCR.ThemRNA level of the gene of interest
was normalized against the mRNA level of b-tubulin in the same sample. The
following primers were used: Npas4, forward: 59-GCTATA
CTCAGAAGGTCCAGAAGGC-39, reverse: 59-TCAGAGAATGAGGGTAGCA
CAGC-39; BDNF, forward: 59-GATGCCGCAAACATGTCTATGA-39, reverse:
59-TAATACTGTCACACACGCTCAGCTC-39; b-tubulin, forward: 59-CGAC
AATGAAGCCCTCTACGAC-39, reverse: 59-ATGGTGGCAGACACAAGGTGG
TTG-39.
50. Flavell, S. W. et al. Activity-dependent regulation of MEF2 transcription factors
suppresses excitatory synapse number. Science 311, 1008–1012 (2006).
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Charged multivesicular body protein 1A (CHMP1A; also 
known as chromatin-modifying protein 1A) is a member of the 
ESCRT-III (endosomal sorting complex required for transport-
III) complex1,2 but is also suggested to localize to the nuclear 
matrix and regulate chromatin structure3. Here, we show that 
loss-of-function mutations in human CHMP1A cause reduced 
cerebellar size (pontocerebellar hypoplasia) and reduced 
cerebral cortical size (microcephaly). CHMP1A-mutant 
cells show impaired proliferation, with increased expression 
of INK4A, a negative regulator of stem cell proliferation. 
Chromatin immunoprecipitation suggests loss of the normal 
INK4A repression by BMI in these cells. Morpholino-based  
knockdown of zebrafish chmp1a resulted in brain defects 
resembling those seen after bmi1a and bmi1b knockdown, 
which were partially rescued by INK4A ortholog knockdown, 
further supporting links between CHMP1A and BMI1-mediated 
regulation of INK4A. Our results suggest that CHMP1A  
serves as a critical link between cytoplasmic signals and  
BMI1-mediated chromatin modifications that regulate 
proliferation of central nervous system progenitor cells.
As part of ongoing studies of human disorders affecting neural progenitor 
proliferation, we identified three families characterized by under-
development of the cerebellum, pons and cerebral cortex (Fig. 1a–d). 
In a consanguineous pedigree of Peruvian origin, three children in 
two branches were affected (Fig. 1e, family 1). Two additional pedi-
grees from Puerto Rico showed similar pontocerebellar hypoplasia 
and microcephaly (Fig. 1e, families 2 and 3). Brain magnetic reso-
nance imaging (MRI) of affected individuals from all families showed 
severe reduction of the cerebellar vermis and hemispheres relative to 
normal individuals. Notably, the cerebellar folds (folia) were relatively 
preserved, despite the extremely small cerebellar size (Fig. 1a–d and 
Supplementary Videos 1 and 2). All affected individuals had severe 
pontocerebellar hypoplasia, although affected individuals in family 1 
showed better motor and cognitive function than those in families 2 
and 3 (Supplementary Note).
Genome-wide linkage analysis of families 1 and 2 using SNP micro-
arrays implicated only one region on chromosome 16q as linked and 
homozygous in all six affected individuals (Fig. 1e and Supplementary 
Fig. 1), with a maximum multipoint logarithm of odds (LOD) score of 
3.68 (Fig. 1e). Although families 2 and 3 are not highly informative for 
linkage analysis, their shared homozygosity provides additional sup-
port for the involvement of this locus. Furthermore, families 2 and 3 
shared the same haplotype (Supplementary Fig. 1), suggesting a 
founder effect. Sequencing of 42 genes within the candidate interval 
at 16q24.3 revealed homozygous variants predicted to be deleterious 
only in the CHMP1A gene. CHMP1A (NM_002768) consists of seven 
exons encoding a 196-amino-acid protein (Supplementary Note). 
Affected individuals in families 2 and 3 had a homozygous nonsense 
variant in exon 3 predicted to prematurely terminate translation 
(c.88C>T, p.Gln30*; Fig. 2a,b). Family 1 showed a homozygous vari-
ant in intron 2 of CHMP1A (c.28–13G>A; Fig. 2a,b) predicted to cre-
ate an aberrant splice acceptor site leading to an 11-bp insertion in the 
spliced mRNA product (Supplementary Fig. 2a). The two mutations 
were absent from dbSNP, 281 neurologically normal European control 
DNA samples (562 chromosomes), the 1000 Genomes Project data-
base4 and approximately 5,000 control exomes from the National 
Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project. 
CHMP1A encodes an essential regulator of BMI1-INK4A 
in cerebellar development
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We sequenced CHMP1A in 64 individuals 
with other cerebellar anomalies without find-
ing additional mutations, but none of these 
affected individuals shared the rare and distinctive pattern of hypo-
plasia seen in the individuals with CHMP1A mutations.
RT-PCR analysis of CHMP1A in lymphoblastoid cells from affected 
individuals from family 1 (CH3101 and CH3105) identified the pre-
dicted aberrant transcript with the 11-bp insertion and a second 
aberrant transcript with a 21-bp insertion but no normal CHMP1A 
transcript (Supplementary Fig. 2b). In the parents of affected chil-
dren from family 1 and in unaffected control samples, only the normal 
transcript was detected, suggesting that the abnormal splice products 
are unstable. Protein blot analysis revealed a single 24-kDa band in a 
normal control individual, but no corresponding band was detected 
in affected individuals from families 1 and 2 (CH3101 and CH2401, 
respectively; Fig. 2c). In the parent (CH3103), the amount of CHMP1A 
was 50% relative to the amount detected in control lysate. Hence, this 
genetic study establishes CHMP1A null mutations as the cause of pon-
tocerebellar hypoplasia and microcephaly in these pedigrees.
CHMP1A has been assigned two distinct putative functions as 
both a chromatin-modifying protein and a charged multivesicular 
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Figure 1 Brain MRI and linkage mapping of 
pontocerebellar hypoplasia with microcephaly. 
(a–d) T1-weighted sagittal brain MRIs of a 
neurologically normal individual (a) and affected 
individuals CH3102 (b), CH2402 (c) and 
CH2701 (d). Compared to control, affected 
individuals show mild reduction in cortical 
volume, thinning of the corpus callosum and 
severe hypoplasia of the pons, cerebellar vermis 
and cerebellar hemispheres. (e) Family 1 is a 
consanguineous pedigree from Peru in which 
three children from two branches are affected. 
Families 2 and 3 are both from Puerto Rico. 
Affymetrix 250K Sty SNP data for each child in 
families 1 and 2 are shown below (red or blue, 
homozygous SNP call; yellow, heterozygous SNP 
call), showing a region of homozygosity (dashed 
box) shared by all affected individuals in distal 
chromosome 16q. The graph aligned with the 
SNP genotyping data shows multipoint LOD 
scores calculated from microsatellite maker 
analysis of family 1 (Supplementary Fig. 1). 
Genes in the region of LOD of >3 are indicated 
to the right of the graph.
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Figure 2 Loss-of-function mutations in CHMP1A and dysregulation of 
INK4A in cell lines from affected individuals. (a) Chromatograms showing 
homozygous mutations (red, indicated by arrows) in intron 2 (CH3101; 
c.28–13G>A; white background) and in exon 3 (CH2401; c.88C>T; 
black background) of CHMP1A. (b) Schematic of full-length wild-type 
(WT) CHMP1A. The mutation in CH2401 leads to premature termination 
of translation. The intronic mutation in CH3101 creates a novel splice 
acceptor site, and usage of this novel acceptor site causes a frameshift 
after exon 2, resulting in termination of translation after 36 amino acids. 
(c) Protein blotting of lysates from lymphoblastoid cell lines from  
CH2401 and CH3101 showing a complete loss of the 24-kDa band 
detected by antibody to CHMP1A in control lysate. Lysate from a cell 
line generated from CH3103 (the mother of CH3101) show 50% of the 
protein amount relative to the control. Protein amounts were normalized 
to the 40-kDa B-actin loading control bands. (d) Lymphoblastoid cell 
lines from CH2401 and CH3101 proliferate at a much lower rate than 
eight control cell lines. (e) qPCR analysis of CDKN2A-derived cDNA 
levels in human lymphoblastoid cell lines from CH2401 and CH3101 
(normalized to GAPDH levels) shows nearly twofold higher expression 
of INK4A in these cells relative to four unrelated, neurologically normal 
control cell lines. The other transcribed isoform at the locus, ARF, shows 
no significant difference in expression in cells from affected individuals 
and control cells. (f) ChIP-qPCR in lymphoblastoid cell lines using an 
antibody to BMI1 shows an approximately eightfold enrichment of INK4A 
promoter DNA relative to a probe targeted 7-kb upstream of the locus in a 
control cell line. Enrichment is nearly half of this in cell lines derived from 
CH2401 with a homozygous mutation in CHMP1A. Enrichment at the  
ARF promoter is not significantly different from that observed in the 
control cell line. Error bars in d–f, s.e.m. 
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body protein1,3. CHMP1A was originally identified as a binding 
partner of the Polycomb group protein Pcl (Polycomblike)3. In the 
nucleus, it has been suggested to recruit the Polycomb group tran-
scriptional repressor BMI1 to heterochromatin, and overexpressed 
CHMP1A has been shown to arrest cells in S phase3. In the cytoplasm, 
CHMP1A is part of the ESCRT-III complex1,2. The ESCRT-III com-
plex localizes to endosomes and interacts with VPS4A and VPS4B5 
to assist in the trafficking of ubiquitinated cargo proteins to the lyso-
some for degradation6.
We investigated the potential effects of CHMP1A on Polycomb 
function by analysis of cell lines from two affected individuals har-
boring different CHMP1A mutations (CH3101 from family 1 and 
CH2401 from family 2), which show severely impaired doubling 
times compared to control cell lines, suggesting essential roles for 
CHMP1A in regulating cell proliferation (Fig. 2d). To examine BMI1 
function in these cells, we performed quantitative PCR (qPCR) 
analysis of expression of the BMI1 target locus CDKN2A, which 
encodes alternative transcripts INK4A (also known as p16INK4A; 
NM_000077) and ARF (also known as p14ARF; NM_058195) in 
humans. This analysis revealed abnormally high expression of 
INK4A, the isoform implicated in cerebellar development, but not 
of ARF (Fig. 2e), suggesting derepression of INK4A. Chromatin 
immunoprecipitation (ChIP) with an antibody to BMI1 in control 
cell lines showed an approximately eightfold enrichment of BMI1 
binding at INK4A promoter DNA relative to a control region 
7 kb upstream, whereas cells from an affected individual (CH2401) 
showed only approximately half this enrichment in BMI1 binding 
(Fig. 2f). Enrichment of BMI1 at the ARF promoter was not substan-
tial in this assay and was similar in both control cells and cell lines 
from affected individuals, consistent with the specificity of regula-
tion of the INK4A isoform by BMI1 (Fig. 2f). Bmi1 has been shown 
to suppress the Cdkn2a locus and be required for neural stem cell 
self-renewal7. Our evidence suggests a role for CHMP1A in mediat-
ing BMI1-directed epigenetic silencing at the INK4A promoter but 
not at the ARF promoter.
We further explored the relationship between CHMP1A and 
BMI1 using morpholino-based knockdown experiments in 
zebrafish. Knockdown of the zebrafish CHMP1A ortholog (chmp1a; 
NM_200563) resulted in reduced cerebellum and forebrain volume 
compared to control, uninjected zebrafish, similar to the effects of 
human CHMP1A mutations and knockdown in zebrafish of BMI1 
orthologs (bmi1a, NM_194366, and bmi1b, NM_001080751; Fig. 3a–e 
and Supplementary Figs. 3 and 4). A second morpholino target-
ing chmp1a led to a similar phenotype, and both morpholinos were 
partially rescued by the introduction of human CHMP1A mRNA, 
confirming morpholino specificity (Supplementary Fig. 4). The 
cerebellum consists of five major cell types, with the principal cell, 
known as the Purkinje cell, deriving from the ventricular epithelium, 
whereas granule cells derive from a separate progenitor pool known 
as the rhombic lip. Granule cell precursors then migrate over the 
outer surface of the cerebellum and form the external germinal layer 
(EGL) before migrating radially past the Purkinje cells to settle in the 
internal granule layer (IGL)8. Within the chmp1a-morphant cerebel-
lum, the internal granule and molecular layers were severely affected 
(Fig. 3a,b), which is consistent with the relatively preserved folia 
pattern of the human cerebellum (thought to primarily be established 
by Purkinje cells) and severely reduced volume (which is determined 
mainly by granule cell quantity).
We then tested genetic interactions between chmp1a and the 
zebrafish ortholog of INK4A (cdkn2a; XM_002660468). Knockdown 
of cdkn2a alone did not result in noticeable abnormalities, and double 
knockdown of chmp1a and cdkn2a resulted in partial rescue of the 
brain morphology defects seen with chmp1a knockdown (Fig. 3f,g). 
This rescue was analogous to the rescue of the Bmi1-knockout mouse 
cerebellar phenotype in Bmi1- and Cdkn2a-double knockout mice9. Of 
note, there were also parallels in brain morphology between individuals 
with CHMP1A mutations and Bmi1-deficient mice, which show cer-
ebellar hypoplasia10,11 (Fig. 3h,i). In Bmi1-null mice, the cerebellar 
architecture was generally preserved, but the thickness of the granular 
and molecular layers was markedly reduced10, and Bmi1-deficient 
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Figure 3 Genetic links between CHMP1A and BMI1 in zebrafish and mice. 
(a,b) In parasagittal sections at 5 days post-fertilization (d.p.f.), zebrafish 
injected with chmp1a morpholino (MO) (b) show reduction in cerebellum and 
forebrain volume relative to control, uninjected zebrafish (a). Insets, images of 
the cerebellum highlighting loss of molecular and internal granular layers in the 
morphant (arrowheads). (c–f) Compared to control, uninjected zebrafish (c),  
embryos with MO-based knockdown of chmp1a (d) show reduced head size, 
with the hindbrain more markedly reduced in thickness (asterisks). This effect is 
similar to that seen with knockdown of the zebrafish orthologs of BMI1, bmi1a 
and bmi1b (e). When the cdkn2a MO is co-injected with the chmp1a MO, the 
chmp1a knockdown phenotype is partially rescued (f). (g) Control or morphant 
embryos were classified 28 hours post-fertilization (h.p.f.) as normal, disrupted 
or severely disrupted (Online Methods). The number above each bar is the total 
number of embryos examined. *P < 0.001, two-tailed Pearson’s C-squared test. 
(h,i) In sagittal cross-sectional areas from the mouse cerebellum at P25, Bmi1−/− 
mice (i) have markedly reduced cerebellum size relative to  Bmi1+/−  mice (h), 
although foliation and the structure of the lobules (indicated by roman numerals) 
are generally preserved. Representative scale bars, 200 Mm in a,c; 500 Mm in h. 
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mice show a modest reduction in cerebral volume10,12, similar to indi-
viduals with CHMP1A mutations (Supplementary Note).
Subcellular localization of CHMP1A seems to vary depending on 
the cell type. Confocal images of NIH 3T3 cells showed prominent 
exclusion of Chmp1a from the nucleus (mouse Chmp1a, NM_145606), 
where Bmi1 was detected (Fig. 4a). In contrast, confocal images of 
HEK 293T cells, although also showing predominantly cytoplasmic 
localization of CHMP1A, showed some nuclear immunoreactivity 
as well (Fig. 4b). Primary cultures of cerebellar granule cells from 
mice also showed predominantly cytoplasmic localization of Chmp1a, 
along with a speckled nuclear pattern (Fig. 4c). Overexpression of 
HA-tagged mouse Chmp1a in cultured granule cells resulted in abun-
dant nuclear Chmp1a with a punctate expression pattern, confirming 
the speckled nuclear localization of endogenous Chmp1a (Fig. 4d) 
and consistent with earlier reports that CHMP1A can be present in 
the nucleus3. Even with Chmp1a overexpression, Chmp1a and Bmi1 
do not prominently colocalize within the nucleus, which is also in 
agreement with previous data3.
Immunohistochemical studies of the developing cerebellum and 
cerebral cortex in mice revealed widespread expression of Chmp1a in 
dividing and postmitotic cells. Chmp1a immunoreactivity was seen 
in the nucleus and cytoplasm of EGL, Purkinje and IGL cells at post-
natal day (P) 2 (Fig. 4e,f and Supplementary Fig. 5). In the nucleus 
of these cells, Chmp1a immunoreactivity was seen in a speckled 
pattern. These speckles may be seen adjacent to Bmi1 signals, but 
they usually did not colocalize (Fig. 4f and Supplementary Fig. 5). 
At later stages of cerebellar development (P4, P10 and P29), Chmp1a 
expression persisted in Purkinje and granule cells (Supplementary 
Fig. 6). Embryonic day (E) 13.5 cerebral cortex showed widespread 
Chmp1a expression in the neuroepithelial cells (Fig. 4g). In the 
postnatal cerebral cortex (at P4, P10 and P29), Chmp1a expression 
in postmitotic neurons of the cortical plate gradually decreased 
and became almost undetectable by P29 (Supplementary Fig. 6). 
These expression studies confirm that Bmi1 and Chmp1a are often 
expressed in the same cells. However, the absence of widespread 
subcellular colocalization of Bmi1 and Chmp1a suggests that the 
regulation of Bmi1 by Chmp1a is perhaps not mediated by direct 
physical interaction.
Our data implicate CHMP1A as an essential central nervous system 
regulator of BMI1, which in turn is a key regulator of stem cell self-
renewal. The dual cytoplasmic and nuclear localization of CHMP1A 
and its connection to the ESCRT-III complex position CHMP1A as 
a potentially crucial link between cytoplasmic signals and the global 
regulation of stem cells via the Polycomb complex.
URLs. UCSC Human Genome Browser, http://genome.ucsc.edu/; 
Primer3, http://frodo.wi.mit.edu/primer3/; NetGene2, http://www.
cbs.dtu.dk/services/NetGene2/; dbSNP, http://www.ncbi.nlm.nih.
gov/projects/SNP/; 1000 Genomes Project, http://www.1000genomes.
org/; NHLBI Exome Sequencing Project, http://evs.gs.washington.
edu/EVS/.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Note: Supplementary information is available in the online version of the paper.
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Figure 4 CHMP1A and BMI1 expression in cultured cells and the 
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cells (a) and HEK 293T cells (b). (c,d) Immunocytochemical analysis of 
mouse dissociated cerebellar granule cells (Cb GC) (c) and of these  
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Chmp1a. (e,f) Immunocytochemical analysis in mice of the developing 
cerebellum at P2 (P2 Cb) (e), P2 EGL cells (f) and the developing cerebral 
cortex at E13.5 (E13.5 Ctx) (g). EGL, external germinal layer; PC, 
Purkinje cells; IGL, internal granule layer; SVZ, subventricular zone; VZ, 
ventricular zone; CP, cortical plate. Scale bars, 20 Mm in a–e,g; 5 Mm in f. 
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ONLINE METHODS
Genetic screening. The genetic study was approved by the Institutional 
Review Boards of Boston Children’s Hospital and the University of 
Chicago. Appropriate informed consent was obtained from all involved 
human subjects.
The affected individuals and their parents from family 1 and the affected 
individuals from family 2 were subjected to genome-wide SNP screening with 
the Affymetrix GeneChip Human Mapping 250K Sty Array, performed at the 
Microarray Core of the Dana-Farber Cancer Institute. Microsatellite markers 
for fine mapping were identified using the UCSC Human Genome Browser13 
and were synthesized with fluorescent labels (Sigma-Genosys). Two-point 
and multipoint LOD scores were calculated using Allegro14, assuming reces-
sive inheritance with full penetrance and a disease allele frequency of 0.001. 
Sequencing primers were designed using Primer3 (ref. 15), and genomic DNA 
was sequenced using standard Sanger technology. Control DNA samples from 
neurologically normal individuals of European descent were obtained from the 
Coriell Cell Repositories (Coriell Institute for Medical Research). All nucleotide 
numbers are in reference to CHMP1A isoform 2 cDNA (NM_002768, with A of 
the ATG start site corresponding to +1) from the UCSC Genome Browser.
Analysis of CHMP1A splicing. Splice prediction software NetGene2 (ref. 16) 
was used to determine the effect of the family 1 allele on CHMP1A splicing. 
Epstein-Barr virus (EBV)-transformed lymphocytes were grown in RPMI-
1640 (Gibco) with 15% FBS (Gibco) and 1% penicillin/streptomycin in 
(Lonza) a humidified incubator at 37 °C in 5% CO2. RNA was isolated using 
the RNeasy Mini kit (Qiagen). Total RNA (5 Mg) was used for first-strand 
synthesis with oligo(dT) primers and SuperScript III First-Strand Synthesis 
SuperMix (Invitrogen), and 1 Ml of the product was used for the subsequent 
PCR reaction, with primers mapping from the 5` UTR to exon 6 of CHMP1A 
(NM_002768). Primer sequences are listed in Supplementary Table 1.
Proliferation assay of lymphoblastoid cell lines. EBV-transformed lympho-
blastoid cell lines from eight control subjects and two affected individuals 
(CH2401 and CH3101) were grown. For each cell line, 2 × 107 cells were 
grown, and 1 × 106 cells were aliquoted into 4 sets of 5 T25 flasks filled with 
10 ml of medium. Each set was allowed to grow for 24, 48, 72 and 96 h. Cell 
densities were estimated using a hemocytometer.
qPCR. EBV-transformed lymphoblastoid cell lines were grown, and cDNA 
was generated. INK4A and ARF levels were quantified using the StepOnePlus 
Real-Time PCR System (Applied Biosystems) with GAPDH as a control. 
Primer sequences are listed in Supplementary Table 1.
ChIP assays. ChIP was assays were performed as previously described17 
with some modifications. For a single experiment, 2 × 107 EBV-transformed 
lymphoblastoid cells and 4 Mg of the antibody to BMI1 (Abcam, ab14389) were 
used. qPCR reactions were performed using SYBR Green reagents (Applied 
Biosystems) and the StepOnePlus Real-Time PCR System. Primers were 
assessed for specificity by analysis of their melt curves, and a standard curve 
was determined using four tenfold serial dilutions for each primer using the 
input DNA samples. The standard curve from the input DNA was determined 
using 3 Ml from each serial dilution as a template. Fold enrichment for each 
ChIP sample was determined by using 3 Ml from each sample as a template and 
comparing the resultant amplification to the standard curve for that primer 
pair. Primer sequences are listed in Supplementary Table 1.
Zebrafish morpholino experiments. ATG-targeting morpholinos were 
designed against chmp1a (chmp1a MO 1), bmi1a, bmi1b and the INK4A zebrafish 
ortholog (cdkn2a) (Gene Tools). In all experiments where bmi1 morpholinos 
were used, bmi1a and bmi1b were injected together. Injections were performed 
at the one-cell stage. Optimal doses for the chmp1a MO 1, bmi1a and bmi1b, 
and cdkn2a morpholinos were 4.5, 1.2 and 4.0 ng, respectively. At 28 h.p.f., the 
embryos were visualized using a stereo microscope (Zeiss). To confirm the spe-
cificity of the effects of the chmp1a MO 1 morpholino, a second ATG-targeting 
chmp1a morpholino (chmp1a MO 2) was designed. For this experiment, the 
dosages of injected chmp1a MO 1 and chmp1a MO 2 were 6.0 and 3.0 ng, 
respectively. Morpholino sequences are listed in Supplementary Table 1.
For the rescue experiment, morphants were screened at 28 h.p.f. and scored 
for the presence of a defect in the angle of the head to the tail (measured at the 
otic vesicle) or a deviation in the straightness of the tail18. Human CHMP1A 
cDNA was PCR amplified from control human lymphoblastoid cell total RNA. 
Primer sequences are listed in Supplementary Table 1. The PCR product 
was subcloned into the pCS2+ vector, and 5`-capped mRNA was synthesized 
in vitro using the mMESSAGE kit (Ambion). mRNA was diluted in 0.1 M KCl 
and was titrated for the rescue experiments.
For histological preparation, morphants were grown at 28 °C for 5 d, fixed 
overnight at 4 °C in paraformaldehyde (PFA) and embedded in 3% low-melt 
agarose blocks (in PBS), which were fixed again in 4% PFA in PBS overnight. 
The fixed agarose blocks were embedded in paraffin and sectioned at 5-Mm 
thickness in the sagittal plane. Sections were stained by standard techniques 
with hematoxylin and eosin and were visualized using a bright field micro-
scope (Nikon).
For protein blotting, zebrafish embryos were harvested at 48 h.p.f. They 
were dechorionated and deyolked as described19 and treated with lysis buffer 
(10% SDS and 0.5 M EDTA in 1× PBS) containing Complete Mini Protease 
Inhibitor Cocktail (Roche). Lysates were mixed with 2× Laemmli sample 
buffer, loaded onto a NuPage 4–12% Bis-Tris gel (Invitrogen) and run at 
100 V for 2 h. Proteins were wet transferred onto Immobilon-P transfer mem-
brane (Millipore) at 300 mA for 1.5 h at 4 °C. The membrane was blocked 
with Odyssey Blocking Buffer (LI-COR) and was incubated first with anti-
bodies against Chmp1a (1:100 dilution; Abcam, ab104103) and B-actin 
(1:10,000 dilution; Abcam, ab6276) and then with IRDye secondary antibodies 
(LI-COR, 926-32212 and 926-68023). The LI-COR Imaging System was used 
for imaging and quantification.
Immunocytochemistry and immunohistochemistry. NIH 3T3 and HEK 
293T cells were grown in DMEM with 10% FBS and 1% penicillin/streptomycin 
and were fixed and stained with antibodies against Chmp1a (1:200 dilution; 
Abcam, ab36679) and Bmi1 (1:250 dilution; Abcam, ab14389) using standard 
techniques. Staining was visualized on a confocal microscope (Nikon).
All animal work was approved by Harvard Medical School, Beth Israel 
Deaconess Medical School and Boston Children’s Hospital Institutional 
Animal Care and Use Committees.
Cerebellar granule neuron cultures from euthanized, P5 mouse pups were 
prepared as described20. After dissociation, cell density was measured using 
a hemocytometer, and 1 × 106 cells were plated on each poly-l-ornithine–
coated coverslip with 500 Ml of plating medium in a 24-well plate. After 1 d 
in vitro (d.i.v.) in a 37 °C incubator, 20 Ml of 250 MM AraC (cytosine-1-B-d-
 arabinofuranoside) was added to each well to arrest mitosis of non-neurons. At 
2 d.i.v., conditioned medium was collected from each well, and the wells were 
washed with DMEM. Cells were then transfected with the HA-Chmp1a mam-
malian expression construct (GeneCopoeia, EX-Mm15805-M06). Transfection 
solution (87.6 Ml of HBSS and 4.4 Ml of 2.5 M calcium chloride with 1.5 Mg of 
plasmid DNA) was prepared at room temperature, and 35 Ml of the transfection 
solution was added to a total of 400 Ml of conditioned medium and then added 
to each well. After an additional 36 h (4 d.i.v.), cells were fixed with 4% PFA 
for 20 min at room temperature, washed with PBS and stained with antibodies 
against HA (1:100 dilution; Abcam, ab9110) and Bmi1 (1:250 dilution; Abcam, 
ab14389). Untransfected cells were processed similarly and were stained with 
antibodies against Chmp1a (1:200 dilution; Abcam, ab36679) and Bmi1.
Tissues were perfused with 4% PFA, dissected and fixed overnight in 4% 
PFA and were then embedded in paraffin and sectioned at 5- or 8-Mm thick-
ness. After rehydration of the slides in serial washes with xylene, 50% xylene 
in ethanol, 100% ethanol, 70% ethanol, 50% ethanol, 30% ethanol and finally 
in PBS, the slides were boiled in antigen-retrieval solution (Retrievagen A, 
BD Biosciences) for 8 min in the autoclave. Slides were blocked with PBS 
with 0.1% Triton X-100 supplemented with 1% donkey serum for 1 h at room 
temperature, and antibodies against Bmi1 (1:400 dilution; Millipore, clone 
F6), Chmp1a (1:300 dilution; Abcam, ab36679 and ab104103) or calbindin 
(Swant, CB300) were added in the blocking solution for overnight incuba-
tion at 4 °C. Slides were washed three times for 5 min per wash in PBS and 
were developed with secondary antibodies conjugated to Alexa-Fluor dyes 
(Invitrogen) for 1.5 h at room temperature. Slides were again washed three 
times for 5 min per wash in PBS and were mounted with Fluoromount-G 
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(Southern Biotech) containing DAPI (1:1,000 dilution) and visualized on a 
confocal microscope (Nikon) or fluorescence microscope (Zeiss). For E13.5 
and P2 cerebral cortex, frozen section specimens were used. For frozen sec-
tions, heads of E13.5 mouse embryos were directly fixed in 4% PFA, and P2 
pups were perfused with 2 ml of 1× PBS and then with 4 ml of 4% PFA in PBS, 
followed by overnight fixation in 4% PFA. They were then placed in gradu-
ally increasing sucrose solutions (10%, 15% and 30%), each overnight, for 
cryopreservation and were then embedded in optimum cutting temperature 
(OCT) compound (Sakura Finetek)  and sectioned at 20-Mm thickness. The 
same antigen retrieval and staining procedure was used as for the paraffin-
embedded sections.
13. Kent, W.J. et al. The human genome browser at UCSC. Genome Res. 12, 996–1006 
(2002).
14. Gudbjartsson, D.F., Jonasson, K., Frigge, M.L. & Kong, A. Allegro, a new computer 
program for multipoint linkage analysis. Nat. Genet. 25, 12–13 (2000).
15. Rozen, S. & Skaletsky, H.J. Primer3 on the WWW for general users and for biologist 
programmers. in Bioinformatics Methods and Protocols: Methods in Molecular Biology 
(eds. Krawetz, S. & Misener, S.) 365–386 (Humana Press, Totowa, New Jersey, 
2000).
16. Brunak, S., Engelbrecht, J. & Knudsen, S. Prediction of human mRNA donor and 
acceptor sites from the DNA sequence. J. Mol. Biol. 220, 49–65 (1991).
17. Flavell, S.W. et al. Genome-wide analysis of MEF2 transcriptional program reveals 
synaptic target genes and neuronal activity–dependent polyadenylation site 
selection. Neuron 60, 1022–1038 (2008).
18. Kimmel, C.B., Ballard, W.W., Kimmel, S.R., Ullmann, B. & Schilling, T.F. Stages 
of embryonic development of the zebrafish. Dev. Dyn. 203, 253–310 (1995).
19. Link, V., Shevchenko, A. & Heisenberg, C.P. Proteomics of early zebrafish embryos. 
BMC Dev. Biol. 6, 1 (2006).
20. Bilimoria, P.M. & Bonni, A. Cultures of cerebellar granule neurons. CSH Protoc. 
2008, pdb prot5107 (2008).
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The EphB family of receptor tyrosine kinases (RTKs) are critical regu-
lators of cell-cell contacts in the developing nervous system, medi-
ating processes as diverse as axon guidance, topographic mapping, 
neuronal migration and synapse formation1–3. In addition to these 
developmental roles, EphB dysfunction in the mature organism con-
tributes to pathologies such as cancer, Alzheimer’s disease and, possi-
bly, autism4–8. The signaling mechanisms underlying EphB-mediated 
development and disease are largely unknown.
As the EphB family of receptors has been shown to regulate a large 
number of developmental processes, it has been particularly diffi-
cult to determine the specific functions of EphBs at defined times 
during brain development. The presence of at least three partially 
redundant EphB family members in the nervous system further 
complicates investigation into the biological functions of EphB pro-
teins. For example, Ephb1, Ephb2 and Ephb3 single and compound 
mutant mice have defects in a number of processes, including stem-
cell proliferation, axon guidance, filopodial motility, dendritic spine 
formation, synapse development and long-term potentiation, but it 
is unclear which of these interdependent phenotypes are direct and 
which are secondary to the disruption of EphB signaling at an earlier 
developmental step9–13.
Another major hurdle in understanding the function of EphBs is 
the complex nature of their signaling capabilities. EphBs can engage in 
bidirectional signaling with their transmembrane ligands, the ephrin-Bs. 
In the forward direction of signaling, the interaction of clustered 
ephrin-B ligands on one cell with EphB receptors on another leads 
to EphB oligomerization and auto-phosphorylation, the induction 
of EphB kinase activity, and the recruitment of cytoplasmic proteins 
via SH2-binding and PDZ-binding motifs of EphBs14. In addition, 
the extracellular region of EphBs, which contains fibronectin repeat 
domains, can recruit binding partners such as subunits of the NMDA 
subtype of glutamate receptor15,16. In the reverse direction of EphB and 
ephrin-B signaling, phosphorylation of the cytoplasmic tail of ephrin-
Bs results in the recruitment of SH2 domain–containing proteins and 
initiation of downstream signal transduction17. Thus, through a com-
plex array of potential signaling pathways, EphBs are able to mediate a 
wide range of processes during nervous system development.
For the most part, it remains unknown which cellular processes 
require EphB RTK activity and which cellular responses are mediated 
by EphB tyrosine kinase–independent signaling events. Cytoplasmic 
deletions of EphBs have been used to assess the requirement of the 
intracellular domain in mediating specific EphB-regulated processes, 
but this approach fails to distinguish kinase activity from other modes 
of cytoplasmic signaling18. In particular, given that ephrin-B bind-
ing to EphBs induces the formation of EphB oligomers in the plasma 
membrane, it remains a likely possibility that EphB oligomerization 
and scaffolding, in the absence of induction of EphB tyrosine kinase 
activity, mediates some of the biological effects of EphBs14. Thus, new 
ways of selectively inhibiting specific functions of EphBs are criti-
cally needed to clarify the kinase-dependent and kinase-independent 
mechanisms by which EphBs control specific developmental events, 
such as axon guidance and synapse formation.
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A chemical genetic approach reveals distinct EphB 
signaling mechanisms during brain development
Michael J Soskis1,5, Hsin-Yi Henry Ho1,5, Brenda L Bloodgood1, Michael A Robichaux2, Athar N Malik1,  
Bulent Ataman1, Alex A Rubin1, Janine Zieg1, Chao Zhang3,4, Kevan M Shokat3, Nikhil Sharma1,  
Christopher W Cowan2,4 & Michael E Greenberg1
EphB receptor tyrosine kinases control multiple steps in nervous system development. However, it remains unclear whether 
EphBs regulate these different developmental processes directly or indirectly. In addition, given that EphBs signal through 
multiple mechanisms, it has been challenging to define which signaling functions of EphBs regulate particular developmental 
events. To address these issues, we engineered triple knock-in mice in which the kinase activity of three neuronally expressed 
EphBs can be rapidly, reversibly and specifically blocked. We found that the tyrosine kinase activity of EphBs was required for 
axon guidance in vivo. In contrast, EphB-mediated synaptogenesis occurred normally when the kinase activity of EphBs was 
inhibited, suggesting that EphBs mediate synapse development by an EphB tyrosine kinase–independent mechanism. Taken 
together, our data indicate that EphBs control axon guidance and synaptogenesis by distinct mechanisms and provide a new 
mouse model for dissecting EphB function in development and disease.
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Much of what is currently known about the role of EphB signal-
ing during axon guidance in vivo comes from studies of retinal and 
cortical axon tracts. Notably, genetic deletion of individual or com-
binations of EphB family members cause marked axon guidance 
defects that result in the abnormal formation of several axon tracks, 
including the ipsilateral retinocollicular projection and axonal tracts 
in the corpus callosum and the anterior commissure9,19. However, it 
remained to be determined whether EphB-dependent axon guidance 
decisions are mediated by the kinase activity of EphBs or by other 
modes of EphB signaling, such as PDZ-domain interactions, cyto-
plasmic domain oligomerization, reverse signaling through ephrin-Bs 
or EphB extracellular domain interactions.
In general, the mechanisms by which the cytoplasmic domains of 
axon guidance receptors signal growth cone attraction or repulsion 
have been difficult to identify. Most axon guidance receptors that have 
been studied to date, such as Robo, DCC, plexins and neuropilins, 
do not possess intrinsic kinase activity, suggesting that the predomi-
nant mode of axon guidance signaling may be kinase independent20. 
With regard to EphBs, studies in the visual system have suggested a 
role for the kinase activity, whereas studies in the cortex have sug-
gested kinase-independent roles of EphBs9,21–24. However, none of 
these experiments were able to directly address the requirement of 
the kinase activity of EphBs when they are expressed at endogenous 
levels in vivo.
In addition to their function in axon guidance, EphBs have been 
shown to be important for cortical and hippocampal synapse for-
mation. Ephb knockout mice or knock-in mice with cytoplasmic 
domain deletions display defects in dendritic spine and synapse 
development in dissociated neuronal cultures and in hippocampal 
slices13,18. Overexpression of kinase-defective dominant-negative 
mutants also results in abnormal spine and synapse development, 
suggesting that the tyrosine kinase activity of EphBs is involved in 
these processes13,15,25. However, these studies did not directly test the 
requirement of the kinase activity of EphBs in the regulation of syn-
apse formation under conditions in which ephrin-Bs and EphBs are 
expressed at physiological levels, thereby complicating the interpreta-
tion of the findings and leaving open the possibility that aspects of 
EphB-dependent synapse development may be kinase independent.
To address the importance of the kinase activity of EphBs for axon 
guidance and synapse development, we combined chemical biology 
with mouse genetic engineering to reversibly inhibit EphB tyrosine 
kinase signaling in cultured neurons, brain slices and live animals. 
By mutating a bulky gatekeeper residue in the ATP-binding pocket 
of EphBs to a smaller alanine or glycine, we rendered the enzymatic 
activity of these kinases sensitive to reversible inhibition by deriva-
tives of the Src inhibitor PP1. These analogs of PP1 do not fit into 
the ATP-binding pocket of wild-type kinases26,27 and therefore do 
not inhibit wild-type EphBs or other kinases. In a previous study, 
this approach was successfully employed to regulate Trk RTK sign-
aling28. We reasoned that this approach would be particularly well 
suited for investigating the more complex EphB family, allowing us 
to inhibit the kinase activity of EphBs while preserving extracellular 
interactions, reverse signaling or other cytoplasmic domain functions 
of EphBs.
We generated a triple knock-in mouse line that harbors ATP-binding 
pocket mutations in EphB1, EphB2 and EphB3. By specifically blocking 
the kinase function of EphBs in these knock-in mice in a temporally 
controlled manner, we found for the first time, to the best of our 
knowledge, a requirement for the kinase activity of EphBs in axonal 
guidance in vivo. In contrast, the kinase activity of EphBs was not 
required for another key EphB-mediated event, the regulation of 
 excitatory synapse formation. Thus, when expressed under physio-
logically relevant conditions, EphBs differentially regulate key 
aspects of neuronal development by kinase-dependent and kinase- 
independent mechanisms.
RESULTS
A chemical genetic approach to studying EphB signaling
To selectively inhibit the tyrosine kinase activity of EphBs, we 
employed a strategy that combines the advantages of both pharma-
cology and genetics and in which drug sensitivity can be engineered 
into a protein29,30. The ATP-binding pocket of all kinases contains 
a bulky hydrophobic gatekeeper residue that is not essential for the 
catalytic function of the kinase domain. However, this gatekeeper resi-
due, when mutated to an alanine or a glycine, can render the kinase 
sensitive to inhibition by PP1 analogs that cannot effectively enter the 
wild-type ATP-binding pocket (Fig. 1a)29,30. We engineered EphBs 
with modified gatekeeper residues and refer to these PP1 analog– 
sensitive EphBs as AS-EphBs.
To design AS-EphB mutants, we compared the amino acid sequence 
of kinase domains of EphBs with those of related tyrosine kinases for 
which analog-sensitive versions had been successfully made26,28. This 
analysis revealed a gatekeeper threonine residue in the ATP-binding 
pocket of mouse EphB1, EphB2 and EphB3 (Fig. 1b). We substituted 
these residues with either alanine or glycine to generate Ephb1T697G, 
Ephb2T699A and Ephb3T706A.
To verify that the mutations introduced into the EphB ATP-binding 
pockets did not affect the kinase activity of EphBs in the absence of the 
PP1 analogs, we assessed the activity of these kinases using a hetero-
logous cell culture system. Activation of EphBs results in receptor 
auto-phosphorylation on several juxtamembrane tyrosine residues. 
We previously generated an antibody that specifically recognizes the 
phosphorylated form of these juxtamembrane tyrosine residues for 
all EphBs, and used the juxtamembrane tyrosine phosphorylation 
detected by this antibody as a readout for receptor kinase activation15. 
We overexpressed EphBs in HEK 293 cells in which EphBs cluster 
spontaneously and become activated in a ligand-independent manner. 
We probed lysates from cells overexpressing AS-EphBs or wild-type 
EphBs with antibody to phosphorylated EphB and found that wild-
type EphBs and AS-EphBs were phosphorylated at their juxtamem-
brane tyrosines to a similar extent (Fig. 1c). This result indicates that 
the analog-sensitive mutation does not affect the ability of EphBs to 
activate their kinase domains in the absence of PP1 analogs.
To test the ability of PP1 analogs to inhibit AS-EphBs, we treated 
HEK 293 cells overexpressing AS-EphBs or wild-type EphBs with 
either of two bulky PP1 analogs, 4-amino-1-tert-butyl-3-(1`-
naphthyl)pyrazolo[3,4-d]pyrimidine (1-NA-PP1) or 1-(tert-butyl)-3-
(3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (3-MB-PP1) 
(Fig. 1a) and assessed EphB tyrosine phosphorylation. We found that 
incubation with 1-NA-PP1 (250 nM) or 3-MB-PP1 (1 MM) blocked the 
phosphorylation of AS-EphBs, but not the phosphorylation of wild-
type EphBs (Fig. 1c). The drug vehicle DMSO alone did not have any 
effect on either wild-type EphBs or AS-EphBs. These results indicate 
that the kinase activity of AS-EphBs was selectively inhibited by PP1 
analogs. Inhibition of kinase activity of AS-EphBs was rapid, occurring 
in minutes (Fig. 1d). Given that PP1 analogs act competitively, inhibi-
tion was readily reversible following removal of 1-NA-PP1 (Fig. 1e). 
The specificity, rapidity and reversibility of the kinase inhibition make 
this chemical genetic strategy an ideal platform for studying dynamic 
biological processes in cells and animals.
To quantify the potency and specificity of 1-NA-PP1 and 3-MB-PP1 
with respect to inhibition of EphB1, EphB2 and EphB3, we conducted 
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dose-response analyses. We determined the half maximal inhibitory 
concentrations of kinase inhibition, which revealed a preference of 
the PP1 analogs for inhibiting analog-sensitive kinases (9–48 nM) 
over wild-type kinases (0.6–8.9 MM) by two orders of magnitude 
(Supplementary Fig. 1a,b). These results indicate that the kinase 
activity of AS-EphBs was selectively inhibited by PP1 analogs.
To confirm that binding of PP1 analogs to AS-EphBs does not 
affect kinase-independent aspects of EphB function, we performed 
in vitro binding assays to compare the effect of 1-NA-PP1 on tyrosine 
kinase–dependent and tyrosine kinase–independent protein-protein 
interactions. The SH2 and SH3 domain–containing adaptor protein 
Grb2 is a classic example of a signaling molecule that interacts with 
RTKs, including EphBs, through a tyrosine kinase–dependent mecha-
nism. Following receptor activation and auto-phosphorylation, the 
phospho-tyrosine residues in the cytoplasmic tails of RTKs, including 
EphBs, recruit Grb2 through its SH2 domain31,32. In contrast, bind-
ing of the PDZ domain–containing protein Pick1 to EphBs occurs 
through the C-terminal PDZ domain–binding motif of EphBs and 
does not require the tyrosine kinase activity of EphBs33. In the binding 
experiments, we found that EphB1 bound strongly to both GST-Grb2 
and GST-Pick1, but not to the negative control, GST alone (Fig. 1f). 
Notably, although 1-NA-PP1 (1 MM) completely abolished the kinase-
dependent interaction between AS-EphB1 and GST-Grb2, the inhibi-
tor treatment had no effect on the kinase-independent interaction 
between AS-EphB1 and GST-Pick1 (Fig. 1f). Thus, these observations 
provide evidence that 1-NA-PP1 specifically targets kinase-dependent 
functions of EphB proteins.
Generation and validation of AS-EphB TKI mice
Encouraged by these initial experiments, we generated knock-in 
mice harboring the gatekeeper mutations in EphB1 (T697G), EphB2 
(T699A) and EphB3 (T706A), the three catalytically active EphB 
RTKs expressed in the developing brain. Ephb1T697G, Ephb2T699A 
and Ephb3T706A single mutant mice were generated individually 
by homologous recombination in mouse embryonic stem (ES) 
cells (Supplementary Fig. 2a–c). ES cell clones were confirmed by 
sequencing the targeted alleles in ES cells (Fig. 2a).
Previous studies have found substantial functional redundancy of 
EphBs in several contexts18,22,34. To overcome potential compensa-
tion by different EphB family members, we intercrossed Ephb1T697G, 
Ephb2T699A and Ephb3T706A single mutants to generate a line that is 
triply homozygous for each of the targeted EphB alleles, which we 
refer to as EphB triple knock-in (AS-EphB TKI) mice.
Although Ephb1, Ephb2 and Ephb3 triple knockout mice suffer from 
marked developmental defects, including morphological abnormali-
ties of the palate and the anogenital region35,36, AS-EphB TKI mice 
developed normally into healthy, fertile adults, indistinguishable 
from wild-type mice. Notably, AS-EphB TKI brains exhibited normal 
morphology and were of equal size to wild-type mouse brains. In vitro 
assays measuring axon guidance, neuronal morphology and syn-
aptic development revealed no differences between wild-type and 
AS-EphB TKI mice (as shown below), suggesting that AS-EphBs function 
normally in the absence of PP1 analogs.
Critical to the interpretation of experiments comparing wild-
type and AS-EphB TKI mice is evidence that EphB mRNA expres-
sion, trafficking and ligand-mediated receptor activation occur 
normally in AS-EphB TKI neurons in the absence of PP1 analogs. 
First, we performed quantitative PCR (qPCR) to measure expres-
sion of the Ephb1, Ephb2 and Ephb3 mRNAs in neurons from wild-
type and AS-EphB TKI mice. We found that mRNAs isolated from 
the mutant mice were expressed at the same levels as in wild-type 
mice (Fig. 2b). We conclude that the gene targeting did not affect 
the expression of Ephb1, Ephb2 and Ephb3 mRNA in AS-EphB 
TKI neurons.
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Figure 1 A chemical genetic approach to studying EphB  
signaling. (a) Chemical structures of the Src inhibitor PP1  
and its analogs 1-NA-PP1 and 3-MB-PP1. (b) Amino acid alignment of kinase domains of mouse  
EphBs with those of avian vSrc and mouse TrkB. The gatekeeper residue is highlighted in red and the  
PP1 analog-sensitive (AS) mutation made in the EphBs is shown on the right. (c) Inhibition of the  
kinase function of AS-EphB proteins. HEK 293 cells expressing the analog-sensitive or wild-type (WT)  
versions of EphB1, EphB2 and EphB3 were incubated with 1-NA-PP1 (250 nM) or 3-MB-PP1 (1 MM)  
for 1 h. Cell lysates were analyzed by western blotting for total EphBs or tyrosine phosphorylated  
EphBs (p-EphB). (d) Time course of AS-EphB1 inhibition after 1-NA-PP1 (250 nM) addition to  
AS-EphB1–expressing HEK 293 cells. (e) Time course of recovery of AS-EphB1 auto-phosphorylation  
after 1-NA-PP1 (250 nM) washout from AS-EphB1–expressing HEK 293 cells. The zero time point  
reflects the moment of 1-NA-PP1 washout after an initial 1-h incubation. (f) Effect of 1-NA-PP1 on  
the ability of AS-EphB1 to bind Grb2 or Pick1. HEK 293 cells expressing AS-EphB1 were incubated  
with either vehicle or 1-NA-PP1. Cell lysates were incubated with GST, GST-Grb2 or GST-Pick1 proteins immobilized on glutathione beads. Proteins 
bound to the beads were analyzed by western blotting for EphB1 (top of gel). The same gel (bottom) was stained with Coomassie blue to verify that 
similar amounts of GST fusion proteins were present in the binding reactions. Uncropped blots are shown in Supplementary Figure 7.
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We next asked whether neurons from AS-EphB TKI mice could 
engage in ephrin-B–induced signaling. We cultured dissociated 
 cortical neurons from embryonic day 16.5 to 18.5 (E16.5–18.5) 
AS-EphB TKI or wild-type mice and stimulated the neurons with 
clustered ephrin-B1 for 30 min. Western blotting of AS-EphB TKI or 
wild-type lysates with the antibody to phosphorylated EphB revealed 
that both wild-type and AS-EphB TKI neurons exhibited robust EphB 
activation at similar levels, indicating that AS-EphBs are fully compe-
tent to engage in ephrin-B–induced kinase signaling in the absence 
of PP1 analogs (Fig. 3a).
To test whether the kinase function of endogenously expressed 
EphBs from AS-EphB TKI mice can be effectively and selectively 
inhibited by PP1 analogs, we pre-incubated cultured E16.5–18.5 neu-
rons with vehicle or PP1 analogs for 1 h before ephrin-B1 stimulation. 
Treatment with 250 nM 1-NA-PP1 or 1 MM 3-MB-PP1 completely 
abolished ephrin-B1–induced EphB activation in the AS-EphB TKI, 
but not wild-type, cells, thereby demonstrating the efficacy and selec-
tivity of these PP1 analogs for AS-EphBs expressed at endogenous 
levels in neurons (Fig. 3a).
To more rigorously test the selectivity of PP1 analogs, we assessed 
the effect of these inhibitors on the kinase activity of EphA4, one of 
the closest relatives of EphBs. We stimulated wild-type cortical neu-
rons that had been pre-incubated with 250 nM 1-NA-PP1 or 1 MM 
3-MB-PP1 with the EphA4 ligand ephrin-A1, immunoprecipitated 
EphA4 with an antibody to EphA4, and analyzed the immunopre-
cipitates for phospho-EphA4 or total EphA4. We found no inhibi-
tion of EphA4 autophosphorylation at concentrations of PP1 analogs 
that fully blocked AS-EphB tyrosine kinase function (Fig. 3b). The 
specificity of analog-sensitive inhibition between subfamilies of Eph 
receptors contrasts with previous unsuccessful attempts at designing 
selective inhibitors for EphBs relative to EphAs37,38.
To determine whether PP1 analogs affect the cell surface expres-
sion or internalization of AS-EphB proteins, we performed surface 
biotin labeling for the EphB2 receptor after chronic inhibition from 
6–12 days in vitro (DIV) in cortical neurons. We found equivalent 
levels of labeled EphB2 in vehicle and 1-NA-PP1 (1 MM)-treated cells 
(Supplementary Fig. 3). This result indicates that surface expression 
of EphBs is not altered by the inhibitor treatment.
Kinase cascades can amplify signals greatly. To test whether 
inhibition of the kinase activity of EphBs effectively blocks the phos-
phorylation of downstream tyrosine kinase substrates, we examined 
phosphorylation of the well-characterized EphA and EphB 
substrate Vav2, a Rho family guanine nucleotide exchange factor 
that mediates growth cone collapse39. Wild-type or AS-EphB TKI 
neurons were incubated in 1-NA-PP1 (250 nM) or 3-MB-PP1 
(1 MM) and stimulated with ephrin-B1 for 30 min to induce Vav2 
tyrosine phosphorylation. Immunoprecipitation of Vav2, followed by 
western blotting with a pan-phospho-tyrosine antibody, revealed a 
substantial increase in tyrosine phosphorylation of Vav2 after ephrin-
B1 stimulation (Fig. 3c,d). Treatment with 1-NA-PP1 (250 nM) 
or 3-MB-PP1 (1 MM) selectively blocked the increase in Vav2 
phosphorylation in AS-EphB TKI cells, but had no effect in wild-
type cells (Fig. 3c,d). We conclude that PP1 analogs can selectively 
Figure 2 Generation of AS-EphB TKI mice. (a) Sequencing reads from AS-
EphB knock-in mouse ES cells showing the gatekeeper (analog sensitive) 
mutation in the Ephb1, Ephb2 and Ephb3 genes. The mutated amino 
acids are shown in red. The arrows indicate the DNA base substitutions. 
(b) Relative mRNA expression of Ephb1, Ephb2 and Ephb3 normalized 
to Actb in AS-EphB TKI and wild-type cultured cortical neurons. Data are 
mean of two biological replicates o s.e.m.
block the kinase signaling of EphBs and the phosphorylation of 
their substrates in AS-EphB TKI cells.
EphB RTK signaling is required for growth cone collapse
EphBs have classically been studied in the context of axon guid-
ance22,40,41. Although some studies have suggested a role for the 
kinase activity of EphBs in axon guidance, others have suggested 
kinase-independent modes of EphB signaling9,21–24. To assess the 
role of EphB kinase activity in axon guidance, we initially chose the 
visual system because the importance of EphBs in this system is well 
established. During development of the visual system, most retinal 
ganglion cell (RGC) axons emanating from the retina enter and cross 
the optic chiasm at the midline to form the contralateral retinal pro-
jections in the lateral geniculate nucleus and superior colliculus24,40. 
However, RGC axons from the ventrotemporal region of the retina, 
which express EphB1, become repelled by the ephrin-B2–expressing 
glia of the optic chiasm and form the ipsilateral projection that is 
required for stereovision42. Ephrin-B2 is thought to repel EphB1-
expressing axons by inducing the collapse of their growth cones, an 
activity that can be recapitulated in vitro.
To begin to address whether the kinase activity of EphBs is required 
for repulsive axon guidance, we asked whether the kinase activity of 
EphBs is required for growth cone collapse. We prepared explants from 
E14 ventrotemporal retinae and visualized growth cones with fluores-
cently conjugated phalloidin (to label F-actin) and axons with antibody 
to neurofilament. In these explants, RGCs extended axons with broad, 
fan-shaped growth cones over a laminin substrate. We measured the 
state of growth cones by two methods. First, growth cones were scored 
as collapsed if they exhibited rod-like morphology and lacked visible 
lamellipodia. This method allowed us to quantify the percentage of 
growth cones that were collapsed in each explant. Second, we meas-
ured the maximum axial width of each growth cone and calculated the 
average axial width of the growth cones in each explant.
When treated with clustered ephrin-B2, growth cones from 
AS-EphB TKI explants exhibited a robust collapse response (Fig. 4a,b). 
Treatment of AS-EphB TKI explants with 1-NA-PP1 (250 nM) or 
3-MB-PP1 (1 MM) led to a marked decrease in the percentage of 
collapsed growth cones following ephrin-B treatment (Fig. 4a,b). 
In addition, AS-EphB TKI explants showed an ephrin-B2–induced 
decrease in growth cone width in vehicle-treated explants, but only 
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a slight reduction in explants exposed to 1-NA-PP1 or 3-MB-PP1 
(Fig. 4c). This inhibitor-dependent blockade of growth cone collapse 
was not seen in wild-type explants; wild-type cells showed a robust 
collapse regardless of the presence of inhibitors, as well as a substantial 
reduction in average growth cone width after stimulation (Fig. 4a–c). 
On the basis of these results, we conclude that the kinase activity of 
EphBs is required for ephrin-B–induced RGC growth cone collapse.
To verify that treatment of explants with 1-NA-PP1 and 3-MB-PP1 
led to inhibition of ephrin-B–dependent EphB tyrosine phosphoryla-
 inhibition. To determine whether the inhibitory effect of 1-NA-PP1 
on growth cone collapse is indeed reversible, we removed 1-NA-PP1 
midway through a 30-min ephrin-B2 stimulation in AS-EphB TKI 
explants. In the presence of 1-NA-PP1, ephrin-B–stimulated growth 
cones did not collapse, but did collapse rapidly after washout 
(Fig. 4d). This finding demonstrates the reversibility of PP1 analog 
inhibition of growth cone collapse in retinal explants from AS-EphB 
TKI mice and rules out a general health issue as a cause of reduced 
growth cone collapse.
Figure 3 Selective inhibition of the kinase 
function of EphBs in AS-EphB TKI mice.  
(a) Inhibition of the EphB kinase activity in  
AS-EphB TKI neurons. We pre-incubated 
15 DIV dissociated AS-EphB TKI embryonic 
cortical neurons with vehicle, 250 nM 1-NA-
PP1 or 1 MM 3-MB-PP1 for 1 h before a 30-min 
ephrin-B1 stimulation. Cell lysates were then 
analyzed by western blotting for phospho-EphB 
or B-actin. (b) Effect of PP1 analogs on the 
kinase activity of EphA4. We pre-incubated 
4 DIV cortical neurons with vehicle, 250 nM 
1-NA-PP1 or 1 MM 3-MB-PP1 for 1 h before 
a 30-min ephrin-A1 stimulation. Lysates were 
immunoprecipitated with an antibody to EphA4 
and blotted for phospho-EphA4 and EphA4.  
(c) Effect of PP1 analogs on ephrin-B1–induced 
Vav2 phosphorylation. We stimulated 4 DIV 
AS-EphB TKI or wild-type cortical neurons with ephrin-B1, immunoprecipitated them with an antibody to Vav2, and blotted them with either a pan-
phospho-tyrosine (pY99) or Vav2 antibody. Cells were pre-incubated with vehicle, 250 nM 1-NA-PP1 or 1 MM 3-MB-PP1 for 1 h before a 30-min ephrin-B1  
stimulation. (d) Quantification of phospho-Vav2/Vav2 band intensity from quantitative western blots in c. Data are mean o s.e.m. (n = 3 biological 
replicates). Values were normalized to the unstimulated AS-EphB TKI vehicle-treated condition. Uncropped blots are shown in Supplementary Figure 7.
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Figure 4 The kinase function of EphBs is required for growth cone collapse in ventrotemporal (VT) retinal ganglion 
cells. (a) Effect of PP1 analog on RGC growth cone collapse. E14 ventrotemporal retinal explants were treated 
with vehicle, 250 nM 1-NA-PP1 or 1 MM 3-MB-PP1 before ephrin-B2 stimulation. Explants were stained for 
neurofilament (red), phospho-EphB (white) and labeled with phalloidin to visualize F-actin (green). White arrows 
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collapsed growth cones from a. A two-way ANOVA revealed a significant interaction between genotype and inhibitor 
treatment in each condition, indicating that the effects of inhibitors were significantly greater in AS-EphB TKI 
neurons than in wild-type neurons (vehicle versus 1-NA-PP1: F1,20 = 6.66, P = 0.018; vehicle versus 3-MB-PP1: 
F1,22 = 7.41, P = 0.012). (c) Quantification of the average growth cone width from a. A two-way ANOVA revealed 
a significant interaction between genotype and inhibitor treatment in each of the conditions (vehicle versus 1-NA-
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containing vehicle. The percentage of collapsed growth cones was then quantified as in b. All data are presented as 
mean o s.e.m. N = 4–8 explants (biological replicates) per condition for each experiment.
tion in RGC axons, we stained explants with 
antibody to phosphorylated EphB. In the 
absence of stimulation, minimal phospho-
EphB staining was observed in growth cones 
from wild-type or AS-EphB TKI explants 
(Fig. 4a). Following ephrin-B2 stimulation, 
punctate patterns of phosphorylated EphB 
staining were seen in the growth cone and 
along the axon (Fig. 4a). This staining was 
blocked in AS-EphB TKI explants treated 
with 1-NA-PP1 (250 nM) or 3-MB-PP1 
(1 MM), but not in wild-type explants, indi-
cating that PP1 analogs selectively inhibit the 
kinase activity of EphBs in AS-EphB TKI RGC 
explants (Fig. 4a).
A crucial feature of this chemical genetic 
approach is the reversibility of kinase 
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EphB RTK signaling mediates retinal axon guidance in vivo
Having established the requirement of the tyrosine kinase activity 
of EphBs for growth cone collapse in vitro, we next asked whether 
this requirement is relevant for repulsive guidance in vivo, where 
growth cones exhibit saltatory motion rather than simple extension 
and collapse. In addition, growth cone collapse in vivo is mediated by 
a number of cues, including membrane-bound ephrin-B rather than 
ectopically added aggregated soluble ephrin-Bs
To determine whether the kinase activity of EphBs is required for the 
repulsive guidance of axons under physiological conditions of ephrin-
B and EphB signaling in vivo, we examined the effect of inhibiting 
the kinase activity of EphBs on axon repulsion at the optic chiasm. 
We treated pregnant mice with 1-NA-PP1 from E13.5 to E16.5, 
the time at which RGC axons encounter the optic chiasm (Fig. 5a), 
and analyzed the retinal projections at E16.5 by DiI labeling.
To assess the degree of ipsilateral versus contralateral retinal 
projection, we measured the fluorescence intensity of a rectangu-
lar region in the ipsilateral projection and divided this by the total 
fluorescence intensity in the combined ipsilateral and contralateral 
projections to derive the ipsilateral index (Fig. 5b)40. In 1-NA-
PP1–treated AS-EphB TKI embryos, we found that the ipsilat-
eral retinal projection was strongly reduced (by 42%) compared 
with untreated AS-EphB TKI embryos (Fig. 5c,d). In many of the 
AS-EphB TKI embryos treated with 1-NA-PP1, the ipsilateral projec-
tion was absent. In contrast, 1-NA-PP1 treatment had no effect on 
the ipsilateral retinal projection in wild-type embryos, indicating 
that the observed guidance deficit was a result of specific inhibi-
tion of EphBs (Fig. 5c,d). These findings suggest that the tyrosine 
kinase activity of EphBs is required for axon repulsion at the optic 
chiasm. They also illustrate the utility of AS-EphB mice for examin-
ing the importance of the tyrosine kinase activity of EphBs in both 
in vitro and in vivo settings. Our results demonstrate that PP1 ana-
logs are capable of entering the brain tissue of an intact organism 
and then effectively and potently inhibiting EphB tyrosine kinase 
 activity. These analogs also completely inhibited EphB tyrosine 
kinase activity in neuronal cultures, making it possible to use the 
AS-EphB TKI neurons to investigate the role of the kinase activity 
of EphBs in a diverse array of neuronal functions.
EphB RTK signaling mediates corpus callosum formation
Based on the finding that EphB tyrosine kinase activity medi-
ates axon guidance at the optic chiasm, we next asked whether a 
similar mechanism might be used during other axon guidance 
decisions. We focused on the role of the tyrosine kinase activity 
of EphBs in the formation of the corpus callosum. Different EphB 
family members have been suggested to mediate this process 
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required for the formation of the ipsilateral  
retinal projection in vivo. (a) Schedule of  
in vivo 1-NA-PP1 administration. Twice-daily  
subcutaneous injections of 80 mg per kg of  
body weight 1-NA-PP1 were administered  
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(c) Representative images of DiI-filled retinal  
projections at E16.5. Pregnant AS-EphB  
and C57BL/6 wild-type mice were treated as  
described in a. Red arrows denote the ipsilateral  
projection. (d) Quantification of the ipsilateral  
phenotype shown in c. The ipsilateral index is defined as ipsilateral/(ipsilateral + contralateral) fluorescence intensity and  
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through both forward and reverse signaling, but the requirement 
of the kinase activity has not been tested22,43.
To address this question, we administered 1-NA-PP1 to pregnant 
AS-EphB TKI mice from E12.5 to E19.0 and visualized major axon 
tracts by L1-CAM staining (Fig. 6a). As expected, untreated 
AS-EphB TKI mice had normal corpus callossa (0 of 6 mice with agene-
sis; Fig. 6b). However, AS-EphB TKI mice treated with 1-NA-PP1 
had partial corpus callosum agenesis with a gap in the dorsal 
midline region (11 of 11 mice with agenesis; Fig. 6b). Wild-type 
mice treated with 1-NA-PP1 had a normal corpus callosum (0 of 6 
mice with agenesis), indicating that the corpus callosal agenesis 
phenotype was specific to inhibition of AS-EphBs (Fig. 6b). These 
data indicate that the tyrosine kinase activity of EphBs is essential 
for proper formation of the corpus callosum in vivo. Taken together 
with our findings on retinal axon guidance, these observations 
 suggest that tyrosine kinase-dependent signaling is likely a general 
mechanism by which EphB forward signaling mediates repulsive 
axon guidance in vivo.
EphB RTK signaling is not required for synaptogenesis
In addition to their role in axon guidance, EphBs have been shown 
in numerous studies to control synapse development and func-
tion12,13,15,16,18,25,44,45. Experiments involving overexpression of 
kinase-defective EphB mutants and the use of knock-in mice containing 
cytoplasmic truncations of EphBs have suggested a role for kinase sig-
naling in synaptogenesis12,13,15,18,25. However, the relevance of tyrosine 
kinase activity of EphBs for synaptogenesis has not been examined 
under conditions in which ephrin-Bs and EphBs are expressed at 
endogenous levels and engage in physiological signaling.
The most notable synaptic defect observed after perturbation of 
EphB expression is the loss of dendritic spines, the sites on dendrites 
where most excitatory synapses form. In neurons from EphB1, EphB2 
and EphB3 triple knockout mice, dendritic spine development is 
severely compromised13,18. To assess the importance of EphB tyrosine 
kinase activity for spine development, we cultured cortical neurons 
from E15–17 AS-EphB TKI or wild-type embryos and treated them 
with 1-NA-PP1 (1 MM) between 10–21 DIV, the peak of spinogenesis. 
To ensure exposure to the full dose of the inhibitor during this long 
period, we changed the culture medium completely every 3–4 d 
with fresh 1-NA-PP1. To visualize the fine dendritic structures, 
we transfected neurons with GFP at 10 DIV and analyzed them at 
21 DIV. To assess spine density, we counted spines per unit dendritic 
length over multiple segments of dendrite totaling more than 50 Mm. 
Notably, we found that 1-NA-PP1 treatment had no detectable effect 
on spine number and length in AS-EphB TKI or wild-type neurons 
(Fig. 7a,b). This result suggests that the tyrosine kinase activity of 
EphBs is not required for dendritic spine development in dissociated 
cortical neurons.
To functionally test the effect of 1-NA-PP1 on synaptogenesis, 
we measured miniature excitatory postsynaptic currents (mEPSCs) 
in dissociated cortical neurons from AS-EphB TKI mice in the 
presence or absence of 1-NA-PP1. These cultures were treated with 
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Figure 7 The kinase activity of EphBs is  
dispensable for the formation of dendritic  
spines and functional excitatory synapses in culture.  
(a) Representative images of dendritic spines from cultured  
AS-EphB TKI and wild-type cortical neurons treated with vehicle  
or 1 MM 1-NA-PP1 from 10–21 DIV. Neurons were transfected at  
10 DIV with GFP and stained with an antibody to GFP. Scale bar  
represents 5 Mm. (b) Quantification of spine density and spine length from a. Data are presented as mean o s.e.m. N = 25–33 neurons from 
independent biological replicates per condition. (c) Representative traces of recordings of mEPSCs from dissociated cortical neurons from AS-EphB 
TKI embryos at 10–12 DIV. Cultures were treated with vehicle or 1-NA-PP1 (1 MM) from 3 DIV until the time of recording. (d) Quantification of mEPSC 
frequency and amplitude from vehicle and 1-NA-PP1–treated neurons. Data are presented as mean o s.e.m. N = 13 cells from independent biological 
replicates per condition. (e) The tyrosine kinase activity of AS-EphBs was inhibited by 1-NA-PP1. Cultures concurrent with those used in d were treated 
with 1-NA-PP1 under identical culture conditions then stimulated for 30 min with ephrin-B1 at 10 DIV. Cell lysates were analyzed by western blotting 
for phospho-EphB and B-actin. Uncropped blots are shown in Supplementary Figure 7.
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1 MM 1-NA-PP1 from 3 to 10–12 DIV, and mEPSCs were measured 
by whole-cell electrophysiological recordings. Consistent with 
the spine analysis, we found no difference in mEPSC frequency 
or amplitude between AS-EphB TKI neurons treated with either 
vehicle or 1-NA-PP1 (Fig. 7c,d), which again strongly suggests that 
the tyrosine kinase activity of EphBs is not required for synapto-
genesis, at least in dissociated neurons. To confirm that chronic 
1-NA-PP1 treatment inhibits EphB tyrosine phosphorylation in these 
cultures, we performed western analysis on concurrent cultures and 
found that exposure of AS-EphB TKI neurons to 1-NA-PP1 (1 MM) 
resulted in a complete inhibition of ephrin-B–induced EphB auto-
phosphorylation (Fig. 7e).
To determine whether the tyrosine kinase activity of EphBs might 
control excitatory synapse development or function in the con-
text of a more intact neural circuit, we also examined the effect of 
1-NA-PP1 inhibition on dendritic spine development, mEPSCs and 
evoked excitatory postsynaptic currents (eEPSCs) in organotypic 
hippocampal slices prepared from AS-EphB TKI mice. Expression 
of shRNAs targeting Ephb1, Ephb2 and Ephb3 led to pronounced 
alterations in spine development (Supplementary Figs. 4a–c and 
5a–d), and mEPSC and eEPSC currents (Supplementary Fig. 6a–d) 
in organotypic hippocampal slice cultures, indicating that EphBs 
are important for excitatory synaptic development under these con-
ditions. However, in sharp contrast with these findings, the addi-
tion of 1-NA-PP1 to slices from AS-EphB TKI mice had no effect 
on dendritic spine growth (Fig. 8a–d), mEPSC characteristics 
(Fig. 8e,f) or eEPSC events (Fig. 8g,h). Taken together, these find-
ings suggest that, at least under the conditions tested, EphB tyrosine 
kinase activity is not required for the formation or maintenance of 
functional synapses.
DISCUSSION
Employing a chemical genetic strategy, we engineered mice in which 
it is possible to acutely, reversibly and specifically inhibit the kinase 
signaling of EphBs in vitro and in vivo. We found that synaptogenesis, 
a process that requires EphB proteins, did not depend on the tyrosine 
kinase activity of EphBs. In contrast, we found a clear requirement for 
the tyrosine kinase activity of EphBs in ephrin-B–mediated growth cone 
collapse in culture and in the repulsive guidance of retinal and corpus 
callosal axons in vivo. Thus, unlike many other axon guidance receptors, 
EphBs mediate axon repulsion via a RTK-dependent mechanism.
Our finding that the kinase activity of EphBs is not required for 
the formation of excitatory synapses was unexpected and suggests 
a possible role for cytoplasmic domain oligomerization and other 
forms of protein-protein interactions in this process. For example, 
the binding of PDZ domain–containing synaptic proteins with the 
cytoplasmic tail of EphBs or the recruitment of NMDA receptors via 
the EphB extracellular region may initiate or stabilize the formation 
of excitatory synapses13,15. Alternatively, EphBs could initiate signal-
ing by recruiting other cytoplasmic kinases, such as the Src family 
of tyrosine kinases44. Although our data strongly suggest that the 
tyrosine kinase activity of EphBs is not required for synaptogenesis 
under a wide range of experimental conditions tested, we cannot 
rule out the possibility that EphB kinase signaling has a role in other 
contexts. It will be important in the future to determine whether the 
kinase activity of EphBs functions instead in the plasticity of these 
synapses, as multiple reports have identified a role for EphBs in long-
term potentiation in the hippocampus10,11.
In contrast with synaptogenesis, our results reveal a requirement 
for the tyrosine kinase activity of EphBs in the formation of the 
ipsilateral retinal projection and the corpus callosum. Our finding 
g
Vehicle
1-NA-PP1
100 ms
20 pA
Ve
hic
le
1-
NA
-P
P1
Ve
hic
le
1-
NA
-P
P1
0
1
2
3
4
5
eE
P
S
C
 fr
eq
ue
nc
y 
(H
z)
 
h
0
2
4
6
8
10
12
14
16
18
20
eE
P
S
C
 a
m
pl
itu
de
 (
pA
) 
eEPSC
frequency
eEPSC
amplitude
Ve
hic
le
1-
NA
-P
P1
Ve
hic
le
1-
NA
-P
P1
0
0.1
0.2
0.3
0.4
m
E
P
S
C
 fr
eq
ue
nc
y 
(H
z)
 
f
0
2
4
6
8
10
12
14
m
E
P
S
C
 a
m
pl
itu
de
 (
pA
) 
mEPSC
frequency
mEPSC
amplitude
Vehicle
1-NA-PP1
e
10 pA
500 ms
Apical
Vehicle
1-NA-PP1
a
AS-EphB TKI WT
c
Vehicle
1-NA-PP1
Basal
AS-EphB TKI WT
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
Ve
hic
le
1-
NA
-P
P1
Ve
hic
le
1-
NA
-P
P1
S
pi
ne
s 
pe
r 
µm
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
S
pi
ne
s 
le
ng
th
 (
µm
)
AS-EphB TKI WT b
Apical lengthApical density 
Ve
hic
le
1-
NA
-P
P1
Ve
hic
le
1-
NA
-P
P1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
S
pi
ne
s 
pe
r 
µm
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
S
pi
ne
s 
le
ng
th
 (
µm
)
d
Basal density Basal length
AS-EphB TKI WT 
Figure 8 The kinase activity of EphBs is  
dispensable for the formation of dendritic  
spines and functional excitatory synapses in  
hippocampal slices. (a) Representative images of apical spines from AS-EphB TKI slices. Slices from postnatal day 5–7 (P5–7) mice were treated  
with vehicle or 1-NA-PP1 from 0–8 DIV. Scale bar represents 5 Mm. (b) Quantification of apical spine density and spine length from a (wild-type +  
vehicle, n = 21 neurons;, wild-type + 1-NA-PP1, n = 11 neurons; AS-EphB TKI + vehicle, n = 30 neurons; AS-EphB TKI + 1-NA-PP1, n = 16 
neurons). (c) Representative images of basal spines from slices as described in a. (d) Quantification of basal spine density and spine length from c.  
(e) Representative traces from recordings of mEPSCs from P5–7 AS-EphB TKI slices at 12–14 DIV. (f) Quantification of mEPSC frequency and 
amplitude from e. (AS-EphB TKI + vehicle, n = 16 neurons; AS-EphB TKI + 1-NA-PP1, n = 19 neurons).1-NA-PP1 did not produce a significant 
change in mEPSC frequency (P = 0.11) or amplitude (P = 0.14) by Student’s t test. (g) Representative traces from recordings of eEPSCs from P5–7 
AS-EphB TKI slices at 12–14 DIV. (h) Quantification of eEPSC frequency and amplitude in hippocampal slices. (AS-EphB TKI + vehicle, n = 7 
neurons; AS-EphB TKI + 1-NA-PP1, n = 7 neurons). 1-NA-PP1 did not produce a significant change in eEPSC frequency (P = 0.67) or amplitude 
(P = 0.33) by Student’s t test. All experiments were done in organotypic hippocampal slices. The concentration of 1-NA-PP1 was 1 MM. All data are 
presented as mean o s.e.m. Samples are independent biological replicates.
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that EphB tyrosine kinase activity is required for retinal guidance is 
 consistent with data from a previous study that found that overexpres-
sion of EphB1 is sufficient to drive retinal axons to ectopically project 
ipsilaterally and that this function requires an intact EphB1 kinase 
domain23. These findings are also consistent with those of a recent 
study in which a knock-in mouse was generated with the intracellular 
region of EphB1 replaced with lacZ24. This mouse displays a loss of 
the ipsilateral retinal projection, which indicates that EphB forward 
signaling is necessary for the formation of the ipsilateral retinal 
projection. Using AS-EphB TKI mice, we found that EphB tyrosine 
kinase activity is directly involved in the formation of the ipsilateral 
retinal projection.
Mutations of the cytoplasmic domains of EphBs or ephrin-Bs sug-
gest that the formation of the corpus callosum is more complex than 
the ipsilateral retinal projection and could involve both EphB forward 
and reverse signaling22. However, our finding that inhibition of the 
kinase activity of EphBs in vivo results in a highly penetrant corpus cal-
losum agenesis phenotype provides clear evidence for the requirement 
of EphB kinase signaling in the development of the corpus callosum.
On the basis of our observations, we favor a model in which EphB 
tyrosine kinase activity is required for repulsive interactions, such 
as in axon guidance, but may not be required for adhesive inter-
actions, such as axon fasciculation and synapse formation. This 
model is consistent with previous theories that have suggested that 
the amount of kinase activation predicts the strength of repulsion46. 
Furthermore, inhibiting kinase activity in a normally repulsive con-
text (such as axon guidance) may lead to unnatural adhesion. Thus, 
it will be interesting to study the fate of the misprojected axons that 
we observed in the optic tract and corpus callosum. It will also be 
important to search for any counterexamples to our model, such 
as an adhesive interaction that is EphB tyrosine kinase dependent. 
The delicate balance between the opposing functionalities of the 
ephrin-B and EphB signaling system underscores the importance of 
studying these interactions under physiological conditions.
Understanding the downstream mechanism by which the tyrosine 
kinase activity of EphBs controls axon guidance represents an impor-
tant direction for future studies. One crucial mediator of this signaling 
might be the Vav family of guanine nucleotide exchange factors for the 
small GTPase Rac. Vav2 is known to control growth cone collapse, and 
Vav2 and Vav3 double mutant mice display defects in the development 
of the ipsilateral retinocollicular projection39,47. We found that the 
tyrosine kinase activity of EphBs was required for ephrin-B–induced 
Vav2 tyrosine phosphorylation. A thorough investigation of how 
EphBs control repulsive axon guidance will require knowledge of the 
full complement of tyrosine kinase substrates of EphBs. As analog-
sensitive kinases accept orthologous ATP analogs that can directly 
label the targets of the kinase48, it should be possible to use AS-EphB 
TKI mice to identify direct kinase substrates of EphBs. Given the 
general limited knowledge of axon guidance mechanisms, identifica-
tion of EphB substrates in the relevant neurons could be a powerful 
approach for uncovering these mechanisms.
Our chemical genetic approach offers several advantages over con-
ventional genetic loss-of-function studies49. Given that we were able 
to block the kinase activity of EphBs while leaving their scaffolding 
and reverse signaling capabilities intact, it was possible to dissect the 
role of the kinase activity of EphBs in vivo under conditions in which 
EphBs were expressed at physiological levels. As there are no Cre/
loxP-based conditional EphB mice of any kind available, AS-EphB 
TKI mice represent an alternative for many experiments that require 
conditional regulation of EphB signaling. In addition, the reversible 
nature and the fine temporal control afforded by the chemical genetic 
approach should permit investigations into the functions of EphBs 
in the mature animal, such as in adult neurogenesis and synaptic 
plasticity, and in pathologies such as Alzheimer’s disease, autism and 
cancer4,7,50. This new window into EphB signaling should also provide 
insights that are crucial for therapeutic drug development for the 
treatment of EphB-mediated disease.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Note: Supplementary information is available in the online version of the paper.
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ONLINE METHODS
Animals. EphB1T697G, EphB2T699A and EphB3T706A single mutants were generated 
individually by homologous recombination in mouse ES cells. Mice harboring 
each of the knock-in mutations were intercrossed to obtain the triple homozygous 
AS-EphB TKI mice.
To generate the targeting constructs, the 5` and 3` arms was PCR ampli-
fied from J1 ES cell DNA using primers listed in Supplementary Table 1 and 
subcloned into a modified pKSNeoDTA vector (originally constructed in the 
laboratory of P. Soriano, Mount Sinai Hospital) containing a loxP-neo-loxP cas-
sette for positive selection and a diptheria toxin A negative-selection cassette 
(DTA). The analog-sensitive mutations were introduced by site-directed muta-
genesis. The targeting constructs were confirmed by sequencing. Linearized 
targeting construct was electroporated into J1 ES cells, which were subse-
quently selected with G418. Correct targeting of ES cells was initially screened 
by PCR and then confirmed by Southern analysis and direct sequencing of 
PCR products amplified from the mutated alleles. The positive clones were 
karyotyped and the neomycin resistance cassette was removed by electroporat-
ing targeted ES cells with a Cre expression plasmid. ES cell clones were micro-
injected into C57BL/6 blastocysts to generate chimeric mice. Male chimeric 
animals were mated to C57BL/6 wild-type females for germline transmission 
of the targeted allele.
The ES cell targeting efficiencies were as follows: EphB1 knock-in (17 of 192, 9%), 
EphB2 knock-in (3 of 186, 2%) and EphB3 knock-in (12 of 96, 13%).
Mice were maintained as homozygotes in a mixed 129 and C57BL/6 back-
ground. Unless noted, wild-type mice were F1 offspring of a C57BL/6 × 129sv 
cross. Animals were housed under a 12-h light/dark cycle. No more than five 
animals were housed in each cage. Mice and embryos were chosen at random, 
regardless of sex, for treatment condition.
All experiments with mice were approved by the Animal Care and Use 
Committee of Harvard Medical School. E0 was defined as midnight preceding 
the morning a vaginal plug was found.
HEK 293 cell culture and transfection. HEK 293 cells were maintained in 
DMEM supplemented with 10% fetal bovine serum (vol/vol, Gibco), 2 mM 
glutamine (Gibco) and penicillin/streptomycin (100 U ml–1 and 100 Mg ml–1, 
respectively; Gibco). HEK 293 cells were transfected using the calcium phosphate 
method, as previously described15.
Antibodies and western blotting. The following antibodies were purchased 
commercially: pan-phospho-tyrosine pY99 mouse monoclonal (Santa Cruz), 
EphB1 (H-80) and EphB3 (H-85) rabbit polyclonal (Santa Cruz), B-actin mouse 
monoclonal (Abcam), PSD-95 mouse monoclonal (Pierce), and synapsin rabbit 
polyclonal (Millipore). Mouse monoclonal antibody to neurofilament (2H3) was 
obtained from the Developmental Studies Hybridoma Bank (T. Jessell, Columbia 
University). Polyclonal rabbit antibodies to Vav2, pan-phospho-EphB and EphB2 
(all at 1:1,000 dilution) were generated in M.E.G.’s laboratory and were described 
previously15. The phospho-specificity of the pan-phospho-EphB antibody was 
validated in HEK 293 cells for EphB1, EphB2 and EphB3 individually. All west-
ern blots were imaged and quantified using the Odyssey Infrared Imaging 
System (Licor) using fluorescently labeled secondary antibodies (Rockland 
Immunochemicals).
Protein binding assays. Full-length human Grb2 and rat Pick1 were PCR 
amplified from plasmids #26085 and #31613 (Addgene), respectively. Grb2 and 
Pick1 were fused to GST at their N termini by cloning them into a pGEX vector 
(Pharmacia), expressed in E. coli, and affinity purified on glutathione sepharose 
beads. GST, used as a negative control, was expressed from the empty pGEX vector. 
AS-EphB1 protein was expressed in HEK 293 cells by transient transfection 
and the cells were treated with either DMSO or 1 MM 1-NA-PP1 for 16 h. Cells 
were lysed in lysis buffer (30 mM HEPES (pH 7.7), 100 mM KCl, 1 mM MgCl2, 
2 mM DTT, 2 mM sodium orthovandadate, 1% Triton X-100 (vol/vol), protease 
inhibitor (Roche, 04693159001) and phosphatase inhibitor cocktails (Sigma, 
P5726, P0044)). The crude lysates were centrifuged at 70,000g for 20 min at 
4 °C to generate the high-speed supernatants. High-speed supernatant was 
incubated with glutathione beads coated with approximately GST, GST-Grb2 
or GST-Pick1 with rotation at 4 °C for 2 h. The beads were washed three times 
with lysis buffer and analyzed by SDS-PAGE and western blotting.
Pharmacology. 1-NA-PP1 was synthesized as described previously27 and 
dissolved in DMSO. 3-MB-PP1 was synthesized using a similar procedure and 
dissolved in DMSO. Dose-response curves using 1-NA-PP1 and 3-MB-PP1 were 
calculated on GraphPad Prism using the least-squares method. The vehicle dose 
was calculated as two orders of magnitude below the lowest dose (0.05 nM). For 
wild-type EphBs, 100% inhibition was defined at 1 mM.
Neuronal cell culture. Cortical and hippocampal neurons were prepared from 
E15–17 mouse embryos as previously described15. Cultured neurons were 
maintained in Neurobasal medium (Invitrogen) supplemented with 1× B27 
(Invitrogen), penicillin/streptomycin (100 U ml–1 and 100 Mg ml–1, respectively) 
and 2 mM glutamine. For biochemistry, neurons were seeded at a density of 2 × 106 
neurons per well of a six-well plate coated with polyornithine (Sigma). For elec-
trophysiology and imaging, neurons were seeded at a density of 7.5 × 104 neurons 
per well on a glial monolayer on glass coverslips coated with polyornithine and 
laminin (Invitrogen).
Organotypic slices. Hippocampal organotypic slices were prepared in ice-cold 
dissection media (1 mM CaCl2, 5 mM MgCl2, 10 mM d-glucose, 4 mM KCl, 
26 mM NaHCO3, 218 mM sucrose, 1.3 mM sodium phosphate and 30 mM HEPES, 
pH 7.4). Brains were isolated from P5–7 pups, and hippocampi were excised 
and chopped into 400-Mm sections. Slices were cultured on Millicell cell culture 
inserts (Millipore) in media containing 20% horse serum, 1 mM l-glutamine, 
0.0012% ascorbic acid (wt/vol), 1 Mg ml–1 insulin, 1 mM CaCl2, 2 mM MgCl2, 
2.3 mg ml–1 glucose, 0.44 mg ml–1 NaHCO3 and 7.16 mg ml–1 HEPES in MEM.
Ephrin stimulation. For ephrin stimulations in dissociated cultured neurons and 
retinal explants, mouse ephrin-B1–Fc or ephrin-B2–Fc (R&D Systems) was pre- 
clustered for 50 min with goat antibody to human IgG Fc (Jackson ImmunoResearch, 
109-001-008) at 22–25 °C in phosphate-buffered saline (PBS) at a molar ratio of 1:1 
before stimulation. Pre-clustered ephrin-B1–Fc or ephrin-B2–Fc was added to the 
appropriate medium at a final concentration of 2.5 Mg ml–1. As a control, clustered 
human Fc in media was applied to neurons where specified.
Cell lysis and immunoprecipitation. Cultured cells were collected and homoge-
nized in RIPA buffer (50 mM Tris (pH 8.0), 150 mM NaCl, 1% Triton X-100, 0.5% 
sodium deoxycholate, 0.1% SDS (wt/vol), 10 mM NaF, complete protease inhibitor 
cocktail tablet (Roche), 1 mM sodium orthovanadate, and phosphatase inhibitor 
cocktails 1 and 2 (1×, Sigma)). After clearing lysates, supernatants were incubated 
with the appropriate antibody for 1 h at 4 °C, followed by addition of Protein-A 
Fastflow agarose beads (Sigma) for 1 h. Beads were washed in lysis buffer or PBS 
three times and eluted in 2× SDS sample buffer followed by boiling.
Surface labeling. Labeling of surface proteins was performed using the Pierce 
Cell Surface Protein Isolation Kit (Thermo Scientific). After chronic treatment 
with vehicle or 1 MM 1-NA-PP1, cultured cortical neurons were incubated with 
EZ-link biotin for 30 min at 22–25 °C , washed with PBS, and lysed in RIPA 
buffer. Lysates were immunoprecipitated with an antibody to EphB2 or a control 
antibody, and probed with either antibody to EphB2 or fluorescently labeled 
streptavidin (Invitrogen).
Retinal explants. Ventrotemporal segments of retina were microdissected from 
E14.5 mouse embryos and cultured as previously described51. Embryos were 
removed from the uterus and decapitated, and heads were placed in ice-cold 
DMEM/F12 (Gibco). Ventrotemporal sections of the retina were excised and 
placed on glass coverslips coated with polyornithine and laminin. Explants were 
maintained in serum free medium (10 mg ml–1 BSA (Sigma), 1% ITS supplement 
(vol/vol) (Sigma), penicillin/streptomycin (20 U ml–1 and 20 Mg ml–1, respec-
tively, Gibco) in DMEM/F12) supplemented with 0.2% methyl cellulose (wt/vol, 
Sigma) to increase media viscosity and minimize explant movement. All experi-
ments were conducted 18–24 h after initial plating.
Immunocytochemistry and growth cone collapse assay. For experiments with 
inhibitor treatment, explants were pre-incubated with vehicle or PP1 analogs for 
1 h, followed by a 30-min ephrin-B2 stimulation, with variations as described in 
the text. Following stimulation, retinal explants were fixed for 20 min at 25 °C 
with 4% paraformaldehyde (PFA)/2% sucrose (wt/vol) in PBS. Explants were 
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then blocked in 10% goat serum (vol/vol), 0.2% Tween-20 (vol/vol) in PBS for 
1 h, followed by incubation with antibody to either neurofilament phospho-EphB 
in 50% blocking solution overnight. After PBS washes, explants were incubated 
in Alexa Fluor–conjugated secondary antibodies (Invitrogen) and Alexa Fluor 
488–conjugated phalloidin (Invitrogen). Explants on coverslips were mounted 
on glass slides using Fluoromount-G (Southern Biotech). Neurons were imaged 
using a laser-scanning Zeiss Pascal microscope using a 40× objective with sequen-
tial acquisition settings at 1,024 × 1,024 pixel resolution. All imaging and image 
analysis were performed blind to the genotype and treatment condition of the 
samples. At least ten growth cones were analyzed per explant.
In vivo 1-NA-PP1 delivery. Pregnant wild-type or AS-EphB TKI mice were 
injected subcutaneously twice daily with 80 mg per kg of body weight 1-NA-PP1 
dissolved in 10% DMSO, 20% Cremaphor-EL and 70% saline (vol/vol) from 
E13.5–16.5 for optic tract experiments or from E12.5–19 for cortical tract experi-
ments. All experiments included data from at least two separate litters of embryos 
per condition. Animals used for in vivo 1-NA-PP1 treatment had no prior 
exposure to 1-NA-PP1 or other drugs.
DiI labeling. DiI labeling was performed as previously described52. At E16.5, 
embryo heads were fixed in 4%PFA/2% sucrose in PBS overnight and then washed 
with PBS. The lens and retina were removed from the left eye and a small crystal 
of DiI (Invitrogen) was placed in the optic disc. The retina was then replaced 
securely and the heads were stored in PBS + 0.1% azide (wt/vol) at 22–25 °C for 
12 d. After labeling, brains were removed and fluorescent optic tracts were imaged 
on a Leica MZ16F fluorescent stereomicroscope. Images were captured using Spot 
Advanced software. Labeling was quantified using Metamorph software by draw-
ing rectangular regions of interest around the ipsilateral and contralateral tracts, 
subtracting background, and calculating the ipsilateral index on the basis of the 
integrated intensity of fluorescence: ipsilateral index = ipsilateral / (ipsilateral + 
contralateral). To compare wild-type and AS-EphB TKI responses with respect to 
1-NA-PP1 treatment, each genotype was normalized to its untreated condition, 
producing a normalized ipsilateral index.
Analysis of corpus callosum phenotypes. E19.0 embryos were fixed in 4% 
PFA/2% sucrose in PBS for 2 d, then stored in PBS + 0.02% sodium azide at 
4 °C. Brains were removed and vibratome sectioned to 70 Mm. Sections were 
blocked in 5% normal donkey serum, 1% BSA, 0.2% glycine (wt/vol), 0.2% lysine 
(wt/vol) with 0.3% Triton X-100 in PBS at 22–25 °C for 1 h. To stain axon tracts, 
sections were incubated with rat antibody to L1-CAM (Millipore, MAB5272MI) 
at a 1:200 dilution in blocking solution at 4 °C overnight. Sections were washed 
three times with PBS and incubated with Cy3-conjugated donkey antibody to rat 
IgG (Jackson) for 1.5 h. Sections were washed 7–8 times with PBS and mounted 
with Aqua-mount (Lerner laboratories). Sections were imaged on an Olympus 
Bx51 epifluorescent microscope at 4× magnification. Corpus callosum partial 
agenesis was scored as the apparent failure of corpus callosal axons to cross the 
midline in a specific region along the rostral-caudal brain axis, and was evident 
by a gap in the dorsal midline region.
qPCR. Total RNA was isolated from mouse 7 DIV cortical cultures using Trizol 
reagent (Invitrogen) according to the manufacturer’s instructions. Isolated 
RNA was treated with DNAseI Amplification Grade (Invitrogen) and a cDNA 
library was synthesized by cDNA High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems). The cDNA was the source of input for qPCR, using a 
Step One Plus Real-Time PCR Instrument and SYBR Green reagents (Applied 
Biosystems). The relative expression plot was generated using concentration 
 values that were normalized to corresponding actin concentrations. The following 
qPCR primer pairs were used: EphB1 forward, ACTGCAGAGTTGGGATGGAC; 
EphB1 reverse, CATCATAGCCACTGACTTCTTCC; EphB2 forward, TTCATGG 
AGAACGGATCTCTG; EphB2 reverse, GACTGTGAACTGCCCATCG; EphB3 
forward, CCCTGGACTCCTTTCTACGG; EphB3 reverse, GCAATGCC 
TCGTAACATGC.
Analysis of dendritic spines. For dissociated neuron experiments, cortical neu-
rons were cultured as described above and grown on a monolayer of astrocytes 
on glass coverslips. Neurons were treated with vehicle or PP1 analogs at 10 DIV 
and media was changed entirely every 3–4 d (using neuronally pre-conditioned 
media). Neurons were transfected with GFP at 10 DIV using Lipofectamine 
2000 and fixed with 4% PFA/2% sucrose in PBS at 21 DIV. Cells on coverslips 
were stained for GFP and mounted on slides using Fluoromount-G.
Neurons were imaged on a Zeiss Pascal confocal microscope, using a 63× 
objective, and maximal z projections were analyzed using Metamorph software. 
Multiple sections of dendrite totaling >50 MM were counted for each neuron.
For experiments in slice, hippocampal slices were treated with vehicle or PP1 
derivatives at 2 DIV and media/drug were fully replaced every 2–3 d. At 2–3 DIV, 
plasmids encoding GFP (or GFP and EphB shRNAs) was biolistically transfected 
using a Helios gene gun. DNA bullets were prepared from 1.6-Mm gold micro-
carrier particles (Biorad). After 8–9 DIV, slices were fixed in 3.2% PFA/5% sucrose 
in PBS for 1 h and stained with chicken antibody to GFP (Aves Labs) and rabbit 
antibody to NeuN (Millipore, clone A60, 1:1,000 dilution) to visualize the struc-
ture of hippocampal fields. Basal and apical dendrites were analyzed separately 
and sections of dendrite totaling >50 MM were counted for each neuron.
Electrophysiology. For experiments in dissociated neurons, whole-cell volt-
age-clamp recordings were obtained using an Axopatch 200B amplifier at 25 °C. 
During recordings, neurons were perfused with artificial cerebrospinal fluid 
containing 127 mM NaCl, 25 mM NaHCO3, 1.25 mM Na2HPO4, 2.5 mM KCl, 
2 mM CaCl2, 1 mM MgCl2, 25 mM glucose, and saturated with 95% O2, 5% CO2. 
Vehicle or 1-NA-PP1 treatment was initiated at 3 DIV and continued through-
out recordings. The internal solution used in all eletrophysiological experiments 
contained 120 mM cesium methane sulfonate, 10 mM HEPES, 4 mM MgCl2, 
4 mM Na2ATP, 0.4 mM Na2GTP, 10 mM sodium phosphocreatine and 1 mM 
EGTA. Osmolarity and pH were adjusted to 310 mOsm and 7.3 with Millipore 
water and CsOH, respectively.
mEPSCs were isolated by exposing neurons to 0.5 MM tetrodotoxin, 50 MM 
picrotoxin, and 10 MM cyclothiazide (all from Tocris Bioscience). Cells with series 
resistance larger than 25 M7 during the recordings were discarded. Data were 
analyzed in IgorPro (Wavemetrics) using custom-written macros. For each trace, 
the event threshold was set 1.5-fold greater than the root-mean-square current. 
Currents were counted as events if they crossed the event threshold, had a rapid 
rise time (1.5 pA ms−1) and had an exponential decay (T < 50 ms for mEPSC).
As a control for inhibition of EphBs, concurrent plates of neurons were treated 
with inhibitor and at the time of recording were stimulated with ephrin-B1 for 
30 min. Neurons were lysed in 1× SDS-sample buffer, run on western blot and probed 
with rabbit antibody to phospho-Eph and mouse antibody to B-actin (Abcam).
For mEPSC experiments in organotypic hippocampal slices, whole-cell volt-
age-clamp recordings were made from visually identified CA1 pyramidal neurons 
and the mEPSC amplitude and frequency measured. Slices were treated with 
vehicle or 1-NA-PP1 from 2 DIV until the time of recording.
To evaluate evoked synaptic transmission, the Schafer collaterals were depo-
larized with an extracellular stimulating electrode and the postsynaptic eEPSC 
response measured from CA1 neurons53. In these experiments, the artificial 
cerebrospinal fluid contained 4 mM Sr2+ instead of CaCl2 and 4 mM MgCl2 so 
that the extracellular stimulation resulted in asynchronous presynaptic vesicle 
fusion. The stimulus strength was set so that the initial postsynaptic response was 
50–100 pA and the current amplitude and frequency of the asynchronous EPSCs 
occurring 400–900 ms post-stimulation was measured. Slices were treated with 
vehicle or 1-NA-PP1 from 2 DIV until the time of recording. Analysis of eEPSCs 
was performed using custom-written macros in IgorPro.
Statistical analysis. All animal experiments contained pups from multiple litters. 
All imaging analyses were done blind to condition. No data points were excluded 
in any experiment. Unpaired t tests and two-way ANOVA (for comparing effect of 
drug on AS EphB TKI versus wild-type neurons) analyses were conducted using 
GraphPad Prism software. All tests are two-sided (standard).
51. Petros, T.J., Bryson, J.B. & Mason, C. Ephrin-B2 elicits differential growth cone 
collapse and axon retraction in retinal ganglion cells from distinct retinal regions. 
Dev. Neurobiol. 70, 781–794 (2010).
52. Plump, A.S. et al. Slit1 and Slit2 cooperate to prevent premature midline crossing 
of retinal axons in the mouse visual system. Neuron 33, 219–232 (2002).
53. Xu-Friedman, M.A. & Regehr, W.G. Presynaptic strontium dynamics and synaptic 
transmission. Biophys. J. 76, 2029–2042 (1999).
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SUMMARY
Despite significant heritability of autism spectrum
disorders (ASDs), their extreme genetic heteroge-
neity has proven challenging for gene discovery.
Studies of primarily simplex families have implicated
de novo copy number changes and point mutations,
but are not optimally designed to identify inherited
risk alleles. We apply whole-exome sequencing
(WES) to ASD families enriched for inherited causes
due toconsanguinity andfind familial ASDassociated
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with biallelicmutations in disease genes (AMT,PEX7,
SYNE1,VPS13B,PAH, andPOMGNT1). At least some
of these genes show biallelic mutations in noncon-
sanguineous families as well. These mutations are
often only partially disabling or present atypically,
with patients lacking diagnostic features of the
Mendelian disorders with which these genes are
classically associated. Our study shows the utility of
WES for identifying specific genetic conditions not
clinically suspected and the importance of partial
loss of gene function in ASDs.
INTRODUCTION
Despite studies suggesting that autism spectrum disorders
(ASDs) are significantly heritable, the basis of this heritability
remains largely unexplained (Devlin and Scherer, 2012). Autism
is characterized by the triad of communication deficits, abnor-
mal social interests, and restricted and repetitive behaviors.
Genome-wide association studies (GWAS) have so far detected
no strong contribution of common alleles (State, 2010), moti-
vating renewed interest in rare variants (Malhotra and Sebat,
2012). Transmitted, rare copy number variants (CNVs), such as
16p11.2 microdeletion/duplication and 15q11.2–q13 duplication
have been found to contribute, although the total number of
cases accounted for by these conditions is small (Levy et al.,
2011; Pinto et al., 2010; Weiss et al., 2008). Significant roles
have also been demonstrated for diverse, de novo CNVs (Levy
et al., 2011; Sanders et al., 2011; Sebat et al., 2007) and more
recently, de novo, protein-altering point mutations (Iossifov
et al., 2012; Neale et al., 2012; O’Roak et al., 2011; O’Roak
et al., 2012; Sanders et al., 2012). In the cohorts examined, de
novo events may be projected to account for up to 15%–20%
of ASD cases. Despite the high total rate of de novo point muta-
tions, estimates of the number of contributing loci to autism
susceptibility are in the several hundreds, so that validating
specific causative genes is a significant challenge, since recur-
rent mutation in any given gene is so uncommon. Nonethe-
less, these studies have been successful at elucidating gene
dosage-sensitive ASD molecular pathways, since the typical
mutations observed are loss/disruption, or sometimes gain, of
one functional copy of a gene or contiguous genes, rather than
biallelic mutations of both copies of a gene. However, despite
the importance of de novo mutations, much of the heritability
of ASDs remains unaccounted for (Devlin and Scherer, 2012).
We hypothesized that at least some cases of autism reflect
rare, inherited point mutations that existing study designs, often
involving families with one or two affected individuals, are not
designed to capture. Consanguineous and multiplex pedigrees
have been extremely useful for identifying inherited mutations
responsible for rare heritable conditions in the setting of extreme
genetic heterogeneity, because single families can provide sub-
stantial genetic linkage evidence (Lander and Botstein, 1987;
Woods et al., 2006). Applying high-throughput sequencing to
such families has been extremely useful in identifying recessive
causes of intellectual disability (Najmabadi et al., 2011). The
potential role of biallelic mutations in ASDs is strongly supported
by a number of syndromic recessive conditions that have
already been associated with autistic symptoms (Betancur,
2011). Additional evidence supporting a role of biallelic muta-
tions comes from studies that have implicated homozygous
CNVs (Levy et al., 2011; Morrow et al., 2008) and long homozy-
gous intervals as significantly associated with ASDs (Casey
et al., 2012). Finally, a recent whole-exome sequencing (WES)
study has suggested a role for biallelic point mutations in
a subset of patients with ASDs that show long runs of homozy-
gosity (Chahrour et al., 2012).
In this study, we apply WES to a cohort of consanguineous
and/or multiplex families with ASD that also show shared
ancestry between the parents, typically as cousins. We find
several families where mapping and sequence analysis allow
the identification of specific causative mutations and show that
many of these mutations represent partial loss of function in
genes where null mutations cause distinctive Mendelian disor-
ders. These hypomorphic mutations confirm the complex and
heterogeneous nature of ASDs, but also highlight the importance
of WES in identifying specific genetic causes underlying this
heterogeneity.
RESULTS
Identifying Inherited Mutations in Three ASD Families
We studied an ASD cohort recruited by the Homozygosity
Mapping Collaborative for Autism (HMCA), an international,
multicenter effort to identify genetically informative ASD families
with consanguinity and/or multiple affected individuals (Morrow
et al., 2008). We first performed genome-wide linkage analysis
on the most informative families, using high-resolution single
nucleotide polymorphism (SNP) arrays, reasoning that some
families would show homozygous, biallelic mutations embedded
within larger blocks of homozygosity inherited from the ancestor
common to both parents. Families were prescreened to exclude
those harboring autism-associated CNVs or other known diag-
noses (Supplemental Experimental Procedures). Three families
provided particularly strong genetic power to localize potential
disease loci.
The first family had three children affected with ASD and
two unaffected children, born to parents who were first cousins
(Figure 1A; Table 1B; see Supplemental Text available online).
Mapping under a single locus, biallelic model (i.e., allowing for
both homozygous and compound heterozygous mutations) ex-
cluded 99.3% of the genome and revealed a single linkage
peak centered at 3p21.31, in a large homozygous interval, reach-
ing the maximum LOD score obtainable in the pedigree, 2.96
(Figure 1B), suggesting a >900:1 likelihood that the responsible
mutation was contained within this homozygous interval. WES
of a single affected child was performed. The linked interval
contained only a single rare, nonsynonymous change that was
absent from known databases and population-matched con-
trols: a homozygous single base substitution in the aminomethyl-
transferase (AMT) gene, encoding an enzyme essential for the
degradation of glycine. The mutation resulted in p.I308F, altering
an Ile residue that is highly conserved in all AMT orthologs
(Figure 1C) and is packed tightly into a hydrophobic pocket
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(Figure 1D; Okamura-Ikeda et al., 2005). Sanger validation
confirmed that the mutation was heterozygous in both parents,
homozygous in all affected children, and absent or heterozygous
in the two unaffected children.
Mutations in AMT classically cause nonketotic hyperglycine-
mia (NKH) (Applegarth and Toone, 2004), a neonatal syndrome
leading to progressive lethargy, hypotonia, severe seizures,
and death within the first year of life (Hamosh and Johnston,
2001). Patients with neonatal NKH have impaired activity of the
glycine cleavage system, leading to abnormal elevation of
glycine levels in serum or cerebrospinal fluid (CSF). Rarer, atyp-
ical forms of NKH have been described in association with hypo-
morphic, missense AMT mutations (Applegarth and Toone,
2001; Dinopoulos et al., 2005), manifesting as later age of clinical
onset, delays in expressive language, behavioral problems, and
variable or absent seizures. Clinical and biochemical evidence
suggests that the p.I308F mutation is hypomorphic. While
individually nondiagnostic, the three affected children in this
family exhibited a range of neurologic symptoms that in aggre-
gate were strongly suggestive of NKH (Supplemental Text).
The eldest child was twelve years old and had, in addition to
a diagnosis of ASD, a history of severe epilepsy, with first
seizures presenting by age 10 months, very consistent with
NKH. The second child was nine years old and also suffered
from a combination of autism and epilepsy, though her seizures
were milder. The third child was two years old, suffered from
language and motor delays, and carried a presumptive PDD
diagnosis. He had had only a single febrile seizure. Though the
two older children had had plasma amino acid screening that
disclosed no abnormalities, milder forms of NKH typically have
no abnormalities on serum biochemical analyses (Applegarth
and Toone, 2001; Dinopoulos et al., 2005).
Direct biochemical analysis of the p.I308F mutation confirms
that it has reduced activity. While wild-type AMT is fully soluble
at 30!C when expressed in bacteria, mutant AMT p.I308F was
very poorly soluble (Figure 1E), indicating a protein folding
defect, similar to that observed with NKH-associated AMTmuta-
tions (Figure S1; Table S1). This defect could be rescued by co-
expressing GroES and GroEL heat-shock proteins at 22!C (Fig-
ure 1E). AMT p.I308F, even after solubilization, retained only
45% (SD 4.1%) and 1.8% (SD 0.5%) of wild-type glycine
cleavage and glycine synthesis specific activity, respectively,
when assayed enzymatically (Figures 1F and S2). When com-
pared to classical NKH-associated alleles, glycine cleavage
activity of AMT p.I308F is at the mild end of the range of previ-
ously reported values (Figures 1F and S2), further suggesting
that the affected autistic children in this family suffer from undi-
agnosed, atypical NKH presenting as ASD and seizures.
A secondconsanguineous family had three children diagnosed
with ASD and three unaffected children, born to unaffected
parents who were first cousins (Figure 2A; Table 1B; Supple-
mental Text). Parametric mapping excluded 97.2% of the
genome and established linkage to a homozygous interval on
6p23 (Figure 2B) (LOD 2.78, themaximum obtainable in the pedi-
gree, under a recessivemodel, indicating a >600:1 likelihood that
this interval contained the disease-causingmutation). WES iden-
tified only one variant, absent from known databases and popu-
lation-matched controls, in this region that was predicted to be
pathogenic: PEX7 p.W75C. This change was homozygous and
altered a highly conserved Trp residue within a WD-40 repeat
of the predicted protein (Figures 2C and 2D). Sanger validation
confirmed that this mutation was heterozygous in both parents,
and heterozygous or wild-type in unaffected children.
PEX7 encodes a receptor required for import of PTS2 (peroxi-
some targeting signal 2)-containing proteins into the peroxi-
some (Braverman et al., 1997). Null mutations in PEX7 cause
rhizomelic chondrodysplasia punctata (RCDP), an inborn meta-
bolic syndrome of abnormal facies, cataracts, skeletal dysplasia,
epilepsy, and severe psychomotor defects, with most cases not
surviving beyond two years of age (Braverman et al., 2002; Brav-
erman et al., 1997; Motley et al., 1997). The affected children in
this family, however, ranged in age from 18 to 31 years. They
were not dysmorphic and did not exhibit skeletal dysplasia,
though two had cataracts and two had epilepsy (Supplemental
Text). The cataracts and seizures in particular suggested partial
loss of PEX7 function, since rare, atypical RCDP cases associ-
ated with hypomorphic compound heterozygous or homozy-
gous mutations have been described that have some but not
all of the features of the classical syndrome, lacking dysmorphic
features and showing only intellectual disability with variable
cataracts (Braverman et al., 2002).
To evaluate whether the p.W75C missense change in this
family could be pathogenic, we assayed its ability to rescue
peroxisomal import in cultured fibroblasts from a RCDP patient.
In RCDP fibroblasts, fluorescent mCherry fused to the PTS2
peroxisomal targeting sequence fails to be imported into perox-
isomes and remains cytosolic (Figure 2E). Cotransfection of wild-
type PEX7 fully restores peroxisomal import (Figure 2E). In
contrast, transfection with PEX7 p.W75C failed to rescue (Fig-
ure 2E): the majority of cells showed cytosolic PTS2-mCherry,
although a fraction showed partial rescue. To characterize this
effect, we utilized a semiquantitative assay of peroxisomal
import. The PTS2 proteins thiolase, phytanoyl-CoA hydroxylase
(PhyH), and alkylglycerone phosphate synthase (AGPS) are
imported into the peroxisome and proteolytically processed
into smaller, mature forms (Figure 2F). Peroxisomal uptake is
thus reflected in the ratio of the mature protein to the preprotein.
In RCDP cells, these three proteins all remain in the preprotein
state, reflecting failure of peroxisomal import. Transfection of
wild-type PEX7 fully restores processing, whereas transfection
of PEX7 p.W75C produced only partial processing (Figure 2F).
These results demonstrate that this allele is pathogenic, but
partial loss of function, consistent with these individuals not
exhibiting full features of the RCDP syndrome.
To our knowledge, a link between mild RCDP and ASDs has
not been described previously. However, two previously re-
ported patients with biochemical evidence of RCDP and cata-
racts, but lacking the dysmorphic features of RCDP, were found
to be compound heterozygous for partial loss-of-function PEX7
mutations (Braverman et al., 2002); one was originally described
as intellectually disabled and the second as neurotypical. We
recontacted these patients. A review of clinical records and reex-
amination of the first child revealed that she had subsequently
been diagnosed with ASD, and the second child was diagnosed
with severe ADHD, providing additional examples of the range of
clinical expressivity of mild mutations in PEX7. Partial loss of
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Figure 1. Identification of Mutations in AMT in a Family with ASD
(A) AU-1700, a Saudi family with three children affected by autism. Shaded symbols indicate affected individuals. The triangle represents a miscarriage. WES
was performed on samples from individuals indicated with a star. Genotyping by Sanger sequencing in additional family members was performed where
indicated (+, reference allele; !, alternate allele).
(B) Mapping to a locus on chromosome 3. Genome-wide linkage plot (top) and maximum obtainable LOD score in the family across the interval (bottom).
(legend continued on next page)
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function for one of the alleles in these patients, S25F, was verified
in fibroblast assays (Figures 2E and 2F).
Analysis of a third large family pointed to a candidate autism
gene potentially implicated in synaptic plasticity, SYNE1. In
this family, five children were born to parents who were double
first cousins. Four were affected with autism and the fifth child
was unaffected (Figure 3A; Supplemental Text). The family
showed linkage to two loci on chromosome 6q25 and 7q33
(LOD 2.83, maximal obtainable in the pedigree, indicating a
>670:1 chance that the disease-causing gene lies in one of
these intervals) (Figure 3B). WES was performed for the entire
nuclear family. No rare, protein-altering variants were found in
the 7q33 linkage interval, whereas 6q25 harbored only one
protein-altering variant, absent from known databases and
population-matched controls, that segregated with disease: a
homozygous missense change in SYNE1 (p.L3206M) (Table 1).
SYNE1 has previously been implicated as an ASD gene candi-
date by the presence of a de novo single nucleotide variant in
a patient with ASD (O’Roak et al., 2011) and has been implicated
in bipolar disorder in aGWAS study (Sklar et al., 2011; Figure 3C).
Truncating, presumably null, mutations in SYNE1 cause cere-
bellar ataxia (Gros-Louis et al., 2007) and a recessive form of
arthrogryposis multiplex congenita (Attali et al., 2009; Figure 3C),
again suggesting that the ASD-associated allele may be hypo-
morphic, since the phenotype is milder. SYNE1 p.L3206M alters
a highly conserved residue that lies within a spectrin repeat (Fig-
ure 3D; SIFT score 0.01).
Full-length SYNE1 encodes a large 8,797 amino acid protein
with two N-terminal actin-binding domains, multiple spectrin
repeats, a transmembrane domain, and a C-terminal KASH
domain. The SYNE1 mutation identified here is predicted
to map to exon 61 of the full-length transcript (RefSeq NM_
182961), although the SYNE1 locus is complex, with many pre-
dicted alternative splice forms (Simpson and Roberts, 2008).
To identify what human transcript(s) might be affected by the
p.L3206M mutation, we mapped transcriptional start sites in
human neurons using ChIPseq (Figure 3E). ChIPseq using anti-
bodies to H3K4Me3, a mark associated with active promoter
sites (Ernst et al., 2011), and to H3K27Ac, a mark associated
with enhancer elements (Heintzman et al., 2009), demonstrated
mapped read peaks corresponding to at least four major tran-
scriptional start sites within the SYNE1 locus (P1–P4), one of
which (P3) lies immediately upstream of the p.L3206M mutation
(Figure 3E). 50 and 30 RACE (data not shown) confirmed the
existence of at least one polyadenylated transcript emanating
from this promoter, corresponding to GenBank mRNA clone
BC039121, encompassing exons 57–63 of the predicted full-
length SYNE1 mRNA. This is the minimal confirmed transcript
that overlaps the p.L3206M mutation, although contributions of
additional or even full-length transcripts cannot be excluded.
SYNE1 has been shown to have roles in cellular nuclear migra-
tion in C. elegans and Drosophila (Starr and Han, 2002; Zhang
et al., 2002), anchoring of synaptic nuclei with postsynaptic
membranes at the vertebrate neuromuscular junction (Grady
et al., 2005), although based upon patients with SYNE1-associ-
ated cerebellar ataxia, it has been suggested that vertebrates
may have compensatory mechanisms for these two processes
and that SYNE1 may have adapted to perform a specialized
function in the brain (Gros-Louis et al., 2007). In rodents, a spec-
trin-rich splice form of SYNE1 called CPG2 has been shown to
control dendritic spine shape and glutamate receptor turnover
in response to neuronal activity (Cottrell et al., 2004). To test
whetherSYNE1might be responsive to neuronal activity, we per-
formed RNaseq on cultured human primary neurons, before and
after depolarization. Transcription of full-length SYNE1 was in-
duced 1.27-fold (n = 5, SE 0.06, p = 0.0203, t test, one-tailed)
by neuronal activity, and transcription of BC039121 was induced
by 1.50-fold (n = 5, SE 0.11, p = 0.0225, t test, one-tailed) across
five biological replicates (Figures 3E and S2). This suggests that
both full-length SYNE1 and the shorter BC039121 isoform may
have neuronal activity-dependent roles in regulating synaptic
strength, like other synaptic genes implicated in autism.
WES for Known Disease Genes
Our findings of inherited, biallelic, hypomorphic ASD mutations
in larger families prompted us to ask whether additional cases
of ASD might be explained by either unsuspected or atypical
presentations of known diseases. Over 450 genes have been
identified that, when mutated, have neurocognitive impact (van
Bokhoven, 2011). To increase the specificity of our analysis,
we chose to analyze a limited subset of 70 of these genes,
each associated with a monogenic, autosomal recessive or
X-linked neurodevelopmental syndrome in which autistic fea-
tures have been previously described (Table S2; Betancur,
2011). We also screened for additional alleles of AMT, PEX7,
and SYNE1. We used WES to screen for mutations in these
genes in a total of 163 consanguineous and/or multiplex families
using established heuristic filtering for rare, high penetrance
disease (Bamshad et al., 2011; Stitziel et al., 2011) to identify
homozygous, compound heterozygous, or hemizygous variants
(C) Ile308 residue is highly conserved across species.
(D) Mapping of the I308F missense mutation onto the human AMT crystal structure (PDB accession 1WSV). (Left) Overview showing I308 in domain 3 of AMT.
(Right) Detail illustrating the hydrophobic pocket in which I308 resides. Neighboring hydrophobic residues are shown in white. The white brackets indicate the
different domains: AMT domain 1 (folding); AMT domain 2 (catalytic); AMT domain 3 (capping).
(E) I308F results in protein misfolding and aggregation. C-terminal 6xHis-tagged human AMT, AMT I308F, and AMT I308A were expressed in E. coli. (Left) When
overexpressed at 30!C by induction with 25 mM IPTG, wild-type AMTwas fully soluble, but I308F and I308A segregated to inclusion bodies despite overall similar
expression levels. W, whole-cell extract; S, supernatant; P, pellet. Right panel, slower induction at 22!C for 44 hr resulted in partially soluble mutants. Near-wild-
type solubility could be achieved by coexpression with GroEL and GroES.
(F) AMT I308F results in partial loss-of-function of glycine cleavage and synthesis activity. Wild-type and mutant 6xHis-human AMT were expressed in E. coli,
purified, and assayed for glycine cleavage and glycine synthesis activity. Relative to wild-type (blue traces), AMT I308F (red traces) demonstrates significant
reduction of activity in glycine cleavage (left) and glycine synthesis (right) assays. R320H, N145I, and G269D are previously reported NKH-associated alleles
(Okamura-Ikeda et al., 2005).
See also Figures S1, S2, and S5 and Table S1.
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with allele frequencies of less than 1% (dbSNP132, 1000
Genomes Project, NHLBI Exome Sequencing Project, and
population-matched controls consisting of 831 exomes from
the Middle Eastern population; see Experimental Procedures
for details) and which were predicted to be protein altering
(missense, nonsense, splice site, or frameshift). Candidatemuta-
tions were confirmed by Sanger sequencing in the entire family
and were required to segregate with disease status within the
family (i.e., homozygous or hemizygous in the affected individ-
uals, inherited in the heterozygous state from parents, and
heterozygous or absent from unaffected siblings). An overview
of the analytic strategy is shown in Figure 4.
In five families (Tables 1A and S4), our screen revealed molec-
ular genetic diagnoses due to severe loss of function (nonsense
or frameshift) hemizygous or homozygous mutations in known
genes. One of these was a nonsense mutation in NLGN4X
(p.Q329X), found in a single affected male child. NLGN4X is
an X-linked gene encoding a neuronal synaptic adhesion
molecule, and mutations in NLGN4X have been described in
individuals with autism, Asperger syndrome, and intellectual dis-
ability (Jamain et al., 2003). This mutation was inherited from
an unaffected mother, consistent with prior observations that
carrier females may be asymptomatic (Su¨dhof, 2008; Table
1A; Figure S4).
In another family, two male children affected with autism
carried a nonsense mutation in the X-linked gene MECP2
(p.E483X), the gene responsible for Rett syndrome (Table 1A).
Their mutation was also inherited from the unaffected mother,
who was heterozygous (Figure S4). The finding of MECP2
nonsense mutations in this family was unusual since these are
typically lethal in males (Chahrour and Zoghbi, 2007), suggesting
that this allele is likely hypomorphic. Consistent with this idea,
p.E483X is a late truncation predicted to remove only the last
four amino acids of the full-length protein.
Two consanguineous families had homozygous nonsense or
frameshift mutations in PAH (Table 1A; Figure S4), the cause of
phenylketonuria and one of the earliest neurometabolic syn-
dromes described as a cause of ASD (Zecavati and Spence,
2009). These families were confirmed to have phenylketonuria
by clinical laboratory testing.
An additional ASD family implicated a syndrome associated
with dysmorphic features and microcephaly. We found a homo-
zygous frameshift alteration in VPS13B/COH1 in the proband in
a consanguineous family who had ASD and mild dysmorphic
features (Figure 5A; Table 1A). The mutation (p.A3943fs) causes
truncation of the C-terminal 54 amino acids of VPS13B/COH1.
Recessive mutations in VPS13B/COH1 cause Cohen syndrome,
characterized by a constellation of intellectual disability, facial
dysmorphism, retinal dystrophy, truncal obesity, joint laxity,
intermittent neutropenia, and postnatal microcephaly (Hennies
et al., 2004) that has previously been associated with autistic
symptoms in some cases (Douzgou and Petersen, 2011). How-
ever, significant variability in the features associated with Cohen
syndrome makes clinical diagnosis challenging (Mochida et al.,
2004; Seifert et al., 2006). The affected child in our cohort had
several features that suggest a diagnosis of Cohen syndrome,
including microcephaly (head circumference 49 cm at age 9,
!3rd percentile) and the characteristic facial dysmorphisms
typically seen in Cohen syndrome (Figures 5B and 5C; Supple-
mental Text).
In addition to severe loss-of-function mutations, a significant
proportion of rare missense variants are also expected to be
significantly deleterious (Kryukov et al., 2007), as underscored
by our AMT and PEX7 findings. Eleven families were found to
have rare, segregating, homozygous or hemizygous missense
changes in known genes (Tables 1B, S3, and S4). While some
of thesemay be expected to be functionally silent, we found clin-
ical and/or biochemical evidence supporting their pathogenicity
in at least four instances (Table 1B).
In one consanguineous ASD family, we identified a linked
homozygous missense change in AMT (p.D198G) in a single
affected child with ASD and intellectual disability (Table 1B).
This variant was heterozygous in both parents and an unaffected
sibling, and disrupts a highly conserved residue of AMT
(SIFT score 0.01). Functional assays of AMT p.D198G demon-
strated that, like p.I308F and other NKH-associated mutations,
p.D198G is poorly soluble (Figure S5). AMT p.D198G also ex-
hibited a temperature-sensitive protein stability defect (Fig-
ure S5). Enzyme specific activity was preserved (Figure S5),
suggesting that pathogenicity may be due to protein misfold-
ing/stability and not catalytic dysfunction, similar to what is
observed for p.G47R, a known NKH-associated AMT mutation
(Figure S1; Table S1). These findings suggest that this child
may have also suffered from undiagnosed, atypical NKH.
A child affected with ASD and moderate intellectual disability
was found to have a homozygous missense change (p.R367H)
in POMGNT1 (Table 1B; Figure S4). POMGNT1 is responsible
for an inherited dystroglycanopathy characterized by brain
malformation, intellectual disability, developmental delay, hypo-
tonia, and myopia; interestingly, rare patients have been re-
ported with severe autistic features (Haliloglu et al., 2004; Hehr
et al., 2007). The p.R367H missense variant in this patient
disrupts a highly conserved residue, and this exact allele has
been reported as causative in a patient with relatively mild clin-
ical disease, as a compound heterozygousmutation in combina-
tion with a splice site mutation (Godfrey et al., 2007).
Finally, in another consanguineous family, the single affected
child was homozygous for a rare missense variant (p.S824A) in
VPS13B (Table 1B; Figure S4). The proband had in retrospect
some but not all features of Cohen syndrome (autism with mild
facial dysmorphism and joint laxity), consistent with mild ver-
sions reported previously (Hennies et al., 2004).
To begin to explore how these results might extend to noncon-
sanguineous families, we screened for mutations in genes impli-
cated from our cohort (AMT, PEX7, SYNE1, VPS13B, PAH, and
POMGNT1) in 612 families from the Simons Simplex Collection
(193 trios with parents and affected child, plus 419 quartets
with parents, affected child, and unaffected sibling). An analysis
of publicly released whole-exome sequence data (Iossifov et al.,
2012;O’Roak et al., 2012; Sanders et al., 2012) showed amodest
trend toward an excess of biallelic, inherited, rare (MAF < 1%),
protein-altering variants in cases (8/612) compared to control
siblings (2/419) (p = 0.21, Fisher’s exact test, two-tailed) in at
least one of the genes we screened (Table S5). As expected
for a nonconsanguineous cohort, all but one were found in the
compound heterozygous state. Although functional validation
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Figure 2. Identification of Mutations in PEX7 in a Family with ASD
(A) AU-3500, a family with three children affected with ASD. Shaded symbols indicate affected individuals. WES was performed on samples from individuals
indicated with a star. Genotyping by Sanger sequencing in additional family members was performed where indicated (+, reference allele; –, alternate allele).
(legend continued on next page)
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of all of these mutations is not available, in at least two cases,
phenotype data are supportive of the mutations’ pathogenicity.
One affected male child was compound heterozygous for two
different mutations in VPS13B (p.W963X/p.G2704R). Gly2704
is a highly conserved residue, while p.W963X leads to early trun-
cation of the protein and has been previously reported in Cohen
syndrome (Kolehmainen et al., 2004). Review of the clinical
phenotype of this individual confirmed that he manifested,
in addition to autism, features of Cohen syndrome including
prominent microcephaly (<3 SD) and somatic dysmorphisms
(Supplemental Text), making the diagnosis of a Cohen syndrome
mutation highly likely. A second, unrelated male child affected
with autism was compound heterozygous for two rare point
mutations in VPS13B, p.S3303R and p.A3691T, both altering
highly conserved residues. In addition to being autistic, this child
also manifested dysmorphisms of the face and extremities as
well as an abnormal hair growth pattern, known to characterize
Cohen syndrome. These data confirm that biallelic mutations
are also found in nonconsanguineous autism cohorts, but anal-
ysis of much larger numbers of genes and patients will be
needed to quantify their prevalence.
DISCUSSION
Our data combine WES with segregation analysis to demon-
strate that biallelic, hypomorphic mutations underlie at least
a subset of ASDs (Chahrour et al., 2012; Morrow et al., 2008),
and together with a report on biallelic null mutations in this
same issue of Neuron (Lim et al., 2013), provide strong evidence
for a role of inherited recessive mutations in contributing to ASD.
We demonstrate the utility of our approach in identifying three
new ASD genes from a relatively small sample enriched for
recessive inheritance. We present three families that simplify
the identification of causative genes by narrowing genetic loci
to 1%–3% of the genome and allow identification of single muta-
tions that are rare and likely to be functional. These analyses
demonstrate a strategy for dissection of an otherwise highly
heterogeneous disorder. We present additional evidence that
biallelic mutations occur in other smaller families, as well as in
European American families from the Simons Simplex Collec-
tion. As high-quality whole-exome sequencing data from addi-
tional cohorts becomes available, it will be valuable to quantify
the prevalence of these biallelic mutations in ASD in general. A
common theme of many of the mutations identified in this cohort
is hypomorphic mutations that partially impair gene function,
though one or two null mutations are also identified.
The finding of partially disabling mutations in AMT and PEX7
suggests that mild forms of neurometabolic conditions may
present with autistic symptoms, although such very mild muta-
tions may be quite rare, especially in nonconsanguineous popu-
lations. Although several neurometabolic disorders have been
associated with autistic symptoms (Zecavati and Spence,
2009; Novarino et al., 2012), milder forms of other metabolic
conditions may also be potentially missed by current newborn
or biochemical screening tests, which have limits to their sensi-
tivity (Watson et al., 2006). In analogous fashion, the rare biallelic
variants we identified in other syndromic neurodevelopmental
genes (VPS13B/COH1, SYNE1, MECP2, POMGNT1) also
seem to represent mutations in genes in which complete
knockout causes more severe syndromes, but which present
with milder ASD phenotypes when partially inactivated. Exome
sequencing will likely improve our ability to recognize these
difficult-to-diagnose cases. Metabolic conditions are especially
critical to identify since for some neurometabolic conditions,
interventions may be available.
In this study, we focused on identifying rare, deleterious,
penetrant variants that are causative of ASD in the families in
question. Our data does not rule out contributions of common
variation to ASD in other cases. While common variants are
under less selective pressure than rare variants and are more
likely to be benign, the functional impact of most common
variants is poorly understood. Some might be expected to lie
in autism gene pathways, impact biochemical function, and
modify disease risk. For example, a common deletion in TMLHE,
encoding the first enzyme in carnitine biosynthesis, has been
recently implicated as a risk factor for autism (Celestino-Soper
et al., 2012).
Genes implicated in this study include ones known to regulate
or be regulated by synaptic activity (MECP2, SYNE1) but also
genes not traditionally thought of as having synaptic roles
(AMT, PEX7, VPS13B/COH1). This could reflect an important
role for nonsynaptic genes and suggest the involvement of
hitherto unexpected pathways in ASDs. Alternatively, given the
strength of genetic evidence implicating genes of the synapse
as causative in ASDs, AMT, PEX7, and VPS13B/COH1 may
have involvement in synaptic pathways that have yet to be
characterized. AMT for example, regulates turnover of glycine,
a crucial inhibitory neurotransmitter (Baer, 2009; Keck and
White, 2009). PEX7 regulates peroxisomal protein import, and
peroxisomes are abundant in dendrites (Kou et al., 2011). Finally,
VPS13B/COH1 has essential roles in vesicle trafficking through
the Golgi apparatus (Seifert et al., 2011). Hence, while null
(B) Mapping to a locus on chromosome 6. Genome-wide linkage plot (top) and maximum obtainable LOD score in the family across the interval (bottom).
A homozygousmissense mutation in the AU-3500 family disrupts a conserved tryptophan (p.W75C) (C) in the first WD40 repeat of PEX7, the receptor responsible
for import of PTS2-containing proteins into the peroxisome (D), and an established cause of rhizomelic chondrodysplasia punctata.
(E) PEX7 W75C and S25F, a previously characterized mutation from a patient with mild RCDP and ASD, result in partial loss of function in a peroxisomal import
assay. In fibroblasts from patients with RCDP, PTS2-tagged mCherry accumulates in the cytoplasm due to lack of PEX7 transport activity (top). Transfection of
wild-type PEX7 cDNA causes PTS2-mCherry to redistribute to small puncta, indicative of restoration of peroxisomal import (bottom). Transfection of mutant
PEX7 W75C or S25F does not restore complete import, with a minority of cells showing partial import (middle). Quantification of defects in peroxisomal import
mediated by ASD-associated PEX7 alleles, scored by visual assay. Error bars represent standard error (right).
(F) Immunoblotting of whole cell lysates illustrates deficient maturation of PTS2-targeted proteins in a RCDP cell line transfected with ASD-associated PEX7
alleles. AGPS, PhyH, and thiolase are imported into the peroxisome and undergo cleavage into a smaller, mature peptide. p, preprotein; m, mature protein; Beta-
tubulin, loading control. Quantification of processing defects by densitometry of transfected cell lysates (right).
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Figure 3. Identification of Mutations in SYNE1 in a Family with ASD
(A) AU-1600, a family with four children affected with ASD. Shaded symbols indicate affected individuals. WES was performed on samples from individuals
indicated with a star. Genotyping by Sanger sequencing in additional family members was performed where indicated (+, reference allele; –, alternate allele).
(B) Mapping rules out themajority of the genome and points out to only two candidate loci, one on chromosome 6 and the other on chromosome 7. Genome-wide
linkage plot (top) and maximum obtainable LOD score in the family across the interval (bottom).
(C) SYNE1 is a complex locus implicated in neuropsychiatric disease. SYNE1 encompasses multiple alternative transcripts (Known Genes, UCSC Genome
Browser), and mutations have been associated with a wide range of neurodevelopmental phenotypes. The location of the recessively inherited missense change
(legend continued on next page)
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mutations in these genes have effects inmany tissues, hypomor-
phic mutations may cause subtler defects primarily limited to
neurons.
Our data support the interpretation that biallelic mutations in
the proper setting can cause a spectrum of clinical phenotypes,
which at one extreme cause a Mendelian disorder, but at the
other extreme represent risk alleles for ASDs. In our multiplex
pedigrees, siblings who share homozygosity for the identical
biallelic mutation still can show a variety of phenotypes, ranging
from ASD to intellectual disability, and including epilepsy and/or
other features. This variable expressivity has parallels in known
associations of ASD with Mendelian genes like FMR1 or TSC2,
which are near fully penetrant for syndromic features of Fragile
X or Tuberous Sclerosis, respectively, but only partially penetrant
for ASD (Hagerman et al., 2010; Wiznitzer, 2004). Variability of
phenotype is also characteristic of recurrent ASD-associated
CNVs, such as 16p11.2, which has been linked not only to
ASD but also to schizophrenia, epilepsy, ADHD, and obesity
(McCarthy et al., 2009; Shinawi et al., 2010; Walters et al.,
2010; Weiss et al., 2008). The common theme of variability of
phenotype despite underlying shared genetic susceptibility
increasingly suggests that highly penetrant mutations associ-
ated strictly with ASD, and never with other conditions, may be
extremely rare or nonexistent.
Our data extend the observation that hypomorphic alleles can
commonly cause conditions that may be dramatically different
from null mutations in the same gene (Walsh and Engle, 2010).
Hypomorphic, biallelic mutations, combined with CNVs and
heterozygous stop mutations (Neale et al., 2012; O’Roak et al.,
2012; Sanders et al., 2012) which completely inactivate one of
two alleles, suggest that a common theme for ASD mutations
in general might be partial loss of gene function and/or dosage
sensitivity. In other words, ASD, and potentially other neuropsy-
chiatric conditions, may be united by incomplete loss of function
of specific synaptic genes. Such incomplete lossmight provide a
general model for the complex genetic architecture, and genetic
heterogeneity, of ASDs. In this respect, neuropsychiatric condi-
tions may increasingly come to be understood as much by their
allelic architecture as by the specific causative genes.
EXPERIMENTAL PROCEDURES
Human Studies
All human studies were reviewed and approved by the institutional review
board of the Boston Children’s Hospital, Beth Israel Deaconess Medical
Center, and local institutions.
Patient Recruitment
The families presented were collected by the Homozygosity Mapping Collab-
orative for Autism (HMCA) (Morrow et al., 2008), with referral centers in Turkey,
the Kingdom of Saudi Arabia, Kuwait, United Arab Emirates, Oman, Jordan,
and Pakistan. Inclusion criteria included a diagnosis of autism or ASD by
a neurologist, child psychiatrist, or psychologist and families with multiple
affected children and/or suspected consanguinity. See Supplemental Experi-
mental Procedures for further phenotyping details. Additional clinical informa-
tion on families described here is provided in Supplemental Text.
Genome-wide Linkage and Homozygosity Scans
Genome-wide SNP screens were performed at the Broad Institute and
Dana Farber Cancer Institute. Families were genotyped using Affymetrix
500K (NspI/Sty) or Affymetrix 6.0 microarrays. Linkage disequilibrium-based
in this study is denoted by the green star. Late truncation (open triangle) causes autosomal recessive arthrogyroposismultiplex congenita (Attali et al., 2009), while
truncating mutations further upstream (closed triangles) cause autosomal recessive cerebellar ataxia (Gros-Louis et al., 2007). An intronic SNP (red square) is
a putative bipolar disorder susceptibility locus (Sklar et al., 2011). A de novo missense change was previously reported in ASD (blue star) (O’Roak et al., 2011).
(D) The homozygous missense mutation p.L3206M disrupts a highly conserved residue.
(E) Human neuronal ChIPseq and RNaseq data demonstrate transcriptional complexity and activity-dependent regulation of the SYNE1 locus. ChIPseq with
antibodies to H3K4Me3 (active promoters) and H3K27Ac (enhancers) demonstrates at least four active promoters (P1-P4) for SYNE1. P3 lies immediately
upstream of the residue mutated in AU-1600 (p.L3206M) and corresponds to the active promoter site for BC039121. RNAseq of cultured human neurons was
performed before (0h, 0 hr) and after (6h, 6 hr) depolarization with KCl. Depolarization induces upregulation of full-length SYNE1 and the BC039121 isoform
compared to untreated neurons (also see Figure S3). The experiment was performed on five biological replicates. Representative tracks are shown. The red
square represents a magnification of the region around BC039121. Sense (+, pink) and antisense (–, blue) transcripts are indicated.
See also Table S5.
Figure 4. Schematic of the Analytical Pipeline
Tiered strategy for examining the cohort of ASD families for inheritedmutations
in known disease genes. Whole-exome sequencing data were used to
systematically survey 70 genes (listed in Table S2) known to be associatedwith
autosomal recessive or X-linked neurodevelopmental illness and autistic
features. Variants were filtered based on rarity (MAF < 1%) in known databases
and our internal, population-matched data set (see Experimental Procedures
for details), and predicted functional effect on the protein. All candidate vari-
ants were validated by Sanger sequencing and were required to segregate
within the family. XL, X-linked; AR, autosomal recessive; MAF, minor allele
frequency; 1000G, 1000 Genomes Project; NHLBI EVS5000, NHLBI Exome
Sequencing Project. See also Figure S4.
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SNP pruning was performed with PLINK, followed by filtering of loci homozy-
gous in all samples and those with Mendelian inheritance errors. Multipoint
LOD scores were calculated using MERLIN, assuming a recessive mode
of disease inheritance, full penetrance, and a disease allele frequency of
0.0001. Runs of homozygosity were calculated using custom Perl scripts,
allowing for no more than two consecutive heterozygous SNPs in a run and
three heterozygous calls in every ten consecutive SNPs. Intervals homozygous
for the same haplotype and shared by all affected individuals were used to
narrow the locus in each family. See Supplemental Experimental Procedures
for details.
Whole-Exome Sequencing and Data Analysis
DNA samples were sequenced at the Broad Institute. Whole blood DNA was
subject to exome capture (SureSelect v2, Agilent Technologies) and whole-
exome sequence (Illumina HiSeq) was obtained on a total of 277 affected
children and 409 parents, with a mean target coverage of 85.6% at R203
and a mean read depth of 1583. For this study, families harboring known
autism-associated CNVs were excluded (Supplemental Experimental Proce-
dures). Reads were aligned to NCBI human genome build v37 and variants
were called and annotated using GATK. ANNOVAR (Wang et al., 2010) and
custom pipelines. All reported variants were confirmed by Sanger sequencing.
See Supplemental Experimental Procedures for additional details.
SSC Exome Reanalysis
Exome data from 612 families from the Simons Simplex Collection were
obtained from dbGAP and NDAR. Raw sequence reads were aligned with
BWA and variants were called with Samtools and annotated as previously
described (Sanders et al., 2012).
Sanger Resequencing
See Supplemental Experimental Procedures for details.
Data Visualization
See Supplemental Experimental Procedures for details.
AMT Expression and Enzymatic Assays
Wild-type and mutant human AMT proteins with a C-terminal His6-tag were
expressed and purified as previously described (Okamura-Ikeda et al.,
2005). I308F, I308A, D198G, or D198A substitutions were introduced using
site-directed mutagenesis, and enzymatic activities were determined as previ-
ously described (Okamura-Ikeda et al., 2010).
For heat stability studies, wild-type and mutant AMTs (about 0.5 mg/ml in
20 mM Tris-HCl [pH 7.5], 1 mM DTT, 20 mM (p-amidinophenyl) methanesul-
fonyl fluoride, and 10% glycerol) were incubated for 1, 2, and 3 hr at 37!C
and 42!C. After incubation, the solutions were centrifuged and the protein
concentrations in the supernatants were determined using Coomassie Plus
(Thermo Scientific, USA) with BSA as standard. The remaining protein con-
centrations in the supernatant were showed as a percent of the initial
concentrations.
PEX7 Peroxisomal Import Assays
A peroxisomal import marker was generated by fusing mCherry fluorescent
protein to the PTS2 signal located in the first 26 amino acids of rat 3-ke-
toacyl-CoA thiolase [P07871.2] (Tsukamoto et al., 1994). N-terminal c-myc
tagged variants of PEX7 (W75C and S25F) were engineered using PCR
based site-directed mutagenesis of the N-myc-PEX7 cDNA [NM_000288]
in pCDNA1. PEX7 and PTS2-mCherry were transiently transfected into
an immortalized RCDP1 fibroblast line with a PEX7 null genotype (p.L292X];
[S132X) and processed at 3 days for direct and indirect immunofluorescence
as previously reported (Braverman et al., 2002). Recovery of peroxisomal
import was assessed by blinded visual scoring of 100 cells each from 3 sepa-
rate transfections. Peroxisomal import was confirmed by colocalization of the
peroxisome membrane protein PEX14. Whole cell lysates from similarly trans-
fected fibroblasts were used for immunoblotting with antibodies to the endog-
enous PTS2 proteins thiolase, PhyH, and AGPS (Zhang et al., 2010). PEX7
protein expression was confirmed with a c-myc antibody (SC789, Santa
Cruz Biotechnology Inc., Santa Cruz, CA).
RNaseq of Human Neurons
Primary human neuronal cells were purchased from Sciencell (Carlsbad, CA).
For RNaseq experiments, neuronal cultures from three biological replicates
were grown for around two weeks (DIV13–16). At the final day in culture,
neurons in the experimental group were stimulated for 6 hr with 55 mM KCl
and were harvested along with the unstimulated control neurons using Trizol
(Invitrogen). Strand-specific and paired-end cDNA libraries were generated
using the PE RNaseq library kit (Illumina). RNaseq was performed using HiSeq
2000 at the Broad Institute. 76-bp RNaseq reads were aligned to the human
GRCh37/hg19 assembly using BWA. See Supplemental Experimental Proce-
dures for details. For quantification of SYNE1 expression in response to depo-
larization, for each biological replicate, expression levels (normalized reads per
bp) of individual exons were calculated, which allowed the calculation of the
average expression level over any isoform of SYNE1 comprising subsets of
Figure 5. Identification of a Mutation in VPS13B, the Cohen Syndrome Gene, in a Patient with ASD
(A) AU-21100, a family with one child affected with ASD. Shaded symbol indicates affected individual. The triangle represents amiscarriage. WESwas performed
on samples from individuals indicated with a star. Genotyping by Sanger sequencing in additional family members was performed where indicated (+, reference
allele; –, alternate allele).
(B) Photographs of proband, demonstrating mild facial dysmorphisms consistent with Cohen syndrome: prominent nasal tip, protruding maxilla, and short
philtrum. For additional clinical details, see Supplemental Text.
(C) Head circumference for proband compared to published population normative data (reprinted with permission from Schienkiewitz et al., 2011). KiGGS: norms
from German Health Interview and Examination Survey for Children and Adolescents, 2003–2006. Prader: previously published Swiss growth curves from 1989.
See also Table S5.
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these exons. Then fold-change ratios (6 hr/unstimulated) of these levels were
calculated for each replicate and isoform, and finally each isoform’s mean and
standard error over the replicates’ fold changes.
ChIPseq of Human Neurons
The mini-ChIP assays were performed as previously described (Adli and Bern-
stein, 2011) on human neuronal cells that had been cultured for around two
weeks. Briefly, cells were cross-linked, lysed, and the fragmented chromatin
was then immunoprecipated with H3K27Ac (Abcam Cat# ab4728) and
H3K27me3 (Millipore Cat# 074490) antibodies. The ChIP DNA was recovered
and precipitated following standard procedures. The ChIP DNA libraries were
then constructed using ChIP-Seq DNA Sample Prep Kit (Illumina) and subse-
quently sequenced using HiSeq 2000 (Illumina) in Biopolymers facility at
Harvard Medical School. ChIPseq reads were aligned to the human genome
(GRCh37/hg19 assembly). See Supplemental Experimental Procedures for
details.
Data Access
Whole-exome sequence data is available online (The National Database for
Autism Research [NDAR] Collection ID: NDARCOL0001918).
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, five tables, Supplemental
Experimental Procedures, and Supplemental Text and can be found with
this article online at http://dx.doi.org/10.1016/j.neuron.2012.11.002.
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